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Hepatitis C virus (HCV) is the major causative agent of non-A non-B
hepatitis worldwide, often leading to chronic disease, cirrhosis and hepatocellular
carcinoma. HCV displays high levels of genetic heterogeneity, and is currently
classified into six major genotypes, which can be further divided into subtypes.
Genotypes of HCV show distinct geographical distributions with type 1, 2 and 3
infections occurring in a wide range of areas whilst types 4, 5 and 6 are generally
confined to more specific regions. The clinical relevance of different genotypes is
becoming increasingly evident, with type 1 infections being associated with a low
rate of sustained response to interferon therapy, and arguably a more rapid course
of disease. Many genotyping assays have been described which involve the analysis
of subgenomic regions of RNA, such as the 5' non coding region (5'NCR), that
have been amplified by the polymerase chain reaction (PCR). Serological
determination of HCV genotype is also possible as high levels of amino acid
variation within certain immunodominant regions of the genome often generate a
genotype-specific antibody response. The foundation of this project was the
development of an indirect serotyping ELISA for the identification of genotypes
1-3. This thesis is concerned with the further development of the serotyping
ELISA.
Initially, the assay was extended by the incorporation of antigen for recently
discovered genotypes 4, 5 and 6. This version of the assay was able to detect type-
specific antibody in 87% sera from blood donors and patients with chronic HCV
xvi
infection from various geographical areas. The specificity of this assay was >97%
when compared to genotyping by a PCR method. This serotyping ELISA was
applied to a number of different population studies, including the U.S.A., Norway,
Pakistan, Egypt and Hong Kong, and in doing so has contributed to current
knowledge of genotype distributions worldwide.
The availability of a large set of samples from blood donors in Hong Kong
lead to an extensive study of HCV type 6, which has a restricted geographical
distribution (Hong Kong, Macau and Vietnam) and for which analysis had
previously been limited. Type 6a accounted for 27% infections of blood donors in
Hong Kong, although type-specific antibody was detected in only 75% these
infections by the serotyping assay. Sequence analysis of type 6a core and NS4
regions revealed that the reduced sensitivity of the ELISA to this genotype was not
due to antigenic variation, and that high levels of sequence similarity exist within
this subtype. Analysis of the risk factors for these donors revealed that a
significantly greater number of those infected with type 6a had reported a history
of drug abuse (66%) than donors infected with type lb (7%).
In an attempt to improve the sensitivity of the assay, peptides corresponding
to an additional immunogenic region in NS4 were included and assessed for their
contribution to the sensitivity and specificity of the assay. The performance of the
serotyping assay was also compared to other PCR-based methods of genotyping.
An investigation into samples producing discrepant results in two distinct cohorts
was performed by sequence analysis of the 5' NCR, core and NS4 regions. The
xvii
frequency of discrepant results was higher when testing samples from
haemophiliacs than from patients with chronic HCV who had no history of multiple
exposure to the virus. Sequence analysis revealed that mis-typing by the ELISA
may have resulted from amino acid changes within NS4 from the non-haemophiliac
study group, whereas little antigenic variation was identified in discrepant
haemophiliac samples. Discrepant results in this multiply-exposed cohort might be
explained by the detection of antibody to genotypes from previous or multiple
infections
Finally, in an attempt to design a new serotyping assay, further subgenomic
regions of RNA were cloned and expressed as recombinant protein for genotypes
1, 2 and 3. An ELISA using amino acids 1360-1454 of NS3 increased sensitivity
for type-specific antibody, although cross reactivity between genotypes 2 and 3 was
observed. To combine the sensitivity of NS3 with the type-specificity of the NS4
region, clones from these two regions were fused together and expressed as
recombinant protein for a final prototype serotyping ELISA.
This work has enabled the specific identification of HCV serotypes causing
infections worldwide by the development of a highly specific serotyping ELISA.
Evidence concerning the possible biological differences between HCV genotypes
suggests that serotyping may become an important method in clinical practice for
the selection of patients for antivirus treatment.
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AIMS
At the beginning of this work a competitive ELISA using type-specific
peptides from the NS4 region had been described for the determination of HCV
antibody serotypes 1, 2 and 3 (Simmonds et al., 1993d). The aim of this thesis has
been to extend this assay to include the more recently discovered genotypes 4, 5
and 6, and to validate it by measuring its sensitivity and specificity (see appendix
1.0) with different patient groups in various geographical populations.
Additional objectives were to improve the sensitivity and specificity of the
assay, including the incorporation of additional antigens from the NS4 region. The
ultimate aim of this work is the production of new serotyping assays based on
several immunodominant regions, resulting in a highly sensitive ELISA which is
able to detect and distinguish between the broad spectrum of genotypes present
worldwide. Such an assay will be an important tool for epidemiological studies and




1.1 GENERAL INTRODUCTION TO HEPATITIS C VIRUS.
1.1.1 NON A NON-B HEPATITIS.
Despite the introduction in many countries of screening of blood donations
for hepatitis B surface antigen in the 1970's, post-transfusion hepatitis continued
to occur. Cases were diagnosed as non-A non-B hepatitis (NANBH) after the
exclusion of infectious agents such as hepatitis A virus (HAV), hepatitis B virus
(HBV) and members of the Herpesviridae such as cytomegalovirus (CMV) and
Epstein-Barr virus (EBV) which were known to cause hepatitis in rare cases.
NANB hepatitis was generally mild in the acute phase with less than 50%
of patients showing any clinical signs or symptoms, although a large proportion of
infections progress to chronic hepatitis, and liver cirrhosis. The incubation period
for post-transfusion NANBH of 8-10 weeks was consistent with an infectious
source, although it was generally shorter than that for HBV infections and longer
than that for HAV infections. This and other clinical evidence suggested that post¬
transfusion hepatitis was caused by an unidentified infectious agent (Feinstone et
al., 1975; Alter et al., 1975; Prince et al., 1974). Parenterally transmitted NANBH
described above remains quite distinct from enteric NANBH, which is now
classified as hepatitis E.
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1.1.2 DISCOVERY OF HEPATITIS C VIRUS.
The causative agent of NANBH remained elusive for many years despite
extensive research. The first advances came in 1979, when the disease was
successfully transmitted into chimpanzees from a batch of factor VIII which had
been associated with the infection of human recipients (Bradley et al., 1979). In
addition, it was found that the agent could be transmitted to other chimpanzees by
the inoculation of plasma or liver preparations from a diseased animal in the acute-
phase of infection. All infected animals developed liver histology characteristic of
viral hepatitis, and all were negative upon serological testing for HAV, HBV, CMV
and EBV. Further evidence that this agent was unrelated to HAV or HBV was the
lack of protection by pre-existing antibody to these viruses in two of the
chimpanzees. Possibly the most exciting result of this study was the identification
by electron microscopy of 25-30nm virus-like particles from both factor VIII and
the first passage chimpanzee liver biopsy by immune electron microscopy which
was recognised using antibodies from a human patient. As these biopsy samples
were consistently negative for HAV and HBV, these virus-like structures were
identified as being the probable infectious agent causing NANBH.
Despite extensive studies using conventional immunological techniques,
specific virus antigens or antibodies were not identified until 1989, when a cDNA
library from chimpanzee plasma with a high infectivity titre was constructed into
bacteriophage X.gtl 1 (Choo et al., 1989). Using serum from a patient with chronic
NANBH as a source of antibody, the phage library was screened for clones
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expressing virus antigen. This lead to the identification of an antibody binding
clone designated 5-1-1. This clone had an open reading frame (ORF) which, when
expressed in E.coli, resulted in a peptide that reacted positively with NANBH
patient serum by Western blotting. To investigate the type of nucleic acid of the
virus, serum was treated with either ribonuclease (RNase) or deoxyribonuclease
(DNase) prior to hybridisation to the cDNA library. Hybridisation signals of nucleic
acid complementary to the cDNA were lost after treatment with RNase but not
DNase, leading to the conclusion that the infectious agent was a RNA virus. As
only one of the strands of cloned cDNA could hybridise to the nucleic acid, (the
strand complementary to that encoding the 5-1-1 ORF), the virus was identified as
having a single stranded positive sense RNA genome and given the name hepatitis
C virus (HCV).
Following this discovery, the first assay for the detection of HCV antibody
was rapidly designed (Kuo et al., 1989). The expression of three overlapping clones
from 5-1-1 in yeast led to the synthesis of a 363 amino acid HCV polypeptide
(CI 00-3), which was solubilised and purified before being coated onto the wells
of a microtitre plate. The resulting ELISA was used to screen for HCV antibodies
in a number of study groups, including blood donors and recipients from post¬
transfusion NANBH cases in the United States, Japan and Italy. It was discovered
that up to 84% of Italian patients diagnosed with post-transfusion NANBH had
antibody specific for HCV. Following these studies commercial assay systems were
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developed, and the routine screening of blood donations for antibody to HCV was
quickly introduced.
The first described HCV genome (figure 1.1.4), consisted of 9379
nucleotides in a single large ORF encoding a virus polyprotein precursor of 3011
amino acids (Choo et al., 1991). A 5' non coding sequence was identified upstream
of the ORF which showed similarity to that found in pestiviruses, and the
polyprotein itself was related to both pestiviruses and flaviviruses. Comparison of
partial sequences isolated from Japanese patients suggested the possibility of
distinct virus genotypes (Enomoto et al., 1990a; Kato et al., 1990a).
1.1.3 CLASSIFICATION OF HCV AMONG OTHER RNA VIRUSES
Analysis of the first cloned nucleotide sequences of HCV revealed
similarities to more than one existing virus family, making classification difficult.
Although specific sequence motifs in certain nonstructural regions of the genome
showed high levels of similarity with Dengue virus (a flavivirus), a greater level
of protein sequence similarity was found with the animal pestiviruses bovine viral
diarrhoea virus (BVDV) and Hog Cholera Virus (HChV), and to a lesser extent
with certain picornavirus and plant viruses (Miller et al., 1990). The recent re¬
classification of pestiviruses from the family Togaviridae into Flaviviridae based
on genome organisation and structure (Collett et al., 1988), led to the consensus
that HCV should also be included in this family. Although members of both the
Flaviviridae and Picornaviridae families possess a single large ORF like HCV, and
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have a similar genome organisation with structural proteins at the 5' end and
nonstructural genes nearer the 3' end, these families have different sizes of
genomes and code for variable numbers of proteins. The Flaviviridae have many
specific properties in common with HCV, including glycosylation of the envelope,
and the cleavage of the polyprotein precursor into individual proteins by both virus
encoded and host cell proteases.
Structurally, the HCV genome is similar to that of pestiviruses (BVDV and
HChV) in both the arrangement of genes (Miller et al., 1990) and the number of
cleavage sites on the polyprotein, as well as physicochemical properties such as a
low buoyant density in sucrose gradients (Miyamoto et al., 1992). The HCV
genome contains a long 5' non coding region (5'NCR), which shows remarkable
similarity in secondary structure to other pestiviruses despite their divergent
sequences, although quite distinct to that in flaviviruses for which a convincing
secondary structure has yet to be proposed (Brown et al., 1992).
For HCV and pestiviruses, the 5' NCR acts as an internal ribosomal entry
site (IRES), and has been shown in picornaviruses to be essential in the initiation
of cap-independent translation as an internal ribosome binding site. Flaviviruses on
the other hand have no such structure, with the ribosome binding to a cap present
upstream of the AUG initiation codon.
The current classification of HCV according to the International Committee
on the Taxonomy of Viruses is as a separate genus in the Flaviviridae named the
Hepaciviruses. Included in this genus are the newly discovered agents GB virus A
6
(GBV-A), GB virus-B (GBV-B) and GB virus-C (GBV-C), possibly misleadingly
known as hepatitis G virus (HGV) (Linnen et al., 1996; Simons et al., 1995; Ohba
et al, 1996). These viruses all have genomes of similar sizes and organisation as
the Flaviviridae, and are more closely related to HCV than other flaviviruses or
pestiviruses (reviewed in Heringlake et al., 1996).
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Figure1.1.4THEHCVGENOME


























































The genome of HCV is organised with genes coding for structural proteins
positioned at the 5' end of the RNA, and non-structural (NS) protein coding regions
towards the 3'end, in the order (5' to 3') core, envelope (El and E2), NS2, NS3,
NS4a, NS4b, NS5a and NS5b (figure 1.1.4).
The 5'NCR is 341-344 bases in length and is highly conserved among
different HCV genotypes. The secondary structure of this region has been shown
to contain an internally base-paired stem loop, as in pestiviruses (Smith et al.,
1995b; Brown et al., 1992b; Han et al., 1991b), thought to function as an internal
ribosome entry site (IRES) during translation (Wang et al., 1993; Tsukiyama
Kohara et al., 1992). Several AUG codons occur within the 5'NCR, each followed
by short ORF's, and it was hypothesised that the translational products from these
may have a role in the regulation or initiation of translation (discussed in section
1.1.5). However, none of these ORF's are conserved between all genotypes of
HCV, suggesting that their function, if any, is not essential for replication. A
polypyrimidine tract between nucleotide positions 191 and 199 has been reported
to play an important role in the initiation of translation (Yen et al., 1995).
The 3' NCR consists of a relatively short sequence 200-235 nucleotides in
length, with a 27-70 base type-specific region immediately following the
termination codon on the polyprotein (Yamada et al., 1996). Downstream of this
region lies a poly A (Han et al., 1991) or poly U (Yamada et al., 1996; Kanai et
al., 1995; Tanaka et al., 1995) tail of variable length (reports of between 10 and
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100 residues), which was first thought to represent the end of the HCV genome.
More recently, a C(U)n repeat has been identified immediately downstream of this
region, followed by a highly conserved "core" element of 98 or 100 nucleotides
capable of forming an internally base paired stem loop structure and terminated
with a 3' OH group (Yamada et al., 1996; Kolykhalov et al., 1996; Tanaka et al.,
1995). Although the biological functions of the poly U tail, C(U)n repeat and the
core element have still to be determined, it has been proposed that poly U binds
part of the NS3 helicase (the function of which is discussed in section 1.1.5) (Kanai
et al., 1995), and that the high levels of conservation in the secondary structure of
the core element implies an important role in the replication of the genome (section
1.1.5).
1.1.5 REPLICATION OF HCV
The lack of an efficient in vitro cell culture system for HCV has meant that
description of the full replicative cycle of the virus remains limited. Full length
HCV sequences have been successfully transfected as DNA into transformed
human hepatoma cells (Yoo et al., 1995), but this resulted in only very low levels
of expression of virus proteins. In addition, in vitro replication of the HCV genome
has been demonstrated in a murine retrovirus-infected human T-cell line (Shimizu
et al., 1992). The majority of information about HCV replication has resulted from
the purification of virus encoded proteins, structural analysis of non-coding regions
and comparisons with other positive stranded RNA viruses such as picornaviruses.
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Transcription of the HCV Genome.
Based on the replication mechanisms of other single stranded positive sense
RNA viruses, HCV is presumed to replicate via the synthesis of a complementary
(antisense) RNA strand produced by an RdRp. Antisense RNA strands would then
act as templates for the production of positive sense RNA. This theory has been
supported by the detection of antisense RNA in the liver (Lanford et al., 1994), and
in rare cases in peripheral blood mononuclear cells (PBMC's) (Mellor et al., 1998;
Lerat et al., 1996).
The subgenomic region encoding the RdRp was identified early on as NS5b,
based on the high levels of sequence similarity with those present in other RNA
viruses (Miller et al., 1990). Using the 3' terminal residue of genomic RNA as a
primer, the HCV RdRp has been shown to synthesise a complementary antisense
RNA strand in a 3' to 5' direction using a "copy back" mechanism, producing a
duplex RNA hairpin structure (Behrens et al., 1996). The carboxyl terminus of NS3
has been shown to encode a virus helicase, which has nucleoside triphosphate
activity and is thought to be involved in the unwinding of the duplex RNA
intermediate during synthesis of positive sense RNA strands (Tai et al., 1996). It
has been hypothesised that the 3' NCR may play an important role in replication
processes due to its highly conserved primary and secondary structure (Yamada et
al., 1996). However, clones of HCV lacking this region have been shown to
replicate in vitro, albeit in low numbers, suggesting that such a role is nonessential
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for replication, and may be responsible for regulatory aspects of the process (Yoo
et al., 1995; Tanaka et al., 1995).
HCV Translation and Polyprotein Processing.
Translation of the HCV genome has been shown to be a cap-independent
process initiated by the presence of an IRES in the 5' NCR (Wang et al., 1993;
Tsukiyama Kohara et al., 1992). The extensive internal base-pairing of this region
results in the formation of a specific secondary structure that is conserved between
genotypes despite sequence variation at the primary level (Smith et al., 1995b;
Brown et al., 1992b), and contains several stem loops which are thought to function
as an IRES. Translation of the single large ORF is initiated at the methionine
(AUG) codon at position 341, and although several small ORF's exist upstream of
this region which were originally thought to express products involved in
translation (Yoo et al., 1992), it seems unlikely that they play an essential role as
nucleotide sequence variation between genotypes at positions can replace up to five
of these initiation codons (AUG) with those coding for alternative amino acids
(Smith et al., 1995b).
The single large ORF encodes a polyprotein of 3011 amino acids, which is
then cleaved into at least 9 individual viral polypeptides by a combination of both
host cell and viral proteinases (Grakoui et al., 1993b). Structural proteins core (the
nucleocapsid), El and E2 (envelope glycoproteins) are cleaved from the polyprotein
precursor by a host signal peptidase located in the lumen of the endoplasmic
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reticulum (Hijikata et al., 1991b). Nonstructural proteins are cleaved by at least two
virus encoded proteases. Cleavage of the NS2 / NS3 junction is performed by a
zinc-dependent metalloprotease encoded by NS2 overlapping with the serine
proteinase domain of NS3 (Hijikata et al., 1993; Grakoui et al., 1993). The
remaining nonstructural proteins are processed by a serine protease encoded by the
amino terminal region of NS3, which acts on junctions NS3/NS4a, NS4a/NS4b,
NS4b/NS5a and NS5a/NS5b (Bartenschlager et al., 1995a; Bartenschlager et al.,
1993a). X-ray crystallography has revealed that this enzyme is folded like a
trypsin-like proteinase, and a structural zinc binding site (Love et al., 1996). This
enzyme forms a stable complex with the NS4a polypeptide (Kim et al., 1997; Kim
et al., 1996), and is responsible for the cleavage of the NS3/NS4a, NS4a/NS4b and
NS4b/NS5a junctions (Lin et al., 1994b; Failla et al., 1995b; Bartenschlager et al.,
1995b). The activity of this enzyme is dependent on the serine residue at position




The core protein is 21-22 kDa in size and is thought to be a component of
the virus nucleocapsid. It has been shown to associate with the membranes of
endoplasmic reticulum in the cytoplasm in vitro and in transfected cells, and to
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possess a highly basic RNA binding domain at the N-terminus of the polypeptide
between amino acids 1 and 75 (Santolini et al., 1994). The mechanism of assembly
of these proteins with RNA into the nucleocapsid is unknown, although an
interaction domain may be present at amino acids 82-102 (Nolandt et al., 1997).
The detection of a core-specific antigen from HCV purified from plasma of 26kDa,
larger than the protein previously detected, suggests that core may be modified
prior to nucleocapsid assembly (Takahashi et al., 1992).
The HCV genome encodes two envelope proteins, El and E2. Each protein
is thought to undergo extensive A-linked glycosylation after translation, resulting
in glycoproteins 31-35 kDa (El) and 68-72 kDa (E2) in size. During polyprotein
processing, two precursors of E2 are produced; E2-NS2 and E2-p7. The cleavage
of these products is carried out in the endoplasmic reticulum by a host signal
peptidase, but this process is inefficient resulting in the production of both E2 alone
and E2-p7 (Lin et al., 1994a). The functions of either p7 or E2-p7 are unknown.
Non-covalent interactions between El and E2 result in the formation of a complex
(E1E2) that is highly immunogenic and capable of producing protective antibody
in chimpanzees (Dubuisson et al., 1994; Ralston et al., 1993). Vaccination of
chimpanzees with both envelope glycoproteins (expressed in a recombinant vaccinia
virus expression vector) was able to prevent infection with HCV in 5/7 animals
challenged with a homologous type 1 virus (Choo et al., 1994). Despite these
encouraging results, the development of a vaccine for HCV is hampered by the
level of heterogeneity within HCV. Envelope proteins are highly variable in amino
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acid sequence between genotypes of HCV, and a hypervariable region (HVR) in
E2 may contribute virus persistence (section 1.2.5). Conserved elements of this
region are several A-linked glycosylation sites and cysteine residues.
NONSTRUCTURAL PROTEINS.
NS2 is a hydrophobic 23kDa protein which is a zinc-dependent
metalloprotease involved in cleavage of the polyprotein precursor (section 1.1.5).
The HCV NS2 protein shows little sequence similarity with its equivalent protein
found in Pestiviruses and Flaviviruses.
The NS3 region encodes a 70-72 kDa protein which functions both as a
serine protease involved in polyprotein processing, and as an RNA helicase
possessing NTPase activity (section 1.1.5). This is typical of several other
Flaviviruses. All cleavage sites contain a cysteine or threonine residue (Lau et al.,
1994).
The 4kDa NS4a protein is a cofactor for efficient cleavage by the NS3
serine protease (section 1.1.5). The function of the 27kDa hydrophobic NS4b
protein is unknown.
Both NS5a (56-58kDA) and NS5b (66kDa) are hydrophilic. NS5b is the
virus RdRp (section 1.1.5), and although the function of NS5a has not been
identified, a high level of sequence similarity with the equivalent gene in
pestiviruses suggests that this protein may be involved in virus replication. In
addition, recent evidence has demonstrated that NS5a associates with a cellular
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serine/threonine kinase in vivo, and is phosphorylated on serine, and less frequently,
threonine residues. This may indicate an important role for phosphorylated NS5a
in the regulation of HCV replication processes, or perhaps a role for the cellular
kinase during replication (Reed et al., 1997).
1.1.7 HCV ANTIGENS
A wide range of both linear and conformational (dependent on secondary
structure) epitopes have been identified within structural and non-structural regions
of HCV. Many antigens have been expressed in either prokaryotic or eukaryotic
systems as recombinant protein, or synthesised as short peptides and used in
immunoassays.
HCV screening assays generally employ enzyme indicators to detect binding
of antibody to a number of different virus antigens coupled to a solid phase
(ELISA). A general explanation of the various types of ELISA used in this work
is included in section 2.1.1. First generation assays consisted simply of the clOO
antigen coated onto microtitre plates, and were successful in the identification of
HCV infection in many blood donors, leading to a reduction in the incidence of
post-transfusion hepatitis (van der Poel et al., 1989; van der Poel et al., 1990). The
sensitivity of HCV screening assays was greatly increased (termed second
generation assays) by the addition of antigens corresponding to part of the core
protein (c22-3) and NS3 (c33c) (Takano et al., 1996; Baath et al., 1992; Aach et
al., 1991), to the existing clOO and 5-1-1 antigens. More recently, third generation
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screening assays have been developed which include a further antigen
corresponding to NS5 (Figure 1.1.4).
Other assays in the form of a recombinant immunoblot (RIBA) are also
available for the serological detection of HCV infection, and the elucidation of the
various antibody specificities that may be present in a sample. These consist of
HCV antigens which have been immobilised onto nitrocellulose strips, and are
generally more time consuming and expensive than the screening ELISA. As the
antigens included in these assays are equivalent to those used in corresponding
generations of screening ELISA, they are generally considered to be supplementary
tests rather than confirmation tests. There is no serological method currently
available for the confirmation of HCV infection.
NS4
The first HCV antigen to be used for the screening of blood donations was
derived from the original HCV clone 5-1-1 (Choo et al., 1989), and the subsequent
analysis of several overlapping clones. This antigen, designated cl00-3, was
expressed in yeast and spanned a section of the NS3 region, as well as the majority
of NS4a and NS4b (amino acids 1569-1931), and it or derivatives have been widely
used in serological assays. Epitope mapping with synthetic peptides has revealed
a number of linear epitopes in the NS4 region (Khudyakov et al., 1995; Simmonds
et al., 1993), including amino acids 1691-1708, 1720-1738 and 1921-1940 (Figure
1.1.7). Many of these epitopes (for example residues 1691-1708 and 1720-1738)
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differ sufficiently between genotypes of HCV to generate type-specific immune
responses. Although this has been successfully exploited in the production of
serotyping assays (section 1.5), this antigenic variation also means that the level of
reactivity to these antigens in commercial serological assays, all of which contain
antigen derived from HCV genotype 1, may vary with different genotypes
(Dhaliwal et al, 1996). The most recent assays (3rd generation) have replaced
cl00-3 fusion protein with synthetic peptides, and in doing so have reduced the
genotype dependence of these assays.
CORE
The core protein is relatively conserved between genotypes of HCV, and
often elicits a strong humoral response early during seroconversion (Sallberg et al.,
1992; Nasoff et al., 1991). Epitope mapping of amino acids 1-190 using synthetic
peptides, each 18 residues in length and overlapping the adjacent peptide by 8
residues, has revealed a number of linear epitopes in this region (Figure
1.1.7)(Sallberg et al., 1992). A high level of reactivity from HCV positive samples
was observed with peptides covering amino acid regions 1-38, 51-68 and 101-118.
The most immunodominant region was between residues 1-28, with reactive
antibody present in more than 90% infected individuals.
A recombinant protein (c22-3) covering a major section of the core region
and expressed in yeast, is incorporated into the majority of second generation
screening assays, resulting in an increase in sensitivity over the first generation
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ELISA using clOO-3 alone. Recently a 3rd generation supplementary immunoblot
(RIBA 3.0) has replaced the recombinant antigen with synthetic peptides to amino
acids 10-53 which has improved the specificity of the assay.
NS3
The NS3 protein is highly immunogenic, with an antibody response present in most
established infections (Gussow et al., 1990). Antibody to c33c is produced early
during seroconversion, and is often the first to be detected by serological assays
(Puoti et al., 1992; Lelie et al., 1992; Diepolder et al., 1995). This antigen (c33c)
was absent in most of the first generation assays but is included in all second and
third generation assays and supplementary immunoblots. Immunoblot analysis has
revealed four linear epitopes within the middle region of NS3 (Figure 1.1.7),
around amino acids 1250/1251 and within residues 1250-1334 and 1407-1412
(Hwang et al., 1996; Khudyakov et al., 1995). However, the majority of epitopes
in NS3 are conformational, having been recognised by monoclonal antibodies
between residues 1363-1454 (Mondelli et al., 1994), and by reactivity of HCV
positive sera towards recombinant proteins representing amino acids 1359-1449
(Claeys et al., 1995).
NS5
Epitope mapping with synthetic peptides has revealed a number of linear
epitopes in NS5a, including amino acids 2271-2313 and 2381-2452 (Figure 1.1.7).
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Relatively few epitopes have been described in NS5b, and those which have been
identified in amino acid regions 2467-2486 and 2894-2913 are marginally
immunoreactive (Khudyakov et al., 1995; Yuki et al., 1992).
Although an NS5 antigen was incorporated into the first generation assay
by Wellcozyme/Murex, other manufacturers did not include this region until
recently in 3rd generation tests. The NS5 recombinant protein was initially
expressed in yeast, and included almost the whole protein (amino acids 2054-2995),
but certain assays (Murex) have reduced the size of this antigen. The NS5 protein
has not improved the specificity of screening assays, since indeterminate results due
to reactivity to NS5 only have almost invariably proven negative by PCR (Dow et
al., 1996a).
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1.2 EPIDEMIOLOGY AND CLINICAL FEATURES
1.2.1 PREVALENCE OF HCV
The prevalence of HCV infection in the general population is highly
variable between different geographical areas, and is dependant upon many factors.
It is difficult to calculate the prevalence of HCV in a population, as study groups
may not reflect the general population as a whole. In most countries, the blood
donor population is used as a reference, although in countries which adopt a "self
exclusion" policy for donors likely to have been at risk of infection, this figure may
underestimate the true prevalence of infection. In the U.K., the prevalence of HCV
in the blood donor population is estimated at 0.015%, although the prevalence in
organ donors may reflect a more accurate number at 1.08%, as this is an
unscreened population (Wreghitt et al., 1994). The lowest prevalence is observed
in the "Western" world, in the United Kingdom, Scandinavia, Western Europe,
North America and Australia, with a higher prevalence of infection in southern and
eastern European countries. Screening of blood donors has estimated the HCV
prevalence in China, Japan and Thailand to be 1-2%, with Middle Eastern countries
such as Egypt and Central/Eastern Africa having the highest prevalence of HCV
in the world, with up to 20% blood donors anti-HCV positive (Botte et al., 1996).
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1.2.2 ROUTES OF TRANSMISSION
HCV is transmitted through contact with infected blood or blood products,
with perhaps the highest risk group being patients affected with genetic disorders
such as haemophiliacs who have been treated extensively with clotting factors. As
hundreds of donations contribute to each batch of clotting factor, the majority of
these patients became infected with HCV (and other agents) until heat-inactivation
procedures were widely introduced in 1985. Another blood product shown to
transmit HCV infection is intravenous immunoglobulin. For example, two major
outbreaks of HCV infection have recently been described, each from a single
source of anti-D immunoglobulin given to rhesus negative pregnant women in
1977/78 (Widell et al., 1997; Power et al., 1995; Power et al., 1994; Meisel et al.,
1995). Prior to the introduction of routine screening of blood donors in the early
1990's, one of the major recognised routes of transmission was blood transfusion.
Another major route of transmission since the 1960's (and in places where
donor screening is practiced, the most frequent) is intravenous drug abuse (IVDA).
The practice of sharing contaminated needles provides a rapid and efficient mode
of transmission for HCV, and it is estimated that up to 80% IVD users may be
infected (Westh et al., 1993; Bolumar et al., 1996). Poor sterile technique may also
be strongly implicated in a high number of infections worldwide. These techniques
include tattooing, piercing, acupuncture and particularly the use of unsterile needles
in medical practice in countries such as Japan, Italy, Sweden and certain areas of
the Third world.
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It is thought that there is a low risk of horizontal and vertical
(transplacental) transmission of HCV, although this may increase if an individual
is co-infected with HIV, or if the level of HCV viraemia is particularly high (Ohto
et al., 1994). A low rate of mother to child transmission has been reported (5-15%)
(Lam et al., 1993; Wejstal et al, 1992; Wejstal et al., 1990; Degos et al., 1991).
Studies have been unable to determine wether transmission occurs in utero / during
birth (vertical transmission) or by close contact within the family group (familial
transmission). However, a greater number of children were found to be infected
with HCV if both parents were HCV positive (10 of 23 studied), than children with
an HCV positive mother only (2 of 10 studied) (Nishiguchi et al., 1992), suggesting
that inter-familial spread may also play a role in HCV transmission and that intra¬
uterine transmission is rare.
1.2.3 DISEASE PROGRESSION
The period between exposure to HCV and the onset of acute hepatitis is
usually 7-8 weeks, after which virus RNA can usually be detected by PCR, and
liver function tests such as the level of alanine aminotransferase (ALT) in sera may
become abnormal. Seroconversion for antibody may not take place until months
later. Acute hepatitis C is asymptomatic in 95% cases. However, clinical features
may include fatigue, anorexia and the patients may become jaundiced. Although
patients have been described in which acute hepatitis C has been followed by the
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clearance of both virus RNA and eventually anti-HCV reactivity (Lelie et al.,
1992), a majority of patients develop chronic hepatitis.
The histological features of chronic hepatitis include the presence of
lymphoid aggregates in portal tracts of the liver, vacuolization and ballooning of
epithelial cells lining the bile ducts and peri-portal inflammation. The stages of
disease have been classified into three major groups; (i) Chronic persistent hepatitis
(CPH) or lobular hepatitis, which is observed in approximately 40% cases and is
histologically defined by a lymphocytic inflammation in widened portal tracts, (ii)
Chronic active hepatitis (CAH), also observed in approximately 40% cases and
recognised by histological damage to all hepatic areas including portal, periportal
and acinar areas, and (iii) CAH with liver cirrhosis in the remaining 20% cases,
(reviewed in Lau et al., 1995). The histological features of disease have also been
related to the mode of transmission of the virus. Infections caused by exposure to
high or repeated doses of virus such as blood transfusion or regular infusion of
infected factor concentrates is associated with a higher incidence of chronic
hepatitis and a more aggressive form of chronic liver disease than, for example,
HCV infection contracted through intravenous drug abuse (Gordon et al., 1993).
The effect of lower doses is shown by the fact that only 50% women infected from
a common source of anti-D showed evidence of persistent infection with HCV
(Meisel et al., 1995).
The progression of chronic hepatitis to cirrhosis and hepatocellular
carcinoma (HCC) is slow, unless the patient is immunosuppressed, for example due
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to co-infection with HIV, or immunosuppressive drug treatment following organ
transplantation. Healthy patients with chronic HCV infection but normal ALT levels
and limited histopathology have been reported, and may represent an asymptomatic
carrier state of the disease (Prieto et al., 1995). Chronic hepatitis C is generally
progressive, and about 20% of patients develop cirrhosis after 20 years of infection,
with liver failure a likely outcome. HCC typically develops only after 30 years of
infection, usually in patients with cirrhosis. The mechanism by which HCV causes
HCC is currently unknown, and was originally thought to result indirectly from
extensive damage of liver cells. Recent reports, however, implicate the RNA
helicase domain of NS3 which has been shown to possess DNA helicase activity
in vitro and may affect cellular processes (Sakamuro et al., 1995). In addition, NS3
is able to transform NIH3T3 cells in vitro (Sakamuro et al., 1995). The treatment
of patients with CAH with interferon-a is associated with a decrease or delay in
the incidence of HCC, despite having no effect on ALT levels (Nishiguchi et al.,
1995).
Disease progression is also thought to be influenced by other host and virus
related factors, such as age of acquisition (disease is more aggressive in patients
infected later in life), virus genotype (section 1.4), and the duration of infection.
1.2.4 TREATMENT OF HEPATITIS C
The only therapy to date which is effective in the treatment of HCV
infection is interferon-a (reviewed in (Hoofnagle et al., 1997). However, the
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success of this drug is limited. Only 50% patients show an initial response, and
50% of these relapse when the treatment is stopped. A long-term sustained
response therefore occurs in approximately 25% patients treated. Response to
interferon is indicated by normalisation of ALT levels, or more sensitively by the
disappearance of HCV RNA by PCR. In sustained responders, virus RNA generally
becomes undetectable 1-4 weeks after the onset of therapy and remains absent for
at least 6 months after treatment, whereas virus RNA promptly returns in patients
who relapse after treatment. Although the standard length of treatment was
originally 6 months, further studies with extended periods of therapy (12-18
months) have usually resulted in a higher rate of sustained response (Craxi et al.,
1996). Interferon-a has also been used to treat patients with acute hepatitis,
resulting in a significant reduction of patients progressing to chronic infection, and
can be associated with a complete recovery (Lampertico et al., 1994; Omata et al.,
1991).
Ribavirin, a nucleoside analogue with a broad spectrum of antiviral activity,
has also been used to treat patients with chronic HCV infection. Although this
drug is effective in decreasing viraemia and ALT levels, these effects are short
lived after treatment is stopped (Di Bisceglie et al., 1992).
Combination therapy with interferon-a and Ribavirin has given the most
promising results to date, with a sustained response in 40% patients who had not
responded or had only a short-term response to interferon-a alone (Brillanti et al.,
1994).
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1.2.5 IMMUNE RESPONSE TO HCV
Although HCV causes persistent infection in the vast majority of patients
evidence from immunocompromised patients suggests that the host immune system
can suppress HCV infection to some extent, since in these patients progression of
disease is more rapid than in the immunocompetent (Eyster et al., 1993).
Both humoral and cellular immune responses follow infection with HCV.
Antibody to non-structural proteins is thought to reflect active replication of the
virus, while antibody to structural epitopes may be present in both current and
cleared infections. IgM antibody production is not restricted to acute infection, and
may also correspond to the level of disease activity as levels of anti-core IgM have
been demonstrated to decline during treatment with interferon (Nagayama et al.,
1994).
The cellular immune response to HCV involves both CD4 (T helper cells)
and CD8 T cells (Cytotoxic T lymphocytes / CTL's). CD8 T cells specific for
epitopes from both structural (core and envelope) and non-structural (NS2, NS3,
NS4 and NS5) proteins have been demonstrated by many groups, although there
are conflicting ideas on how they relate to the course of infection (Battegay et al.,
1995; Ferrari et al., 1994; Koziel et al., 1993). A CD4 T cell response to core
epitopes has been established with asymptomatic disease (Botarelli et al., 1993),
although in other patients this response correlates with progression to chronic
infection, while those with self-limiting disease generally have CD4 T cells specific
for NS3 more readily (Diepolder et al., 1995). Five different CD4 T cell epitopes
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have been identified on the core protein, and in 3 larger domains within El, which
are thought to represent the specific peptides processed by antigen presenting cells
(e.g. macrophages) for the activation of CD4 T cell proliferation via major
histocompatibility (MHC) class II molecules on the cell surface (Lechmann et al.,
1996). Interestingly, this study reported that the response of CD4 T cells towards
presented virus peptides was inversely proportional to the level of B cell antibody
response to non conformational antigens, and that this was often observed in
patients who had cleared the virus. This was recently confirmed, in part, by Nelson
et al (Nelson et al., 1997) who have suggested that CD8 T cell activity also
corresponded with a low level of viraemia, however a higher level of disease
activity was noted in these patients.
The mechanism of persistence of HCV is poorly understood, although
consensus leads to the idea of immune escape via selective mutation within
epitopes in the envelope protein. Hypervariable regions present in the envelope
genes mutate readily, and in doing so change the antigenicity of the protein
allowing an escape from neutralising antibodies (Weiner et al., 1992). This
hypothesis is favoured by the observation that a higher rate of amino acid
substitution within HVR-1 exists in immunocompetent patients, than in the
immunocompromised host (Kato et al., 1993; Kumar et al., 1994). Another possible
mechanism for the persistence of HCV may be virus interference with antigen
presentation processes. A peptide, thought to have no stimulatory effect towards T
helper cells, has been discovered within the core protein, which is able to bind to
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MHC class II molecules, and in theory compete for this site with processed virus
epitopes.
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1.3 GENETIC HETEROGENEITY OF HCV
1.3.1 VARIATION OF DIFFERENT SUBGENOMIC REGIONS
The extent of nucleotide and amino acid sequence heterogeneity between
different variants of HCV first became apparent when isolates from Japan were
cloned and sequenced (Takamizawa et al., 1991; Kato et al., 1990) and showed
92% nucleotide sequence similarity with each other but only 79% similarity with
the genome of the prototype virus from the U.S.A. (Choo et al., 1991).
The level of heterogeneity between variants of HCV is not unlike that
observed in other single stranded positive RNA viruses, for example polioviruses
and coxsackie viruses, with as much as 34% divergence existing between complete
genomic sequences (discussed in section 1.3.2). The amount of sequence and amino
acid heterogeneity is not evenly distributed between different subgenomic regions,
but is maintained over the genome as a whole. The levels of divergence in non¬
structural genes is relatively constant, but is lower in the 5' NCR and core, and
greater in the envelope regions. Regions of sequence constraint generally exist
where important biological processes require a specific amino acid motif or the
presence of a specific secondary structure. Mutations in these regions are more
likely to generate a defective virus which is unable to replicate and therefore
survive.
The 5' NCR has a highly conserved secondary structure consisting of
internally base-paired stem loops thought to function as an IRES for the initiation
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of translation of the genome (Tsukiyama Kohara et al., 1992; Brown et al., 1992).
Although limited sequence variation does occur between genotypes of HCV, the
secondary structure remains relatively constant (Smith et al., 1995b). Nucleotide
substitutions, and in some variants single and double nucleotide insertions, occur
in non-base-paired regions, and therefore do not alter the secondary structure of the
RNA. In contrast, substitutions occurring within the base-paired stem of the loop
are often covariant, so that internal bonding of stem loop structures is preserved.
A similar constraint on both sequence and amino acid heterogeneity is
observed in the core region which is thought to code for the components of the
virus nucleocapsid. Recent evidence suggests that the 5' end of the core region
remains part of the IRES domain, and therefore important in translational processes
(Reynolds et al., 1996; Kamoshita et al., 1997). This is supported by the
observation of a highly conserved 5' end of the core protein, concluding a marked
reduction in the frequency of synonymous substitutions compared with the rest of
the genome (Smith et al., 1997). A number of other highly conserved sequence
motifs have been identified in core which are thought to be vital for the efficient
replication of the virus. These include a possible RNA binding site represented by
10 residues of arginine and lysine between amino acid positions 39 and 62, and two
nuclear localisation domains PRRGPR and PRGRRQP at positions 38-43 and 58-64
respectively (Bukh et al., 1994).
Much higher levels of sequence variation exist in the regions coding for the
envelope glycoproteins (El and E2) than in other parts of the genome, with up to
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50% divergence between other HCV variants. One hypothesis is that amino acid
substitution in these regions are promoted by "immune escape" of the virus, hence
providing a mechanism of persistence in the host. An especially high mutation rate
is observed at the amino terminus of E2 (amino acids 384-414) known as
hypervariable region 1 (HVR1), which may contain epitopes that can neutralise the
virus (section 1.2.5) (Weiner et al., 1992).
1.3.2 HCV CLASSIFICATION INTO GENOTYPES
Until recently, the classification of HCV variants into genotypes led to
confusion as research workers from various countries proposed a number of
different systems of nomenclature. Initially, the variants were classified in their
order of discovery, with the clones from the U.S.A. known as type I and those
from Japan as type II. However, as more divergent variants were discovered, and
their sequence similarity to existing viruses analysed more closely, this system has
been reviewed (Simmonds et al., 1994a; Simmonds et al., 1993a). Phylogenetic
analysis of either entire genomes or subgenomic sequences divides HCV variants
into 6 major groups (genotypes), many of which could be further divided into
subtypes. More than 31% divergence (i.e. less than 69% nucleotide sequence
similarity) was observed between complete genomic sequences of different
genotypes and 20-23% between subtypes. Variants with less than 9% sequence
divergence are classified as isolates of the same virus subtype. Phylogenetic
analysis of subgenomic regions, including core (Bukh et al., 1994), El (Bukh et al.,
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1993), NS4 (Bhattacherjee et al., 1995) and NS5 (Simmonds et al., 1993b),
provides the same groupings of HCV variants as analysis of entire genomic
sequences, leading to the conclusion that any of these regions of the genome could
be used for classification.
Although the majority of new isolates are easily classified within the
existing subtypes, recently discovered variants from South East Asia (Mizokami et
al., 1996; Mellor et al., 1995; Tokita et al., 1995; Tokita et al., 1994;
Apichartpiyakul et al., 1994) have proven ambiguous. These isolates were initially
classified as additional major genotypes and several subtypes, as sequence analysis
revealed a higher level of genetic heterogeneity from any of the six existing
genotypes than that defined by subtype boundaries (i.e. more than 23%). However,
phylogenetic analysis demonstrated that these variants were more closely related
to type 6a than to other genotypes, and could therefore be considered as divergent
subtypes of type 6 (Mellor et al., 1995a).
1.3.3 GEOGRAPHICAL DISTRIBUTION OF HCV GENOTYPES
The major genotypes, and certain subtypes of HCV show clear geographical
differences in distribution. Types la, lb, 2a, 2b and 3a cause infections over a
broad spectrum of geographical areas, predominating in North America and
Western Europe although they occur elsewhere at a lower frequency. Other
genotypes are confined to specific regions. For example type 5 is rarely found
outside of South Africa, and type 6a is generally found only in South East Asia.
32
Genotype 4 is mainly confined to Central and North Africa and the Middle East.
Type 3 is responsible for the majority of HCV cases in Pakistan, Bangladesh and
Eastern India, and also for a limited number of infections in a broad range of
geographical areas.
Specific differences in geographical distribution have also been found
between certain subtypes, for example, type la is most common in the United
States, whereas type lb is responsible for 73% HCV infections in Japan (Takada
et al., 1993), and type la infections in Japan are limited to haemophiliacs who have
used clotting factor concentrates exported from the U.S.A (Okamoto et al., 1992).
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1.4 BIOLOGICAL IMPLICATIONS OF HCV GENOTYPES
1.4.1 DISEASE PROGRESSION
The implications of infection with different genotypes of HCV on the
severity of disease and the rate of disease progression is currently an active but
confusing area of research. Numerous publications describe conflicting conclusions
regarding the effect of virus genotype on the level of viraemia during infection,
ALT abnormalities, the development of chronic disease and the severity of liver
damage.
Although it has been suggested that infection with genotype 1 is associated
with a higher level of viraemia, and a more rapid progression of liver disease in
patients with chronic HCV (Kobayashi et al., 1996; Booth et al., 1995), more
recent evidence derived from assays equally sensitive for RNA, describes similar
levels of HCV RNA in serum from patients infected with different virus genotypes
(Hawkins et al., 1997; Smith et al, 1996; Zeuzem et al., 1996; Lau et al., 1996).
Similarly, although ALT levels are elevated more frequently in individuals infected
with type 1 than with type 2 (Prati et al., 1996), no correlation between genotype
and liver function tests was discovered in studies of either chronic HCV patients
(Zeuzem et al., 1996) or patients having undergone liver transplant (Zhou et al.,
1996).
There is a greater propensity for the development of chronic disease with
type 1 infections compared to type 2 or 3 (Prati et al., 1996; Feray et al., 1995),
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and this is also observed for liver transplant patients, for whom the exact duration
of infection is known (Feray et al., 1995). In this latter study at least, the argument
that type 1 infections are often associated with a longer duration of infection
(Pawlotsky et al., 1995), and therefore a more advanced stage of disease, can be
ruled out. Despite the observation that type 1 infected blood donors are more likely
to progress to chronic disease than those infected with type 2 (Prati et al., 1996),
there was no correlation between genotype and the severity of liver damage in this,
or a number of other studies (Benvegnu et al., 1997; Zhou et al., 1996; Zeuzem et
al., 1996; Prati et al., 1996). On the other hand, there are a number of reports
suggesting that a connection between genotype 1 infection and the development of
cirrhosis / increased liver damage may exist (Nousbaum et al., 1995; Feray et al.,
1995; Booth et al., 1995; Kobayashi et al., 1996; Gordon et al., 1997).
Further research is clearly needed into this subject, taking account of factors
that may independently influence the progression of disease, such as age, duration
of infection, route of transmission and the level of viraemia. It remains possible
that certain genotypes are particularly pathogenic. This may result from amino acid
variation in proteins leading to a greater cytopathic effect on liver cells, and/or to
more efficient mechanisms of immune escape. The observation that two
hypervariable regions exist in HCV type lb as opposed to one in other variants is
consistent with either hypothesis (Kato et al., 1992; Hijikata et al., 1991).
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1.4.2 DEVELOPMENT OF HEPATOCELLULAR CARCINOMA
Another active area of research involves the association between virus
genotypes with the eventual development of HCC. The majority of relevant
publications to date describe an association between type lb infections and HCC,
although many of these studies fail to consider additional epidemiological or host-
related factors which may effect the conclusion of such studies, such as duration
of infection and/or the prevalence of certain HCV genotypes in different
geographical areas. Many research groups have analysed the genotype distribution
among patients with HCC, and found a high percentage to be infected with type
lb (Kao et al., 1995; Tanaka et al., 1996; Haydon et al., 1995). However, before
any conclusions can be made from such study groups, one should first consider the
relative prevalence of this genotype in the general population and other factors such
as the duration of infection, age of acquisition and mode of transmission. Similar
studies, which have attempted to control some of these parameters, have provided
conflicting results. Analysis of cirrhotic patients with and without HCC in Taiwan,
revealed a significantly higher percentage of type lb infection in the HCC cohort
(69%) compared to those without HCC (46%). Though the mean age of both
groups of patients in this study was similar, the duration of infection of each could
not be identified. Similar results were obtained from a study of Greek patients,
where type lb was identified as a risk factor associated with development of HCC
even after the differences in age had been accounted for (Hatzakis et al., 1996).
Another study in the U.S.A. revealed that from 40 patients undergoing liver
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transplantation, all of whom had end-stage liver disease, HCC had developed in
23% patients infected with type lb, compared with just 3% those infected with
other genotypes (mostly subtype la). Possibly the largest survey has been described
by a collaboration of groups in Japan (Yamada et al., 1995), in which a total of
4176 chronic HCV patients with various stages of liver disease were analysed.
Patients infected with type 1 and type 2 had similar age distribution and histories
of blood transfusion, and the percentage of type 1 infections in each disease
category (e.g. chronic hepatitis, patients with cirrhosis) was similar at 69-76%.
However, a 7% higher frequency of type 1 infections and a 7% lower frequency
of type 2 infections was observed in patients progressing to HCC.
Only a few publications argue that HCV genotypes do not differ in their
ability to cause HCC. Analysis of Japanese patients with and without cirrhosis, all
of whom were infected by blood transfusion and had a similar duration of
infection, revealed no significant difference in the number of type lb infections in
each group (Yotsuyanagi et al., 1995). Indeed, one study from Korea identified a
lower percentage of type lb infections in HCC patients (60%) than in blood donors
(80%) (Lee et al., 1996). The HCV genotype distribution in HCC patients from
Thailand corresponded to that in the general population (62.5% type 3), although
only 11 patients were analysed (Songsivilai et al., 1996).
Indisputable evidence regarding the relative abilities of different HCV
genotypes to cause HCC will only become available from longitudinal studies
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which control for the patients age at the time of infection, the route, dose and
frequency of exposure and the duration of infection. Confirmation of a type-specific
association with the likelihood of developing HCC may eventually be provided
through the identification of the mechanism for cell transformation by HCV.
1.4.3 RESPONSE TO ANTIVIRAL THERAPY
There are numerous clinical studies of the host and virus related factors
which may predict the response to interferon therapy. Characteristics associated
with a sustained response to treatment, are a lower age and duration of infection
(Hino et al., 1994; Yoshioka et al., 1992), the absence of cirrhosis prior to
treatment (Craxi et al., 1995; Tsubota et al., 1994), a low level of viraemia prior
to treatment (Le Guen et al., 1997; Pawlotsky et al., 1996; Martinot Peignoux et
al., 1995; Craxi et al., 1995; Tsubota et al., 1994; Hino et al., 1994) and infection
with a genotype other than type 1 (Zein et al., 1996; Kanai et al., 1995; Martinot
Peignoux et al., 1995; Craxi et al., 1995; Tsubota et al., 1994; Chemello et al.,
1994). The strongest evidence that infection with type lb is associated with a lower
rate of sustained response to interferon has come from several studies that control
for other factors such as patient age, the duration of infection and the level of
viraemia (Pawlotsky et al., 1996; Martinot Peignoux et al., 1995; Tsubota et al.,
1994). Multivariate analysis in such studies has revealed genotype to be a
statistically independent factor associated with a response to treatment, having a
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relative calculated risk of 16.23 compared to 5.43 for the presence of liver fibrosis
and 3.56 for a high level of viraemia prior to treatment (Tsubota et al., 1994).
Although the lower rate of response with type 1 is clear, the reasons why
this should be so remain unknown. Little is known about the mode of action of
interferon on clearing HCV infection, and the lack of an efficient cell culture
system for the virus creates a giant hurdle for research into this subject. Interferon
has been documented as having direct antiviral activity by the activation of target
cells to synthesise effector proteins such as 2' 5'-oligo-adenylate synthetase (OAS).
OAS polymerises ATP into 2' 5' oligoadenylates, thus activating a latent
endoribonuclease which can destroy virus RNA during replication. However,
interferon also has an immunomodulatory effect through enhanced expression of
class I MHC antigens. Which of these mechanisms is involved in the action of
interferon on HCV is not known, although reports of direct antiviral activity have
been described (Grander et al., 1996; Shimizu et al., 1994; Brillanti et al., 1991).
The lack of response to interferon of HCV type 1 infection is a relative,
rather than an absolute phenomenon, and it is possible that amino acid substitutions
in certain variants of type 1 create interferon resistant mutants. One group has
recently suggested that unique amino acid substitutions in the carboxyl terminus of
NS5a are connected with interferon resistance (Enomoto et al., 1996; Enomoto et
al., 1995), however, these observations have not yet been reproduced by other
research groups.
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1.4.4 ANTIGENIC VARIATION BETWEEN GENOTYPES
It is recognised that a high level of amino acid variation exists between
genotypes of HCV within certain immunodominant regions of the genome. The
presence of type-specific antigens has important implications for both the efficient
screening of blood prior to transfusion and the development of an effective vaccine.
The lack of a cell culture system means that neutralisation studies for HCV cannot
be carried out, although experiments with other viruses showing similar levels of
genetic heterogeneity (e.g. serotypes of dengue virus) have revealed that the
immune response generated against one virus type is unable to protect against
infection with other serotypes.
Evidence suggesting that certain epitopes in HCV are type specific has been
obtained from the analysis of reactivity towards recombinant protein or peptide
antigens used in commercial screening enzyme immunoassays, all of which are
derived from HCV type 1. It was discovered that only 32% sera from type 2 or 3
infections showed reactivity to the cl00-3 (NS4) antigen in first generation assays,
compared to 90% of type 1 sera (McOmish et al., 1993). Similarly, reactivity of
sera from non-type 1 infections with second generation assays was often limited
to c22 (core) and c33c (NS3) antigens and absent from 5-1-1 and clOO-3 (Zein et
al., 1995; McOmish et al., 1994). Third generation screening assays use type 1
antigens derived from the core, NS3, NS4 and NS5 regions. A recent evaluation
of reactivity levels in individuals infected by different genotypes, which also takes
into account the level of viraemia and other host related factors, has revealed that
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sera from blood donors with type 1 infections showed levels of reactivity more than
four times greater than samples from individuals infected with type 2 or 3
(Dhaliwal et al., 1996).
The presence of type-specific antigens in certain regions of the genome has
led to the development of a number of different serotyping assays (section 1.5), and
suggests that any future vaccine would have to be multivalent in order to protect
against all known genotypes of HCV.
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1.5 HCV TYPING ASSAYS
1.5.1 THE ROLE OF GENOTYPING
Different genotypes of HCV can be identified by the analysis of the
sequence heterogeneity within subgenomic regions. The most reliable method
involves the sequencing and phylogenetic analysis of amplified PCR products for
coding regions of the genome. More rapid methods have also been described which
allow the classification of HCV variants into genotypes and / or subtypes by the
analysis of PCR products or through the detection of type-specific antibody
(serotyping). These techniques play a central role in many aspects of HCV
research, including epidemiological studies based on geographical differences in
distribution and the efficiency of detection of different genotypes. HCV genotyping
is also becoming increasingly important in clinical practice, with implications for
disease progression and the prediction of response to antiviral therapy.
1.5.2 GENOTYPING METHODS
A number of different genotyping methods have been described which are
able to type HCV variants because of type-specific sequences present in various
subgenomic regions. The advantages and disadvantages of each method are
summarised in table 1.5.2.
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Amplification of PCR fragments using type-specific primers.
One of the first genotyping assays involved the amplification of core
sequences with type-specific primers, designed so as to produce fragments of
different length for genotypes la (I), lb (II), 2a (III) and 2b (IV) (Okamoto et al.,
1992). This method involves two rounds of nested PCR, with universal primers in
the first round, with the second round PCR using a universal sense primer and a
mixture of four subtype-specific antisense primers directed to variable regions
within core. The PCR products of different sizes were separated by gel
electrophoresis. This assay was later modified to include primers specific for type
3 (Okamoto et al., 1993), although problems associated with non-specific priming
were encountered. The risk of non-specific amplification of products is greatly
increased if sequence mismatches are present in the 3' end of the primers, and
subsequent analysis of type 3 sequences revealed that 3 of the 5 terminal bases in
this additional type 3 primer were also present in type la / lb sequences. Further
modification of primers and conditions (Widell et al., 1994) has improved the assay
to a certain extent, with fewer infections of mixed genotypes being obtained than
with the original assay, which was often due to the non-specific amplification of
genotypes.
A further modification of this assay has recently been described which uses
type-specific primers in the core region for the identification of types la, lb, 2a,
2b, 3a, 3b, 4, 5 and 6a (Ohno et al., 1997). Although this assay claims to be more
accurate than its predecessors, a limited number of types 4-6 were analysed, and
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only 23 of 68 samples producing discrepant results between this assay and that
described by Okamoto et al (Okamoto et al., 1992) could be confirmed by
sequencing.
Reverse-hybridisation to type-specific probes.
HCV genotypes can also be distinguished by a line-probe assay (LiPA),
which involves the amplification of 5' NCR sequences with universal biotinylated
primers, and the subsequent hybridisation of these PCR products to type-specific
probes immobilised as parallel lines on a membrane strip. The first generation
assay (Stuyver et al., 1993) used probes directed to variable regions of the 5' NCR
for types la, lb, 2a, 2b, 3 and 4. The specificity of this assay was relatively high,
with even single mismatches sufficient to prevent cross-hybridisation between
types, and reactivity to multiple probes was only observed with genuine dual
infections. Despite this, sequence similarity between certain subtypes led to
misinterpretation in some cases (generally type 1 subtypes, and cross-hybridisation
between types 1 and 4).
A second generation assay (Stuyver et al., 1996b) has a total of 21 probes
from 7 variable regions of the 5' NCR for the identification of types la, lb, 2a/c,
2b, 3a, 5 and 6a. This version of the assay was highly specific for the majority of
samples, although new problems were encountered as unusual HCV variants were
discovered in South East Asia (now classified as additional subtypes of type 6)
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which contained 5' NCR sequences identical to those of type lb (Mellor et al.,
1995; Tokita et al., 1995; Tokita et al, 1994).
The misidentification of subtypes la and lb in the first generation assay
gave rise to the addition of probes directed to parts of the core region for both
types 1 and 2 (Stuyver et al., 1995), although this version of the assay was never
commercially available. This increased the specificity of the assay for these
subtypes, this assay remains unable to identify the novel type 6 subtypes.
Restriction fragment length polymorphism (RFLP).
Genotyping by this method involves the PCR amplification of sequences
from the 5' NCR with universal primers, and the subsequent digestion of these
products with specific restriction enzymes to reveal patterns of fragments with
different sizes corresponding to each genotype. The assay was initially designed to
distinguish between genotypes 1-3, then 1-6 (McOmish et al., 1994), and was later
extended to be able to discriminate between subtypes la/lb, 2a/2b and 3a/3b by
means of an additional enzyme digestion step (Davidson et al., 1995). Other
variations of this method have been described (Murphy et al., 1994), with the use
of a number of different enzymes, and all have proven highly accurate. However,
single base mutations within the 5' NCR may give rise to misleading results, and
sequence identity in this region between type 6 subtypes and type 1 may have led
to the misidentification of these variants in previous studies. This problem has been
recently been addressed by Mellor et al. (Mellor et al., 1996) who have developed
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an RFLP assay for the core region which is able to distinguish between subtypes
la, lb and type 6 variants from S.E. Asia. While the use of this assay alone is not
feasible due to the narrow range of subtypes identified, when used in combination
with the 5' NCR RFLP it provides an accurate method for the identification of
novel subtypes present in certain populations.
Other methods of genotyping.
Various other typing methods have been described, but which have been
limited in the number of genotypes identified or in their sensitivity or specificity.
A DNA enzyme immunoassay involving the hybridisation of amplified cDNA from
the core region to type-specific probes attached to a solid phase (Viazov et al.,
1994) has been designed for the identification of types 1-3, and similarly a slot-blot
hybridisation technique (Enomoto et al., 1990b) using amplified NS5 sequences can
distinguish between types 1 and 2, albeit with limited sensitivity.
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1.5.3 SEROTYPING METHODS
The level of amino acid variation between genotypes of HCV is sufficient
to cause certain epitopes to elicit a type-specific immune response, and as a result,
a number of assays have been devised which are able to distinguish between
different antibody serotypes. The majority of these are in the form of an ELISA,
and involve the binding of HCV antibody present in serum to a type-specific
antigen coated onto a solid phase (in the form of synthetic peptides or recombinant
protein), followed by a second step in which bound HCV antibody is detected by
the addition of secondary antibody (an anti-human antibody-enzyme conjugate).
The principles and components of this assay are described in further detail in
chapter 2.
Serotyping assays for types 1 and 2 have been developed using antigens
from both the core and NS4 regions (Tanaka et al., 1994; Machida et al., 1992).
An ELISA using synthetic peptides from the core region as antigen reported a
highly specificity ("specificity" representing how accurately the assay has identified
different HCV serotypes, see appendix 1.0) but a lower sensitivity ("sensitivity"
representing the proportion of samples tested for which a serotype could be
identified; see appendix 1.0) being able to detect antibody in only 68% of type 1
infections and 56% of type 2 infections. On the other hand, an assay based on
recombinant proteins from NS4 (amino acid positions 1676-1760) was 98%
sensitive when testing sera from patients with chronic hepatitis C in Japan (Tanaka
et al., 1994).
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Recently, a serotyping method for the detection of patient antibody response
to HCV types 1-3 has been developed in the form of an immunoblotting proceedure
using a solid phase that incorporates peptides from both the NS4 and core regions
(known as a RIBA strip). HCV serotype is inferred from the relative intensity of
antibody reactivity towards the type-specific NS4 peptides. Reactivity to core
peptides is used to analyse patients sera that are unreactive to NS4 (Dixit et al.,
1995).
All the above assays involve the direct binding of type-specific antibody to
antigens on the solid phase, which involves a potential risk of non-specific binding
by heterologous-type antibody (or any other non-specific binding of antibody). A
different approach is to use type-specific NS4 peptides in a competitive ELISA (see
chapter 2) for the detection of types 1-3 (Simmonds et al., 1993d). In this assay,
antigens specific to all genotypes are coated onto the solid phase, and antibody
serotypes detected by the co-incubation of a competing solution of type-
heterologous peptides with the patient's serum. Homologous type antibody is not
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CHAPTER 2
2.1 GENERAL INTRODUCTION TO ENZYME LINKED
IMMUNOSORBENT ASSAYS (ELISA'S)
2.1.1 IMMUNOASSAYS
An immunoassay is an assay that uses antigens for the determination of
specific antibodies. A number of different types of immunoassay have been
developed, which use various methods for the detection of antibody. The most
common methods include radioimmunoassays (RIE), which use radioisotopes as a
label and determine the presence of antibody by scintillation counting, and
flouroimmunoassays (FIE), which are flourimetric assays that use a flourescent
compound as a label. Perhaps the most common type of immunoassay is the
enzyme immunoassay (EIA). These assays are mostly colourimetric, and reveal the
presence of specific antibody through an enzyme label, which upon addition of the
appropriate substrate compound will display a colour which can be recognised by
eye and measured accurately by spectrophometry.
The term ELISA is used for all kinds of EIA, and does not indicate a
particular assay mechanism.
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2.1.2 PRINCIPLES OF ELISA
Direct / Indirect ELISA's
The difference between direct and indirect assays lies in the component
under detection. An indirect ELISA is used to screen for specific antibodies via
capture by antigen that is coated onto the solid phase. A direct ELISA is used for
the detection of soluble antigens in serum. Microtitre plates are coated with antigen,
and enzyme labelled antibody (specific to the antigen on the plate) is prevented
from binding if free antigen is present in the sample.
The basic principles of an indirect ELISA (used throughout this work) are
shown in figure 2.1.2. Antigen (specific to the antibody under detection) is
synthesised and coated onto the solid phase. In this work the antigen used consists
either of branched peptides or recombinant protein. Incubation of a sample
containing specific antibody for this antigen will result in the binding of the
antibody to the antigen on the solid phase. After a washing step, bound antibody
is detected via a secondary antibody (conjugate) which is selected to recognise the
type of antibody under detection (IgG, IgM etc) and has been labelled with an
enzyme. Examples of enzymes commonly used are horseradish peroxidase (HRP)
and alkaline phosphatase. The enzyme label produces a colourimetric reaction upon
incubation with a particular substrate compound. The two most sensitive substrates
used with HRP are o-phenylenediamine (OPD) and tetramethylbenzidine
hydrochloride (TMB), with both compounds being able to detect low levels of
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Figure 2.1.2 Basic principles of an indirect ELISA.
HRP - Horseradish peroxidase enzyme
OPD - o-phenylenediamine substrate
enzyme. The reactivity of OPD with HRP requires the presence of a catalyst which
provides oxygen ions such as hydrogen peroxide.
Competitive assays
Many types of competitive ELISA have been developed, including those
which compete for antigen and those which compete for antibody. The competitive
nature of the serotyping assay used throughout this work involves the coincubation
of type-specific antigen with NS4 antibody in the sample. If antigen in the
competing solution is specific to the same genotype as the antibody present in the
sample, it will effectively block this antibody and prevent binding to antigen on the
solid phase. However, if only competing antigens specific to heterologous
genotypes are present in solution, the antibody present in the sample will remain
free and able to bind to the solid phase antigen. The serotyping assay incorporates
various different combinations of competing antigens specific to different genotypes
in order to differentiate between the different types of antibody.
2.2 ELISA's FOR HCV ANALYSIS
2.2.1 HCV IgG ANTIBODY DETECTION
Serum samples were tested for the presence of anti-HCV IgG antibody with
the Murex anti-HCV enzyme immunoassay kit (VK47/48) according to the
manufacturers protocol. Briefly, 20/il serum was diluted 1:10 in sample diluent and
incubated for 1 hour at 37° C in microtitre wells coated with antigens derived from
the core, NS3, NS4 and NS5 regions of HCV. The plate was washed 5 times with
glycine/borate solution prior to the addition of 100//1 horseradish peroxidase-
labelled mouse anti-human IgG conjugate. After 30 minutes at 37° C, the wash
procedure is repeated, and 100/zl TMB substrate solution was added and the plates
were incubated for 30 minutes at 37° C. Reactions were stopped by the addition of
50/il 2M sulphuric acid and the absorbance of each well at 450nm was read within
15 minutes.
2.2.2 HCV SEROTYPING ASSAY FOR TYPES 1-3
Optimisation experiments for the serotyping assay (e.g. concentrations of antigens
coating plates and in competing solutions) were carried out during the development
of this ELISA (prior to this work) by Mr Ken Rose (Simmonds et al., 1993d).
Preparation of Immunoplates
NS4 peptides were dissolved in AnalaR water (BDH) at a concentration of
lmg/ml. Insoluble peptides were first dissolved in 25(A of 30% acetic acid, and
then made up to a concentration of lmg/ml with distilled water (type 3 peptides),
or suspended in distilled water by vortexing and bubbling through approximately
0.5ml ammonia vapour.
Stock peptide solutions were stored at 4°C for up to two weeks, but not
frozen to avoid precipitation of the peptide. 96 well flat-bottomed microtitre plates
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(NUNC Maxisorp, GIBCO/BRL) were coated with 100//1 per well of phosphate
buffered saline (PBS, SIGMA) containing eight NS4 peptides corresponding to two
antigenic regions for HCV types 1, 2 and 3, each at a concentration of 50ng/ml
(5ng / well) and incubated at 4° C overnight. Columns 1 and 7 were not coated and
served as controls for non-specific binding to the solid phase.
Plates were washed 5 times with PBST (PBS containing 0.05% Tween 20
(BDH)) and air dried. Plates could be stored at 4°C for several months without a
loss in reactivity.
Competing peptide solutions.
The serotyping assay relies on the complete blocking of antibody binding
to epitopes that are shared between more than one genotype, therefore solutions
containing different NS4 peptide combinations at the empirically derived
concentration of 100 fold excess that used for coating the plates were added to the
wells prior to the addition of serum.. Competing solutions containing only
heterologous peptides (i.e. those different from that which the typing well is to
detect) were added to each of the three typing wells, as well as an additional well
with competing peptides for all genotypes present ("fully blocked" negative control)
(Figure 2.2.3). Competing solutions contained peptides at a concentration of
500ng/well, i.e. 100 times the coating concentration.
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Assay Procedure
Immediately prior to use, plates were coated with 125/il PBS containing 2%
bovine serum albumin (BSA, SIGMA) for 1 hour at room temperature, in order to
prevent the non-specific binding of antibody to any remaining protein binding sites
in the plastic wells, after which the plates were washed in PBS.
Each test serum was diluted 1/40 with PBST containing 2% BSA (a
concentration which gave high absorbence readings in combination with low levels
of background reactivity when the assay was initially developed), and 100/d
volumes added to each of the six test wells (uncoated negative control, unblocked
positive control, fully blocked negative control and typing wells 1, 2 and 3). Plates
were sealed and incubated at 37° C for 1 hour. After washing 5 times with PBST,
100^1 of anti-human IgG HRP conjugate (SIGMA) diluted 1:20000 in 2% BSA in
PBST, was added to each well. After incubation at 37° C for 1 hour, the washing
step was repeated prior to the addition of 100/d per well of o-phenylenediamine
(OPD) substrate (Appendix 2.2) and incubation of the plates for 30 minutes at
room temperature in the dark. The colourimetric reaction was stopped with 50//1
8M sulphuric acid, and the plates read against an uncoated well negative control
at a wavelength of 450nm. Samples showing relatively weak reactivity (i.e. those
containing only low concentrations of HCV antibody) could be retested using
higher or lower dilutions of serum in order to give a clear result.
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Calculation of results
The serotype of HCV antibody in a sample can, in most cases, be identified
by eye, as the assay involves a colourmetric reaction (section 2.1). However,
conclusive identification of HCV antibody serotype transpires only if the
absorbance values meet the following criteria (formulated by Murex Biotech Ltd
for the commercialisation of this assay);
(1) The absorbance value in the "unblocked control" well minus the absorbance
value in the "fully blocked" control well is greater than or equal to 0.1.
(2) The highest absorbance value (from the typing wells) divided by the absorbance
value in the "unblocked control" well is greater than or equal to 0.4.
In general, the "unblocked control" should give the highest absorbance value as this
represents the reactivity of all HCV antibody in the sample which is able to react
with the combination of type-specific antigens on the solid phase. The "fully
blocked" control contains competing peptides specific to all HCV genotypes being
tested, resulting in the binding of only non-specific NS4 antibody to the solid phase
and therefore a low absorbance value. Criterion (1) represents the cutoff value for
reactivity, by calculation of the level of reactivity of type specific antibody.
Criterion (2) represents the cutoff value for which antibody reactivity in the typing
wells can be considered indicative of the presence of HCV type specific antibody.
Although failure of both criteria means that the sample is untypeable, if criterion
(2) only is not met and has only just failed (e.g. typing well / unblocked control
= 0.37), the sample may contain very low levels of type-specific antibody and
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should therefore be retested at a higher concentration. Similarly, if a high level of
background reactivity is present, then criterion (2) may be met by more than one
(or all) of the typing wells. In this case the absorbance value in the fully blocked
control should be subtracted from the absorbance values and both criteria
recalculated. If more than one typing well meets criterion (2) with a low level of
background reactivity, the sample is considered to contain HCV antibody to more
than one serotype, representing a multiple infection.
2.2.3 HCV SEROTYPING ASSAY FOR TYPES 1-6
Methods were identical to those for the 1-3 assay with the following
exceptions.
Preparation of Immunoplates
The uncoated negative control well was omitted (BSA had been shown to
be an effective blocking agent against non specific binding of antibody) to fit the
maximum number of test samples on one plate, and so all 96 wells were coated
with antigen, and one column of 8 wells used per sample (unblocked positive
control, fully blocked negative control and typing wells 1 through 6). All the
peptides for genotypes 4, 5 and 6 were soluble in ammonia vapour.
Competing solutions consisting of heterologous peptides only were added
to each typing well as shown in figure 2.2.3. The "fully blocking" compering
solution contained 100/il of each of 21 peptides.
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Figure 2.2.3 COMBINATIONS OF NS4 PEPTIDES USED IN
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Figure 2.2.4 MICROTITRE PLATE SHOWING POSITIVE REACTIVITY
FOR HCV TYPES 1-6 USING THE 1-6 SEROTYPING ASSAY
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A positive reaction is indicated by a blue colour in the well of the microtitre plate.
UB Unblocked positive control well
FB Fully blocked negative control well
HCV serotyping assay for genotypes 1-6 (Murex Biotech)
After the development of the 1-6 serotyping assay, a commercial kit was
produced by Murex Biotech. The procedure for this assay was identical for the "in
house" assay except that samples were diluted 1/40 in a total volume of 200/il
sample diluent per well, and the substrate, TMB, was mixed with an equal volume
of tri-sodium citrate / hydrogen peroxide solution. A colour change from pink to
blue is observed during a positive reaction.
2.3 THE POLYMERASE CHAIN REACTION (PCR)
2.3.1 EXTRACTION OF VIRUS RNA
In order to avoid degradation of RNA by nucleases, all solutions used in the
purification of virus RNA were made up with distilled water treated with
diethylpyrocarbonate (DEPC) at 0.05% for a minimum of 2 hours before being
autoclaved, and gloves were worn at all times
Stock solutions of TNE buffer + 0.5% SDS + 10% (0.11M NaCl; 55mM
Tris pH 8.0; l.lmM EDTA pH 8.0; 0.55% SDS), proteinase K (Boehringer)
(lOmg/ml) and RNA buffer / carrier poly-adenylic acid (poly A; Pharmacia)
(2mg/ml) were prepared. Extraction buffer was made by adding 9 volumes TNE
buffer, to 1 volume of proteinase K and 20/il poly A, thereby giving a working
solution of 0.1 M NaCl; 50mM Tris pH 8.0; ImM EDTA pH 8.0; 0.5% SDS, with
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lmg/ml proteinase K and 40/ig/ml poly A. This solution was incubated at 37° C for
10 minutes to allow the degradation of nucleases present in the solution.
Next, 100//l serum was added to 400/d extraction buffer in a 1.5ml
eppendorf tube, mixed thoroughly on a vortex mixer and then incubated in a 37° C
water bath for 1.5-2 hours. RNA was extracted by the addition of 450/il water-
saturated phenol (Rathburn Chemicals) to each tube, which were then placed on a
shaker at 300 revs / second for 5 minutes. The aqueous phase was separated by
centrifugation at 15,000 rpm for 5 minutes, leaving unwanted cellular proteins in
the bottom layer (phenol).The top aqueous layer containing nucleic acids was added
to a new eppendorf containing 450/il chloroform / isoamyl alcohol (50:1). After
mixing / centrifuging as before, the aqueous layer was transferred to a new
eppendorf tube containing 40/A 3M sodium acetate pH 5.2, and an equal volume
of 100% ethanol added prior to incubating at -20° C overnight to precipitate the
nucleic acids.
Nucleic acids were pelleted by centrifugation at 15,000 rpm for 10 minutes
at 0°C, washed by adding 600(A 80% ethanol (kept at 0°C). and recentrifuged. The
nucleic acid pellet was dried on a hot block at 42° C for 10 - 15 minutes prior to
re-dissolving in 25 /A DEPC treated water.
2.3.2 REVERSE TRANSCRIPTION OF VIRUS RNA
In order to copy virus RNA into complementary DNA (cDNA), 5/A nucleic
acid dissolved in DEPC water was added to buffer containing 50mM Tris-HCl pH
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8.0; 5mM MgCl2; 5mM DTT; 50mM KC1; 0.05/ig/ml BSA, and 600[M of each
of dGTP, dATP, dTTP and dCTP, with 20% DMSO, 1.5//M primer (outer
antisense; Table 2.3), 10 units reverse transcriptase (RT, Promega) and 5 units
RNAsin (RNase inhibitor - Promega), in a final volume of 20/il made up with
DEPC water. The mixture was then incubated at 42° C on a hot block for 30
minutes.
In the majority of this work, the primer used for reverse transcription was
the outer antisense PCR primer, but where only small sample volumes were
available, less efficient random priming by hexameric oligonucleotides was chosen.
2.3.3 PCR AMPLIFICATION OF DNA
Two rounds of nested PCR were performed for each sample; a primary PCR
reaction using "outer" nested primers which were positioned outside the desired
region, and a secondary reaction using "inner" nested primers flanking the sequence
of DNA to be amplified. The nucleotide sequences of primers used in this work is
shown in Table 2.3.
For primary PCR, 5/il cDNA was made up to a final volume of 50/il with
lx PCR buffer with 1.5mM MgCl2 (10X stock, Promega), containing 33/iM each
of dGTP, dATP, dTTP and dCTP, 0.5//M of each of the outer primers and 20
units/ ml Taq DNA polymerase. A layer of liquid paraffin was added to prevent
evaporation, and the tube placed on a thermal cycler for 25 - 30 heat cycles
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Table 2.3 HCV Primers
Primer Orientation Genotypes Primer Sequence (5'—>3') Reference
5'NCR
209 I/AS 1-6 ATACTCGAGGTGCACGGTCTACGAGACCT *
939 I/S 1-6 CTGTGAGGAACTACTGTCTT *
211 O/AS 1-6 CACTCTCGAGCACCCTATCAGGCAGT *
940 O/S 1-6 TTCACGCAGAAAGCGTCTAG *
Core
410 I/AS 1-6 ATGTACCCCATGAGGTCGGC t
954 I/S 1-6 ACTGCCTGATAGGGTGCTTGCGAG t
951 O/AS 1-6 CAGGTRAGGGTATCGATGAC t
953 O/S 1-6 AGGTCTCGTAGACCGTGCATCATG t
NS3
753 O/AS 1-6 GCGTCATAGCACTCACAGAGGAC 1
751 O/S 1-6 TTYCGGGCNGCYGTGTGCACC t
593 I/AS 1-6 CACAAGCTTARCAGTCKATSACNGARTC t
594 I/S 1-6 ACCRCTGCAGAYCCYAACATNGAGGARGT t
593-T6 I/AS 6 CACAAGCTTAACAGTCGATGACAGAATC This woik
594-T6 I/S 6 ACCRCTGCAGATCCTAACATAACAGAGAC It
LP8 I/S 1+2 GCGGATCCCTACMSNAACATMGAGGAGGT "
LP9 I/S 3 GCGGATCCCTATYCTAACATCGAAGAAGT It
LP10 I/AS 1-3 CCACTCGAGRCAGTCKATSACNGAGTC II
NS4
007 O/AS 1-3 AACTCGAGTATCCCACTGATGAAGTTCCACAT H
220 I/AS 1-3 CACATGTGCTTCGCCCAGAA f
53510 O/S 1-4 1111GGATCCATGCATGTCAGCTGATCTGG 11
5668 O/S 1 ATGCATGTCRGCTGAYCTGGA Thiswoik
865 O/S 6 CTGGAGGTTATCACNAGCACNTGG II
866 I/S 6 RTCCTCGTGGGTGGAGTCCTN GC II
867 AS 6 TTCCACATRTGYTTNKSCCAGAA II
LP2 O/AS 1 GTACTGTATCCCGCTGATGAARTTCCACA II
LP3 I/AS 1 TTCCACATGTGYTTCGCCCAGA II
LP4 O/AS 3 GTATTGGATCCCACTCACAAAATTCCACA II
LP5 I/AS 3 TTCCACATATGCTTGTGCCAGA It
LP6 I/S 1 CTGGAGGTCGTCACTAGCACCTGG II
LP7 I/S 3 CTGGAAGTAACCACCAGCACCTGG II
LP11 I/S 1 GCTCTCGAGCCYGACAGGGARGTYCTCTAC II
LP12 I/S 2 GCTCTCGAGCCSGACAAGGARRTCYTNTAT II
LP13 I/S 3 GCTCTCGAGCCAGACAAAGAGGTGTTGTAT II
LP14 I/AS 1 CAAAGCTTAGAAYTGCTCGGCGAGCWKCATYCC II
LP15 I/AS 2 CAAAGCTTANAGCATCTCSGCNATCCGCTGCCC If
LP 16 I/AS 3 CAAAGCTTAGAACTGGTGGGCTATTACCTGAGC II
pRSET
d632 S CATGGTATGGCTAGCATGAC §
d662 AS TATTGCTCAGCGGTGGCA §
pTAG
8819 S GCTATGACCATGATTACGCCAA §
9130 AS ACACGTGTGGTCTAGAGC §
* Chan et al., 1992. t Mellor et al., 1995.
£ Dr. V. Bhattacherjee; Personal Communication 11 Simmonds et al., 1993.
§ d632 / d662 were obtained from Murex Biotech Ltd, Dartford, U.K.
8819 / 9130 were designed by Dr. C Blake, University of Edinburgh.
Restriction sites are underlined
For secondary PCR, a 1/il aliquot from the primary PCR reaction was
transferred to a tube containing 19/il PCR buffer containing inner nested primers
and cycled as before.
2.3.4 ANALYSIS OF PCR PRODUCTS BY GEL ELECTROPHORESIS.
20 fA amplified PCR product was loaded onto a gel containing 2% agarose
in lx TBE (89 mM Tris borate; 89 mM boric acid; 2 mM EDTA) and ethidium
bromide at 0.05/ig/ml. Electrophoresis was carried out in lx TBE buffer for 15 min
at 150 Volts, and amplified DNA visualised on a u.v. transilluminator.
2.4 RESTRICTION FRAGMENT LENGTH POLYMORPHISM
ANALYSIS (RFLP)
Due to the high levels of sequence variation displayed by HCV, it is
possible to distinguish between different genotypes and some subtypes, by the
digestion of 5' NCR and core regions with specific restriction endonucleases
(Mellor et al., 1996; Davidson et al., 1995; McOmish et al., 1994).
Amplified 5'NCR was cleaved with 4 different restriction endonucleases
(appendix 2.3), in two separate reactions; (i) Rsa I / Hae III and (ii) Mva I / Hinf
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I (all Promega). Each double digest was incubated at 37°C overnight and contained
10 units (1/il) of each enzyme, 3 fA of the appropriate manufacturers lOx buffer
and 25/A amplified PCR product. DNA fragments were then separated by
electrophoresis through a 4% METAPHOR agarose (Flowgen) gel containing
0.05/ig/ml ethidium bromide for 1 hour at 150 V. The combination of patterns from
the two double digests was used to indicate the genotype of HCV present in the
test sample (Smith et al., 1995b; McOmish et al., 1994b).
Subtypes of type 6 from South East Asia which produced RFLP patterns
corresponding to type 1 with the above enzymes (Mellor et al., 1996) were
identified by an additional restriction digest using the enzymes Dde I / Hpa II.
DNA sequences of type 1 and novel variants of type 6 could be further
distinguished by RFLP of the core region (Mellor et al., 1996). Amplified core
sequences were digested separately with the restriction endonucleases Ava I and
Sma I. Type 6 subtypes were identified by the patterns al2s5, alOsl or al3s5
(Mellor et al., 1996). Reactions were carried out at 37°C overnight using 10 units
restriction enzyme with 3/zl manufacturers lOx buffer with 26(A amplified PCR
product.
Subtypes a and b of genotypes 1, 2 and 3 were distinguished by RFLP of
the 5' NCR using either ZtotUl (type 1) or Scrfl (types 2 and 3).
For type 1 samples, 25/A PCR product was digested with 5 units ZlsrUl,
0.3/il 1M MgCl2, 0.375/il 4M NaCl, 0.3/d 0.1M DTT and 3.5/i distilled water at
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60°C for a minimum of 4 hours. DNA fragments were separated by electrophoresis
and subtypes identified according to the pattern of fragments produced (Davidson
et al., 1995). Subtypes 2a/b and 3a/b were identified by the digestion of 25 /A PCR
product with 5 units Scrfl in 3/il manufacturers lOx buffer and lfA distilled water,
at 37°C for a minimum of 4 hours.
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2.5 DNA SEQUENCING
2.5.1 DIRECT SEQUENCING OF AMPLIFIED DNA PRODUCTS
Single stranded template DNA was prepared for sequencing using
streptavidin coated magnetic beads (DYNABEADS; DYNAL Ltd.). Positive
samples were re-amplified from the 1° PCR product in which one primer was
biotinylated, in a final volume of 100/il. Beads (20/il per sample), were washed
with 40/u\ 0.1% BSA pH 7.2, and then with 40/il BW (lOmM tris HC1 pH 7.5;
ImM EDTA; 2.0M NaCl). The beads were resuspended in 40/A BW, and incubated
with an equal volume of PCR product for 20 minutes at room temperature. The
efficient binding of biotinylated DNA to the streptavidin beads was promoted by
gently resuspending the mixture several times during the incubation. The beads
were washed in 40/il BW, and then resuspended in 8/il 0.15M NaOH for 10 min
at room temperature to denature the DNA into single strands. The beads were then
washed once in 50/il 0.15M NaOH, followed by 40/il BW and a final wash in 40/il
TE buffer (lOmM tris HC1; ImM EDTA) pH 7.0, before being resuspended in 20/il
TE.
Sequencing was performed using the Sequenase Version 2.0 DNA
sequencing kit (United States Biochemicals). Primer of opposite sense to the
biotinylated primer was annealed to 5/il single stranded template DNA, by the
addition of 2/A 5x annealing reaction buffer (200mM tris-HCl pH 7.5; lOOmM
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MgCl2; 250mM NaCl), 2/il diluted primer (50ng) and 1/il DMSO (final
concentration 10%). Tubes were heated to 65°C for 5 min, and then left to cool to
room temperature over 20 minutes. Four termination mixes, ddGTP, ddATP, ddTTP
and ddCTP were prepared (80/iM each dNTP; 8/iM specific ddNTP; 50mM NaCl;
10% DMSO) and 2/il aliquots of each incubated at 37°C. The labelling reaction
was carried out by the addition of 1/il each of labelling mix (7.5/iM dGTP, 7.5 /iM
dTTP, 1/iM dCTP) diluted 1:20 in distilled water, 0.1M DTT, [ct-35S]-dATP and
2 units Sequenase (T7 DNA polymerase) diluted in TE pH 8.0, to the annealed
DNA mixture, and incubating at room temperature for 2-5 min. Next, 3.5/A of
labelling reaction was added to each of the termination solutions (G, A, T and C)
and incubation was continued at 37°C for a further 5 min. The reactions were
stopped by the addition of 4/il stop solution (95% formamide; 20mM EDTA;
0.05% bromophenol blue; 0.05% Xylene cyanol FF). DNA was denatured by
heating at 90°C for 2 minutes and then separated by polyacrylamide gel
electrophoresis (section 2.4.3).
2.5.2 SEQUENCING OF CLONED DNA FRAGMENTS
Double stranded plasmid DNA was denatured with alkali by adding 1 /A 2M
NaOH/2mM EDTA to 10/il miniprep DNA and incubated at 37°C for 30 minutes.
The DNA was precipitated with 1/il 3M sodium acetate and 30/il ethanol at either
-70°C for 15 minutes, or -20°C for more than 2 hours. A pellet of denatured DNA
was obtained by centrifugation at 13000 revs / min for 10 minutes, and washed in
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50/U.l 70% ethanol. The washed pellet was dissolved in 10/ul DEPC water, and 5fA
used for each sequencing reaction. DNA sequencing was carried out as in section
2.5.1, with plasmid primers 8819 (sense) and 9130 (antisense).
A typical sequencing gel is shown in figure 2.5.2.
2.5.3 DENATURING POLYACRYLAMIDE GEL ELECTROPHORESIS
Denatured sequencing reactions were resolved by electrophoresis through
a 6% polyacrylamide gel. Glass plates were thoroughly cleaned with distilled water,
acetone and finally methanol, and assembled with 1mm wide spacers. Gels were
prepared by dissolving 21g urea (AnalaR - BDH), 6ml Long Ranger Gel Solution
(50% stock; Flowgen), 5ml lOx Sanger TBE (appendix 2.5) and 0.05g ammonium
persulphate (APS) in distilled water to a final volume of 50ml. Polymerisation was
initiated by the addition of 20/A TEMED (N, N, N', N'-Tetramethylethylediamine,
SIGMA), after which the gel was poured immediately and left to set for
approximately 1 hour. Denatured sequencing reactions were loaded onto the gel in
the order G, A, T, C for each sample, and running buffer (lx Sanger TBE) added
to fill both the anode and cathode chambers of the apparatus. Electrophoresis was
carried out at 75 watts for 2-3 hours depending on the position of the sequence
required in comparison with the primer used for sequencing. Gels were removed
from the glass plates, transferred onto filter paper and vacuum dried at 80°C for 1.5
hours. The gels were then exposed to X-ray film (Kodak Biomax MR) in a light
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tight cassette for 12-24 hours, and developed by kind permission of the radiography
department at the Royal Infirmary of Edinburgh.
2.6 CLONING OF AMPLIFIED DNA INTO pTAg VECTOR
2.6.1 PREPARATION OF AMPLIFIED DNA FOR CLONING.
Amplified DNA fragments were cloned directly from PCR products into a
dideoxy T (ddT) tailed vector (pTAg). This method (Marchuk et al., 1991; Holton
et al., 1991) exploits the non-proofreading properties of Taq DNA polymerase (i.e.
the absence of a 3' to 5' exonuclease activity which is present on certain other
DNA polymerases) and its tendency to add a single adenosine (A) overhang to the
3' end of amplified PCR products.
The single A 3' overhangs are easily removed by nucleases, and so the
highest efficiency of cloning is achieved by the use of unpurified PCR products,
since there is a lower chance of nuclease contamination. To eliminate any residual
polymerase activity, the PCR product was treated with an equal volume of
chloroform:isoamyl alcohol (24:1), vortexed for 1 minute, and then spun in a
microfuge (13000 rpm, 1 minute). The aqueous phase was then transferred to a new
tube, and up to 2fA DNA used for ligation reactions. If the PCR reactions produced
non-specific bands, the target DNA was purified using the Geneclean II kit (Bio
101 Ltd). The required DNA band was excised from an agarose-TBE gel with a
scalpel, and transferred to a 1.5ml eppendorf. The total volume was made up to
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100/A with DEPC water, before adding 3 volumes sodium iodide (Nal) stock
solution and 50/zl TBE modifier (if from an agarose / TBE gel) and melting the
agarose in a water bath at 45-55°C for 5 minutes. 5/A resuspended glassmilk (silica
matrix) was added to the DNA in solution and vortexed prior to centrifugation in
a microfuge for 10 seconds. The pellet was then washed three times with 500/il
NEW WASH (NaCl, ethanol, water), being careful to resuspend the pellet fully
with each wash. DNA was finally eluted by resuspending the washed pellet in 5 (A
water and incubating at 45-55°C for 2 minutes. The glassmilk was pelleted by
centrifugation for 30 seconds, and the supernatant containing DNA removed to a
new tube. This elution step was repeated to give a final volume of 10/A. Prior to
cloning, residual polymerase activity was eliminated as described above.
2.6.2 LIGATION OF DNA INSERT INTO pTAg
Amplified DNA fragment are ligated with plasmid vectors in a 1.5ml
eppendorf, containing 50ng (1//1) pTAg vector, 1 /A lOx ligase buffer (200mM Tris-
HC1 pH 7.6, 50mM MgCl2), 0.5/il lOOmM DTT and 0.5/il lOmM ATP. A
maximum of 2/A PCR product was added to the tube and the volume made up to
9.5fA with nuclease free water. After mixing briefly on a vortex, the mixture was
collected at the bottom of the tube by pulsing in a microfuge, and 0.5/il (2-3 Weiss
units) T4 DNA ligase added. The solution was mixed gently with a pipette tip, and
incubated at 16°C overnight.
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2.6.3 TRANSFORMATION INTO E. COLI COMPETENT CELLS.
The introduction of plasmid DNA into E. coli cells (transformation) enabled
the identification of copies which had been successfully ligated with the DNA
insert. The efficiency of transformation is increased by the use of "competent '
cells, which have been treated with calcium chloride to improve DNA binding to
the cell wall, and therefore DNA uptake after heat-shock. The genotype of the
competent cells provided with this kit was endA1 /25t/R17(rk12-mkl3+) supE44thi-\
recAl gyrA96 relAl lac[F' /?roA+B+/aclqZ±M15::TnlO(TcR)].
Competent cells were defrosted slowly on ice, and 20/A aliquots dispensed
into pre-cooled eppendorf tubes. I/A plasmid DNA from the ligation reaction was
added to the cells and mixed by tapping gently. After a 30 minute incubation on
ice, the tubes were heat-shocked at 42°C for 40 seconds and returned to ice for 2
minutes. 80/il SOC medium was added to the cells, which were then grown at 37°C
for 1 hour in a rotary shaking incubator (200-250rpm). The cells were spread on
selective LB agar plates, containing 50//g/ml ampicillin, 15/ig/ml tetracycline,
80//g/ml X-Gal (5-Bromo-4-chloro-3-indolyl-|TD-galactopyranoside) and IPTG
(isopropyl-thiogalactoside) to 0.5mM. The presence of ampicillin ensures the
presence of only transformants with the plasmid which carries the gene for
ampicillin resistance (P-lactamase), and tetracycline the presence of the Lac Z gene
on the F' plasmid of the cell. Transformants containing the DNA insert were
identified by screening for |3-galactosidase activity. pTAg contains the LacZa
peptide sequence, which acts together with the LacZ peptide synthesised in
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competent cells to produce the enzyme (3-galactosidase. This enzyme, when in the
presence of an inducer such as IPTG, is able to degrade the lactose analogue X-gal
into a blue product. When a DNA insert is cloned into the plasmid, the LacZ gene
is interrupted and therefore usually not expressed in an active form. The result is
an absence of (3-galactosidase activity, leaving X-gal intact and the colony white.
2.6.4 SCREENING OF COLONIES FOR DNA INSERTS
White colonies were screened for the presence of a DNA insert by PCR
(Gussow et al., 1990). Using a sterile toothpick, the edge of the colony was
transferred into a tube containing 20/Ul PCR reaction mix (section 2.3.3) containing
plasmid primers 8819 (sense) and 9130 (antisense) (table 2.3). The solution was
overlayed with paraffin oil and placed on a thermal cycler for 30 cycles of 94°C
for 1.5 minutes, 50°C for 30 seconds and 72°C for 3 minutes, followed by an
incubation at 20°C for 7 minutes. PCR products were electrophoresed through a 2%
agarose/TBE gel containing 0.05/ig/ml ethidium bromide for 15 minutes with
molecular weight markers for reference. Colonies giving rise to amplified DNA
fragments of the correct size were selected.
2.6.5 PREPARATION OF PLASMID DNA
E. coli colonies containing DNA inserts were picked and grown in 3ml LB
(appendix 2.6) at 37°C overnight in a rotary shaking incubator (200-250 rpm). The
culture was split, with 1.5ml added to 0.5ml sterile glycerol and stored at -20°C,
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and the other 1.5ml used for the preparation of plasmid miniprep DNA by alkaline
denaturation.
In a 1.5ml Eppendorf tube, the culture was centrifuged in a microfuge for
15 seconds to pellet the cells, and the supernatant discarded. Bacterial cell wall
polymers were degraded by resuspending the pellet in 100fA GTE (50mM glucose;
25mM Tris.Cl pH 8.0; lOmM EDTA) with lysozyme (SIGMA). The pH of the
solution was raised to 12.5 by the addition of 200/il NaOH/SDS (ice, 5 minutes)
to denature the DNA (plasmid DNA can renature as it is supercoiled), followed by
the addition of acid (solution III; appendix 2.6) to aggregate the denatured DNA,
making it insoluble. The tubes were centrifuged in a microfuge for 8 minutes to
pellet the cellular DNA and debris, and the supernatant containing plasmid DNA
transferred to a new tube. Plasmid DNA was precipitated by adding 290/A
isopropanol, incubating at room temperature for at least 15 minutes, and pelleting
in a microfuge at 13000 revs / min for 10 minutes. The pellet was washed with





Cloned DNA sequences were expressed using the pRSET "Xpress
System"™ (Invitrogen corporation) (Kroll et al., 1993). This system is an
adaptation of that devised by Studier et al (1990) (Studier et al., 1990) whereby
protein expression is driven by T7 RNA polymerase acting on the T7 promoter
present upstream of the pRSET multiple cloning site (figure 2.7.1). Also upstream
of the DNA insert is a fusion peptide, whose sequence encodes an ATG translation
initiation codon, a row of six histidine residues, a transcript stabilizing sequence
derived from gene 10 of bacteriophage T7 and an enterokinase cleavage site. The
hexahistidine tag is present to provide a metal binding domain, which allows rapid
purification of the expressed protein by Metal Chelate Affinity Chromatography
(MCAC) on nickel ion affinity resins.
The vector is transformed into E.coli strain JM109, and protein expression
induced via derepression of the lac promoter (by the addition of 1PTG), which
subsequently induces the expression of T7 RNA polymerase from M13/T7
bacteriophage when added to the culture. It is this enzyme which finally acts on the
T7 promoter in the vector to drive expression of the cloned DNA sequence.
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2.7.2 SUBCLONING INTO pRSET
DNA sequences cloned into pTAg were subcloned into pRSET for protein
expression. The DNA insert was isolated from pTAg by restriction endonuclease
digestion with the enzymes BamHI / Hindlll, by the addition of 0.5/A (5 units)
each enzyme and 2/A lOx Buffer E (Promega) to 11 /A miniprep DNA followed by
incubation at 37°C for 1 hour. Products were electrophoresed through a 1% TAE
agarose gel containing 0.05/ig/ml ethidium bromide. Along with molecular weight
markers bands of the appropriate size were excised from the gel and purified as
described previously (section 2.6.1). DNA fragments were then ligated with pRSET
(previously cleaved with BamHI / Hindlll) by the addition of 5/A miniprep DNA
to 3/A cleaved pRSET, 2/A lOx Ligase Buffer, 0.5/zl T4 DNA ligase and nuclease
free water to a final volume of 20/A. Reactions were incubated at room temperature
overnight prior to transformation into JM109 E.coli competent cells (kindly
provided by Murex Biotech, genotype recAl s«/?E44 endAl hsdRll gyrA96 relAl
thiA(lac-proAB)F'[traD36 proAB+ lacF /£ZcZaM15]) as described previously with
the exception that 50/A cells per reaction were used with 5/A ligated DNA, and
transformed cells were grown in 450pi SOC medium. Transformants were selected
by plating on SOB agar (appendix 2.7) which contained ampicillin at 50/zg/ml.
Colonies were screened for the presence of the DNA insert by direct PCR using
pRSET primers 632 and 662 (Murex Biotech, table 2.3) as previously described




Cloned DNA sequences were initially expressed in 50ml cultures, to
determine the kinetics of the reaction and the conditions required for maximum
yield of expressed protein. 5ml E.coli overnight culture was transferred to a sterile
250ml conical flask containing 45ml SOB broth with ampicillin (50,ug/ml), and
incubated at 37°C in a rotating incubator. When the O.D.600 of the culture reached
0.3, IPTG was added to a final concentration of ImM, and growth continued at
37°C for 1 hour. The O.D.6(X) of the culture was measured again, and the cell
concentration calculated on the basis that an O.D.6()0 of 1.0 represents a
concentration of 109 cells/ml. Protein expression was induced by the addition of
M13/T7 bacteriophage (kindly provided and titred by Murex Biotech) to the culture
at a multiplicity of infection (MOI) of 5 plaque forming units (pfu) per cell, and
the new cultures incubated overnight at 37°C in a rotating incubator. The
timecourse of protein production was monitored by removing 1ml samples from the
cultures, pelleting the cells in a microfuge, and resuspending them in 100/zl distilled
water before analysis by SDS-PAGE (section 2.7.4) and Western blotting (section
2.7.5).
At the end of the culture period (overnight), the cells were pelleted in a
centrifuge at 5000 rpm for 10 minutes, the supernatant aspirated and the pellet
resuspended in 1ml Lysis buffer (appendix 2.7). E.coli cell walls were degraded by
adding 10/il lysozyme (lOmg/ml) to the sample and incubating at room temperature
for 1 hour (swirling continuously). 10//1 sodium deoxycholate (5% w/v) was added
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to the tubes to solubilise the sarcoplasmic reticulum, at which stage the solution
becomes viscous, and finally lO^l 1M Mg S04 and 4/il (40-200 Units) DNase
(RNase free; Boehringer). The tubes were incubated at room temperature with
swirling for 1 hour, or until the viscosity disappeared. Inclusion bodies and other
insoluble material were pelleted in a microfuge at 13000 rpm for 5 minutes, the
supernatant transferred to a new tube, and the pellet resuspended in 1ml 8M urea
containing lOmM DTT. Proteins expressed from cloned DNA were present in either
the periplasm of the E.coli cells (supernatant) or in inclusion bodies (cell pellet),
and were identified by SDS-PAGE.
2.7.4 DENATURING POLYACRYLAMIDE GEL ELECTROPHORESIS OF
PROTEINS
Proteins were separated according to their molecular weight by denaturing
polyacrylamide gel electrophoresis (PAGE). Proteins were denatured in the
presence of SDS, an anionic detergent which disrupts noncovalent interactions
between and within proteins, and DTT which disrupts disulphide bonds. SDS
anions bind to the denatured protein to give a net charge proportional to that of the
mass, and proteins are then separated by electrophoresis towards the anode.
Two glass plates were cleaned first with water, and then methanol, and
assembled with 0.75mm spacers in the manufacturers stand (BioRad). A 15%
resolution gel was prepared (appendix 2.7), and poured between the plates using
a pipette until the level reached approximately two thirds from the bottom. The
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surface of the gel was overlayed with methanol, and left to polymerise at room
temperature for 45 minutes. The methanol was poured off, and a 15% stacking gel
prepared (appendix 2.7). Stacking gel solution was poured on top of the resolution
gel, and a 0.75mm comb placed between the plates. This was again left to
polymerise at room temperature for 45 minutes. The comb was removed carefully,
and the gel placed into the electrophoresis apparatus (BioRad), and submerged with
lx SDS-PAGE running buffer (appendix 2.7).
Samples were prepared by the addition of an equal volume of 2x SDS
sample buffer (appendix 2.7), and heating to 100°C for 5 minutes. Samples were
then loaded into the appropriate wells using a flat tipped pipette and
electrophoresed at 200 Volts for 45 minutes. Protein bands were visualised by
soaking the gel in Coomassie blue staining solution (appendix 2.7) for 30 minutes,
followed by the removal of residual dye with destaining solution (appendix 2.7) for
2 hours - overnight.
2.7.5 WESTERN BLOTTING
Expressed proteins were distinguished from E.coli proteins by Western
blotting (Salinovich et al., 1986) of polyacrylamide gels onto nitrocellulose
membranes, and probing with antibody specific for the hexahistidine tag. The gels
were transferred to nitrocellulose membranes which had been activated by soaking
in methanol. Sandwiched between 4 pieces of filter paper soaked in lx transfer
buffer (appendix 2.7), the gel and membrane were placed on electrophoresis
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apparatus (Biorad) with the nitrocellulose membrane facing the anode, and a
current of 350 mA applied for 45 minutes. The membrane was removed and soaked
in lx cast solution (appendix 2.7) for 1 hour at room temperature, and then reacted
with conjugate CM-POD (Sigma) at a concentration of 1:1000 (lmg/ml stock) in
lx cast solution for 30 minutes. After washing 3 times in PBS/Tween, the colour
was developed with diaminobenzidine (DAB) substrate for 2-3 minutes, and the
reaction stopped by washing in water.
2.7.6 LARGER-SCALE PROTEIN PREPARATION
To prepare quantities of antigen sufficient for ELISA work, expression of
cloned DNA was carried out in 2 X 500ml cultures per sample. The procedure was
as for pilot expression except that lysozyme was added to a final concentration of
4/zg/ml for 30 minutes at 4°C followed immediately by sonication of the cells on
ice for 3 x 30 seconds with 15 second intervals, and prior to the separation of
insoluble material by centrifugation, 5ml 10% Triton buffer TX 100 was added to
the solution.
Purification of Expressed proteins by Metal Chelate Affinity Chromatography
Proteins expressed in a vector with an N-terminal fusion peptide of
polyhistidine residues were purified by Metal Chelate Affinity Chromatography
(MCAC) (Hochuli, 1990; Porath et al., 1975) on columns containing ProBond1M
Resin (Invitrogen corporation). The resin, consisting of nickel ions (Ni2+) covalently
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bound to nitrilotriacetic acid (NTA) (Hochuli et al., 1987), binds to the
hexahistidine tail of the expressed protein via the imidazole side chains of the
histidine residues, leaving E.coli proteins to be washed through the column. Bound
protein is eluted from the resin by washing with a high concentration of imidazole,
which at a constant pH will displace the polyhistidine tail from the Ni2+. All buffers
used in this process are described in appendix 2.9.
ProBond™ columns were filled with resuspended resin until the packed volume
reached the top of the narrow section of the column, and equilibrated with 10ml
lx Binding buffer. Prepared cell lysate (containing soluble expressed protein) was
loaded onto the column, and the flowthrough collected for analysis by SDS-PAGE.
The resin was washed three times with 10ml lx Binding buffer, followed by
individual washes with lOmM imidazole solution and 30mM imidazole solution.
Histidine-tagged proteins were finally eluted with ten 1ml washes of 300mM
imidazole solution. Fractions containing the purified protein were identified by
SDS-PAGE of the flowthrough samples.
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CHAPTER 3
3 DEVELOPMENT AND APPLICATION OF A
SEROTYPING ASSAY FOR HCV TYPES 1-6.
3.1 HCV 1-3 ASSAY
3.1.1 INTRODUCTION
The hypothesis that amino acid variation between HCV genotypes could
generate a type-specific immune response towards certain epitopes was put forward
shortly after the introduction of the first-generation enzyme immunoassays for the
routine serological screening of blood donors. It was observed that serological
reactivity towards NS4 antigens specific for type 1 virus (for example clOO-3 and
5-1-1) was relatively infrequent amongst sera from individuals infected with types
2 or 3 (McOmish et al., 1993). As sequences of genotypes 1 and 2 encoding the
clOO-3 antigen show only 75-77% amino acid identity, the existence of type
specific antibodies to this antigen was conceivable.
3.1.2 DEVELOPMENT OF A SEROTYPING ASSAY FOR HCV TYPES 1-3.
Consensus sequences for genotypes 1, 2 and 3 were compared and a set of
82 oligopeptides spanning NS4 (amino acid residues 1679-1768) prepared for each.
Each peptide was 9 residues in length and overlapped the adjacent peptide by 8
residues. The antibody reactivity towards individual peptides was confined to three
specific regions, of which two were at the same positions for all genotypes.
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Antigenic region 1 included amino acid residues 1691-1708, and region 2 spanned
positions 1720-1738. The different positions within NS4 of antigenic region 1
(NS4A) and region 2 (NS4B) are such that they are cleaved in vivo. The level of
cross-reactivity between antibody and peptides from different genotypes was
investigated by the reaction of sera from HCV infected blood donors with
heterologous peptides, and by comparing results with the reactivity against peptides
from a homologous genotype to that causing infection. Although cross-reactivity
was observed, this was weak and generally confined to region 1, with the exception
of type 3 antibody, which showed weak cross-reactivity with type 1 peptides in
both regions 1 and 2.
The discovery of type-specific antibody towards epitopes in the NS4 region
led to the development of a serotyping ELISA for genotypes 1, 2 and 3 (Simmonds
et al., 1993d). Branched peptides representing antigenic regions 1 and 2 of
genotypes la/b, 2b and 3a were synthesised on p-
hydroxymethylphenoxymethylpolystyrene resin with a branched lysine core, to
obtain eight copies of the sequence per molecule and the maximum level of
binding. Variations between single amino acid residues within type 1 were
accommodated by the incorporation of equimolar amounts of the alternatives,
resulting in a total of 8 peptides, which were coated onto microtitre plates at equal
concentrations.
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In this assay, reactivity of sera from HCV infected blood donors to type-
homologous peptides was observed more frequently than towards type-heterologous
antigen. In order to eliminate the cross-reactivity observed between different
genotypes, the assay was modified by the addition of a one hundred fold excess
concentration of type-heterologous peptides. All 8 peptides were present on the
solid phase, and blocking solutions of heterologous peptides were added to three
separate typing wells (i.e. the well responsible for the identification of type 1
specific antibody would have a blocking solution containing type 2 and 3 peptides
added). No competing peptides were added to a positive control well, while all 8
peptides were added at blocking concentrations to a negative control well. Initial
studies revealed that this assay was able to detect NS4 antibody in 95%, and type-
specific antibody in 89% HCV positive blood donors from Scotland. Serotyping
results were concordant with the genotype identified by RFLP of the 5'NCR in
99.2% samples (Simmonds et al., 1993d).
3.1.3 RESULTS
Application of the 1-3 Serotyping Assay to Samples from Patients in the U.S.A.
The 1-3 serotyping assay was used for the detection of type-specific
antibody in a total of 217 samples obtained from patients with chronic hepatitis C
in the United States. Genotyping of the samples by RFLP analysis of the 5' NCR
revealed that there were 163 type 1, 30 type 2 and 11 type 3 infections, while 13
sera were negative by PCR. The serotyping assay detected type-specific antibody
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in 148/163 (90.8%) type 1 samples with 100% specificity (Table 3.1.3). The
sensitivity of the assay towards samples infected with type 2 virus was higher at
96.7%, but in one sample type 1 specific antibody was detected. Similarly, one
sample from an individual infected with genotype 3 virus was type 1 by serotyping.
The majority (11/13) of PCR negative samples could be serotyped, revealing nine
serotype 1 samples and two serotype 2 samples. Overall, the sensitivity of the 1-3
serotyping assay in this study was 91.2%, with type-specific antibody detected
corresponding to the genotype identified by RFLP in 98.9% samples.
3.1.4 DISCUSSION
Shortly after the development of the serotyping ELISA for HCV types 1-3,
the analysis of sera from a broader range of geographical areas led to the discovery
of additional genotypes of HCV. Type 4 was discovered initially in Africa, type 5
in South Africa and type 6 in Hong Kong (reviewed in Simmonds, 1993a). The
sensitivity of the serotyping assay was greatly reduced in populations where
genotypes 4, 5 and 6 were prevalent, as antigens for these additional genotypes
were not present.
In addition to the discovery of genotypes 4-6, a more intensive investigation
of the genotype distribution within European countries revealed that subtypes 2a
and possibly 2c were as common as type 2b (Davidson et al., 1995), and that the
use of type 2b peptides alone may reduce the sensitivity of the assay to these
subtypes (discussed in chapter 4).
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3.2 DEVELOPMENT OF A SEROTYPING ASSAY FOR THE
DETECTION OF HCV GENOTYPES 1-6.
3.2.1 INTRODUCTION.
In order to be able to design type-specific NS4 peptides for genotypes 4, 5
and 6 it was necessary to compare a number of sequences for each. In total, six
type 4 samples, four type 5 samples and two type 6 samples were obtained from
HCV positive blood donors in Egypt, South Africa and Hong Kong respectively
(Bhattacherjee et al., 1995).Virus genotypes were confirmed by comparison of 5'
NCR sequences with published sequences.
For each sample, a portion of the NS4 region including both antigenic
regions 1 and 2 was amplified and sequenced (Figure 3.2.1). The inferred amino
acid sequences were used to produce a consensus sequence for each genotype from
which type-specific antigenic region 1 and 2 peptides could be designed (Table
3.2.1). A total of 21 branched peptides corresponding to the consensus sequences
for all six genotypes were synthesised.
PCR amplification and sequence analysis of samples containing types 4, 5 and 6
was carried out by Vasker Bhattacherjee, while the branched peptides were
synthesised by Dr. Brian Rodgers at Murex Biotech, Dartford, U.K.
82
Figure3.2.1ACOMPARISONFNS4INCIDSEQUE CESROMDIFFE ENTG NOTYP














la lb lc Id
HC-PT HC-H HC-J HCVUK 4TY4 HC-G9
LEWTSTWVLVGGVLAALAAYCLSTGCWIVGRWLSGKPAIIPDREVLYREFDEMjECSQHLPYIEQGMMLA OFiPK LGLLOTASROAEVIAPAVQTNWOKLETFWAKH IQH..TV .T. .T..II. .II. .1. .II..V. •W. •V.■Q. ■Q.•AS. ■AS.■Q. ■Q. ■AA..A...H..Q. .AA.X..L....H.
.TK...AA..V.ESK.RA..V. .TK...AA..V.ESK.RA.... .K...AAV.V..S....V... T .HS
2a 2b 2c






•K. •K. ■K. .K.
,IM.
.S.I.GIH.NQRTV.A..K.
.EA. .EA, .EA. .EA. .EA.
.ASRAAL .ASKATL ■ASKAAL •ASKAAL .ASRTAL
















■QQY •QQY •QQY ■QQY
.AA. .AA. .AA. .AA.































■QQ. ■QQ. ■QQ. ■QQ. ■QQ. ■QQ.
.K. ■K. ■K. ■A. •K. ■K.
.LV.H.LQ. .LV.H.LQ. .LV.H.LQ. .LV.H.LQ. .LV.H.LQ. .LV.H.LQ..
.A. ,.V. .A. ,.V. .P ,.V.
.SF.GK. .NL.GK. .NF.GK. .NF.GK. .TF.GK.
.QEAT.VI. .QEAT.VI, .QEAT..I, .QEA..M., .QEAT..I,
FA. FA. FA. FA. FA.
.NI.GK..QEAT.VI.W.FA.
■Q. ■Q. ■Q. ■Q. ■Q. ■Q.
T478 SC6 SC23 SC24
.I .I .1. .I
.V .V .V .V
..TV.S.T....II..,R. ..TV.S.G....II..,R. .STV.S.AI.,R ..TV.S.A....II...R.
■QQ. ■QQ. ■QQ. ■QQ.
.TSMDEARAIG.V .AS...MDEARAI.G...E.M. .TS...MDEARAI.R...E.V. .TS...MDEARAI.G...E.V.














Table 3.2.1 NS4 peptides used in the 1-6 Serotyping ELISA.
ANTIGENIC ANTIGENIC
REGION 1 REGION 2
la KPAIVPDREVLYREFDEM ECSQHLPYIEQGMMLAEQF
lb R. . VI Q A
2a RAV.A. .K. . . . EA . . . . . . ASRAAL. .E.QRI. .ML
2b RVWT. .K.I. .EA. . . . .. ASRAAL .. E . QRI .. ML
HCV 2c RTV.A. .K. . . .EA. . . . . . ASRTAL . . E . HRI . . ML
TYPE
3 ...L...K.... QQY ... . . . . AA AQVI . H . .
4 Q . . VI QQ . . . . . . . K. . . LV . H . LQ
5 R . . . I QQ . . . . . . . TS . . . MDEARAI . G . .
6 . . . W. . . . I . .QQ. . . . . . .R.I. .LAE.QQI. . . .
Table reproduced from Bhattacherjee et al. 1995.
Sequence identity to the type la sequence
3.2.2 ASSAY FORMAT
The overall design of the assay was the same as for the 1-3 serotyping
ELISA but with a few minor modifications. As the total number of peptides had
now been increased to 21 and the number of peptides representing each of the six
genotypes was not the same, the concentrations used for coating plates was
adapted. Equal concentrations of each individual peptide were used to coat plates
for the 1-3 serotyping ELISA, whereas the final concentrations of peptides specific
to each genotype were equal for coating plates for the 1-6 assay. Concentrations
of blocking peptides were a 100 fold excess of that used for coating the plates as
before. Better results were obtained with a 1:20 test dilution of serum rather than
1:40 used for the 1-3 assay, and finally the layout of the plate was modified in
order to fit the maximum number of samples per plate, with one column of 8 wells
per sample (Figure 2.2.4).
3.2.3 SAMPLES.
The different genotypes of HCV show specific geographical distributions,
with types 1-3 existing in a wide range of areas compared with types 4, 5 and 6
which exist in relatively confined regions (Central Africa and the Middle East,
South Africa and South East Asia respectively). A thorough evaluation of the
capability of the 1-6 ELISA to identify type-specific antibody for these types was
carried out.
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All the samples used in this investigation were analysed by RFLP of
amplified 5'NCR sequences in order to identify the genotype of HCV causing
infection. Type 1 samples (n=39) were obtained from Norwegian patients with
chronic HCV (section 3.3), and included subtypes la (n=25) and lb (n=12).
Samples from individuals infected with type 2a (n=14) were acquired from HCV
positive blood donors in Taiwan (section 3.3), whereas samples infected with type
2b (n=18) were mostly from the Norwegian patients, with only two samples from
Taiwan. Samples infected with type 3 (n=55) were also from Norway. Types 4
(n=62), 5 (n=16) and 6 (n=6) were obtained from HCV positive blood donors in
Egypt, South Africa and Hong Kong respectively. A total of 210 HCV positive
samples were analysed using the 1-6 assay, along with 20 samples from healthy
blood donors as negative controls (Table 3.2.4).
3.2.4 RESULTS.
From 210 HCV positive samples tested with the assay, type-specific
antibody was detected in a total of 183, giving an overall sensitivity (Appendix 1.0)
of 87.1%. The type-specific antibody detected in 178 of these samples was in
agreement with genotyping by RFLP, giving the ELISA an overall specificity of
97.3% (Table 3.2.4).
Although the specificity (appendix 1.0) was high for the majority of
genotypes analysed, the sensitivity of the assay for different genotypes was more
variable. From 39 type 1 sera tested, type-specific antibody was detected in 36
84
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(sensitivity 92.3%) with only one discrepant result (genotype lb, serotype 6).
However, for subtype la both the sensitivity (96%) and specificity (100%) of the
assay were higher than for subtype lb (83.3% and 90%). High performance criteria
were observed for the 32 samples from individuals infected with type 2 with only
1 sample showing no reactivity (NR) to the NS4 peptides, and 1 giving a discrepant
result being identified as serotype 1. Type-specific antibody was detected in 51/55
type 3 samples (sensitivity 92.7%) with 1 discrepancy (identified as serotype 2).
The sensitivity of the ELISA towards type 4 was lower at 80.6%, with 9 samples
untypeable by the assay despite showing reactivity towards the NS4 peptides in the
positive control well (NTS; non-type-specific), and 3 samples in which no NS4
antibody could be detected. The sensitivity of the assay to types 5 and 6 samples
were also lower, although fewer samples were available for analysis. Type-specific
antibody was detected in 11/16 type 5 samples, with 1 discrepant result (serotype
1), and similarly only 4/6 type 6 samples could be serotyped by the assay. All the
negative controls were unreactive.
3.2.5 DISCUSSION
The production of type-specific antibody directed towards epitopes of HCV
which show relatively high levels of amino acid variation between genotypes has
been exploited by a number of workers for the development of serological typing
assays (Tanaka et al., 1994; Machida et al., 1992). However, these assays were
restricted to the detection of types 1 and 2, and as the identification of serotype
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was based on a direct comparison of reactivity towards different antigens, they
carried a potential risk of cross-reactivity and hence the misidentification of
serotypes. The development of a competitive ELISA for the identification of types
1-3 (Simmonds et al., 1993d) largely eliminated this risk and was demonstrated as
being both sensitive and accurate within populations containing these genotypes,
although the subsequent discovery of additional genotypes demanded an assay with
greater capabilities for use worldwide.
Analysis of amplified NS4 sequences for genotypes 4, 5 and 6 revealed
type-specific differences in the two antigenic regions previously identified by
epitope mapping (Simmonds et al., 1993d), although types 4-6 were relatively less
distinct from type 1 in antigenic region 1. Peptides were synthesised towards
consensus sequences for types 4-6, and incorporated into the serotyping assay.
From a total of 210 PCR positive samples from individuals infected with
a full range of HCV genotypes, the work described here has shown that the 1-6
serotyping assay was able to identify type-specific antibody in 183 (87.1%) (Table
3.2.4). All these samples were HCV positive by PCR. The samples showing no
reactivity towards the NS4 antigens (NR) could in theory have been obtained from
immunocompromised patients, for example, those who were co-infected with HIV
or had undergone recent liver transplantation (perhaps due to HCC or cirrhosis).
However, as the majority of these samples (all except type 1, type 3 and most of
type 2b isolates which were obtained from Norweigan patients with chronic
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hepatitis C) were obtained from blood donors for which a donor health assessment
was unavailable, the likelihood of these individuals being immunocompromised is
low. In addition, there was no difference in the frequency of unreactive samples
between those originating from blood donors and those from hepatitis patients. An
absence of NS4 antibody might also be observed if the individual had a specific
inability to make an antibody response towards this epitope, or had only recently
been infected and the sample taken prior to seroconversion.
In general, the level of antibody reactivity towards antigens in the 1-6
serotyping assay was lower than that in the 1-3 serotyping assay, and so a 1/20
dilution was used for the 1-6 assay as opposed to 1/40 serum dilution used in the
1-3 assay. The lower level of antibody reactivity to peptides in the 1-6 assay may
be due to cross reactivity between competing peptides corresponding to types 1 and
4-6 (Table 3.2.1). This cross reactivity would mean that only antibody specific for
region 2 peptides would be able to bind to the solid phase, and so reduce the
signal.
The specificity of the 1-6 assay was high, with 97.3% of samples being
serotyped in agreement with the genotype identified by RFLP. Although the assay
was 100% accurate for the detection of types la and 2a, for other types discrepant
samples included the detection of type 6 antibody in a patient infected with type
lb, type 1 antibody in a sample genotyped as 2b, type 2 antibody in sera from
patients infected with either types 3 or 4 and finally a sample from an individual
infected with type 5 which was serotyped as type 1. Discrepant results may be
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explained by the existence of unusual variants of HCV in which amino acid
variation within regions coding for the peptides used in the assay could lead to
cross reactivity with antigen towards heterologous genotypes, or that the consensus
sequence used to design peptides for each genotype may not be fully representative
of all isolates. This may be the case with the type 6 peptides, which were based on
the analysis of only two sequences. Another possible explanation is that the assay
has detected circulating antibody induced by a previous infection with a different
genotype. This is especially likely in patients with a history of multiple exposure
such as haemophiliacs. Finally, discrepant results could arise if an individual were
infected with a recombinant virus which contained sequences in the 5' NCR and
NS4 specific to different genotypes. However, there is no strong evidence for
recombination of HCV. A more detailed study of discrepant results is described in
chapter 6.
A high frequency of type 4 samples (14.5%) contained non-type-specific
antibodies (9/62 - table 3.2.4) suggesting that cross reactivity with other peptides
in competing solutions prevents binding to peptides on the solid phase. Type 4 is
one of the most heterogenous genotypes of HCV with numerous subtypes described
(a-h) (Simmonds, 1995; Bukh, 1995; Fretz et al., 1995). The type 4 specific
peptides used in the assay represent only subtype 4a, and it is quite likely that
samples giving non-specific reactivity may be from individuals infected with other
subtypes of type 4 with divergent NS4 sequences. Similarly, the difference in the
specificity of the ELISA between types la and lb may represent a higher variation
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in antigenic regions for lb than observed in the sequences analysed. The sensitivity
and specificity of the assay for genotypes 5 and 6 were both relatively low, but
only a few samples were available for serotyping analysis.
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3.3 APPLICATION OF THE 1-6 SEROTYPING ELISA.
3.3.1 INTRODUCTION.
After confirmation that the 1-6 serotyping assay was able to successfully
distinguish between type-specific antibody produced towards infections with all six
HCV genotypes, an investigation was carried out into the performance of the assay
when applied to specific populations.
The application of the serotyping assay towards different populations was
also carried out to investigate further the epidemiology of HCV, and the genotype
distribution in geographical areas for which little or no information had previously
been acquired.
3.3.2 SAMPLES.
Samples were obtained from Pakistan, Egypt, Taiwan and Norway.
Pakistan.
A total of 87 samples from patients with chronic hepatitis C in Karachi,
Pakistan were collected (Dr. Hasnain Ali-Shah, Department of Medicine, The Aga
Khan University, Pakistan) and screened with the Murex anti-HCV enzyme
immunoassay VK47/48 for the presence of HCV antibody, and by PCR for the
detection of virus RNA. Samples producing negative results with both methods
were excluded from the study, leaving a total of 62 sera for further analysis by
RFLP of the 5' NCR and serotyping.
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Egypt.
52 samples were obtained from patients with chronic hepatitis C in Cairo
(Professor A. El-Zayadi, Cairo Liver Centre, Giza, Egypt) and analysed by PCR,
RFLP and serotyping using the 1-6 ELISA.
Taiwan.
A set of 49 HCV positive blood donor samples from Taiwan were obtained
from a larger study performed by Dr. F. Davidson. Samples had been previously
analysed by PCR and the HCV genotype determined by RFLP in those which were
positive.
Norway.
A total of 118 samples from Norwegian patients with chronic HCV were
collected (Dr. Helge Bell, Aker University Hospital, Oslo), and analysed by PCR
and RFLP to determine the genotype of HCV causing infection.
3.3.3 RESULTS.
Pakistan
Virus RNA was amplified in 48/62 HCV antibody positive samples, and
RFLP analysis of the 5' NCR revealed genotype 1 in 3 samples (6.25%), type 2 in
1 sample (2.1%), type 3 in 43 samples (89.6%) and type 5 in 1 sample (2.1%).
When all 62 samples were analysed with the 1-6 serotyping assay (Table
3.3a), both the sensitivity and specificity of the ELISA towards type 3 was low.
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Type-specific antibody was detected in only 23/43 (52.3%) type 3 samples, while
two samples that were type 3 by RFLP were serotyped as type 2 or type 4.
Type specific antibody was detected in 6/14 PCR negative samples, 5 of
which were serotyped as type 3. Sequence analysis in the 5' NCR of two samples
identified by RFLP as type 3 (one of each producing NTS and NR results on the
ELISA) revealed that these variants were more specifically type 3b. RFLP analysis
of these samples was carried out by Miss. J. Ellender.
Egypt.
From a total of 51 samples, 35 were PCR positive and could be genotyped
by RFLP. Apart from one type 1 sample, all were type 4 (34/35; 97.1%). Type-
specific antibody was detected in 37 sera (Table 3.3b), and was in each case
concordant with the genotype identified by RFLP. Of 34 samples from individuals
infected with type 4, type-specific antibody was detected in 27 (sensitivity 79.4%)
with the remaining 7 samples untypeable despite showing reactivity towards NS4
peptides in the unblocked control well of the assay (NTS). Similarly, of the 16
samples which were PCR negative, 8 were serotype 4, 1 was serotype 1 and 3
samples showed non-type-specific reactivity towards NS4 peptides although 4 were
unreactive.
Taiwan.
Genotyping of 49 samples from Taiwan by RFLP prior to this study
(Davidson 1995) had revealed subtypes la (n=2), lb (n=27), 2a (n=14), 2b (n=4)
with 2 samples negative by PCR. The sensitivity of the serotyping assay in this
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study ranged from 77.8% (type lb) and 78.6% (type 2a) to 100% for types la and
2b (Table 3.3c). The only discrepant result was a genotype 2 sample which was
serotyped as type 1. Both PCR negative samples were identified as type 1 by
serotyping.
Norway.
The genotype distribution in 108 Norwegian samples HCV positive by PCR
was 24.1% type la, 10.2% lb, 13.0% 2b, 50.9% 3a and 0.9% type 4. Ten sera
were PCR negative.
The overall sensitivity of the serotyping assay was 93.5% (101/108
samples), with the detection of type-specific antibody corresponding to the
genotype identified by RFLP in all but 2 samples (Table 3.3d). All but one of the
samples which were negative could be serotyped, and consisted of three serotype
1, one serotype 2 and five serotype 3.
3.3.4 DISCUSSION.
In this study, the 1-6 serotyping ELISA was applied to samples obtained
from various different populations to investigate the distribution of HCV variants
causing infection in these areas, and to estimate the ability of the assay in the
detection of type-specific antibody generated towards them.
Prior to this study, the HCV genotype distribution in Pakistan had not been
investigated. Infection with type 3 was identified by RFLP in the vast majority of
samples (89.6%) with the remainder type 1, 2 or 5. The predominance of type 3
93
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in this area has since been confirmed in a study by Tong et al in which 15 HCV
positive samples were type 3 by RFLP (Tong et al., 1996). The sensitivity of the
serotyping assay for type 3 was much lower for isolates originating from Pakistan
(sensitivity 52.3%) than for Norway (sensitivity 92.7%) (Table 3.3.4). The type 3
peptides used in the assay are derived from subtype 3a sequences, and the
Norwegian patients are likely to be infected with this subtype, as sequence analysis
of type 3 isolates in Europe has revealed the majority to be subtype 3a (McOmish
et al., 1994; Bukh et al., 1993). In contrast, the existence of novel subtypes of type
3 in Pakistan, India, Bangladesh and Nepal has been established by sequence
analysis in other studies (Valliammai et al., 1995; Tokita et al., 1994; Mellor et al.,
1995). The relatively low sensitivity of the serotyping assay in Pakistan suggests
that the level of amino acid variation between type 3 subtypes may be sufficient
to prevent the recognition of type-specific antibody by type 3a peptides alone.
Indeed, two of the samples which were untypeable by serotyping were type 3b by
sequence analysis. The sensitivity of the serotyping assay to type 3 variants could
theoretically be increased by the addition of peptides specific to further subtypes.
However, at least seven and possibly as many as seventeen subtypes of type 3 have
been described, and so this may not be practical.
The high prevalence of type 4 in Egypt described previously (McOmish et
al., 1994; Simmonds et al., 1993) was confirmed in this study. Although nine
subtypes of type 4 were identified among a relatively small number of HCV
infected individuals in regions of Central Africa (Stuyver et al., 1994; Bukh et al.,
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1994; Bukh et al., 1993), the majority of type 4 infections in Egypt are thought to
be caused by type 4a. The serotyping of 79.4% type 4 Egyptian samples using type
4a peptides is consistent with this although the inability to serotype seven genotype
4 samples suggests the presence of additional subtypes.
The serotyping ELISA was able to detect extra genotypes not previously
observed in some of the study groups, for example, type 4 in Norway and type 5
in Pakistan. Risk factors were not available for these individuals, but it is likely
that these infections have been acquired elsewhere, perhaps if the individual was
an immigrant. Although the different HCV genotypes display specific geographical
distributions, the recent increase in world travel and immigration has tended to
break down these differences. For example, type 4 infections have been described
in the U.S.A. (Lau et al., 1996), types 4, 5 and 6 in France (Stuyver et al., 1996a;
Pawlotsky et al., 1997a) and type 5 in Ireland (Chamberlain et al., 1997), so the
assay should be efficient not only in the identification of genotypes commonly
found in a specific region but also in the isolation of unusual variants within a
larger population. Certain genotyping methods, for example the use of type-specific
primers for the amplification of virus DNA by PCR (Okamoto et al., 1990;
Okamoto et al., 1992), are designed to be able to identify genotypes present in a
specific area, and will therefore be unable to recognise unusual variants, or will
identify them incorrectly.
Although the addition of peptides specific for certain HCV subtypes (la, lb,
2a, 2b, 2c) to the assay has increased the sensitivity of the ELISA towards these
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isolates, the level of antigenic variation between these subtypes is too low for the
assay to be able to distinguish between them. Although certain genotyping methods
are able to distinguish between some HCV subtypes, for example types la/b, 2a/b
and 3a/b by RFLP of the 5' NCR (Davidson et al., 1995) and la/b, 2a/b by the line
probe assay (Stuyver et al., 1996b), problems may still be encountered. The
nucleotide sequences for types 2a/2c in the 5' NCR are too similar to allow these
subtypes to be distinguished by either method, and similarly, the identity between
novel subtypes of type 6 and type 1 in this region has prevented the identification
of these isolates by such assays (discussed in chapter 5).
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CHAPTER 4
4 THE ROLE OF NS4 ANTIGENIC REGION 3 IN HCV
SEROTYPING.
4.1 GENERAL INTRODUCTION.
The previous chapter has described how the prototype serotyping ELISA for
HCV genotypes 1-3 using synthetic peptides corresponding to two antigenic regions
in NS4, was successfully extended to identify antibody to all six genotypes.
Although the sensitivity and specificity of the 1-6 serotyping assay was high,
differences in reactivity were observed for individual genotypes. Type-specific
antibody was detected in 80.6%, 68.8% and 66.6% samples infected with types 4,
5 and 6 respectively compared with 92.3%, 96.9% and 92.7% for samples infected
with types 1, 2 and 3 (chapter 3; Table 3.2.4.). A comparison of NS4 sequences for
all six genotypes (chapter 3; Figure 3.2.1) revealed similarities between region 1
peptides of types 1, 4, 5 and 6, suggesting that cross-reactivity in region 1 may
account for the reduced sensitivity of the assay for types 4-6 since successful
serotyping would therefore rely on antibody produced towards antigenic region 2.
In order to overcome this problem, the possibility of including a third
antigenic region was investigated.
4.2 SYNTHETIC PEPTIDES FOR ANTIGENIC REGION 3.
Epitope mapping of the NS4 region (Simmonds et al., 1993d) was
previously carried out using a set of 82 overlapping nonapeptides from amino acid
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positions 1679-1768, each overlapping the preceding peptide by eight residues.
Antibody reactivity to individual peptides revealed two major antigenic regions,
spanning amino acid positions 1691-1708 (region 1) and 1720-1738 (region 2).
Reactivity towards a third region was also detected (Figure 4.2) which covered a
less defined area, ranging from amino acid positions 1743-1755 in type lb while
extending to position 1763 in types la and 2b, but with only intermittent peaks of
reactivity towards peptides corresponding to type 3 sequences. A comparison of
NS4 sequences (chapter 3; Figure 3.2.1) revealed significant levels of amino acid
variation between the six major genotypes, and consequently peptides spanning
region 3 were synthesised (corresponding to amino acids 1738-1757) for genotypes
la, lb, lc, 2a, 2b, 2c, 3a, 3b, 4, 5 and 6 (Table 4.2).
Region 3 peptides were incorporated into the serotyping ELISA in three
ways; (i) regions 1 and 3, (ii) regions 2 and 3 and (iii) regions 1, 2 and 3, and the
antibody reactivity to each compared with that observed with the standard assay
using regions 1 and 2. Concentrations of peptides used both for coating microtitre
plates and in competing peptide solutions were identical for each version of the
assay, as was the concentration of serum used for each test. All proceedures and
conditions for each assay, such as incubation times and temperatures, were also
kept constant.
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Table 4.2 AMINO ACID SEQUENCES FOR NS4 PEPTIDES IN
ANTIGENIC REGION 3












Sequence identity to type la sequence
4.3 SAMPLES.
Samples were as described for chapter 3, section 3.3.2 and were from
Norway (type la, n=10; type lb, n=10; type 2b, n=10; type 3, n=20), Taiwan (type
2a, n=9) or Egypt (type 4, n=20). Samples from individuals infected with types 5
(n=5) or 6 (n=2) had also been used previously in the evaluation of the serotyping
ELISA (section 3.2.3).
Where sufficient volumes of serum were available, each sample was tested
in triplicate using all four versions of the assay. The serotype of antibody within
each sample was inferred from the mean of the absorbance readings from all three
results.
4.4 RESULTS
Significant differences were observed between the overall sensitivity of each
assay for all virus genotypes and also in the serological reactivity induced by
individual virus genotypes to different combinations of NS4 peptides. The
serotyping ELISA that used antigenic regions 1 and 3 was by far the least efficient
of the four assays, with type-specific antibody being detected in only 42.9%
samples tested (Table 4.4a). Of 18 type 4 samples, the only three sera that were
typeable using peptides designed towards regions 1 or 3, were mistyped, and the
majority of type 4 samples (14/18) displayed non-type-specific reactivity. The
sensitivity of the 1+3 assay for other genotypes was also low, ranging from 0%
(type 6) to 65% (type 3). However, the type-specific antibody detected in samples
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from individuals infected with types la, lb, 2a, 2b and 5 were all concordant with
the genotype identified by RFLP analysis.
In contrast, the other three versions of the ELISA (regions 2 and 3, regions
1, 2 and 3 and the standard assay using regions 1 and 2) were all more sensitive.
The overall sensitivity of the assay based on regions 2 and 3 (Table 4.4b) was
75.6%, although this assay was only able to detect type-specific antibody in 4/9
(44.4%) samples from individuals infected with type 2a in comparison with 5/9
samples for the 1+3 assay. On the other hand, the 2+3 assay detected type-specific
antibody in 100% of samples from individuals infected with type la (regions 1 and
3; 40%) and 85% of samples from individuals infected with type 4 (region 1 and
3; 16.7%). Serotyping using regions 2 and 3 was accurate in the majority of cases
except for type 3 samples, where two discrepant results were observed with
reactivity towards type 1 and type 5 peptides, while one sample from an individual
infected with type lb was identified as type 6.
The overall performance of assays using antigens derived from regions 1
and 2 (Table 4.4d), or from all three regions (Table 4.4c) was identical, although
there were slight differences in the sensitivity and specificity towards individual
genotypes. The presence of region 3 peptides seemed to enhance type-specific
reactivity for one sample infected with type 2a, but reduced reactivity for single
samples from individuals infected with type 2b or type 3. The significance of
region 3 peptides for the detection of type 6-specific antibody was difficult to
determine, as only two samples with sufficient volumes were available. However,
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Table 4.4a DETECTION OF TYPE-SPECIFIC ANTIBODY IN HCV
POSITIVE SAMPLES USING A SEROTYPING ELISA BASED ON NS4
PEPTIDES FROM ANTIGENIC REGIONS 1 AND 3
Genotype Serotype
(RFLP) 1 2 3 4 5 6 NTS* NRf Total Sensitivity Concordance
la 4 . . - - 5 1 10 40% 100%
lb 3 - - - 4 3 10 30% 100%
2a - 5 - - - - 2 2 9 55.6% 100%
b - 6 - - - - 2 2 10 60% 100%
3 - - 12 -■ - 1 4 3 20 65% 92.3%
4 1 2 - ■- - - 14 1 18 16.7% 0%
5 - - 1 - 5 - 5 20% 100%
6 2 - 2 0% n/a
Total 38 12 84 42.9% 88.9%
Table 4.4b DETECTION OF TYPE-SPECIFIC ANTIBODY IN HCV
POSITIVE SAMPLES USING A SEROTYPING ELISA BASED ON NS4
PEPTIDES FROM ANTIGENIC REGIONS 2 AND 3
Genotype
(RFLP) 1 2 3
Serotype
4 5 6 NTS NR Total Sensitivity Concordance
la 10 10 100% 100%
lb 7 - - - 1 - 2 10 80% 87.5%
2a - 4 - - - 3 2 9 44.4% 100%
2b - 9 - - - 1 - 10 90% 100%
3 1 - 12 - 1 - 5 1 20 70% 85.7%
4 - - - 17 - - - 3 20 85% 100%
5 - - - 2 - - 3 5 40% 100%
6 1 - 1 2 50% 100%
Total 9 12 86 75.6% 95.4%
* Non-type-specific reactivity (appendix 1.0)
t Non reactive
Table 4.4c DETECTION OF TYPE-SPECIFIC ANTIBODY IN HCV
POSITIVE SAMPLES USING A SEROTYPING ELISA BASED ON NS4
PEPTIDES FROM ANTIGENIC REGIONS 1, 2 AND 3
Genotype Serotype
(RFLP) 1 2 3 4 5 6 NTS* NRf Total Sensitivity Concordance
la 10 _ 10 100% 100%
lb 7 - - - 1 1 1 10 80% 87.5%
2a - 9 9 100% 100%
2b - 9 - 1 - 10 90% 100%
3 - - 14 - - 1 3 2 20 75% 93.3%
4 - - - 16 - - 4 - 20 80% 100%
5 - - - 2 - 2 1 5 40% 100%
6 - - - - 1 1 - 2 50% 100%
Total 12 4 86 81.4% 97.1%
Table 4.4d DETECTION OF TYPE-SPECIFIC ANTIBODY IN HCV
POSITIVE SAMPLES USING A SEROTYPING ELISA BASED ON NS4
PEPTIDES FROM ANTIGENIC REGIONS 1 AND 2
Genotype
(RFLP) 1 2 3
Serotype
4 5 6 NTS NR Total Sensitivity Concordance
la 10 10 100% 100%
lb 7 - - - 1 1 1 10 80% 87.5%
2a - 8 - - - 1 - 9 88.9% 100%
2b - 10 10 100% 100%
3 - - 15 - 1 1 3 20 80% 93.8%
4 - - - 16 - - 4 - 20 80% 100%
5 - - - 2 - 2 1 5 40% 100%
6 - 2 2 0% n/a
Total 9 7 86 81.4% 97.1%
* Non-type-specific antibody (appendix 1.0)
t Non reactive
Table 4.5 A COMPARISON OF ABSORBANCE VALUES FROM
INDIVIDUAL SAMPLES PRODUCING DIFFERENT RESULTS WITH
FOUR VERSIONS OF THE SEROTYPING ASSAY
Well on Microtitre plate




1.696 0.057 1.800 0.061 0.068 0.082 0.080 0.094 1
1+3 1.202 0.018 0.034 0.030 0.034 0.014 0.012 0.023 NTSij:
2+3 0.739 0.062 1.786 0.103 0.100 0.074 0.138 0.093 1




1.158 0.032 1.302 0.028 0.024 0.031 0.050 0.051 1
1+3 0.044 0.006 0.007 0.029 0.003 0.007 0.000 0.016 NRU
2+3 1.464 0.050 1.379 0.029 0.041 0.118 0.076 0.216 1




1.771 0.028 0.049 1.741 0.078 0.087 0.050 0.038 2
1+3 1.853 0.025 0.044 1.782 0.037 0.052 0.046 0.025 2
2+3 0.014 0.013 0.011 0.018 0.002 0.004 0.016 0.020 NR




0.508 0.017 0.022 0.538 0.023 0.026 0.015 0.015 2
1+3 0.012 0.012 0.036 0.037 0.036 0.033 0.027 0.033 NR
2+3 0.775 0.039 0.050 0.700 0.026 0.021 0.045 0.072 2




1.812 0.170 0.210 0.147 1.801 0.055 0.035 0.044 3
1+3 1.760 0.019 0.046 0.020 1.733 0.042 0.053 0.025 3
2+3 1.057 0.060 0.140 0.081 0.932 0.061 0.041 0.057 3




1.932 0.294 0.347 0.446 0.228 1.789 0.222 0.277 4
1+3 1.757 0.046 0.169 0.067 0.087 0.100 0.150 0.139 NTS
2+3 1.864 0.438 0.062 0.067 0.218 1.830 0.182 0.334 4




1.529 0.370 0.444 0.383 0.318 0.416 1.837 0.362 5
1+3 1.878 0.127 0.117 0.164 0.197 0.094 0.175 0.112 NTS
2+3 1.611 0.228 0.404 0.449 0.293 0.330 1.563 0.269 5




0.186 0.039 0.029 0.058 0.032 0.030 0.040 0.128 6
1+3 0.757 0.042 0.072 0.051 0.124 0.046 0.035 0.041 NTS
2+3 0.132 0.024 0.030 0.042 0.029 0.021 0.022 0.116 6
1+2+3 0.215 0.028 0.030 0.038 0.020 0.038 0.037 0.113 6
* Unblocked positive control well f Fully blocked negative control well
$ Non-type specific reactivity H Non reactive
one of these samples was typeable by the assays which included regions 2 and 3
together.
4.5 DISCUSSION.
Despite the ability of the 1-6 serotyping ELISA to detect type-specific
antibody in samples from HCV infected patients from various geographical
locations, the extensive heterogeneity observed between different isolates creates
a constant challenge for the improvement of assay sensitivity and specificity. One
reason for the lower sensitivity of the 1-6 assay observed for types 4-6 in some
studies (Bhattacherjee et al., 1995) could be amino acid sequence similarity
between these genotypes and type 1 in NS4 antigenic region 1.
A panel of samples was analysed using four versions of the assay,
consisting of each possible combination of peptides for three antigenic regions of
NS4. The results indicate that the presence of peptides corresponding to antigenic
region 2 of NS4 is essential for the discrimination between type-specific antibody
induced by different HCV genotypes. The sensitivity of the assay based on regions
1 and 3 alone was only 42.9%, compared with 75.6%-81.4% observed using other
combinations of antigenic regions but including region 2. Type 6-specific antibody
was only detected in the presence of both antigenic regions 2 and 3, although only
two samples were available and further studies using additional samples would be
necessary to confirm this.
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A detailed comparison of absorbance values in individual typing wells for
the same sample in different versions of the assay revealed that type-specific
reactivity was often dependent on only one antigenic region (Table 4.5). For
example samples N4, N17, N2, EG3, C1016116 and T3950 were only typeable
using versions of the assay which included antigenic region 2. Similarly, antibody
specific to type 2a was dependent upon the presence of antigenic region 1 peptides
in sample T3, as the sensitivity of the assay based on regions 2 and 3 was only
44.4%. In samples where serotyping was dependent on region 2 alone, antibody
generated towards antigenic region 1 or 3 might be present in the serum but remain
undetected because of to cross reactivity with heterologous competing peptides.
Such cross reactivity may occur between type 1 peptides for region 1 and those for
types 4-6 because of their relatively high level of amino acid sequence identity, but
cross reactivity seems unlikely for antigenic region 3 where the level of identity is
lower.
The specificity of all versions of the serotyping assays was relatively high,
with the lowest value observed for the regions 1+3 assay (88.9%). In the absence
of region 2 the majority of samples infected with type 4 (83.3%) were untypeable,
and the three samples in which type-specific antibody could be detected were
identified as either type 1 or type 2. The amino acid sequence "QPAV" is present
both at the beginning of the genotype 4 region 1 peptide, and within the type 2a
region 3 peptide and cross-reactivity between these peptides may contribute towards
the misidentification of type 4 samples. The large number of type 4 samples with
102
"NTS" reactivity with the 1+3 assay confirms the suspicion that region 1 peptides
for type 4 cross react with those for type 1, and that an antibody response to region
3 is either rare, or also lacking in specificity. Similarly, the difference in the
sensitivity of the 1+3 assay towards different HCV genotypes may reflect the
amount of sequence similarity between type 1 and type 4-6 peptides for antigenic
region 1, as type-specific antibody could be detected in 55-65% samples infected
with types 2a, 2b or 3, compared with 0-40% samples infected with types 1, 4, 5
or 6.
One of the major disadvantages of the 1-6 serotyping assay in comparison
with many PCR-based genotyping assays is the inability to distinguish between
different subtypes of HCV. A number of groups have suggested that a greater
pathogenicity (Hatzakis et al., 1996; Tanaka et al., 1996), and a lower rate of
sustained response to interferon therapy (Pawlotsky et al., 1996; Martinot Peignoux
et al., 1995; Tsubota et al., 1994) may be associated not simply with infections
caused by type 1, but specifically by type lb. If these associations are confirmed,
the importance of subtyping would be greatly increased. The type 1 specific
peptides for antigenic region 3 display a number of subtype-specific amino acid
motifs (Table 4.2), which could possibly be exploited in an ELISA for subtyping.
However, the low frequency of antibody reactivity to region 3 peptides observed
in this study suggests that the sensitivity of such an assay would be low.
Since no significant improvement was observed in the sensitivity and
specificity of the serotyping ELISA with the addition of peptides for antigenic
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5 HCV INFECTION IN HONG KONG; PROPERTIES OF
GENOTYPE 6.
5.1 GENERAL INTRODUCTION.
The discovery of unusual HCV variants in samples from Hong Kong, which
contained a characteristic 2bp insertion in the 5' NCR at position -143 (Simmonds
et al., 1993c; Bukh et al., 1992c) preceded the classification of these variants based
on sequence analysis of NS5 as a new major virus genotype (type 6a) (Simmonds
et al., 1993b). Geographical surveys of the distribution of HCV genotypes revealed
that type 6a infections were common only in South East Asia (Tokita et al., 1994a;
Davidson et al., 1995a; McOmish et al., 1994a). The restricted distribution of this
genotype has limited the number of samples available for analysis. Although a few
sequences have been obtained for El (Bukh et al., 1993) and core (Zhang et al.,
1995; Bukh et al., 1994), the level of genetic heterogeneity within type 6a, and the
existence of additional subtypes has been relatively unexplored.
More recently, several groups have reported the existence of novel
genotypes related to type 6a of countries in South East Asia such as Thailand and
Vietnam (Tokita et al., 1994a; Mellor et al., 1995a; Apichartpiyakul et al., 1994a).
Although these variants are closely related to type 6a, the levels of sequence
variability between these viruses is higher than observed between subtypes of other
HCV genotypes. For this reason, the classification of these variants as either
additional major genotypes 7, 8 and 9 (Tokita et al., 1995; Tokita et al., 1994), or
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as diverse subtypes of type 6 (Delamballerie et al., 1997; Simmonds et al., 1996;
Mizokami et al., 1996) has been a matter of debate. Although the coexistence of
type 6 group variants with type 6a has been confirmed in Vietnam (Tokita et al.,
1994a), the presence of these variants in Hong Kong has yet to be investigated.
The availability of a large set of samples from blood donors in Hong Kong
allowed an extensive study of both the sequence variation within HCV type 6 and
clinical features associated with infection with this genotype.
5.2 IDENTIFICATION OF HCV INFECTION IN BLOOD DONORS
FROM HONG KONG.
5.2.1 INTRODUCTION
There are several reports on the prevalence of HCV infection in different
groups of individuals from Hong Kong. HCV antibody was detected in 0.5%
samples from individuals in the general population (n=910), compared with 70%
for a cohort consisting of intravenous drug users, haemophiliacs and patients with
chronic NANB hepatitis (Chan et al., 1992). Similarly, the prevalence of anti-HCV
among blood donors in Hong Kong was reported as 0.4% (Lin et al., 1992),
although this study group was restricted to donors who were negative for hepatitis
B surface antigen (HBsAg). A larger study of 29,000 blood donors confirmed the
presence of HCV RNA by RT-PCR in 0.13% subjects tested (McOmish et al.,
1994). The number of HCV viraemic blood donors in this study was almost double
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that among Scottish blood donors (0.07%) but less than that in other countries such
as Egypt (8.7%) and Taiwan (1.7%) (McOmish et al., 1994).
5.2.2 SAMPLES
Samples were obtained from voluntary blood donors attending the Hong
Kong Red Cross Blood Transfusion Service in 1991-1994. 900 samples that were
repeatedly reactive using the Abbott 2nd generation EIA, and were either positive
or indeterminate upon supplementary testing with the Abbott Matrix 2nd generation
recombinant immunoblot assay (RIBA 2.0) were analysed in this study.
In this study, the detection of HCV RNA in anti-HCV positive samples
selected from blood donors in Hong Kong was carried out using the RT-PCR, and
the presence of HCV antibody confirmed using a third generation enzyme-
immunoassay (EIA) (Murex VK48).
5.2.3 RESULTS
Each sample was re-tested with the Murex anti-HCV screening ELISA
producing similar results to those obtained with the Abbott 2nd generation assay
used for routine analysis of donations in Hong Kong. Analysis of the first 200
samples revealed that absorbance values for samples with indeterminate RIBA
reactivity, were lower than those in samples that were unequivocally positive by
RIBA.
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Figure 5.2.3 CORRELATION BETWEEN HCV VIRAEMIA AND RIBA
REACTIVITY IN BLOOD DONOR SAMPLES FROM HONG KONG
200 samples
(anti-HCV positive)
93 RIBA positive 107 RIBA indeterminate
14 PCR 79 PCR 106 PCR 1 PCR
negative positive negative positive
(15.1%) (84.9%) (99.1%) (0.9%)
HCV RNA was detected by PCR of the 5'NCR in 80/200 samples. A
breakdown of results for the 200 anti-HCV positive samples tested revealed that the
majority of viraemic donors (79/80) were also RIBA positive (Figure 5.2.3). HCV
RNA was detected in 79/93 (84.9%) RIBA positive samples, but in only 1/107
(0.9%) samples with indeterminate RIBA reactivity. This single PCR positive,
RIBA indeterminate sample was also negative with the Murex anti-HCV screening
ELISA and was from a donor with a normal ALT level (17.1U/L).
5.2.4 DISCUSSION
Because anti-HCV screening assays often produce false positive results, the
capability of supplementary tests such as RIBA for the confirmation of infection
with HCV needs to be high. The consistently higher absorbance values on the
Murex anti-HCV ELISA with RIBA positive samples was expected, since the
antigens used in each assay are similar (Core, NS3 and NS4).
The Abbott Matrix RIBA supplementary test used in this study was able to
discriminate between the majority of viraemic blood donors, with 79/80 PCR
positive samples confirmed by the assay, and only one PCR positive sample RIBA
indeterminate. However, 15.1% of RIBA-confirmed samples were PCR negative,
and are likely to represent donors who have cleared virus infection but have
circulating HCV antibody. All but one of the samples with indeterminate RIBA
status were negative by PCR, and may therefore represent non specific cross-
reactivity towards antigens in the assay. Alternatively, these samples may have
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come from individuals who cleared HCV infection long ago and in whom the level
of circulating antibody has fallen. One PCR positive sample was positive by Abbott
anti-HCV ELISA and displayed indeterminate RIBA reactivity but gave a negative
result with the Murex anti-HCV assay. This was from a donor with a normal ALT
level. This donor may have been infected recently, and undergoing seroconversion
at the time when the sample was collected. HCV infected blood taken before
seroconversion will not be detected by serological screening assays. Blood taken
from a donor in this situation creates a risk that infected blood will be transfused.
The only safeguard against HCV transmission from this type of sample is the
routine screening of all donations by PCR, which under current technologies is
expensive and time consuming. However, since plasma pool screening by PCR in
the U.K. and Europe becomes mandatory in April 1998, there is a pressure to
develop automated PCR screening methodology that can be used routinely in blood
donor centres. Routine donor screening by HCV PCR has already been initiated in
Germany and is under development in the U.K.
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5.3 IDENTIFICATION OF HCV GENOTYPES IN HONG KONG
5.3.1 INTRODUCTION
The study of the geographical distribution of HCV genotypes has had
important implications for many aspects of HCV research and clinical practice,
including epidemiological studies (Power et al., 1995), the prediction of disease
outcome (Zein et al., 1996) and the efficient detection of the virus in infected
individuals (Salmeron et al., 1996). Although a number of different genotyping
assays have been described, these are often only able to detect genotypes which are
broadly distributed around the world such as types 1, 2 and 3 (Smith et al., 1995a).
Such assays would be inappropriate in populations where genotypes 4, 5 and 6 are
prevalent. A previous study using RFLP of sequences amplified from the HCV 5'
NCR has revealed that type 6a is responsible for nearly one third of HCV
infections in Hong Kong blood donors (McOmish et al., 1994). Other reports have
described the presence of type 6a in neighbouring countries such as Macau and
Vietnam, where it accounts for 22% and 19% of infections respectively (Tokita et
al., 1994a; Davidson et al., 1995a; Tokita et al., 1995a).
Recently, variants of type 6 have been identified in South East Asia, that
may have 5' NCR sequences identical to those present in types la or lb (Mellor
et al., 1995; Tokita et al., 1994), and which may therefore have been typed
incorrectly in previous studies which have relied on assays based on the 5' NCR.
Two additional RFLP assays have recently been developed, which provide a
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method for distinguishing between these type 6 variants and type 1 in both the 5'
NCR and core (Mellor et al., 1996). Restriction enzyme digestion of 5' NCR
sequences with Dde \/Hpa II (because of single base polymorphisms present in
some variants of the type 6 group), produces distinct patterns with type 1 isolates
(pattern A), type 6a (pattern D) and type 6 group variants (patterns B and C). Other
variants of the type 6 group which have identical 5' NCR sequences to types la or
lb can be identified by RFLP analysis of the core region. Cleavage with the
enzymes Ava I and Sma I in separate reactions results in distinct patterns of
fragments for type 1 sequences (type la - alsl or a2sl; type lb - a3sl or a4s5)
from those produced by members of the type 6 group (type 6a - al2s5; type 6
group variants - alOsl, al2s5 or al3s5) (Mellor et al., 1996).
The presence of type 6 group variant viruses was investigated in Hong
Kong using RFLP analysis based on 5' NCR and core regions, and sequence
analysis.
5.3.2 SAMPLES
From 264 RIBA confirmed and 107 RIBA indeterminate samples obtained
from blood donors in Hong Kong (section 5.2), a total of 212 that were PCR
positive (211/264 RIBA confirmed and 1/107 RIBA indeterminate) were genotyped.
All samples were analysed using the three versions of the RFLP assay in the 5'
NCR; (1) enzymes Rsa \/Hae III and Mva l/Hinf I for the identification of
genotypes 1-6 (McOmish et al., 1994; Davidson et al., 1995) (2) identification of
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subtypes la/lb using Bst UI and 2a/2b, 3a/3b using Scr FI (Davidson et al., 1995),
and (3) differentiation between type 1 sequences and certain type 6 group variants
using a combination of the enzymes Dde l/Hpa II (Mellor et al., 1996). All type
1 or type 6 samples (n=73) were also analysed with a core based RFLP assay for
the presence of type 6 group variants.
5.3.3 RESULTS
In order to investigate the presence of type 6 group variants in HCV
positive blood donors from Hong Kong, a subset of 73 samples were initially
genotyped (and subtyped) by RFLP analysis of the 5' NCR (McOmish et al., 1994;
Davidson et al., 1995). Samples provisionally identified as either types 1 or 6 by
this method were subjected to two additional enzyme digestion reactions (Dde
l/Hpa II in the 5' NCR; Ava I and Sma I in core) to enable sequences
corresponding to the novel type 6 variants to be distinguished (Mellor et al., 1995).
All samples except two produced recognisable restriction patterns upon
digestion with Rsa l/Hae III and Mva l/Hinf I, allowing the genotype to be
identified (Table 5.3.3a). Two samples produced unusual combinations of
restriction patterns (dA and eA). Subtyping using enzyme Bst UI (type 1 samples)
or Scr fl (type 2 or 3 samples) confirmed the presence of types la, lb, 2a, 2b and
6.
All samples with a type 1 RFLP pattern in the 5'NCR were further analysed
using Dde l/Hpa II and consistently produced pattern A, confirming that none of
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Figure 5.3.3a CLEAVAGE PATTERNS PRODUCED WITH TYPES 1
AND 6 WITH ENZYMES Dde l/Hpall.
A 67 27 12 18 127
B 67 27 12 145
C 67 27 12 18 25 102
D 67 27 12 18 130
E 67 27 12 148
F 67 27 12 18 28 102
Cleavage sites are indicated by vertical lines.
Numbers represent the sizes of DNA fragments in base pairs.
Patterns A-D are as described previously in Mellor et al., 1996.i.e.A=type la, B
and C represent type 6 group variants, D= type 6a.
Patterns E and F represent sequences obtained in this study.
Table 5.3.3b HCV GENOTYPE DISTRIBUTION IN BLOOD DONORS
FROM HONG KONG











* Mixed infection with genotypes 3a and 6a
Figure 5.3.3b PHYLOGENETIC ANALYSIS OF CORE SEQUENCES
AMPLIFIED FROM HONG KONG BLOOD DONORS INFECTED WITH
HCV TYPE 6a
6variant
Core sequences amplified from blood donors infected with type 6a were compared
with representatives of other genotypes, using the programs DNADIST and
NEIGHBOR from the PHYLIP package (Felsenstein et al., 1993), and are shown
as an unrooted tree.
these sequences contained substitutions at positions -127 or -155 characteristic of
certain type 6 group variants (Table 5.3.3a and Figure 5.3.3a). Cleavage of samples
from individuals with type 6 with these enzymes produced pattern D.
RFLP analysis of type 1 samples in the core region did not reveal any of
the restriction patterns associated with type 6 group variants (alO-13, sl/s5) and
was successful in distinguishing between types la (pattern al) and lb (pattern a3).
All type 6 samples analysed produced pattern al2s5, and these were confirmed as
subtype 6a by sequence analysis of the core gene. Phylogenetic analysis of 20 type
6a core sequences revealed a high level of sequence conservation within isolates
from Hong Kong, as demonstrated by a tight cluster of branches on the
phylogenetic tree (Figure 5.3.3b).
The two samples producing unusual results with enzymes Rsa l/Hae III
were identified as type lb by core RFLP, and this was confirmed for one of these
samples by sequencing of the core gene. All results from RFLP analysis of the 5'
NCR were consistent with RFLP and sequence analysis of the core gene (Table
5.3.3a).
The remaining 139 samples were therefore typed using all 5'NCR RFLP
assays. All 139 samples produced recognisable patterns of fragments with both the
genotyping and subtyping RFLP assays, but unusual restriction patterns were
observed for two samples (HK582 and HK620) upon digestion with Dde l/Hpa II.
These patterns were similar to pattern D produced by type 6a sequences, although
each contained both a 130bp fragment and an additional larger (HK582) or smaller
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(HK620) band. In order to investigate the possibility that these unusual patterns
represented mixed infections, virus sequences were obtained by amplification of
cDNA at limiting dilution. Three different patterns were observed among single
cDNA molecules amplified from HK582, including patterns A, D and a new pattern
provisionally named E (Figure 5.3.3a). Single molecules from HK620 produced a
combination of patterns D and a new pattern F which was similar to pattern C
produced by certain type 6 group variants. Sequence analysis of the amplified 5'
NCR from each of the different single molecules revealed three different virus
sequences in HK582, including type 3a (which had produced pattern A by RFLP
analysis) and two different sequences each containing the CA insertion at position
-146 and C at position -138 characteristic of type 6a sequences. This individual
therefore has a mixed infection with types 3a and 6a. The production of pattern E
by these type 6a isolates in addition to pattern D can be explained by a nucleotide
substitution at position -154 of C for T in one of the sequences causing the loss of
an Hpa II cleavage site. Sequence analysis of amplified 5' NCR from the different
single molecules producing restriction patterns D and F from sample HK620
revealed three distinct sequences all corresponding to type 6a. Although one of
these sequences produced pattern D typical of this subtype, the nucleotide
substitution of A for G at position -126 in the other two sequences presented a
cleavage site for Dde I identical to that observed in certain type 6 group variants
originally classified as NGII (Mellor et al., 1996). However, despite this region of
sequence identity, these sequences were classified as type 6a because of the
114
presence of the insertions at positions -146 and -138, which are exclusive to this
subtype.
The HCV genotypes identified in this survey (Table 5.3.3b) included type
la (n=13), lb (n=127), 2a (n=8), 2b (n=3), 3a (n=4) and 6a (n=56) and a mixed
infection with types 3a and 6a in one donor.
The reactivity of samples from donors infected with each genotype towards
each of the type la specific antigens in the Abbott Matrix RIBA (core, NS3, and
NS4) was compared (Table 5.3.3c). All samples from donors infected with type la
were reactive against all antigens in the assay, in comparison with only 88% type
lb and 67% type 6a samples. No significant difference in the reactivity towards
core or NS3 antigens was found between genotypes, but 11% type lb sera and 32%
type 6a sera were unreactive towards the NS4 antigen.
5.3.4 DISCUSSION
This survey has revealed that the majority of HCV positive blood donors
from Hong Kong are infected with HCV type lb (59.9%) or type 6a (26.4%), with
the remainder infected with types la (6.2%), 2a (1.4%), 2b (1.4%), 3a (1.9%) or
a mixed infection with types 3a and 6a (0.5%). These results are similar to those
found in a previous study of 37 donors, in which type 6a was responsible for 32%
infections (McOmish et al., 1994), although type 3 had not been detected in this
population previously. In contrast, a survey of the genotype distribution in HCV
positive patients with chronic hepatitis from Hong Kong revealed type 6 infection
115







































* atle st1fromtwoNS-4reactionsinhessay,(antigexpressedb thyea tndE.c li)
in only 14% samples (Zhang et al., 1995). This difference may be explained if type
6a has only recently spread to Hong Kong, and had therefore not been present in
the local population long enough to cause significant disease. Alternatively, it is
also possible that type 6a causes a less severe course of disease than type lb. The
relative pathogenicity of types 4-6 has not yet been reported, but is discussed in
section 5.5.
No type 6 group variants were identified amongst a subset of the blood
donors using RFLP analysis of the 5'NCR or core, or sequence analysis of the core
gene. This has lead to the conclusion that despite the coexistence of type 6 group
variants with type 6a in other countries such as Vietnam, subtypes other than 6a
were not prevalent in Hong Kong.
The discovery of two type 6a sequences in this study which contain
previously unidentified nucleotide substitutions in the 5' NCR, brings into question
the efficiency of cleavage with the enzymes Dde l/Hpa II for the identification of
type 6 group variants. Although these sequences have new restriction patterns (E
and F), these differ from those already described for type 6 variants (patterns B and
C) by an increase of only 3 bp. This small difference in size is unlikely to be
clearly discovered upon electrophoresis of cleaved DNA fragments, and it is likely
that such variants would be misidentified as type 6 group variants. Despite this
confusion between type 6 isolates, the assay was consistently accurate in the
identification of type 1 samples in this population.
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An important factor in the prevention of HCV transmission is the efficient
detection of the virus in blood donors. Current screening assays use antigens
derived from type 1 sequences, and a reduced reactivity of antibody generated
towards types 2, 3 and 4 has been reported (McOmish et al., 1994; Dhaliwal et al.,
1996), leading to the possibility that virus detection could be less effective in
countries where novel genotypes are prevalent. A lower frequency of antibody
reactivity towards type 1 antigens in the RIBA was also detected with type 6a
samples in this study, suggesting that the type-specific reactivity reported for types
2, 3 and 4 may also apply to type 6a. The success of HCV detection within such
populations may be increased in the future by the development of screening assays
that use a combination of antigens from the full range of genotypes prevalent in
that area.
5.4 TESTING THE 1-6 SEROTYPING ELISA ON HCV POSITIVE
BLOOD DONORS IN HONG KONG
5.4.1 INTRODUCTION
A previous study has suggested that the 1-6 serotyping ELISA may be less
sensitive towards antibody produced in individuals infected with type 6 (66.6%) in
comparison with antibody elicited upon infection with type 1 (92.3%) or type 2
(96.9%). However, the number of samples from individuals infected with type 6
available for analysis in previous studies (n=6) has been limited. The sensitivity of
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the assay to type 6, might be low because the type 6 peptides in the 1-6 ELISA
were designed from a comparison of only two sequences, and might therefore not
fully represent the level of amino acid variation within this genotype.
The availability of a large number of HCV positive samples from Hong
Kong has allowed a more thorough investigation of the ability of the 1-6 serotyping
assay in the detection of type-specific antibody in individuals infected with type 6,
and the extent of variation of type 6a sequences within NS4 antigenic regions 1 and
2.
5.4.2 SAMPLES
A total of 212 HCV positive blood donor samples in which the genotype
of infecting virus had been determined by RFLP analysis (Section 5.3) were tested
using the 1-6 serotyping assay.
5.4.3 RESULTS
(1) SEROTYPING
Type-specific antibody was detected in 164/212 HCV positive samples,
giving an overall sensitivity of 77.7% (Table 5.4.3). A difference in the sensitivity
of the assay for individual HCV genotypes was noted, although the relevance of
results for types 2a, 2b and 3a is questionable due to the small number of samples
present in this study. The analysis of a larger number of samples from individuals
infected with types lb and 6a (n=128 and 55 respectively) revealed that the ELISA
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was more sensitive towards type lb antibody (84.4%) than type 6a antibody
(63.7%).
In all but five samples, the type-specific antibody detected by the assay was
concordant with the genotype previously identified by RFLP analysis, giving the
assay a specificity of 97.0%. Of the five samples producing discordant results, three
were from individuals infected with type 6a but were identified by the serotyping
assay as type 1. The other discrepant results consisted of a donor infected with type
lb, and a donor infected with type 3a both of which serotyped as type 6.
One sample confirmed as having a mixed infection with types 3a and 6a by
PCR based genotyping (section 5.3) contained type-specific antibody to only to
type 3a. However, a mixture of type-specific antibody was present in two other
samples. In each of these samples the genotype identified by RFLP was concordant
with one of the types identified by the serotyping assay.
(2) SEQUENCE ANALYSIS OF NS4
To investigate the specificity of type 6a peptides used in the assay, a total
of 12 samples were amplified in the NS4 region by nested PCR and analysed by
sequencing (Figure 5.4.3a). Comparison of the sequences revealed a high level of
amino acid conservation within both antigenic regions 1 and 2, and a tight
clustering of branches on a phylogenetic tree (Figure 5.4.3b). Amino acid
substitutions were limited, with only two changes from the peptide sequence in
region 1 (glutamate for lysine at position 1707 in one sample, and valine for
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Figure 5.4.3b PHYLOGENETIC ANALYSIS OF NS4 SEQUENCES
AMPLIFIED FROM HONG KONG BLOOD DONORS INFECTED WITH
HCV TYPE 6a
NS4 sequences amplified from blood donors infected with type 6a were compared
with representatives of other HCV genotypes, using the programs DNADIST and
NEIGHBOR in the PHYLIP package (Felsenstein et al., 1993) and shown as an
unrooted tree (appendix 5.3).
Sequences from Hong Kong blood donors infected with type 6a are highlighted in
bold.
isoleucine at position 1694 in two sequences) and one substitution within region 2
(histidine for aspartate at position 1714 in one sample). Sequence analysis of
sample HK114 confirmed the presence of HCV-6a, despite this being identified as
type 1 by the serotyping assay, and moreover, the sequence obtained from this
sample was identical to that of the peptides used in the 1-6 serotyping assay.
5.4.4 DISCUSSION
The results of a previous study using the 1-6 serotyping assay for the
detection of type-specific antibody from samples infected with type 6 suggested
that the assay may have a lower sensitivity towards type 6 (66.6%) in comparison
to types 1-5 (Chapter 3, Bhattacherjee et al., 1995), although the small number of
samples analysed challenges the significance of this conclusion. The availability of
a larger number of samples in this study enabled a more thorough investigation
which confirmed the original findings, with type-specific antibody being detected
in only 63.7% samples from individuals infected with type 6. In comparison, the
assay was able to recognise type-specific antibody in 84.4% samples from
individuals infected with type lb, which also agreed with previous findings
(83.3%).
The overall sensitivity of the assay for samples from Hong Kong blood
donors was 77.7%, and antibody specificity was concordant with the genotype
identified by RFLP in 97% of samples. The sensitivity of the assay in Hong Kong
was lower than observed in other studies, for example in Norway (93.5%) and an
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investigation of a wider range of geographical areas (87.1%), although the assay
was also less effective in other regions such as Pakistan (52.3%) and Egypt
(72.5%) (Chapter 3). The reduced sensitivity of the serotyping ELISA in Pakistan
may have resulted from a higher level of amino acid sequence variation within type
3 than accounted for by the peptides used in the assay. Indeed, a large number of
type 3 subtypes (a-f) have now been identified (Tokita et al., 1994a). The presence
of antigenic variation within type 6 in Hong Kong was investigated by the
sequence analysis of NS4, revealing that type 6 isolates were well conserved within
this region, and that the type 6 peptides used in the assay should be sufficiently
specific. A high level of sequence conservation within type 6a has also been
described in the core region (section 5.3 and Zhang et al., 1995, Mellor et al.,
1995). The relatively high number of type 6 samples producing NTS results with
the 1-6 serotyping assay suggests that another explanation for the low sensitivity
towards type 6 may be the event of cross reactivity with heterologous peptides
present in competing solutions. It has been noticed previously that region 1
peptides for types 4-6 are similar to those for type 1, and therefore the successful
detection of type-specific antibody in samples infected with these genotypes may
be more reliant on antibody generated to region 2. It is also possible that region 1
is more antigenic in individuals infected with type 6 isolates than for other
genotypes, so that the majority of antibody in type 6 samples cross reacts with
region 1 competing peptides and gives a NTS result with the assay. Epitope
mapping of type 6 could confirm this hypothesis.
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5.5 DETECTION OF TYPE-SPECIFIC ANTIBODY IN SAMPLES FROM
INDIVIDUALS INFECTED WITH TYPE 6 GROUP VARIANTS
5.5.1 INTRODUCTION
Sequence analysis of HCV type 6 group variants has revealed a higher level
of sequence similarity with genotype 6a than any of the other major genotypes
(Mellor et al., 1995). However, a number of these isolates show identity to type 1
sequences in the 5' NCR, which has led to the misidentification of these viruses
using existing typing assays such as RFLP analysis of the 5' NCR (Davidson et al.,
1995) and Inno-LiPA (Stuyver et al., 1996b). This problem has been overcome to
a certain extent by use of a core RFLP assay (Mellor et al., 1996), as sufficient
sequence variation is present in the core region of type 6 isolates to enable this
genotype to be distinguished from type 1. As the serotyping ELISA is often a
cheaper alternative to genotyping methods involving PCR, an accurate assay which
is able to identify these regional variants would be valuable in poorer countries.
The ability of the 1-6 serotyping assay to detect antibody generated during
infection with novel type 6 group variants was investigated, and the NS4 amino
acid sequences of such isolates compared with the type 6a peptides used in the
ELISA.
The samples from individuals infected with type 6 group variants, classified
as NGI (also classified as type 8a/b; n=l), NGII (type 7a/b; n=5) and NGIV (type
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9a; n=4), were obtained from Thailand blood donors, as described in previous
studies (Mellor et al., 1995; Mellor et al., 1996).
5.5.2 RESULTS
A low level of reactivity towards type 6 peptides was observed in the
sample from an individual infected with NGI, and in 2 out of 5 samples from
individuals infected with NGII (Table 5.5.2). However, other samples from
individuals infected with NGII displayed reactivity towards both type 1 and 6
peptides, to type 3 peptides alone or non-type-specific reactivity. Type-specific
antibody was not detected in any of the samples from individuals infected with
NGIV.
NS4 regions were amplified and sequenced from isolates corresponding to
NGII and NGIV, revealing identity with a significant number of amino acids from
the antigenic region 1 type 6a peptide used in the serotyping ELISA, for example,
the two glutamine residues at positions 1703 and 1704 (Figure 5.5.2). In antigenic
region 2, sequences from NGII differed from type 6a by only one amino acid
substitution of alanine for valine at position 1719, whereas NGIV sequences had
four amino acid substitutions between positions 1718-1724 (Figure 5.5.2).
5.5.3 DISCUSSION
Although the recently identified type 6 group variants in South East Asia
have been shown to have a closer genetic relationship to type 6a than to other
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Table 5.5.2 DETECTION OF TYPE-SPECIFIC ANTIBODY IN HCY
POSITIVE BLOOD DONORS FROM THAILAND INFECTED WITH
TYPE 6 GROUP VARIANTS
Sample Provisional name* Classification! Serotype
EUTH 49 NG I (type 8)! 6 (weak)
EUTH 7 NG II (type 7c) 1+6 (weak)
EUTH 28 t! 6
EUTH 36 It 3
EUTH 61 II NTSU
EUTH 89 H 6
EUTH 1 NG IV (type 9c) NTS
EUTH 21 ti NTS
EUTH 22 M NR
EUTH 39 NTS
* as described by Mellor et al., 1996
t Previous classification in parenthesis (Tokita et al., 1994, 1995)
! Groups with, but distinct from, types 8a and 8b found in Vietnam upon
phylogenetic analysis
If Non-type-specific reactivity
Figure 5.5.2 AMINO ACID SEQUENCES OF TYPE 6 GROUP
VARIANTS IN NS4 ANTIGENIC REGIONS 1 AND 2.
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major genotypes, the level of similarity observed overlaps the boundaries
previously identified between subtypes of the same virus type and this has
produced confusion over their classification. Analysis of samples from individuals
infected with types NGI, NGII and NGIV by the 1-6 serotyping assay, revealed the
presence of type 6 specific antibody in some samples from individuals infected
with NGII. This observation is partially explained by sequence analysis of NS4 for
both NGII and NGIV, since the extent of amino acid variation observed between
these variants and the type 6a peptides used in the assay was greater for the NGIV
sequence than for the NGII sequence. In addition, many of the amino acid
substitutions in NGII were to residues of similar size or charge compared with
those present in the type 6a peptides. Substitutions in the NGIV sequences were
more likely to alter the structure or hydrophobicity of the antigen, for example,
alanine (small, hydrophobic) for proline (hydrophilic and prone to influence protein
architecture) at position 1719 and glutamine (hydrophilic, uncharged) for alanine
(hydrophobic) at position 1723.
For the 1-6 serotyping assay to be able to successfully identify the type 6
group variants, additional peptides would have to be incorporated into the assay.
Although this is theoretically possible, the relatively confined geographical
distribution of these isolates fails to justify such measures in areas such as the
U.S.A., Europe and Japan, where these genotypes are unlikely to be encountered
in the indigenous population. In populations where the type 6 group variants are
more common, an single additional well containing antigens representing all of
124
these variants together may be beneficial, and this would certainly be a more
practical solution for the addition of these variants to the existing assay. Such an
assay may also prove important in Western populations in the future, as world
travel continues to increase, creating a risk that these isolates may spread to
different geographical areas. This has already been the case with types 5 and 6a
now detected in Canada (Bernier et al., 1996) and type 6a in Australia (Dr L.
Moaven, pers. comm).
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5.6 CLINICAL FEATURES ASSOCIATED WITH INFECTION WITH
HCV TYPE 6a
5.6.1 INTRODUCTION
The epidemiology and clinical features HCV genotypes 1, 2 and 3 have
been extensively studied in recent years, revealing a number of differences between
these virus genotypes. For example, infection with type 3 has been associated with
younger patients who are more likely to have IVDA as a risk factor in Scotland
(McOmish et al., 1993), France (Pawlotsky et al., 1995) and in the U.S.A. (Lau et
al., 1996), while a higher proportion of infections with type lb have been acquired
through blood transfusion. Other clinical features such as the level of ALT have are
similar between the types 1-3, but may be lower for type 4 (Lau et al., 1996). In
contrast, there is no difference between any of the six major genotypes in the level
of viraemia produced upon infection. The ability of HCV type 1 to cause a more
severe disease than types 2 or 3 is currently a matter of debate, with numerous
reports both in favour (Kobayashi et al., 1996; Prati et al., 1996; Booth et al.,
1995; Dusheiko et al., 1994) and to the contrary (Benvegnu et al., 1997; Zeuzem
et al., 1996; Zhou et al., 1996).
Unlike genotypes 1-3, very few studies have been performed on the clinical
features associated with types 4-6, and such investigations may be important in the
identification of either routes of transmission, disease progression or the response
to treatment. As the first step in such a study for infection with type 6, information
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such as sex, age, ALT level and risk factors for infection was compared for a total
of 210 Hong Kong blood donors infected with different HCV genotypes.
5.6.2 RESULTS
More males than females were infected with all genotypes, but this bias was
even greater for type 6a infections (5:1), than for type lb infections (3:1). In
contrast, the mean age for infections with types lb and 6a was similar at 33 and
34 years respectively, and the age of infected donors in Hong Kong ranged between
16 and 59 years (Figure 5.6.2a), and was also similar for all genotypes. Median
ALT values (Figure 5.6.2b) were in the normal range (7-53U/1) for all genotypes
except type 2b, although only three samples were infected with this genotype. ALT
values in donors infected with type 6a were lower than for infection with type lb,
but this difference was not statistically significant by the Spearmans rank
correlation (p=0.094).
Risk factors were available for 43 samples (Table 5.6.2), and included blood
transfusion prior to 1989, IVDA, tattooing and acupuncture. While 66% of donors
infected with type 6a reported IVDA as a risk factor, this was true for only 7%
donors infected with type lb. Similarly, only 33% of individuals infected with type
6a had received a blood transfusion prior to 1989 in comparison to 83% of donors
infected with type lb.
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Figure 5.6.2b COMPARISON OF ALT VALUES OF DONORS
INFECTED WITH DIFFERENT HCV GENOTYPES IN HONG KONG
Line indicates upper normal ALT range.
5.6.3 DISCUSSION
Donor populations generally contain a preponderance of male donors, and
a larger proportion of male blood donors infected with type 6a in comparison to
lb has also been reported previously in the U.S.A. for other genotypes such as
types 3 and 4 (Lau et al., 1996).
The association of infection with HCV type 6a in this study with the risk
factor of IVDA is not in agreement with a previous analysis in which a total of 8
patients infected with type 6a were thought to have contracted the disease through
blood transfusion (n=7) or occupational exposure (n=l) (Zhang et al., 1995).
Infection with type 3 has also been linked with IVDA in previous studies, however,
this finding was also connected with a lower age of acquisition, whereas in this
study there was no difference in the age distribution between different genotypes.
The median ALT level in donors infected with type 6a was slightly lower
than that observed in type lb infections, although this was not statistically
significant. The majority of studies have reported no difference in ALT levels
between different genotypes (Dusheiko et al., 1994; Smith et al., 1996; Dhaliwal
et al., 1996), however, a higher ALT level with type 3 has been reported by some
groups (Preston et al., 1995; McOmish et al., 1993), although this is not necessarily
reflective of more severe disease.
The restricted diversity of type 6a is consistent with the recent spread of this
genotype into Hong Kong. This hypothesis would also explain its specific
association with drug use as this has become the major route of HCV transmission
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in most countries since screening blood donors for HCV. Finally, the under-
representation of type 6a in hepatitis patients (Zhang et al., 1995) also suggests
recent entry of this genotype to the Hong Kong population, as clinically significant
disease may take 20-30 years to become recognised. Clearly a valuable further
investigation would be a specific comparison of genotype distribution in stratified
age groups. As a possible analogy, the spread of type 6a to Australia was initially
associated with the immigration of Vietnamese nationals (Dr. L. Moaven. Pers.
Comm.), and has since become specifically associated with drug abuse in major
cities such as Melbourne and Sydney.
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CHAPTER 6
6 SEQUENCE ANALYSIS OF HCV VARIANTS
PRODUCING DISCREPANT RESULTS WITH TWO
DIFFERENT TYPING ASSAYS
6.1 GENERAL INTRODUCTION
Two of the most widely used commercial typing assays are the 1-6
serotyping ELISA described in this work (HC02 - Murex Biotech) and a line probe
assay (InnoLiPA 2.0, Innogenetics, Belgium). Both assays have various advantages
and disadvantages. The line probe assay is able to distinguish between subtypes la
and lb, and 2a/c and 2b and other major genotypes 3-6, and since it involves the
direct detection of virus RNA it can be used in immunocompromised patients. On
the other hand, this method involves the amplification of HCV RNA by PCR,
which is expensive, time consuming and may require specialised equipment that is
not routinely available in a clinical laboratory. The serotyping assay can be
performed directly on the serum from an infected individual within 3 hours using
non-specialised equipment, but is unable to distinguish virus subtypes or be used
in immunocompromised patients.
The specificity of both methods is high, with the 1-6 serotyping assay
showing a concordance (see appendix 1.0) of 97% (Bhattacherjee et al, 1995),
98% (Bell et al., 1996) and 100% (Navas et al., 1997) with RFLP, and the
InnoLiPA showing a concordance of 98.2% (Lau et al., 1996). The InnoLiPA and
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serotyping assays have also been reported as being 98.5% concordant with each
other (Lau et al., 1996).
Although the specificity of both the InnoLiPA genotyping and 1-6
serotyping assays are high, a small number of samples have been shown to produce
discrepant results between the two assays. As the InnoLiPA is based on the reverse
hybridisation of type-specific probes to amplified 5'NCR sequences, the specificity
of this assay relies on the high level of sequence conservation of the 5'NCR within
individual HCV genotypes. One of the major strengths of this assay, which allows
the discrimination of a number of subtypes as well as genotypes, is the sensitivity
of the probes towards even single nucleotide differences (Stuyver et al., 1996b;
Stuyver et al., 1993b). However, this level of sensitivity may also provide an
explanation for discrepant results produced by this assay, since variants with
unusual nucleotide substitutions in the 5' NCR might hybridise, or fail to hybridise,
to probes specific for a particular genotype. Similarly, antigenic variation within
the region of NS4 corresponding to the peptides used in the serotyping assay could
lead to the binding of antibody towards heterologous type peptides, and produce
an inaccurate serotyping result. Although the levels of genetic variation within
individual genotypes has been shown to be low for both the 5' NCR (Smith et al.,
1995b; Simmonds et al., 1993b), and NS4 (Bhattacherjee et al., 1995), reflected in
the high specificity of both these assays, an increasing number of unusual HCV
variants are being reported (Tokita et al., 1995; Mellor et al., 1995; Tokita et al.,
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1994; Stuyver et al., 1996; Smith et al., 1995) which may test the limits of these
assays.
The successful identification of HCV genotypes using methods based on
subgenomic regions is also dependent on the assumption that such regions are
representative of the genome as a whole. Recombination between different HCV
genotypes could lead to the discrepant typing of a sample if the two assays were
based on different regions of the genome. Although recombination has been
observed in other RNA viruses, there are few reports describing this event in HCV
(Yun et al., 1996; Kato et al., 1992), and the possibility of artifactual
recombination during PCR (Meyerhans et al, 1990), PCR contamination or a
mixed infection have not been ruled out in these studies. In contrast, the great
majority of groups have reported that sequence relationships of subgenomic regions
consistently reflect those of complete genomes (Stuyver et al., 1994; Simmonds et
al., 1994; Smith et al., 1995; Ohba et al., 1995).
Finally, discordant results obtained with the two assays could be explained
by the difference in detection of virus RNA (InnoLiPA) and circulating antibody
(serotyping ELISA) in individuals infected with more than one HCV genotype. If
an individual infected with HCV is reinfected with a different genotype, it is likely
that the genotype of virus identified directly by PCR based methods such as
InnoLiPA would differ from the serotype of circulating antibody during the
"window period" for the superinfecting virus. Similarly, the "reactivation" of
132
different genotypes within a mixed infection is often followed by a corresponding
change in the serotype of antibody detected (Jarvis et al., 1994).
A number of discrepant samples were obtained from two studies of a group
of haemophiliacs and a group of patients with chronic hepatitis C. Virus sequences
in these samples were investigated by sequencing in the 5' NCR, core and NS4
regions in order to confirm the virus genotype and identify the possible reasons for
the differences in typing results.
6.2 SAMPLES
Haemophiliacs
A total of 11 samples producing discrepant results with InnoLiPA (second
generation assay) and 1-6 serotyping assays were obtained from a study of 78 HCV
PCR positive haemophiliacs from Frankfurt in Germany. For 8 samples the
genotype identified in the 5' NCR (InnoLiPA) was type 3a, while type 1 specific
antibody was detected by the serotyping assay (Table 6.2). Two samples (GD10
and GD11) were type 2b according to InnoLiPA and type 1 by serotyping, and
sample GD6 was the opposite, with type lb by InnoLiPA and type 2 by serotyping.
The remaining sample (GDI) was type 3a in the 5' NCR while a mixed infection
with types 1 and 2 were detected by the serotyping assay.
Patients with chronic hepatitis C
From a study involving 88 patients with chronic hepatitis C in France, 4
samples produced discrepant results between the serotyping and InnoLiPA assays.
133


























































































































"w"=weakresult*GD=erm ndiscrep t(ha mophiliacs);Frenchch nicpatit sents)
Two of these samples (FD3 and FD4) were HCV-3a by InnoLiPA (1st generation
assay) but type 1 by serotyping (Table 6.2). Sample FD1 was identified as type lb
in the 5' NCR while the serotyping ELISA detected type 4 specific antibody, and
sample FD2 was type 4 or 5 by InnoLiPA, but type 1 by serotyping.
Genotyping and serotyping was carried out in the country of origin, by Dr.
A. Berger (Institut fur Medizinische Virologie der J.W. Goethe-Universitat
Frankfurt, Germany) and Dr. J-M Pawlotsky (Department of Bacteriology and
Virologie, Hopital Henri Mondor, Universite de Paris XII, Cretiel, France).
6.3 RESULTS
6.3.1 HCV POSITIVE HAEMOPHILIACS
RNA sequences from all 11 samples were amplified by PCR in the 5' NCR,
and for the majority of samples, also in the core and NS4 regions. The HCV
genotype identified by sequence analysis of the 5' NCR was concordant with that
detected by the InnoLiPA assay in all 11 samples (Figure 6.3a), and in each case
was confirmed by phylogenetic analysis of sequences amplified from either the core
or NS4 regions.
Since haemophiliacs have been multiply exposed to virus through infected
batches of factor concentrates derived from many blood donors, the presence of a
dual infection with different HCV genotypes was investigated using PCR primers
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specific for NS4 of types 1, 2 and 3. In all but two samples, a positive PCR result
was observed only with the primers corresponding to the genotype identified by
InnoLiPA (Table 6.2). In samples GD2 and GD8, NS4 sequences were amplified
weakly with type 1 primers and more strongly with type 3 specific primers.
Multiple clones from each PCR product were analysed by sequencing, revealing the
presence of type 3a in all cases irrespective of the primers used for the PCR. There
was little amino acid variation within NS4 antigenic regions 1 and 2 in these
samples, with isolated amino acid substitutions to residues of similar size or charge
as those present in the corresponding peptide used in the serotyping assay (Figure
6.3b)
6.3.2 PATIENTS WITH CHRONIC HEPATITIS C
All four discrepant samples from French patients with chronic hepatitis C
were successfully amplified by PCR in the 5' NCR, core and NS4 regions.
Sequence analysis in all three regions confirmed the genotype identified by the first
generation InnoLiPA, with sample FD2 recognised more specifically as type 5
(Table 6.2).
Amino acid substitutions in NS4 were more frequent than in the
haemophiliac samples, and occurred in both antigenic regions 1 and 2. In addition,
the substitutions in sample FD1 produced a sequence with similarities to the type
4 peptides used in the serotyping assay (Figure 6.3b).
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Figure 6.3b COMPARISON OF NS4 AMINO ACID SEQUENCES
OBTAINED FROM DISCREPANT SAMPLES WITH THOSE OF
PEPTIDES USED IN THE SEROTYPING ASSAY
indicates sequence identity to HCV-PT.
Sequences of the discrepant samples are highlighted in bold.
Samples identified with a decimal point represent the reference number of the
clone, for example sample GD 3.6 represents clone number 6 from sample GD3.
Amino acid sequences of type-specific peptides used in the serotyping assay are
in boxes.
GD2A, GD8A; Sample GD2, GD8 amplified with type 1 specific primers.
GD2B, GD8B; Sample GD2, GD8 amplified with type 3 specific primers.
6.4 DISCUSSION
Recombination
As the two assays are based on subgenomic regions which are at opposite
ends of the virus RNA, a recombinant virus with a cross over point lying between
the 5' NCR and NS4 would produce different results by InnoLiPA and serotyping.
In this study however, the same genotype was identified by sequencing in the 5'
NCR, core and NS4 regions, providing no evidence for such an event.
Multiple infection
Discrepant results were more common in the multiply exposed haemophiliac
patient group (14.1%) than in the chronic hepatitis patients (4.5%) in whom
multiple exposure would be expected to be less common. In all samples the
genotype identified by InnoLiPA was confirmed by sequencing of the 5'NCR, core
and NS4 regions. In the haemophiliac samples, sequence analysis of the NS4 region
failed to provide evidence that the serotyping assay had incorrectly identified the
specificity of the antibody response because of antigenic variation of regions 1 and
2. Amino acid substitutions present in these regions often involved residues of a
similar size and charge as those present in the peptides used in the serotyping
assay, and therefore unlikely to cause cross reactivity with peptides specific to a
different genotype. For example the substitution of valine for alanine at position
1723 in region 2, which was observed in 3/9 type 3 sequences in this study, and
the substitution of lysine with arginine in region 1 of GD 4.2. Only one sample in
this risk group (GD11) showed an obviously nonconservative amino acid
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substitution that might alter the antigenicity of NS4, occurring at position 1691 of
region 1 with the substitution of arginine for glutamine.
One possible explanation for the discrepant results between the two assays
would be that the ELISA had detected circulating antibody from a previous
infection with a different genotype, but despite the high risk of multiple exposure
in these individuals, no evidence for infection with more than one genotype was
found by PCR with type-specific primers. However, taking into account the high
frequency of multiple infections in haemophiliacs (Jarvis et al., 1994), this remains
the most likely explanation for the discrepant results in this patient group. Previous
studies have demonstrated that the serotyping assay is efficient in the detection of
more than one type-specific antibody in serum (Jarvis et al., 1994; Simmonds et
al., 1993), although only one serotype was identified in all the haemophiliac
samples except for one sample. This suggests that reinfection or the reactivation of
genotypes from a multiple infection in these individuals has been recent.
Considering that all factor VIII and IX concentrates have been subjected to virus
inactivation procedures since 1985, the recent reinfection of these individuals is
unlikely. On the other hand, it has been well documented that the major circulating
genotype within a multiple infection can often change over a number of years
(Jarvis et al., 1994). The genotype identified by PCR based methods generally
precedes the corresponding change in type-specific antibody, and has been shown
to cause discrepant results between the two methods in previous studies (Jarvis et
al., 1994). In addition, the RNA amplified by PCR will represent only the major
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circulating virus type in plasma, with the possibility of minor populations in the
liver remaining undetected by this method. The absence of a significant level of
amino acid variation in NS4 and a risk factor of IVDA in two of the patients with
chronic hepatitis C (FD3 and FD4) also suggests that an infection with more than
one genotype may explain the discrepant results obtained with these samples.
Antigenic variation
Another possible explanation for misidentification of type-specific antibody
by the serotyping assay would be in the event of significant amino acid variation
within NS4 antigenic regions 1 and 2 leading to cross reactivity with heterologous
type peptides in the assay. Amino acid substitutions were much more frequent in
samples from patients with chronic hepatitis C than amongst those from
haemophiliacs, and this may have lead to cross reactivity in two of the samples.
Sample FD1 was originally identified as type 1 by InnoLiPA (and
confirmed by sequencing), yet showed the presence of type 4 specific antibody in
the serotyping assay. Amino acid substitutions were present in both antigenic
regions 1 and 2, and the substitution of glutamine for histidine at position 1720
(region 2) also occurs in the corresponding peptide for type 4.
Sample FD2 was identified as type 4 or 5 by InnoLiPA (type 5 by
sequencing) but type 1 by the serotyping assay. In region 1, the amino acid
sequence corresponded closely to one of the type 1 peptides used in the assay. Only
one amino acid substitution was present in this sample in antigenic region 2, with
aspartic acid being replaced with glycine at position 1718. Although this change
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does not show any similarity to the other peptides used in the assay, it is significant
both in size and charge, and may have altered the structure of the antibody
sufficiently to prevent the adsorption to the peptides in the assay.
The results in this study suggest that the reliability of serological typing methods
may be influenced by the patient groups under investigation, and that PCR based
typing methods may be more appropriate in groups of individuals which have been
multiply exposed to HCV such as haemophiliacs.
139
CHAPTER 7
7 DEVELOPMENT OF HCV SEROTYPING ASSAYS BASED
ON OTHER REGIONS OF THE GENOME
7.1 INTRODUCTION
The discovery of type-specific epitopes in NS4 has lead to the development
of a serotyping ELISA for HCV genotypes 1-3 (Simmonds et al., 1993d) which
was subsequently extended to include all six major genotypes (Bhattacherjee et al.,
1995). The degree of amino acid variation in NS4 between genotypes resulted in
a high level of specificity, with the serotype of antibody detected concordant with
genotyping methods in up to 97% samples tested (Chapter 3, Table 3.2.4).
However, the sensitivity of this assay was lower, with the detection of type-specific
NS4 antibody in 87% samples from HCV infected individuals. The absence of
reactivity towards any of the NS4 antigens may be explained by either an
immunocompromised state, a recently infected individual prior to seroconversion
or the lack of an immune response towards this epitope.
A strong immune response to other regions of the genome has been
described as a result of the addition of antigens from core (c22-3), NS3 (c33c) and
NS5 to NS4 antigens (cl00-3) to second and third generation screening assays. It
was discovered that as many as one third of post-transfusion patients with NANB
hepatitis did not develop anti-clOO antibody for up to 1 year after infection (Alter
et al., 1989), and using a second generation RIBA, it was reported that all highly
viraemic patients had a response to core and NS3 antigens, in comparison to 78%
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and 85% patients for NS4 (cl00-3) and NS5 respectively (Yuki et al., 1994).
Similarly, the most common antibodies detected in HCV infected individuals are
NS3, core and NS5 (Chien et al., 1992). In addition, a much earlier immune
response can be detected towards NS3 (a mean of 91 days after infection) and core
(133 days), than for NS4 (143 days) (Lelie et al., 1992).
For these reasons the possibility of a serotyping assay based on other
immunodominant regions of the genome having a higher sensitivity than that using
NS4 was investigated.
A number of different groups have developed serotyping assays for HCV,
the majority of which involve antigens from the NS4 region either alone (Tanaka
et al., 1994; Simmonds et al., 1993), or in association with those derived from the
core and NS5 regions (Zhang et al., 1995; Dixit et al., 1995). Only one method
based exclusively on a region other than NS4 has been described (Machida et al.,
1992), which uses peptides from core in an ELISA to distinguish between types 1
and 2. However, despite the success of this assay in the identification of these
serotypes in Japanese blood donors, the level of amino acid variation in this region
between the remaining genotypes is considered too low to be able to extend this
assay further.
In addition to core, the NS3 region is reported as being highly immunogenic
(Chien et al., 1992; Yuki et al., 1994), and is often associated with an immune
response much earlier after infection than NS4 (Puoti et al., 1992; Lelie et al.,
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1992). Furthermore, phylogenetic analysis of amplified NS3 sequences has
demonstrated a similar level of amino acid variation between genotypes as occurs
in the other nonstructural regions (Chan et al., 1992). Recent studies into the
reactivity of different genotypes (types 3 and 4) with type lb specific antigens
present in third generation screening assays / RIBA have suggested that reactivity
towards NS3 contains a detectable type-specific component (Dow et al., 1996b).
Amongst epitopes identified in NS3, most were conformational as opposed
to linear. Little reactivity was observed towards overlapping synthetic peptides in
this region, despite the obvious immune response towards NS3 antigens present in
screening assays (Khudyakov et al., 1995). Further evidence was obtained when a
conformational epitope from amino acids 1363-1454 was recognised by monoclonal
antibodies (Mondelli et al., 1994) and by antibody reactivity towards recombinant
protein (Claeys et al., 1995). Immunoblot analysis has also revealed at least four
linear epitopes in NS3, of which the most immunodominant exists around amino
acid residues 1250/1251, and three others within the middle portion of this gene
(between amino acids 1250-1334, and 1407-1412) (Hwang et al., 1996).
The combination of an early and frequent immune response to this region,
and the apparent type-specific reactivity, has lead to the investigation of NS3 as a




Serum samples were obtained from individuals in which the presence of
RNA corresponding to HCV genotypes lb, 2b and 3a had been previously
identified by RFLP analysis of the 5'NCR. Samples NH15 (type lb), LJ823.2 (type
2b) and LJ516A (type 3a) used for the preparation of NS3 antigens, were obtained
from U.K. haemophiliacs (provided by Dr. L. Jarvis). All samples used in ELISA
experiments had also been analysed previously using the NS4 1-6 serotyping assay.
Samples from individuals infected with type 1 (n=7) were selected from blood
donors in Hong Kong, type 2 samples were obtained from either Hong Kong (n=6)
or patients with chronic hepatitis C in Pakistan (n=l) and those from individuals
infected with type 3 were all obtained from Pakistan (n=5).
Preparation of antigen
Amplification of a 286bp fragment of the NS3 region by PCR was
performed using nested primers (Table 2.3; numbers 753, 751 and LP8-10) and the
products cloned into pTAg. Sequence analysis of clones was carried out using
plasmid primers 8819 and 9130 (Table 2.3). A detailed description of these
methods is provided in chapter 2. NS3 recombinant proteins were expressed in E.
coli and purified at Murex Biotech Ltd, Dartford, U.K.
Microtitre plates were coated with individual type-specific NS3 antigens at
Murex Biotech Ltd, at a concentration of 25ng/well (types lb and 2b) or
200ng/well (type 3a). Serotyping plates were coated with a combination of all three
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antigens, each at a concentration of 25ng/well. As the recombinant proteins were
expressed in E. coli, the addition of bacterial lysate blocker to sample diluent (1:50
dilution) was necessary to prevent the reactivity of antibody produced against this
organism with any contaminating E. coli proteins remaining after the purification
of the antigen.
7.3 RESULTS
7.3.1 DEVELOPMENT OF A SEROTYPING ELISA FOR HCV USING
RECOMBINANT PROTEINS FROM THE NS3 REGION
Amplification of NS3
Serum samples from individuals infected with genotypes lb, 2b and 3a were
amplified by PCR in the NS3 region between nucleotides 4417-4703, and cloned
into pTAg. Nucleotide sequences of each clone were translated into their
corresponding amino acids (residues 1360-1454), and compared to published
examples of the same genotype (Figure 7.3.1). The sequences obtained from
samples NH15 (type lb), LJ823.2 (type 2b) and LJ516A (type 3a) were considered
to be representative of each genotype, and were therefore selected for expression
into recombinant proteins for use as type-specific antigens in an ELISA.
Reactivity of type-specific antibody with NS3 antigens
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In order to confirm that each of the recombinant antigens could recognise
HCV antibodies, serum samples from individuals infected with genotypes 1, 2 and
3 were incubated on microtitre plates which had been coated with the individual
NS3 antigens.
Homologous reactivity (for example, sera from individuals infected with
type 1 analysed using a plate coated with type 1 specific antigen) towards each of
the three antigens was high, with the majority of absorbance values greater than 2.0
(Table 7.3.1a).
Previously, a 1/40 or 1/20 dilution of serum was necessary to be able to
detect a strong signal against NS4 peptides. However, used against NS3 antigen,
this dilution consistently produced absorbance values which were too high for our
spectrophotometer to read (>2.0). As the design of the serotyping assay is such that
it relies on the effective blocking of antibody in solution with competing antigen,
both the concentration of antibody (in serum) and competing antigen in each well
is critical. To be able to determine the optimum dilution of serum in this assay,
samples were tested at dilutions of 1/40, and 1/100 on plates coated with
homologous type antigen. In the same experiment, titrations of homologous type
competing antigen were also included to determine the level of competition needed
for the effective blocking of antibody. The amounts of competing antigens used
were the same concentration as that coating each well (1:1), at a ten fold excess
(lOx) and at a one hundred fold excess to the concentration of protein coating each
well (lOOx).
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Table 7.3.1a A COMPARISON OF NS3 TYPE-SPECIFIC ANTIBODY
REACTIVITY WITH HOMOLOGOUS TYPE NS3 ANTIGENS
Homologous type antigen
SD*
Sample Type 1/40 1/100
HK430 lb >2.0f >2.0
HK437 lb 0.218 0.225
HK438 lb >2.0 >2.0
HK469 lb >2.0 >2.0
HK347 2a 1.545 0.619
HK8 2b >2.0 >2.0
HK156 2b >2.0 >2.0
HK559 2b >2.0 >2.0
PK24 2 >2.0 >2.0
PK6 3a >2.0 >2.0
PK9 3a >2.0 >2.0
PK13 3a >2.0 >2.0
PK21 3a >2.0 >2.0
PK36 3a >2.0 >2.0
PK38 3a >2.0 >2.0
PK39 3a >2.0 1.828
PK45 3a >2.0 >2.0
* Serum Dilution
f Absorbance values correspond to the level of reactivity of samples containing type-
specific antibody, with antigens specific to a homologous genotype.
For each genotype, the majority of reactive samples had absorbance values
of >2.0 at both the 1/40 and 1/100 dilutions (Table 7.3.1b). It is also noteworthy
that certain samples which were tested at a dilution of 1/200 also produced high
absorbance values, although the level of antibody in most of these cases was
visibly diminished.
In the presence of homologous competition at 1:1 concentration, absorbance
values were unchanged (Table 7.3.1b). In the presence of competing protein at a
lOx excess, the absorbance values were reduced in some of the samples, indicating
that competing protein was effectively blocking antibody reactivity towards
antigens coating the plate. However, sufficient levels of antibody remained to
produce a clear signal, with absorbance values reduced only to around 1.0, and in
many samples (particularly those from individuals infected with type 2), there was
no obvious reduction. When incubated with a solution of lOOx excess competing
antigen, the antibody reactivity was significantly lower in all but one sample, and
in the majority of cases, absorbance values were reduced below a level of 0.6, a
difference which would be easily distinguishable by eye.
For these reasons, the optimum concentration of serum to be used in this
ELISA was 1/100, i.e. lfA in 100/zl sample diluent, with the efficient blocking of
antibody achieved in the presence of a lOOx excess concentration of competing
antigen.
Under these conditions, samples in which very little or no reduction in
reactivity was observed were infrequent, and contain an extremely high level of
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Table 7.3.1b A COMPARISON OF NS3 ANTIBODY REACTIVITY
WITH HOMOLOGOUS TYPE ANTIGEN IN THE PRESENCE OF
DIFFERENT CONCENTRATIONS OF COMPETING ANTIGEN
Serum Concentration of Competing Antigen*
Sample Type Dilution None 1:1 10:1 100:1
HK430 lb 1/40 >2.0 >2.0 >2.0 0.962
1/100 >2.0 >2.0 1.828 0.729
HK434 lb 1/40 0.746 NDf 0.174 0.060
1/100 0.280 ND 0.098 0.026
HK461 lb 1/40 1.112 ND 0.334 0.065
1/100 0.414 ND 0.242 0.028
HK186 2a 1/40 >2.0 >2.0 >2.0 1.681
1/100 >2.0 >2.0 >2.0 0.701
HK8 2b 1/40 >2.0 >2.0 >2.0 >2.0
1/100 >2.0 >2.0 >2.0 0.969
HK559 2b 1/40 >2.0 >2.0 >2.0 0.599
1/100 >2.0 >2.0 0.988 0.276
PK6 3a 1/40 >2.0 >2.0 >2.0 0.771
1/100 >2.0 >2.0 >2.0 0.381
PK13 3a 1/40 >2.0 >2.0 1.310 0.178
1/100 >2.0 >2.0 0.816 0.234
PK21 3a 1/40 >2.0 >2.0 >2.0 0.590
1/100 >2.0 >2.0 >2.0 0.574
* Competing antigens were of a homologous genotype to that identified in the sample
under investigation, and are represented as an excess level to that coating the wells of
the microtitre plate. For example, 10:1 concentration represents the addition of a ten
fold excess level of protein to that present coating each well.
t Sample not done
NS3 antibody. Although in these cases a 1:1000 concentration of competing antigen
would most likely be effective, this level of competition would be impractical in
a final version of the assay due to the volumes of competition needed in each well
affecting serum concentrations. In practice, these samples would be repeated at a
higher dilution.
NS3 Serotyping ELISA
Using the results obtained so far, a competitive assay using NS3 antigens
for the detection of type-specific antibody was designed. Microtitre plates were
coated with equal concentrations of NS3 proteins corresponding to genotypes 1, 2
and 3, and serum samples incubated at a 1/100 dilution. Solutions containing
heterologous type competing antigens at a 100 fold excess concentration were
added to the typing wells, and a solution containing all antigens to the fully
blocked negative control well, as previously described for the NS4 serotyping
ELISA (section 2.1.2).
From seven type 1 samples analysed, only four were typed correctly by the
assay, of which two displayed high levels of background reactivity (Table 7.3.1c),
making identification difficult by eye. Two samples (HK434 and HK461) were
reactive in the unblocked well, but showed no reactivity in the typing wells, and
one sample was unreactive towards the NS3 antigens.
In all but one of the samples from individuals infected with type 2, antibody
of the corresponding serotype was detected by the assay. However, in 3/6 of these
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Table 7.3.1c ANALYSIS OF SERUM SAMPLES FROM INDIVIDUALS
INFECTED WITH TYPES 1-3 USING THE NS3 SEROTYPING ASSAY
Typing Well
Sample Type UB FB 1 2 3 Interpretation
HK434 lb 0.753 0.141 0.135 0.208 0.201 NTS
HK437 lb 0.045 0.012 0.047 0.107 0.067 NR
HK438 lb >2.0 0.423 1.718 0.401 0.700 1
HK461 lb 0.404 0.034 0.058 0.068 0.062 NTS
HK467 lb >2.0 1.040 >2.0 1.858 1.104 1*
HK363 la 0.941 0.118 0.774 0.112 0.124 1
HK406 la >2.0 0.637 1.338 0.738 0.652 1*
HK186 2a >2.0 0.329 0.111 0.402 0.487 2+3
HK315 2a >2.0 0.089 0.074 0.162 1.029 3
HK409 2a >2.0 0.839 0.842 >2.0 1.210 2*
HK8 2b >2.0 0.309 0.368 0.646 0.796 2+3
HK156 2b >2.0 1.343 1.441 >2.0 1.769 2*
HK559 2b 1.258 0.068 0.093 0.780 0.162 2
PK24 2 >2.0 0.312 0.252 1.180 >2.0 2+3
PK9 3a >2.0 0.546 0.313 0.431 1.829 3
PK13 3a 0.284 0.049 0.034 0.059 0.056 NTS
PK21 3a 1.730 0.314 0.254 0.410 0.694 3*
PK36 3a >2.0 0.178 0.044 0.126 1.056 3
PK38 3a 0.104 0.070 0.048 0.052 0.058 NTS
UB; Unblocked control well
FB; Fully Blocked control well
NTS; Non type-specific reactivity
NR; Non reactive
* High levels of background reactivity
samples a positive reaction was also evident in the third typing well, suggesting
that both type 2 and 3 specific antibody was present. The NS3 serotyping ELISA
was able to detect type-specific antibody in 3/5 samples from individuals infected
with type 3, with the remaining two sera showing non-type-specific reactivity.
These results suggest that a certain level of cross reactivity may exist between
types 2 and 3, and although the overall detection of NS3 antibody by the serotyping
ELISA was high, its ability to distinguish between different serotypes was
somewhat less successful.
Investigation of cross reactivity between genotypes 2 and 3
In order to investigate the possibility of cross reactivity between types 2 and
3 further, the ability of type 3 competing antigen to block the reactivity of type 2
antibody with type 2 antigen on the solid phase was examined, and vice versa. In
total, 15 samples from individuals infected with either type 2 or 3 were reacted
against homologous type antigen, in the presence of (i) no competing antigens, (ii)
type 2 competition only, (iii) type 3 competition only and (iv) a competing solution
containing both type 2 and 3 protein (Table 7.3.Id). In the absence of cross
reactivity, a positive result would be expected to be confined to the unblocked well
and the well containing heterologous type competing antigen, with lower
absorbance values present in the wells containing competition with type
homologous antigen.
148









































































































































































UBnblockedp sitivec n rolwell NTSontype-specificreact vity(ap nd x1.0) NRonreactive
All type 2 sera were positive in the unblocked well with the majority of
absorbance values >2.0, confirming the presence of a high titre of NS3 antibody
in these samples. Although a higher level of reactivity was observed in the well
containing only type 3 competing antigen in 5/15 samples, the remaining samples
analysed presented a reduction in reactivity with all three combinations of
competing antigen. These results (Table 7.3.Id) confirm that both type 2 and 3
protein is able to recognise NS3 antibody produced against certain type 2 isolates.
A positive reaction in the unblocked well confirmed the presence of NS3
antibody in 13/15 samples from individuals infected with type 3. Type 3 specific
antibody was correctly identified by a reaction in the well containing type 2
competition alone in 8/13 samples analysed, with the complete eradication of
reactivity in any of the typing wells observed in the remaining 5 sera. Interestingly,
the "unblocked" absorbance values for samples in which the competing proteins
removed all reactivity were lower than with the other samples. Although cross
reactivity also occurs between type 2 protein and type 3 antibody, this seems to be
less frequent than that observed between type 3 protein and type 2 antibody.
The development of a serotyping ELISA using NS3 recombinant protein as
antigen was successful in increasing the sensitivity towards type-specific antibody,
but lacked the specificity of NS4 in the ability to distinguish between types 2 and
3. In an effort to combine the sensitivity of the NS3 assay with the specificity of
the NS4 assay, I reasoned that both antigens together could compensate for the
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cross reactivity observed using NS3 alone, and therefore result in an improved
version of the serotyping ELISA. This was investigated by the production of type-
specific fusion proteins consisting of both the NS3 and NS4 antigenic regions in
the form of a single recombinant protein, for use in a competitive serotyping
ELISA.
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7.3.2 THE DEVELOPMENT OF A SEROTYPING ASSAY USING A
COMBINATION OF NS3 AND NS4 ANTIGENS
(1) PREPARATION OF NS3/NS4 ANTIGENS
Cloning of NS3 and NS4 regions
Samples in which the presence of genotypes lb, 2b and 3a had been
confirmed by RFLP were amplified by PCR in the NS3 and NS4 regions using
type-specific primers (Table 2.3; LP2-7 and LP11-16) containing complementary
restriction sites at each end (Figure 7.3.2a). Each PCR product was cloned into
pTAg, and analysed by sequencing to confirm the genotype. The individual clones
(NS3 = 286bp; NS4 = 98bp) were cleaved from the plasmid DNA using the
relevant restriction enzymes and ligated together prior to a further ligation reaction
to insert the 384bp fragment into a pTAg backbone with prepared corresponding
restriction sites (section 2.6).
Each NS3/NS4 clone (renamed FP1-3) was analysed by sequencing, and
translated into the corresponding amino acids to confirm that both regions were in
frame prior to expression (Figure 7.3.2a). FP1, 2 and 3 were constructed from
isolates NH15 (type lb), LJ823 (type 2b) and LJ516 (type 3a).
Protein expression
The NS3/NS4 clones were subcloned into pRSET for expression in E. coli
(section 2.6). Expressed proteins (128 amino acids in length) were visualised by
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PAGE (Figure 7.3.2b) in the supernatant from the bacterial culture, and their
identity confirmed by Western blotting (section 2.6.5) (Figure 7.3.2c).
Each protein was purified using metal chelate affinity chromatography
(section 2.6). Proteins were recovered with ten consecutive elutions with 300mM
imidazole, and identified in the third elution (E3) by PAGE (Figure 7.3.2d).
The concentration of each protein in E3 was calculated by PAGE, with a
comparison of the band density produced from lfA (or 0.1/il) E3 with standard
concentrations of BSA. The concentration of type 1 protein was 15 mg/ml, type 2
was the highest concentration at 65 mg/ml and a relatively low yield of type 3
protein was obtained at 3 mg/ml.
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Figure 7.3.2b IDENTIFICATION OF EXPRESSED HCV NS3/NS4
PROTEIN IN E. COLI CULTURE SUPERNATANT
HCV-lb HCV-2b
1 2 3 4 5 6
Pilot expression of HCV type lb and type 2b NS3/NS4 fusion proteins in E.
coli.
Lanes 1-6 represent samples taken from the E. coli culture supernatant at the
following time points;
Lane 1= addition of IPTG (0 hours)
Lane 2= Induction with M13/T7 bacteriophage (1 hour)
Lane 3= 2 hours post induction
Lane 4= 3 hours post induction
Lane 5= 4 hours post induction
Lane 6= 16 hours (overnight) post induction
Figure 7.3.2c IDENTIFICATION OF HCV NS3/NS4 PROTEINS BY
WESTERN BLOTTING
Type lb Type 2b
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Identification of expressed NS3/NS4 fusion proteins for type lb and type 2b by
Western blotting.
Lanes 1-6 correspond to the time point for which the samples were taken from
the E. coli culture during a pilot expression. Lane 1= addition of IPTG (0
hours); Lane 2= induction with M13/T7 bacteriophage (1 hour); Lane 3= 2
hours post induction; Lane 4= 3 hours post induction; Lane 5= 4 hours post
induction; Lane 6= 16 hours post induction
Figure7.3.2d IdentificationofHCVNS3/NS4fus onprote srtypelb(A)and2bBbyme alch latefi itychromat graphy. Lanes1-6correspondtsam leskfrhflowth oughafterwashingll winlumnsitll i g solutions; Lane1=E.coliulturesupernatantflowthr gh Lane2=Bindingbufferwash#1 Lane3=Bindingbufferwash#2 Lane4=Bindingbufferwash#3 Lane5=lOmMimidazolewash Lane6=30mMimidazolewash LanesE1-E7correspondtsampleskfrohlowth oughco s cutiveelutiowashith300 Mimidaz le.
Figure 7.3.2d IDENTIFICATION OF HCV NS3/NS4 PROTEINS DURING
PURIFICATION BY METAL CHELATE AFFINITY
CHROMATOGRAPHY
A E1 E2 E3 E4 E5 E6 E7
1 2 3 4 5 6
(2) ANTIBODY REACTIVITY TOWARDS NS3/NS4 ANTIGENS
To enable a direct comparison of the performance of this assay with that
using NS3 antigen alone, the same samples were used for each analysis. Similarly,
microtitre plates were coated with the same concentration of each antigen, and
competing antigen solutions contained a lOOx excess amount of antigen. All other
conditions, for example reagents and incubation times also remained as standard.
Homologous and Heterologous reactivity
The reactivity of antibody with antigen corresponding to the same genotype
was high for each of the samples from individuals infected with types 1, 2 and 3.
In the absence of competing antigen, the reactivity of type-specific antibody with
antigens specific to heterologous genotypes was also observed, although the
absorbance values in such cases were significantly lower. The lower level of
heterologous reactivity was also observed in type 2 and 3 samples which had been
cross reactivity using NS3 antigens alone. Using NS3/NS4 antigens, lower
absorbance values were produced during reactions between type 3 antibody and
type 2 antigen, and vice versa (Table 7.3.2a).
Serum Titrations
Samples were analysed at dilutions of 1/40, 1/100 and 1/200. Identical
samples produced slightly lower absorbance values with NS3/NS4 antigens than
previously detected with NS3 only, but this may have been caused by the longer
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Table 7.3.2a A COMPARISON OF ANTIBODY REACTIVITY WITH
HOMOLOGOUS AND HETEROLOGOUS TYPE NS3/NS4 ANTIGENS
Type 1 antigen Type 2 antigen Type 3 antigen
SD * SD SD
Sample Type 1/40 1/100 1/40 1/100 1/40 1/100
HK434 lb 0.380 0.137 0.550 0.280 0.276 0.151
HK438 lb >2.0 >2.0 >2.0 >2.0 >2.0 >2.0
HK461 lb 1.203 0.539 0.266 0.126 0.479 0.197
HK469 lb 1.576 1.199 >2.0 1.756 1.592 1.087
HK186 2a 0.785 0.682 >2.0 >2.0 >2.0 >2.0
HK315 2a 0.158 0.145 1.936 1.293 1.534 1.275
HK8 2b 1.390 1.284 >2.0 >2.0 >2.0 1.837
HK156 2b 0.283 0.108 >2.0 >2.0 1.799 1.587
PK6 3a 0.130 0.088 >2.0 >2.0 >2.0 >2.0
PK9 3a 0.145 0.070 1.667 1.270 >2.0 >2.0
PK13 3a 0.053 0.023 0.507 0.229 >2.0 1.740
PK21 3a 0.380 0.191 1.687 0.941 1.559 1.043
* Serum Dilution
duration of storage in combination with additional freeze/thaw cycles leading to a
reduction in antibody concentration. The optimum dilution of serum for reactivity
was 1/100, with absorbance values generally between 1.0 and 2.0 (Table 7.3.2a).
In addition, the reactivity of the majority of samples at this dilution was reduced
to background levels in the presence of lOOx excess competing antigen.
Investigation of cross reactivity between genotypes 2 and 3
The frequency of cross reactivity between type 2 or type 3 specific antibody
with heterologous competing antigen was investigated using identical samples and
experimental conditions as for NS3 (section 7.3.1). A comparison of the results
from seven samples from individuals infected with each genotype are compared in
Table 7.3.1d.
Using NS3/NS4 antigen, cross reactivity between type 2 antibody and type
3 competing antigen was less frequent than with NS3 alone. Only 1/7 sera (HK8)
tested using the NS3/NS4 antigens produced misleading results due to cross
reactivity with heterologous competing antigen, in comparison with 4/7 identical
samples with NS3. The use of a combination of both antigens has compensated for
the cross reactivity observed with NS3 alone in two samples, HK186 and PK 24
(Table 7.3.Id). The results of sample HK315 are regarded as inconclusive, as
analysis with the NS4 serotyping assay was unable to confirm the presence of type
2 specific antibody, despite the identification of this genotype by RFLP.
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An even greater improvement "in the level of type specific reactivity was
observed with samples from individuals infected with type 3. All samples but one
were reactive in the well containing only homologous competing antigen, whereas
only three samples failed to cross react with type 2 competition using NS3 alone.
In particular, sample PK38 had previously shown no reactivity towards NS3
antigens, suggesting that the reactivity observed against NS3/NS4 antigens was
directed towards the NS4 epitope of the fusion protein. Similarly, both an increase
in reactivity and specificity was observed for sample PK13 using NS3/NS4
antigens.
NS3/NS4 Serotyping ELISA
Samples from individuals infected with each of genotypes 1, 2 or 3 were
analysed using a serotyping ELISA based on the NS3/NS4 antigens, with a higher
number of samples producing accurate results than in a previous study of the same
samples using the serotyping assay based on NS3 antigens (Table 7.3.2b).
Type-specific antibody was detected in 5/6 samples from individuals
infected with type 1, of which two (HK437 and HK461) had previously been
untypeable using the NS3 assay (Table 7.3.2c). Despite the use of type lb antigen,
two sera from type la infected individuals were also serotyped successfully.
Similarly, much clearer results were obtained with samples containing type 2
antibody, with 5/6 samples identified correctly by the assay. Unlike the results
obtained with identical samples using the NS3 assay, background absorbance levels
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were relatively low and the results clearly distinguishable by eye. In addition, two
samples producing non type-specific reactivity with NS3 were identified correctly
using the NS3/NS4 ELISA (Table 7.3.2c). The highest level of specificity by this
assay was observed with samples from individuals infected with type 3. From a
total of seven samples analysed, type-specific antibody was detected in all but one
(Table 7.3.2b). This sample also had a higher level of reactivity in the typing well
corresponding to type 3 than in the other two wells, although the difference in
absorbance was too low to clearly define this serotype.
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Table 7.3.2b ANALYSIS OF SERUM SAMPLES FROM INDIVIDUALS
INFECTED WITH TYPES 1-3 USING THE NS3/NS4 SEROTYPING
ASSAY
Typing Well
Sample Type UB FB 1 2 3 Interpretation
HK434 lb 0.270 0.000 0.054 0.061 0.016 NTS
HK437 lb 1.754 0.317 1.725 0.483 0.383 1
HK461 lb 0.330 0.141 0.373 0.203 0.231 1 *
HK363 la 1.012 0.206 0.646 0.290 0.309 1
HK406 la >2.0 0.128 0.493 0.199 0.362 1 *
HK469 lb >2.0 0.225 0.723 0.508 0.566 1 *
HK186 2a >2.0 0.301 0.220 1.574 0.240 2
HK409 2a 1.843 0.040 0.047 0.213 0.027 2
HK8 2b 1.971 0.067 0.039 0.047 0.084 NTS
HK156 2b >2.0 0.597 0.438 1.488 0.594 2
HK559 2b 1.158 0.027 0.025 0.215 0.025 2
PK24 2 >2.0 0.650 0.680 1.940 1.680 2+3
PK6 3a 1.955 0.095 0.104 0.102 1.350 3
PK9 3a >2.0 0.388 0.390 0.373 1.744 3
PK13 3a 1.315 0.071 0.062 0.069 0.965 3
PK21 3a 1.426 0.136 0.165 0.267 0.316 NTS
PK36 3a 1.971 0.086 0.120 0.095 1.541 3
PK38 3a 0.499 0.034 0.040 0.039 0.380 3
PK39 3a 0.530 0.029 0.018 0.006 0.390 3
UB Unblocked positive control well
FB Fully blocked negative control well
NTS Non type-specific reactivity
High levels of background reactivity
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7.4 DISCUSSION
The NS4 serotyping assay has been shown to be successful in the detection
of HCV type specific antibody. However, the high level of specificity may be
compromised by a reduced sensitivity in some individuals who lack an immune
response to NS4. The hypothesis that a more sensitive ELISA could be designed
using antigens from the NS3 region followed a number of reports suggesting that
NS3 was associated with both a more frequent (Chien et al., 1992; Yuki et al.,
1994) and earlier (Lelie et al., 1992) immune response in HCV infected
individuals. In addition, a significant level of type-specific reactivity has been
identified by certain genotypes towards type 1 NS3 antigens in second and third
generation screening assays (Dow et al., 1996b).
Preliminary experiments demonstrated that a significantly higher level of
reactivity was produced with NS3 antigens in comparison to NS4. Indeed, up to a
five fold increase in antibody concentration was observed in many sera, as
absorbance values >2.0 were detected from a 1/200 serum dilution against NS3
proteins in comparison to 1/40 dilution against the same concentration of NS4
peptides.
The ability of the NS3 serotyping assay to distinguish between antibody
serotypes was less successful. Although a number of the samples analysed were
identified correctly, particularly those from individuals infected with type 1, a
significant number of samples from individuals infected with types 2 or 3 produced
inaccurate results. Subsequent investigations confirmed that cross reactivity between
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types 2 and 3 in some infections, but not others, could take place, and that this
seemed to occur more frequently with antibody generated during type 2 infections
than type 3. A comparison of NS3 amino acid sequences (Figure 7.3.1) revealed
that the motif "arginine-glycine-methionine" (amino acids 1408-1410) was present
in both these genotypes but different in others. One possibility may be that in
samples which are cross reactive, this common motif represents the major epitope
towards which the immune response is directed, whereas in cases where no cross
reactivity between the two genotypes is observed, other more type specific epitopes
are immunodominant, for example that existing at amino acids 1382-1386 (type 2
= "LAFI"; type 3 = "TATX") or at amino acids 1404-1407 (type 2 = "LAAA"; type
3 = "IASK"). The higher frequency of cross reactivity observed in type 2 infections
may reflect a more immunodominant role of amino acids 1408-1410 in type 2
isolates.
The relatively high concentrations of NS3 antibody in HCV infected
individuals, together with a more frequent immune response in comparison to NS4
made this antigen an ideal candidate for the development of a more sensitive
serotyping ELISA. Similarly, the appearance of NS3 antibody significantly earlier
during seroconversion would theoretically allow the determination of HCV serotype
much earlier during an infection, which may be advantageous in clinical practice
as both the genotype of HCV and duration of infection are factors associated with
a sustained response to interferon. However, despite these many favourable
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characteristics associated with NS3, the significant level of cross reactivity
observed between types 2 and 3 indicates that this antigen is unsuitable for the
detection of type-specific antibody.
In an effort to combine the sensitivity of NS3 antigens with the specificity
of NS4 within a single serotyping ELISA for HCV, the two regions were united
in the form of a single recombinant protein. The high sensitivity of NS3 was
maintained in this assay, with sufficient concentrations of antibody present in a
1/100 dilution of serum (1 fA per well) to ensure clear results by the majority of
samples. In a number of samples, the incorporation of NS4 was able to compensate
for cross reactivity observed between types 2 and 3 in the NS3 region alone (Table
7.3.2c), resulting in the detection of type-specific antibody in a higher number of
samples.
A further advantage of the combined antigen could be in the event of an
individual in which an immune response towards one of these regions was absent.
This was demonstrated in sample HK437, which was unreactive towards NS3
antigens alone, and yet the presence of type 1 specific antibody was clearly
detected using NS3/NS4 antigen. There have been a number of reports of an earlier
(Lelie et al., 1992), and more frequent immune response towards NS3 in
comparison to NS4 (Chien et al., 1992; Yuki et al., 1994), suggesting that a higher
number of samples will rely on the reactivity to the NS3 region alone. In some of
these cases, the cross reactivity between types 2 and 3 may still present a problem,
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however, the identification of type-specific antibody in a significant number of NS4
"non reactive" samples would become a possibility with this new ELISA.
Clearly a much higher number of samples must be analysed before the exact
role of the NS3/NS4 serotyping ELISA can be assessed, including particularly those
which had produced non type-specific results, or were unreactive with the NS4
assay. Furthermore, the addition of antigens for other HCV subtypes may increase




8 DISCUSSION ; PROBLEMS AND FUTURE DEVELOPMENTS OF
THE HCV SEROTYPING ASSAY
Diversity of HCV
The aim of this thesis was to develop a sensitive ELISA which would be
able to detect and distinguish between the broad range of HCV genotypes
distributed worldwide. Prior to this work, a competitive ELISA based on antigenic
regions of the NS4 genome, was only capable of detecting HCV serotypes 1-3, and
therefore was only successful in countries such as the U.S.A, Japan and
Northern/Western Europe, where these genotypes predominated.
In this study the assay was extended to incorporate antigens for genotypes
4, 5 and 6, resulting in an assay which could be used effectively in the detection
of the full range of HCV genotypes occurring worldwide (Chapter 3). There was
no decrease in the sensitivity of the assay for types 1-3, while a large proportion
of samples from individuals infected with types 4, 5 and 6 were correctly
identified. However, studies using samples from HCV-infected individuals in
certain countries, such as Pakistan and Egypt, revealed a higher frequency of non¬
specific reactivity as compared with studies from Western countries (Chapter 3).
The most likely explanation for the reduced specificity of the assay in these areas
is the occurrence of additional subtypes for which the antigens in the assay are less
cross-reactive. In order to be able to increase the sensitivity of the assay towards
these subtypes, it would be necessary to incorporate additional subtype-specific
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NS4 peptides. For example, the assay already incorporates peptides for subtypes 2a,
2b and 2c, resulting in an increase in the sensitivity and specificity of the assay for
this type 2. However, given the vast array of subtypes identified in recent years,
it may not be possible to extend this to the full range of subtypes currently
identified for this and other genotypes. For example, up to 17 subtypes of type 3
have been identified, and it would be impossible to incorporate this number of
antigens (17x2 = 34) into the assay because of limitations in the amount of each
antigen binding to the plate. In addition, because each antigen is present at lOOx
the coating concentration in the competition mix, this may exagerate cross-
reactivity and lead to a reduction in the specificity of the assay for other genotypes.
One alternative would to be to produce a kit which contains antigens specific to the
genotypes prevalent in the geographical area under investigation, but the cost of
development of a separate assay for each geographical region would be prohibitive.
Serotyping analysis of samples from individuals infected with type 6 group
variants was successful in only some of the samples, as a result of amino acid
variation present within the NS4 antigenic regions corresponding to the peptides
used in the ELISA (Chapter 5). Although it may be possible to increase the
sensitivity of the assay towards type 6 group variants by incorporation of the
corresponding peptides, the relatively confined geographical distribution of these
isolates in South East Asia fails to justify such measures. Similar problems are
faced by current genotyping methods. Type 6 group variants are currently unable
to be identified by many assays which are based on the 5'NCR such as RFLP
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analysis and InnoLiPA, as these isolates show a high degree of sequence similarity
to type 1 in this region. Owing to the extreme diversity of HCV, it is unlikely that
a genotyping assay which is able to detect all HCV variants will ever be produced.
Clinical Significance of a Serotyping Assay for HCV
The clinical significance of different HCV genotypes is currently an active
area of research, and the vast majority of reports suggest that infection with type
1 is associated with a lower frequency of sustained response to Interferon treatment
than infection with types 2 or 3. One important application of the serotyping assay
in clinical practice is therefore in the selection of HCV infected individuals for
Interferon treatment, as this drug is expensive, and often associated with severe side
effects. Although Interferon therapy is currently based on PCR analysis, the use of
the serotyping assay would provide a relatively inexpensive and rapid method of
genotype determination from large patient groups prior to confirmation by PCR.
The clinical significance of genotypes 4-6 is relatively unknown, with only
a few papers to date, suggesting that infection with type 4 may be associated with
a poor response to interferon (Lau et al., 1996; El Zayadi et al., 1996). The 1-6
serotyping assay may play an important role in such studies, in the determination
of HCV genotypes causing infection in patients undergoing treatment. However, in
the event that a lower frequency of sustained response is associated with only type
1, the development of an ELISA which is able to distinguish type 1 from any of
the other major genotypes may be more relevant in clinical situations.
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Some groups have suggested that non-responsiveness to interferon treatment
is specifically associated with type lb. However, many of these studies have been
performed in countries where this genotype predominates, such as Japan, and so
direct comparison with subtype la has not always been possible. If this difference
is confirmed, there would be a greater demand for assays which are able to
distinguish between type 1 subtypes, in addition to other genotypes. Insufficient
amino acid variation is present in NS4 antigenic region 1 and 2 to be able to
differentiate between subtypes of type 1, and it would be necessary to investigate
the possibility of using additional antigens for this purpose. A comparison of amino
acid sequences in NS4 antigenic region 3 revealed some variation between types
la and lb, but a low frequency of antibody reactivity was observed in this study
when using this antigen in a serotyping ELISA (chapter 4).
In conclusion, the 1-6 serotyping assay may play an important role in the
identification of HCV genotypes causing infection in individuals who are under
consideration for interferon treatment. In addition, the ability of the assay to
identify genotypes 4-6 will be important in future studies concerning the clinical
significance of infection with these genotypes.
Improvements to the HCV Serotyping Assay
In an attempt to increase the sensitivity of the serotyping assay, the ability
of antigens from the NS3 region for the detection of type-specific antibody was
investigated (Chapter 7). A higher reactivity of NS3 antibody was observed in the
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majority of samples compared with NS4, with strong reactivity produced from as
little as 1/il of serum. This would be particularly useful for the analysis of samples
from immunocompromised patients, in which the concentration of antibody is often
low, and may improve the sensitivity of the serotyping ELISA when analysing
groups of patients such as haemophiliacs or post-transplant patients on
immunosuppressant drugs.
Although the sensitivity of the NS3 serotyping assay was greater in
comparison with the NS4 assay, the specificity of type-specific NS3 antigens was
much lower due to a high frequency of cross-reactivity between types 2 and 3. This
problem was addressed by the incorporation of antigens from both regions in the
form of a NS3/NS4 fusion protein. In this format, the specificity of the assay was
increased, with the successful detection of type-specific antibody in some samples
which had produced non-type-specific results using NS3 antigens alone. Although
the specificity of the NS3/NS4 serotyping assay for the identification of types 2 and
3 is unlikely to exceed that of the NS4 serotyping assay, the sensitivity towards
types 1, 2 and 3 has been increased.
Possible future developments of the serotyping assay
Future development of the NS3/NS4 serotyping assay might include the
incorporation of antigens for genotypes 4, 5 and 6, and an investigation into the
potential of antigens from individual subtypes. One advantage of the incorporation
of the NS3 (c33c) antigen into second generation screening assays has been in the
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earlier detection of antibody during HCV infection following seroconversion, as
this protein is often the first to generate an immune response (Puoti et al., 1992;
Lelie et al., 1992). This may also apply to the NS3/NS4 serotyping assay, and it
would be interesting to analyse samples from HCV positive individuals which had
previously been unreactive on the NS4 serotyping assay. The number of false
negative results on the serotyping assay could theoretically be reduced further by
the incorporation of additional antigens, such as core, El and NS5. However, the
core region is relatively conserved between genotypes, and has only been successful
in the detection of types 1 and 2 (Machida et al., 1992).
This work represents a significant improvement of serotyping assays for
HCV, and may prove valuable in clinical practice for the selection of patients for
drug therapy.
SUMMARY
■ This work has resulted in the successful development of a competitive
ELISA which is able to distinguish between all six major genotypes of HCV.
■ The application of this assay to samples obtained from a number of different
geographical areas has provided information about the HCV genotype distribution
in various countries, including Hong Kong, Egypt, Norway, Pakistan and Taiwan.
■ HCV serotyping has also contributed to both epidemiological and clinical
studies, including the identification of a possible link between type 6a infection in
Hong Kong and the transmission of this genotype by drug abuse.
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■ The sensitivity of the existing serotyping assay was improved by the
addition of antigen (in the form of recombinant protein) to the NS3 region. This
has resulted in an assay which is able to distinguish between HCV serotypes 1-3
from only 1/il serum.
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1.0 GLOSSARY OF TERMS COMMONLY USED THROUGHOUT THIS
WORK.
(a) Sensitivity
The sensitivity of the serotyping assay is a calculation of the percentage of
samples analysed in which NS4 antibody can be detected. This value is calculated
by dividing the number of samples which are reactive to the NS4 antigens by the
total number of samples analysed.
i.e. No. samples reactive on serotyping assay*
Total number of samples analysed
* This includes samples which were reactive to the NS4 antigens collectively but
for which type-specific antibody was not obvious ("NTS" results).
(b) "Specificity" and "Concordance"
The serotyping assay shows a high level of "specificity" (or is highly
specific), if a high percentage of the serotyping results obtained during analysis are
in agreement with (i.e. are "concordant" with) the genotype of virus identified by
PCR based methods such as RFLP or sequencing.
The level of concordance is calculated by dividing the number of results
which were ingreement with the genotype of infecting virus identified by PCR
207
based methods by the total number of samples which were reactive on the
serotyping assay.
i.e. No. of serotyping results which agree with genotyping analysis
No. of samples reactive on the serotyping assay
(c) Discrepant
A serotyping result is "discrepant" if it is not in agreement with the result
obtained using other methods of genotyping.
(d) Non-type-specific (NTS)
Samples showing non-type-specific reactivity are those which show the
presence of NS4 antibody (by reactivity in the unblocked well), but the serotype
cannot be distinguished by the assay. This kind of reactivity can be observed on
the microtitre plate in two ways; (1) The unblocked well is positive with all other
wells negative. In these cases, cross reactivity may be taking place between the
NS4 antibody in the sample and one or more of the competing peptides in solution.
This may occur if a patient is infected with an unusual subtype of HCV, in which
NS4 antigenic variation in NS4 has resulted in shared epitopes with those of a
different genotype. (2) All eight wells show high levels of reactivity. The antibody
titre in these samples may be at too high a level for the 100 fold excess competing
peptide solution to absorb all non specific antibody. Clearer results are usually
observed in these cases if the sample is retested using a higher dilution of serum.
(e) Non Reactive (NR)
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Samples which are unreactive in all eight wells on the assay do not contain




OPD substrate was dissolved in citrate phosphate buffer pH 4.0 at a concentration
of 0.5mg/ml, with 0.1% hydrogen peroxide (Dako Ltd) being added immediately
prior to use.
Citrate phosphate buffer; 0.08M citric acid (SIGMA)
0.1M Na2HP04
Adjust pH to 4.0 with NaOH
Store at 4°C, maximum 4 weeks.
2.3 RESTRICTION ENDONUCLEASES
The restriction sites for the restriction enzymes used in this study are as
Rsa I GT/AC
Hae III GG / CC
Mva I CC / (A,T)GG
Hinf I G / ANTC
I CG / CG
ScrF I CC / NGG
2.5 DNA SEQUENCING
lOx Sanger TBE; 162g Tris base (AnalaR, BDH)
42.5g Boric Acid (Scientific Imaging Systems, Eastman
Kodak Co., Rochester, NY)
9.5g EDTA (Scientific Imaging Systems)
Made up to 1 litre with distilled water
2.6 CLONING
Luria Broth; lOg tryptone (DIFCO)
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5g yeast extract (GIBCO. BRL)
5g NaCl (Fisher scientific)
Made up to 1 litre with distilled water
Adjust pH to 7.0-7.5 with NaOH
Solution III; 29.5ml glacial acetic acid (AnalaR. BDH)
Adjust to pH 4.8 with KOH pellets (AnalaR. BDH)
Made up to 100ml with distilled water
2.7.3 PROTEIN EXPRESSION
SOB Agar; 20g Bacto Tryptone
5g Yeast extract
0.5g NaCl
Add distilled water to 1 litre
Adjust to pH 7.5 with KOH, Autoclave
Add 20ml lm MgS04 prior to use.
Lysis buffer 20mM Tris-HCl pH 7.9
0.5M NaCl (5mM imidazole)
Protease inhibitors; Leupeptin, Pepstatin, E64 (all at 1 /ig/ml)
N.B. No EDTA or DTT must be present if the proteins are
to be purified by immobilised metal affinity chromatography, as












2.5ml 0.5M Tris pH 6.8
0.1ml 10% SDS
1.3ml Acrylamide / Bisacrylamide
50/il Ammonium persulphate
10 Ad TEMED
lx SDS-PAGE running buffer
10% Ultra Pure lOx Tris (0.25M) / Glycine (1.92M) / SDS (1%)
(National Diagnostics)
90% distilled water
2x SDS sample buffer





Distilled deionised water to 100ml
4X Tris-HCl / SDS pH 6.8
0.5M Tris-HCl
0.4% SDS
pH 6.8 with IN HC1
water added to 100ml.
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Solution is filter sterilised through a 0.45/urn sterile filter.
Coomassie Blue staining solution
50% (v/v) methanol
0.05% (v/v) Coomassie Brilliant blue R-250 (BioRad).
10% (v/v) acetic acid
40% distilled deionised water
Coomassie blue is dissolved in the methanol prior to the addition of















75ml 10% Casein solution (Caseign Hamersten; DIFCO)
25ml 2M Tris pH 7.5
10ml Bronidox-L
Adjust to pH 7.8 +/- 0.2 using 5M NaOH or HC1
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Add distilled water to 1 litre
2.9 PROTEIN EXPRESSION BY MCAC.
8 X Binding buffer
4M NaCl
160mM Tris-HCl pH 7.9
40mM Imidazole
lOmM Imidazole wash
12.5ml 8X Binding buffer
0.5ml 2M Imidazole
Adjust pH to 7.9 with HC1
Make up to 100ml with MilliQ water.
30mM Imidazole wash
As above with 1.5ml 2M Imidazole.
300mM Imidazole wash
As above with 15ml 2M Imidazole.
5.3 PHYLOGENETIC ANALYSIS OF NUCLEOTIDE SEQUENCES
Phylogenetic trees can be either rooted or unrooted. A rooted tree indicates
the direction of evolution, with the root representing the common ancestor of all
the sequences analysed. An unrooted tree specifies the relationship among the
sequences but does not define the evolutionary path.
There are a number of methods avalable for the construction of phylogenetic
trees, which are classified into either distance matrix or character based (maximum
parsimony) methods. Distance matrix methods involve the calculation of
evolutionary distances (pairwise distances) between the sequences, whereas
maximum parsimony methods construct a phylogenetic tree by considering the
214
shortest pathway which leads to certain character states such as nucleotides at a
specific site in the sequence.
There are two different types of methods available for testing the reliability
of a phylogenetic tree. These are the maximum likelihood method (Felsenstein,
1981) and the bootstrap test (Felsenstein, 1985). The maximum likelihood method
examines the reliability of every interior branch of the tree, and is generally time
consuming and limited to use with small data sets. The bootstrap involves random
resampling of the data from which the tree was constructed, in order to produce
another tree. This process is repeated several hundred times and the frequency at
which particular branches are encountered in the newly constructed trees is
calculated to give a probability for each branch in the original tree. This statistical
method is used with both neighbor-joining and maximum parsimony methods.
215
Journal of Medical Virology 53:237-244 (1997)
Sequence Analysis of Hepatitis C Virus Variants
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Methods for identifying the genotype of hepati¬
tis C virus (HCV) in clinical specimens are fre¬
quently based upon the direct characterisation
of viral RNA sequences by polymerase chain re¬
action (PCR) amplification, or by serologically
based methods, in which the infecting genotype
is inferred from the pattern of antibody reactivity
to type-specific peptides or recombinant pro¬
teins used as antigens in an Enzyme Linked Im¬
munosorbent Assay (ELISA). Although genotyp¬
ing by direct, PCR-based methods show gener¬
ally highly concordant results with the genotype
inferred from serological typing assays (>95%
agreement), there exist a small number of
samples that produce discrepant results. To in¬
vestigate the underlying reasons for the discrep¬
ancies, we obtained eleven samples from hae¬
mophiliacs and four samples from patients with
chronic hepatitis C that produced discordant re¬
sults between a PCR based assay (InnoLipa I and
II) and a serotyping assay (Murex HC02). Nucleo¬
tide sequences in the 5'noncoding region
(5'NCR), core, and NS4 region were used to
identify the genotype of the circulating virus and
to identify amino acid changes in NS4that might
alter antigenicity. In 14 samples, sequence
analysis of all three regions was concordant with
the results of the InnoLipa assay. There were few
if any amino acid substitutions in NS4 that might
have accounted for the discrepant serotyping re¬
sults, which were found predominantly in
samples from individuals with a history of mul¬
tiple exposure to HCV. It remains unclear wheth¬
er the detection of antibody in such discrepant
samples corresponds to previous expression of
a different genotype than detected by PCR, or
whether the virus population in plasma is more
restricted in genotype diversity than the popula¬
tion in the liver or at other sites of viral replica¬
tion. J. Med. Virol. 53:237-244, 1997.
© 1997 Wiley-Liss, Inc.
© 1997 WILEY-LISS, INC.
KEYWORDS: serotyping; genotyping; geno¬
type; NS4; 5' noncoding region
INTRODUCTION
Hepatitis C virus (HCV) is a positive strand RNA
virus which was first cloned in 1989 and is the major
aetiological agent of non-A non-B hepatitis worldwide
[Choo et al., 1989]. The virus genome is approximately
9400 nucleotides in length, and displays up to 30% se¬
quence divergence between each of the six major types,
each of which can be further divided into numerous
subtypes [Simmonds et al., 1993a; Bukh et al., 1993a;
Simmonds et al., 1994a; Mellor et al., 1995a],
Recent investigations have suggested that infections
with HCV type 1 are associated with more rapid dis¬
ease progression and are more likely to cause hepato¬
cellular carcinoma than infection with other genotypes
such as types 2 or 3 [Takada et al., 1996; Kobayashi et
al., 1996], Another reason for investigating the infect¬
ing HCV genotype in clinical samples is in the evalua¬
tion of patients for antiviral treatment, since there is
an increased frequency of sustained response to inter¬
feron in individuals infected with types 2 and 3, com¬
pared to HCV type 1 [reviewed in Davis, 1994, Dush-
eiko et al., 1994],
Because of these clinical associations, a number of
different methods have been developed to identify the
virus genotypes in infected individuals. The majority of
techniques are based on the amplification of subge-
nomic fragments of HCV by the polymerase chain re¬
action (PCR). Genotypes can be distinguished using
amplified DNA sequences in three different ways: (1)
by differential amplification using type specific primers
[Okamoto et al., 1992; Okamoto et al., 1993; Widell et
Correspondence to: P. Simmonds, Department of Medical Mi¬
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al., 1994; Ohno et al., 1997], (2) by the digestion of
amplified PCR products from the 5' noncoding region
(5'NCR) with combinations of restriction endonucle-
ases, to reveal patterns of fragments specific to indi¬
vidual genotypes [McOmish et al., 1994; Davidson et
al., 1995; Mellor et al., 1996], or (3) by the reverse hy¬
bridisation of labelled PCR products to immobilised
type specific probes [Stuyver et al., 1993; Stuyver et al.,
1995; Stuyver et al., 1996], A different, indirect method
for typing virus in infected individuals is based upon
the observation that sequence diversity between geno¬
types results in the production of type-specific antibod¬
ies, which can be detected by ELISA [Machida et al.,
1992; Tanaka et al., 1994; Simmonds et al., 1993;
Zhang et al., 1995; Dixit et al., 1995; Bhattacherjee et
al., 1995], The usefulness of serotyping assays lies in
their rapidity and ease of use, as long as this is not at
the expense of sensitivity or accuracy.
In this study, we have compared the performance of
one direct (Inno-LiPA I and II) and one indirect (Murex
1-6 serotyping) typing assay on two distinct popula¬
tions: a group of haemophiliacs from Germany, and pa¬
tients with chronic hepatitis C from France. Discrepant
samples were further investigated by sequence analy¬
sis of the 5'NCR, core and NS4 regions.
MATERIALS AND METHODS
Samples
Serum samples were obtained from haemophiliacs in
Frankfurt, Germany, and from patients with chronic
HCV infection in France. Additional samples were ob¬
tained from some individuals with discrepant results in
order to permit sequence analysis.
Genotyping
Isolates were genotyped using Inno-LiPA HCV ver¬
sion I or version II (Innogenetics, Antwerp, Belgium)
according to the manufacturer's instructions. This as¬
say used labelled PCR products from the 5'NCR as
probes for reverse hybridisation to oligonucleotides im¬
mobilised on strips [Stuyver et al., 1993; Stuyver et al.,
1996],
Serotyping
Type-specific antibody was determined by the Murex
1-6 serotyping assay HC02 (Murex Biotech, Dartford,
UK), or where specified, the Murex 1-3 serotyping as¬
say HC01, according to the manufacturer's instruc¬
tions. Type-specific peptides corresponding to two epi¬
topes in NS4 were used as antigen in a competitive
ELISA [Simmonds et al., 1993; Bhattacherjee et al.,
1995],
RNA Extraction and Nested
Reverse-Transcription PCR (RT-PCR)
Virus RNA was directly extracted from 100 pel serum
using proteinase K/sarcosyl and phenol/chloroform ex¬
traction. RNA was precipitated at -20°C overnight in
ethanol and dissolved in 25 pel DEPC treated water
prior to RT-PCR [Davidson et al., 1995].
(1) 5' NCR. Reverse transcription of RNA used the
outer antisense primer 209, followed by primary PCR
with primers 209 and 939 (outer sense) and secondary
PCR with inner primers 940 (sense) and 211 (anti-
sense) [Chan et al., 1992],
(2) Core. Core specific antisense primer 410 was
used for reverse transcription of RNA, followed by PCR
amplification with primers 410 and 954 (outer sense),
and inner primers 951 (sense) and 953 (antisense)
[Mellor et al., 1995].
(3) NS4. NS4 amplification was achieved using
combinations of universal primers, and type-specific
primers designed for HCV types 1, 2 and 3, as follows;
outer antisense primers included 007 [Simmonds et al.,
1993b], LP2 (type 1 specific) 5'GTACTGTATCCCGCT-
GATGAARTTCCACA 3', and LP4 (type 3 specific)
5'GTATTGGATCCCACTCACAAAATTCCACA 3'.
Outer sense primers were 5668 5'ATGCATGTCRGCT-
GAYCTGGA 3' and 53510 [Bhattacherjee et al., 1995],
For the second round of PCR, primers were 220 [Sim¬
monds et al., 1993b], 865 [Prescott et al., 1996], LP3
(antisense, type 1) 5'TTCCACATGTGYTTCGCCCAGA
3', LP6 (sense, type 1) 5'CTGGAGGTCGTCACTAG-
CACCTGG 3', LP15 (antisense, type 2) 5'CAAAGCT-
TANAGCATCTCSGCNATCCGCTGCCC 3', LP12
(sense, type 2) 5'GCTCTCGAGCCSGACAAGGARRT-
CYTNTAT 3', LP5 (antisense, type 3) 5'TTCCA-
CATATGCTTGTGCCAGA 3' and LP7 (sense, type 3)
5'CTGGAAGTAACCACCAGCACCTGG 3'. PCR prod¬
ucts were electrophoresed through a 2% agarose gel
containing 0.5 pl/ml ethidium bromide, and viewed on
a u.v. transilluminator.
Sequencing
PCR products were either sequenced directly (5'NCR
and core regions) or from clones. Direct sequencing in¬
volved the re-amplification of the 2° PCR product with
one of the primers biotinylated, followed by immobili¬
sation on streptavidin-coated magnetic beads (Dyna-
beads M280, Dynal) as previously described (Kleter et
al., 1994). Sequencing reactions were performed using
T7 DNA polymerase (Sequenase version 2.0, United
States Biologicals, USB) according to the manufactur¬
er's instructions. Sequences from the 5'NCR, core, and
NS4 regions have been submitted to GenBank and bear
the accession numbers AF007498-AF007522.
Cloning of NS4
TA cloning of amplified NS4 fragments into the
pTAG vector was carried out using the LigATor kit
(R&D systems, Europe, Ltd.) according to the manu¬
facturer's instructions. Cloned NS4 fragments were se¬
quenced after the denaturation of miniprep DNA with
2M NaOH/2mM EDTA, followed by precipitation in
ethanol at -70°C for 15 minutes. To investigate the
possibility of a mixed infection, up to five different
clones were sequenced for samples GDI, GD3, GD4,
GD5, and GD7. Between five and ten individual clones
were sequenced for each PCR product from samples
giving positive PCR results with more than one set of
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-160 -140 -120 -100
la HCV-PT ATTGCCAGGACGACCGGGTCCTTTC—TTGGAT-CAACCCGCTCAATGCCTGGAGATTTGGGCGTGCCCCCGCAAGACTGCTA
la HC-J1 -A. . c.
lb HCV-J ....G.
lb BK ....G.
GD 6 . ...G.
FD 1
lc HC-J9 -T. .
2a HC-J6 G . .A. # T -A. . . .A. .T. C..TC
2a K2a G
2b HC-J8 ...A..G A.A. .T — -A. . . .A. • T. ..T.C..TC AC
2b K2b ...A..G . .A. .T -- -A. . . .A. .T. ..T.C..TC




3a NZL1 ..C..TG. .GT. G- .A..CA..A G. .TCA...
3a HPCHK6
GD 1 ..C..TG .GT. G-T... .A..CA..A G. .TCA...
GD 2 ..C..TG .GT. G-T... .A..CA..A G. .TCA...
GD 3 ..C..TG .GT. G- .... . . . .A..CA..A G. .TCA...
GD 4 ..C..TG .GT. G-T... .A..CA..A G. .TCA...
GD 5 ..C..TG .GT. G-.... •A..CA..A G. .TCA...
GD 7 ..C..TG .GT. A- .A..CA..A .TCA...
GD 8 ..C..TG .GT. A- . . . .A..CA..A G. .TCA...
GD 9 ..C..TG .GT. G- .A..CA..A G. .TCA...
FD 3 ..C..TG .GT. G- .A..CA..A . . .G. .TCA...
FD 4 G. .TCA... i
3b Tr ..C...G. . .T. A- C...A G. .TCA...
3b NE137 ..C...G. A-T... ....C...A.... ....G. .TCA...
10a JK049 . .C. G. .TT. A-.T.. ... .CI ... A ... . G.
4a ED43 ..C...G. . .T. -T... ....C...A....
4a EG13
5a SA1 G. . .T. -A. . . ....C ....G.
5a SA7 G. . .T. -A. . . ....c ....G.
FD 2 G. . -T- -A
6a HK4 CA CA...
6a T3950 . .T. CA CA...
11a JK046 ....G..
Fig. 1. Comparison of 5' NCR nucleotide sequences obtained from the discrepant samples with sequences specific for each genotype.
type-specific primers (GD2 and GD8). Sequencing re¬
sults from the remaining haemophiliac discrepant sera
were based on analysis of single clones only.
RESULTS
HCV Positive Haemophiliacs
From a group of 78 HCV PCR positive German hae¬
mophiliac samples tested with both the Inno-LiPA II
assay and the Murex 1-6 serotyping assay, a total of
eleven gave discordant results (Table I). In eight cases
the genotype identified in the 5' NCR was HCV-3a,
with type 1 specific antibody being detected by the
ELISA. Two samples (GD10 and GD11) were type 2b
by Inno-LiPA and type 1 by serotyping, while GD6 was
the opposite, being typed as lb by Inno-LiPA II and as
type 2 by serotyping. In sample GDI, types 1 and 2
were detected by serotyping, but the genotype was
HCV-3a by Inno-LiPA.
RNA sequences from the eleven samples were ampli¬
fied by PCR in the 5' NCR and NS4 regions, and where
serum volume permitted, in the core region. The HCV
genotype identified in each sample by direct sequence
analysis of the 5'NCR [Smith et al., 1995] was concor¬
dant with that detected by the Inno-LiPA II assay (Fig.
1), and in each case phylogenetic analysis of sequences
in both the core and NS4 regions gave the same geno¬
type assignments as deduced for the 5'NCR. In order to
rule out the possibility of a dual infection, PCR ampli¬
fication of NS4 was carried out using primers specific
for the genotypes detected by Inno-LiPA and serotyp¬
ing (types 1, 2, or 3). In all but two samples, a positive
PCR result was identified only when we were using
primers specific to the genotype identified by Inno-
LiPA (Table I). However, NS4 sequences could be am¬
plified from samples GD2 and GD8 by both type 1 and
type 3 specific primers, although the PCR products
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TABLE I. Identification of Genotypes in Discrepant Sera Using Different Typing Assays and Sequencing







1-6 T1 T2 T3 5'NCR Core NS4
GDI 3a 1 + 2 + 3a _ 3a
GD2 3a — 1 +w + 3a 3a 3a
GD3 3a — 1 — + 3a 3a 3a
GD4 3a — 1 — + 3a 3a 3a
GD5 3a — 1 _ + 3a — 3a
GD6 lb — 2 + — lb lb lb
GD7 3a — 1 — + 3a — 3a
GD8 3a — 1 +w + 3a 3a 3a
GD9 3a — 1 — __ 3a — —
GD10 2b — 1 — + 2b 2b 2b
GD11 2b — 1 — + 2b 2b —
Inno-LiPA
T
FD1 lb NR 4 lb lb lb
FD2 4-5 1 1 5 5 5
FD3 3a NR 1 3a 3a 3a
FD4 3a NR 1 3a 3a 3a
w - weak result.
duced a sequence that resembled that of the peptide of
HCV-4a used in the serotyping assay.
with type 1 primers were much weaker under U.V.
transillumination than the corresponding bands on the
gel using type 3 primers. Multiple clones from each
PCR product from GD2 and GD8 were analysed by se¬
quencing, and each was identified as type 3.
One potential explanation for the cases of mistyping
by the serotyping assay is that amino acid variation
within NS4 in the discrepant samples was sufficient to
produce cross-reactivity with peptides normally spe¬
cific to a different genotype. However, few amino acid
differences were observed from the peptides used for
serotyping, and were generally restricted to substitu¬
tions of residues with similar size and charge (Fig. 2).
Although the analysis of multiple clones revealed the
same genotype for each isolate, where amino acid se¬
quences from multiple clones show variation, each se¬
quence is shown for comparison.
French Patients With Chronic Hepatitis C
A total of 88 samples from patients with chronic
hepatitis C infection in France were analysed using
Inno-LiPA I, and the Murex 1-6 serotyping assay. Four
samples were discrepant; sample FD1 was typed as
HCV-lb by Inno-LiPA I and yet only had evidence of
type 4 specific antibody upon testing by the ELISA,
FD2 was type 4 or 5 by Inno-LiPA I, but HCV-1 by
serotyping, while samples FD3 and FD4 were HCV-3a
by Inno-LiPA I but type 1 by serotyping (Table I).
Sequence analysis in 5'NCR of FD1, FD3, and FD4
confirmed the genotype as that identified by Inno-LiPA
I, while sample FD2, identified as 4-5 in the 5'NCR by
genotyping, was type 5 upon sequencing in all three
regions (Fig. 2).
Amino acid substitutions in NS4 were more frequent
than in the haemophiliac samples, and occurred in both
peptide regions 1 and 2 (Fig. 2). Two amino acid sub¬
stitutions occurring in region 2 of sample FD1 pro¬
DISCUSSION
Genotyping assays are usually based upon the am¬
plification ofHCV sequences in the 5'NCR. These allow
the identification of each of the six major genotypes but
are more limited in their ability to differentiate be¬
tween subtypes, such as type la and lb, or between
type 2a and 2c, which are often identical in this region
[Stuyver et al., 1995; Smith et al., 1995]. In addition,
the use of genotyping assays presupposes access to
PCR technology in the laboratory, and until automa¬
tion becomes widely available, such methods will be
relatively time consuming and expensive. Serotyping
assays based on antigenic variation of NS4 or core can
distinguish between virus types but are unable to dif¬
ferentiate between subtypes [Machida et al., 1992;
Bhattacherjee et al., 1995; Dixit et al., 1995; Zhang et
al., 1995]. However, the assays are generally quick and
easy to perform and use equipment and techniques
that are commonplace in any diagnostic virology labo¬
ratory.
A high concordance has been found between the
genotypes identified by PCR and the detection of geno¬
type-specific antibody. For example, among reactive
samples from Scottish blood donors to branched pep¬
tides from NS4, the antibody specificity was 99.2% con¬
cordant with the genotypes identified by restriction
fragment length polymorphism (RFLP) [Simmonds et
al., 1993b]. Similarly, 98.5% of samples were concor¬
dant with genotyping by Inno-LiPA I [Lau et al., 1996].
Serologically typeable samples in the modified assay
that extended serological detection of types 4, 5, and 6
showed a similar concordance with RFLP (100%, Na-
vas et al., 1997; 98%, Bell et al., 1996; 97%, Bhattach¬
erjee et al., 1995) and other PCR-based typing methods







Prototype AAYCLSTGOV VIVGRWLSGKPAIIPDREVLYREFDEMEECSQHLPYIEQGMMLAEQFKQ KALGLLQTAS RQAEVIAPAV QTNWQKLETF
I Genotype 1 peptides
R. .W Q
R. .V Q
lb HCV-J T..S II...R..V Q AS Q





T. .S II V. .













;Genotype 2 peptides RAV.A. .K. . . • EA ..ASKAAL. . E.QRM. .ML
RVWT. .K.I. . EA ..ASRAAL. •E.QRI. .ML
RTV.A. .K. . . .EA ..ASRTAL. .E.HRR. .ML
RAWA. .K. . . .EA....
2a HC-J6 A- C.I . LHVNQRAWA. .K. . . .EA... ...ASRAAL. .E.QRI. .ML.S • IQ. ...Q.. K. .QD.Q... •AS.P.V.Q.
2a Dl1353 A- S.I .LHINQRAV.A. .K. . . .EA... ...ASKATL. .E.QRI. . ML. S .IQ. ...Q.. K. .QD.Q... ..S.P.V.Q.
2b HC-J8 A. . I S.I . LH. NDRVWA. .K.I. .EA... ...ASKAAL. •E.QRM. .ML.S .IQ. ...Q.T .QD.Q..I •SS.P...Q.
2b T59 A. .1 S.I . LH. NDRVWT. .K.I. .EA ...ASKAAL. .E.QRM. .ML.S .IQ. ...Q.T •QD.Q.V. .SS.P...Q.
GD 10 . . .A. . I S.I •LH.NDQVI.A. .K.I. .EA... ...ASKAAL. .E.TRM. .ML.S .IQ. ...Q.T E. .QDMQ..1 RSS.P...Q.
GD 11.2 A. S.I .LH.NDQVWA. .K.I. .EA... ...ASKAAL. •E.HRI. .ML.S .VQ. ...Q.T .QD.Q..1 .SS.P...Q.
2c BEBE1 A. S.I •IHVNQ.TI.A. .K. . . .EA.. . ...ASRTAL. .E.HRI. .ML.S .IQ. •M.Q.. K. .QGVQ... .AT.P...Q.
2c T983 A. S.I GIH.NQRTV.A. .K. . . .EA... ...ASRTAL. .E.HRR. .ML.S .IQ. •M.Q.. K. .QD.Q.V. . GT
Genotype 3 peptides AA AQVI.H. .
3a NZL1 .V. . . HIE.E .LV .K. . •QQY.. AA AQVI.H. . E .1. . . . R. T Q.QA. E.I. T A.
3a HPCHK6 .LV .K. . •QQY.. AR AQVI . H . . E .V. . . . R. T Q.QA. E.I. VS VL
GD 1.1 .V. . . ....HIE.G .LV .K. . .QQY.. AA AQVI .H. . E .V. . . . R. T Q.QA. E.I. VS . . .N. VL
GD 1.3 • V. . . ... IE.G .LV .K. . .QQY.. AA AQVI .H. . E .V. . . . R. T Q.Q
GD 1.5 SG. . • V. . . HIE.G .LV GK. . .QQY.. AA AQVI .H. . E . VF . . .R.T Q.QQAVIEPI W
GD 2A.5 .V. . . ....HIE.G .LV .K. . .QQY.. AA AQVM.H. . E .V. . . .R.T Q.QA. E.I. AS..K.. V.
GD 2B.5 .V. . . ....HIE.G .LV .K. . .QQY.. AA AQVM. H . . E .V. . . .R.T Q.QA. E.I. AS..K.. V.
GD 3.4 SS. . • E. . . HIE.G .LV .K. . .QQY.. AA AQAI. .. E .SF. . .R.T Q QA. E.I. T..R.R.
GD 3.5 .E.S. HIE.G .LV .K. . .QQY.. AA AQAI .H. . E .1. . . .R.T Q.QA. E.I. T A.
GD 3.6 .A. . . HIE.G .LV .K. . .QQY.. AA AQAI. H . . E .1. . . .R.T Q.QA. E.I. A. . .
GD 4.2 .V. . . ....HTE .G R. .LV .K. . .QQY.. AA AQAI . H . . E .1. . . .R.T Q.QA. E.I. A A.
GD 4.3 .V. . . HIE.G .LV. .K. . .QQY.. AA AQAI .H. . E .1. . . .R.T Q.QA. E.I. V A.
GD 5.1 SG. . .V. . . E...HIE.G .LV. .K. . .QQY.. AA AQVI.H. . E .V. . . .R.T Q.QA. E.I. VS VS
GD 5.2 SG. . .V. . . ....HIE.G .LV. .K. . .QQY.. AA AQW. H . . E .V. . . .R.T Q.QA. E.I. VS A .
GD 5.3 SG. . .V. . . HIE.G • LV. .K. . .QQY.. AA AQVI.H. . E • V. . . .R.T Q.QA. E.I. VS V.
GD 7 GH. .V. . . HIE.G .LV. •QQY.. AA AQVI .H. . E .V. . . .R.T Q.QA. E.I. V
GD 8A.2 RP. . .V. . . HIE.G .LV. .K. . .QQY.. . .G. . .AA AQVI.H. . E .V. . . .R.T Q.QA. E.I. VS
GD 8A.4 S. . . .V. . . HIE.G .LV. .K. . .QQY.. AA AQVI. H . . E .V. . . .R.T Q.QA. E.I. VS AT,
GD 8B.5 S. . . .V. . . HIE.G .LV. .K. . .QQY.. AAL AQVI.H. . E .V. . . .R.I Q.QA. E.I. TS AT,
GD 8B.6 S. . . .LV. .K. . .QQY.. AA AQVI.H. . E .V. . . .R.T Q.QA. E.I. VS AT,
FD 3 .V. . . HIE.G .LV. .K. . .QQY.. AA AQAI . H . . E .1.. . .R.T Q.QA. E.I. A A.
FD 4 G .LV. .KD. .QQY.. AA AQVI.H. . E .V. . . .R.T Q.QA. E.I. A. . .
3b Tr .V. . . HIE.G .LV. . .Q. .QQY.. SA AQAI .Q. . D .V. . . .R. . Q.EAE R.I. .SQ...A A.
10a JK049 .VI. QK .AD 5* H>
Genotype 4 peptides Q. .V. .QQ... .| K. ..LV.H.LQ
4a ED43 .v.s. Q. .V. ■ QQ.- - K...LV.H.LQ • NF.G K..QEAT.VI .S.FA.. Q.
4a EG13 .v.s. o. .QQ... K...LV.H.LQ . .V. .NL.G K..QEAT.VI .S.FA.. Q.






TV.S. T II. . .R QQ. -K.
TV.S. G II...R..V QQL. . .
STV.S. A I...R QQ
TV.S. A II...R QQ





.D .V...IG..G QK..TLK..A TSM.NRA.Q.
.E .M...IG..G Q...TLK..A TSM.H.V.Q.
.E .V...IG..G QK..TLK..A TSM.NRA.Q.
.E .VPR.IG..G Q...TLK..A TSM.H.V.Q.
.TS...MGEARAI.G...E .V...IG..G EK..TLK..A TSM.NRA.Q.
Genotype 6 peptides .1..QQ ...R.I..LAE.QQI
6a HK4 V C..IT.T W I..QQ
6a T3950 V C...T.T W I..QQ




.V ASA K...ELK... HSA.P.V.E.
.V ASA K...ELK... HSA.P.M.E.
NV...I.VTT K...ELK... HSA.P...Q.
Fig. 2. Comparison of NS4 amino acid sequences obtained from the discrepant samples with those of peptides used in the serotyping assay.
Peptides used in the serotyping assay are in boxes. indicates sequence identity to HCV-PT. Samples identified with a decimal point represent
the reference number of the clone (e.g., GD 3.6 represents clone 6 from GD 3). GD 2A, 8A: sample GD2 and GD8 amplified with type 1 specific
primers. GD 2B, 8B: sample GD2 and GD8 amplified with type 3 specific primers.
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such as Inno-LiPA, of 94% [Vandoorn et al., 1996].
Other serological typing assays involving the detection
of type specific antibody to the core protein have also
been shown to be concordant with PCR based typing
methods (99%, Dixit et al., 1995 and 100%, Machida et
al., 1992), although the genotypes that were detected
by these assays was restricted to types 1 and 2.
Discrepancies between the results of serotyping by
Inno-LiPA and by the serotyping assay could arise be¬
cause the serotyping assay detects circulating antibody
rather than the infecting virus, and so discrepant re¬
sults could result from antibody induced by previous
infections, especially for samples from individuals with
a history of multiple exposure, such as haemophiliacs.
Alternatively, the Inno-LiPA and serotyping assays
could produce discrepant results if an individual were
infected with a recombinant virus that contained
5'NCR and NS4 sequences derived from viruses of dif¬
ferent genotypes. Finally, the discordant results could
be due to mistyping by one or other of the assays. Un¬
usual nucleotide sequence variation in the 5' NCR
could produce inappropriate hybridisation of genotype-
specific probes. Alternatively, amino acid changes in
NS4 could influence the adsorption of antibody to pep¬
tides normally specific for a heterologous genotype and
produce an incorrect result in the serotyping assay.
Multiple Infection
A higher frequency of discrepant results between the
two assays was observed in haemophiliacs, who have
been multiply exposed to a range of HCV variants
(14.1%), than in a patient group where multiple expo¬
sure would be expected to be less common (4.5%). Se¬
quence analysis of discrepant samples revealed that
the sequence of the 5'NCR was always consistent with
the genotype of the predominant circulating variant
identified by Inno-LiPA. Furthermore, in all discrepant
samples, both the core and NS4 sequences were con¬
sistent with the genotype identified by sequencing of
the 5'NCR. Type-specific primers in NS4 generally am¬
plified the genotype detected by Inno-LiPA, and in the
two cases where amplification was obtained using both
the type 1 and 3 primers, only type 3 sequences were
detected among the clones derived from the PCR prod¬
ucts. Overall, we found no evidence for concurrent in¬
fection with multiple genotypes in this risk group.
However, there was also no evidence for that the sero¬
typing assay incorrectly identified the specificity of the
antibody response since the NS4 amino acid sequence
of virus from the discrepant samples corresponded
closely to that of the corresponding type-specific pep¬
tide in both regions 1 and 2 (Fig. 2). Substitutions oc¬
curring in these regions were generally to residues of
similar size and charge to those in the peptides (an
example was the substitution of lysine to arginine in
region 1 of GD 4.2). Another conservative amino acid
substitution occurred at position 1723 of type 3a vi¬
ruses, where valine was often replaced with alanine.
Only GD 11 showed an obviously nonconservative
amino acid substitution that could affect the antigenic¬
ity of NS4a, occurring at the N-terminal end of the
region 1 peptide.
For the above reasons, the most likely explanation
for the observed discrepant results is multiple infec¬
tion, particularly in the haemophiliacs who have been
exposed to a large number of HCV-contaminated blood
products in the past. For example, if a patient initially
infected with type 1 was recently reinfected with type
3, only antibody specific for type 1 would be detected
within the "window period" for the superinfecting vi¬
rus, and a discrepant result would be obtained. How¬
ever, since 1985, all factor VIII and IX concentrates
have undergone virus inactivation treatment, so recent
de novo infection in this patient group can be ruled out.
On the other hand, we have previously found that the
major circulating genotype changed in around 30% of
haemophiliacs over the seven to ten years during treat¬
ment with exclusively heat-inactivated clotting factor.
In the absence of re-exposure to HCV, these changes in
genotype must have resulted in reactivation rather
than reinfection, which indicates that variants of HCV
may persist for several years but can remain undetect¬
able by PCR of plasma [Jarvis et al., 1994], In some
haemophiliacs, changes in circulating genotype were
followed by corresponding changes in type-specific an¬
tibody, whereas in others, no change in antibody speci¬
ficity developed, and the delays or absence of the ap¬
pearance of antibody to the new genotype in this study
group led to several discrepant results between the se¬
rotyping and genotyping assays. Multiple infection is
also a possible explanation for the discrepant results
observed in FD1, FD2, and FD3, as their risk factors
for infection were intravenous drug abuse, an activity
likely also to lead to multiple exposure and infection
with more than one genotype. Without a comprehen¬
sive analysis of genotypes present in the liver or pos¬
sible extrahepatic sites of HCV replication, we there¬
fore cannot conclude that genotypes detected in plasma
are necessarily the only replicating variants of HCV in
vivo. Further work characterising the variants in dif¬
ferent organs targeted by HCV is clearly necessary to
further explore the significance of the discrepant re¬
sults.
Recombination
There are some reports describing recombinants of
HCV [Yun et al., 1996; Kato et al., 1992], although it is
difficult to exclude the possibility that these observa¬
tions resulted from mixed infection, PCR contamina¬
tion or artifactual recombination during PCR [Meyer-
hans et al., 1990]. Indeed, a consistent feature of other
studies has been that sequence relationships between
subgenomic regions always reflect those of the com¬
plete genome [Ohba et al., 1995; Smith et al., 1995;
Simmonds et al., 1994; Stuyver et al., 1994]. In this
study, the same genotype was detected by sequencing
5'NCR, core, and NS4 regions, including the NS4 se¬
quences amplified using type-specific primers. Recom¬
bination was therefore not the explanation for any of
the discrepant results observed in this study.
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Antigenic Variation of NS4
Heterogeneity of the deduced NS4 amino acid se¬
quences in the regions targeted by the serotyping assay
was greater in two samples from the French hepatitis
C study group than for any from the German haemo¬
philiacs. Sample FD 1 (Inno-LiPA type lb; serotyping
assay type 4) had amino acid substitutions in both pep¬
tide regions 1 and 2 (Fig. 1), including the substitution
of glutamine for histidine at position 1720. This sub¬
stitution is also present in the type 4 peptide and is
consistent with the observed cross-reactivity in the se¬
rotyping assay.
Sequence differences from the type 5a peptide were
also observed in sample FD 2 (Inno-LiPA type 4-5, se¬
rotyping type 1). In region 1 (positions 1691 and 1694)
the sequence of FD2 corresponded closely to one of the
type 1 peptides used in the assay (Fig. 2), while
in region 2, a substitution of aspartate to glycine (po¬
sition 1719) was observed, although the sequence re¬
mained quite distinct from the region 2 peptides of type
1 (Fig. 2).
In conclusion, the reliability of serological typing
methods may be influenced by the patient groups un¬
der investigation. Methods based on direct virus detec¬
tion (such as Inno-LiPA) may be more appropriate for
use with patients previously known to have been mul¬
tiply exposed, such as haemophiliacs, since circulating
antibody from previous or multiple infection may occur
in these individuals. However, the frequency of dis¬
crepant results within samples from patients with
chronic disease was much lower, and the simplicity and
rapidity of the serotyping assay suggests that it may be
a suitable alternative in such study groups.
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Detection and Clinical Features of Hepatitis C Virus
Type 6 Infections in Blood Donors From Hong Kong
L.E. Prescott, P. Simmonds, C.L. Lai, N.K. Chan, I. Pike, P.L. Yap, and C.K. Lin
Edinburgh and South East Scotland Blood Transfusion Service (L.E.P., P.L.Y.) and Department of Medical
Microbiology, University of Edinburgh (P.S.), Edinburgh and Murex Biotech (I.P.), Dartford, United Kingdom; Hong
Kong Red Cross Blood Transfusion (C.L.L., N.K.C., C.K.L.), Yaumatei, Hong Kong
The genotype distribution of hepatitis C virus
(HCV) was investigated in 212 viraemic blood do¬
nors from Hong Kong. A subset of the samples
was investigated usingthreedifferentgenotyping
assays to establish the accuracy of each in this
population. These assays were restriction frag¬
ment length polymorphism (RFLP) of amplified 5'
noncoding region (5'NCR)sequences, RFLPofthe
core region, and a serotyping assay using pep¬
tides from two antigenic regions of NS4.
Genotypes detected in Hong Kong blood do¬
nors were 1a (6.2%), 1b (58.8%), 2a (1.4%), 2b
(1.4%), 3a (1.9%), and 6a (27.0%). All genotyping
assays produced concordant results. No evi¬
dence was obtained for the presence of type 6
group variants recently identified in Southeast
Asia, other than type 6a. A serotyping assay
based upon the detection of type-specific anti¬
body to epitopes in NS4 produced similar results
to the genotyping assays (98% concordance), but
a reduced sensitivity (75%) compared with geno¬
typing methods. Sequence variation in NS4 was
not the cause of the reduced rate of detection of
type 6 antibody in this population.
Eighty-four percent donors infected with type
6a were male, compared to 75% donors infected
with type 1b. The median alanine transaminase
(ALT) level in type 6 infected donors was lower
than in type 1b, (43.8 and 51.1 U/l, respectively)
although these values were not statistically sig¬
nificant (P= 0.094). There was no significant
difference between the ages of donors infected
with types 1b and 6a. Risk factors for HCV
infection in the blood donors included blood
transfusion, intravenous drug abuse, and tat¬
tooing. A significantly greater number of donors
infected with HCV-6a reported a history of drug
abuse (66%) than donors infected with HCV-1b
(7%). © 1996 Wiley-Liss, Inc.
KEY WORDS: HCV, genotypes, serotypes,
blood donor, Southeast Asia
INTRODUCTION
Hepatitis C virus (HCV) is the primary aetiological
agent of posttransfusion non-A, non-B hepatitis world¬
wide. The genome comprises single-stranded, positive
sense RNA of approximately 9,400 nucleotide bases in
length. As with many other RNA viruses, HCV displays
extensive sequence variation. At least six major geno¬
types have been described to date, each of which can be
further divided into subtypes according to their degree of
sequence similarity to each other, and by their branching
order using phylogenetic analysis [Simmonds et al.,
1993a, 1994; Bukh et al., 1993], For example, there is
approximately 70% overall sequence identity between
the major genotypes and 80% between subtypes. Infec¬
tions in the United States and western Europe are gener¬
ally caused by HCV genotypes 1, 2, and 3, although
these are also distributed worldwide. Type 4 is found in
Central Africa and in the Middle East, while type 5 is
common only in South Africa. Of the six major geno¬
types, type 6a shows one of the most confined geographi¬
cal locations, having been found only in Hong Kong,
Macau, and Vietnam [Mellor et al., 1996; Tokita et al.,
1994; Simmonds et al., 1993a], or in emigrants from
these countries [Murphy et al., 1994]. Several groups
have recently reported the existence of novel genotypes
in southeast Asian countries such as Thailand and Viet¬
nam, and have shown these to be closely related to type
6a [Mellor et al., 1996; Tokita et al., 1994, 1995].
Whether or not these are to be classified as separate
major genotypes or as further subtypes of HCV-6 has
still to be decided [Doi et al., 1996; Mellor et al., 1996].
One potentially important reason for genotype identi¬
fication is the observation that virus genotype, along
with virus load and host-related factors (severity of liver
disease), may influence the response to antiviral treat¬
ment [Hino et al., 1994; Dusheiko et al., 1994]. Conse¬
quently, a number of techniques have been developed
to identify HCV genotypes in clinical specimens. The
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majority of these methods use the polymerase chain reac¬
tion (PCR), and involve three main procedures to distin¬
guish between genotypes. These are 1) the use of type-
specific primers [differential amplification, Okamoto et
al., 1992, 1993], 2) the use of type-specific probes to
hybridise with amplified HCV DNA after PCR [Stuyver
et al., 1993,1995; Tisminetzky et al., 1994], and 3) diges¬
tion of the amplified PCR product using combinations
of restriction enzymes [Mellor et al., 1996; Davidson et
al., 1995;McOmish etal., 1994]. Serologically based HCV
typing methods are competitive or noncompetitive en¬
zyme-linked immunosorbent assays (ELISAs) that de¬
tect antibody to type-specific epitopes in the core and
NS4 regions [Bhattacherjeeetal., 1995; Dixit etal., 1995;
Zhang et al., 1995b; Simmonds et al., 1993c; Tanaka et
al., 1994; Machida et al., 1992].
Previous studies have compared the accuracy of these
different typing methods [Dixit et al., 1995; Lau et al.,
1995], but these have not examined more recently dis¬
covered variants such as type 6 virus. In this study, we
have carried out an extensive survey of samples from
Hong Kong blood donors including a large proportion of




A total of 212 serum samples obtained from Hong
Kong blood donors (Red Cross Blood Transfusion Ser¬
vice, Yaumatei, Hong Kong) were used in this study.
All had previously been identified as either anti-HCV
positive or indeterminate using the Abbott Matrix assay.
Seventy-four of these samples were used for the compari¬
son of different genotyping assays. Abbott Matrix re¬
sults, donor sex, age, and serum alanine transaminase
(ALT) levels were available for all 212 samples, and risk
factors for infection could be identified in 43 cases.
RNA Extraction and Nested Reverse
Transcription-PCR (RT-PCR)
Virus RNA was directly extracted from 100 p.1 serum
using proteinase K/sarcosyl and phenol/chloroform. The
RNA was precipitated in ethanol at -20°C overnight
and dissolved in 25 p.1 DEPC-treated water prior to RT-
PCR [Davidson et al., 1995],
5' Noncoding region (5'NCR). RNA was reverse
transcribed using the 5' NCR-specific outer antisense
primer 209, followed by nested PCR amplification involv¬
ing outer primers 209 and 939 (sense) and inner primers
211 (antisense) and 940 (sense) [Chan et al., 1992].
Core. Core-specific antisense primer 410 was used
for reverse transcription of extracted RNA. Outer prim¬
ers used for PCR amplification were 410 and 954 (sense),
followed by inner primers 953 (antisense) and 951
(sense) [Mellor et al., 1995].
NS4. Based on currently available HCV-6a NS4 se¬
quences [Bhattacherjee et al., 1995], type-specific prim¬
ers were designed for hemi-nested RT-PCR amplifica¬
tion. Antisense primer 867 was 5'TTCCACATRTGY




Amplified DNA was incubated with combinations of
restriction endonuclease enzymes overnight, then elec-
trophoresed through a 4% Metaphor agarose gel (con¬
taining 0.5 p-g/ml ethidium bromide) in 1 X TBE. Re¬
striction patterns of cleaved DNA were viewed on a UV
transilluminator.
5'NCR RFLP. All PCR-positive samples were geno-
typed using a combination of restriction endonucleases
Haelll/Rsal and Mval/Hinfl to distinguish between
types 1-6 [McOmish et al., 1994]. As the 5' NCR of type
6 group variants found in Southeast Asia has previously
been shown to produce restriction patterns identical to
those of type 1 isolates [Mellor et al., 1996], amplified
DNA was also cleaved using enzymes Ddel/Hpall, which
are able to distinguish some, but not all, of these differ¬
ent variants from type 1. Subtyping of HCV types 1,2,
and 3 was carried out using enzymes jBsHJI (type 1) and
ScrFI (types 2 and 3) as previously described LDavidson
et al., 1995].
Core RFLP. Samples identified as type 1 or 6 by
RFLP in the 5' NCR were amplified using primers from
the core region and cleaved using the restriction endonu¬
cleases Anal, Smal, and Haell [Mellor et al., 1996].
1-6 Serotyping Assay
The serotyping ELISA is a competitive assay using
type-specific peptides from two antigenic regions of NS4
[Bhattacherjee et al., 1995].
Sequencing
Primary PCR products were reamplified with one of
the primers biotinylated and then they were bound onto
streptavidin-coated magnetic beads (Dynabeads M280,
Dynal). DNA strands were denatured using 0.15 M
NaOH and then separated magnetically. The bound
strand was sequenced using the "Sequenase" kit version
2.0 (United States Biologicals, USB) according to the
manufacturer's instructions.
Statistical and Phylogenetic Analyses
Statistical analysis was carried out using standard
statistical software (SYSTAT). Phylogenetic trees were
constructed using the PHYLIP program, NEIGHBOR
[Felsenstein, 1993],
RESULTS
Comparison of Genotyping Methods
A total of 74 HCV-positive samples were genotyped
using three different assays, each based on different
regions of the genome. In addition, the majority of the
samples were sequenced in the core region to confirm
the genotype identification. The first genotyping assay
was based on RFLP of amplified sequences from the
5'NCR, and three versions of this assay were used to
analyse the samples. The original 5'NCR RFLP used
enzymes Haelll/Rsal and Mval/Hinfl to identify geno-
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TABLE I. Identification of Genotypes by RFLP and Sequencing in the 5'NCR, Core, and NS4 Regions
Sequencing
5'NCR" Core" Core NS4
designation No. Haelll/Rsal Mval/Hinfl BsiUI Serf! Ddel/Hpall Smal Aval No. Type No. Type
Type la 3 b A A A si al
1 b A A A s5 al i la — —
Type lb 41 b A B A si a3 9 lb — —
1 d A B A si a3 1 lb — —
1 e A B A si a3 — — — —
Type 2 a 3 c D — D — — — 2 2a — —
Type 2b 2 d D — F
Type 6a 21 h B — — D s5 al2 20 6a 11 6a
"Restriction patterns classified according to previous analyses: 5'NCR [Davidson et al., 1995]; Core [Mellor et al., 1996J.
types 1 through 6 [McOmish et al., 1994]. The other
versions used included a modification of the assay involv¬
ing the use of enzymes Ddel/Hpall to identify novel
genotypes isolated from South East Asia, and a further
assay used to subtype genotypes 1, 2, and 3 [Davidson
et al., 1995], The second genotyping assay was based on
RFLP of the core region [Mellor et al., 1995] and was
used to distinguish between type 1 and type 6 group
variants that may otherwise have produced identical
RFLP patterns in the 5'NCR. The third assay was a
serotyping assay [Bhattacherjee et al., 1995] which used
competitive binding to detect genotype-specific antibody
to two antigenic regions in NS4.
The 74 samples were amplified by PCR using primers
from the 5'NCR. Amplified DNA was cleaved using
Haelll/Rsal and Mval/Hinfl, allowing all but two of the
samples to be provisionally genotyped as types 1, 2, and
6 (Table I). Two samples produced unusual combinations
of RFLP patterns (A with Mval/Hinfl but d or e with
Haelll/Rsal) [Smith et al., 1995]. Subtyping was carried
out on the type 1 samples using BstUI and indicated
type la in 4 and type lb in 43 of the 47 type 1 samples.
Three type 2a and two type 2b samples were identified
using ScrFI.
Restriction analysis with Ddel/Hpall revealed that
none of the type 1 samples contained substitutions at
positions —127 and —155 previously associated with
some type 8 group variants [Mellor et al., 1996], To
confirm the genotype identifications of the 5'NCR RFLP
assay, all of the type 1 and type 6 samples were amplified
in the core region and cleaved with Smal and Aval.
These enzymes distinguish type la (pattern al with
Aval) from type lb (pattern a3) and other type 1 variants
(patterns a2,a4) from type 6 and type 6 group variants
(patterns al0-al3, sl/s5) [Mellor et al., 1996].
All of the samples identified as type 6 produced the
pattern al2s5, confirming their identification. Amongst
the four samples identified as type la by RFLP in the
5'NCR using BstUI, all produced the al pattern. Simi¬
larly, all of the type lb samples identified using BstUI
produced the a3 pattern. The two samples with unusual
Haelll/Rsal patterns (d, e) were typed as lb using Aval
and Smal, and this was confirmed for one of these sam¬
ples (d) by sequencing in the core region. This analysis
failed to reveal any samples of type 6 group variants
apart from 6a, and indicates that genotyping in the
5'NCR is accurate in this particular population.
All but two of the samples were assayed for type-
specific antibody to NS4 peptides [Bhattacherjee et al.,
1995] (Table II). Of those samples with detectable anti¬
body, all but one reacted specifically with the peptides
of the genotype identified by RFLP. The only exception
was a type 6 sample that reacted with type 1 peptides.
This sample was confirmed as type 6 by sequencing in the
core and NS4 regions. The reason for the inappropriate
activity is unclear. Type-specific antibody was not de¬
tected in 18 samples, giving the serotyping assay an
overall sensitivity of 75%.
To investigate whether the HCV-6a-specific peptides
used in the serotyping assay fully represented the anti¬
genic variability within the genotype, 11 type 6a samples
were amplified and sequenced within this region. Results
indicate that the type 6 region on which the NS4 peptides
were based in the assay was highly conserved (Fig. 1).
Variants of type 6a show highly restricted variability
through the NS4 region, displaying only two to three
nucleotide differences over the 275 bases sequenced. Rel¬
atively tight clustering of type 6a variants is observed
upon phylogenetic analysis of the NS4 region, compared
with the diversity amongst variants of other genotypes
such as lb and 4a (Fig. 2).
Genotype Distribution
HCV RNA was extracted from a further 138 serum
samples from Hong Kong blood donors (total 212). Hav¬
ing established the accuracy of the 5'NCR genotyping
assay in this population, we used this method (Haelll/
Rsal and Mval/Hinfl followed by BstUI (type 1) or ScrFI
(types 2, 3) to identify the genotypes present in these
samples (Table III). From the 212 positive sera, the two
genotypes most frequently detected were types lb
(n = 127, 60%) and 6 (n = 57, 27%). Other genotypes
identified were types la (n = 13), 2a (n = 8), 2b (n = 3),
and 3a (n = 4). A mixed infection was observed in only
one donor who was infected with both genotypes 3a
and 6a.
Reactivity in the Abbott Matrix Assay
All ELISA positive samples were tested by the Abbott
Matrix assay which uses antigens (core, NS3, and NS4)
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TABLE II. Detection of Type-Specific Antibody in Samples From Hong Kong
Blood Donors
Serotype
Genotype 1 2 6 NTS NR Total Sensitivity (%) Concordance (%)
Type la 3 0 0 0 1 4 75 100
Type lb 33 0 0 6 4 43 77 100
Type 2a 0 2 0 1 0 3 67 100
Type 2b 0 2 0 0 0 2 100 100
Type 6a 1 0 13 5 1 20" 70 93
Total 37 4 13 12 6 72 75 98
"Two samples not serotyped due to lack of serum.
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Fig. 1. Comparison of HCV-6a amino acid sequences in the NS4 region with the prototype sequence
(HCV-PT; Choo et al., 1991) and corresponding serotyping results. Antigenic regions to which serotyping
peptides are made are in boxes. Well U = "Unblocked", well 1 = type 1 and well 6 = type 6 specific
antibody. (?), sequence not determined. sequence identity to HCV-PT.
derived from type la sequences. All 11 sera from individ¬
uals infected with type la (Table IV) reacted with all
antigens of the assay, but 11% of the type lb sera and
32% of the type 6 sera were unreactive with the NS4
antigen. No significant differences in reactivity were
found between genotypes in the core or NS3 proteins.
Epidemiological and Clinical
Background of Donors
HCV-positive blood donors were predominantly male
(male/female ratio of 3:1; Table III) and this ratio was
even higher within the type 6 group (5:1). The sample
groups for genotypes la, 2a, 2b, and 3a were too small to
detect any significant trend in these cases. No significant
differences were found in the ages of donors infected
with different genotypes (Fig. 3) and the range of ages
for infected donors (16 to 59 years) was similar for all ge¬
notypes.
Median ALT values for all genotypes fell within the
normal range (7-53 U/L) with the exception of type 2b
(which are based on very few values) (Fig. 4). Although
the ALT values of patients infected with type 6 were
slightly lower than those infected with type lb, this was
not found to be statistically significant using Spearmans
rank correlation (P = 0.094).
Risk factors were obtained from 43 HCV-positive do¬
nors. These include intravenous drug abuse (prior to
1984), blood transfusion (prior to 1989), tattooing, and
acupuncture. In many cases, donors were identified as
having been exposed to more than one risk factor. How¬
ever, in donors with only one identifiable risk factor,
66% of those infected with HCV-6 had a history of drug
abuse, compared to 7% donors with type lb, while 33%
HCV-6 infected donors had been previously transfused
compared to 83% of those with type lb (Table III).
DISCUSSION
The identification of HCV genotypes is important in
the investigation of the natural history and clinical out¬
come of HCV infection. Many different methods which
have various advantages and disadvantages, exist to
identify genotypes. Although assays should be sensitive
and specific, other important considerations include
cost, time consumption, and ease of use. In our study,
all of the genotyping methods used involved the analysis
of amplified HCV cDNA by RFLP, while serotyping was
carried out by means of a competitive ELISA using syn¬
thetic peptides from two antigenic regions of NS4. Al¬
though type 6 group variants, described as types 7-9
and 11 [Tokita et al., 1994, 1995; Mellor et al., 1996],
have also been detected in countries close to Hong Kong
such as Vietnam, no evidence for these variants was
found in the Hong Kong population.
When used on the population of Hong Kong blood
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Fig. 2. Phylogenetic analysis of NS4 nucleotide sequences, showing
HCV-6a samples from this study in bold.
donors, serotyping using NS4 peptides was found to be
75% sensitive. This low sensitivity may be explained by
the observation that detection rates for types lb and 6
are lower than for other genotypes [Bhattacherjee et al.,
1995], at 83% (type lb; compared to 96% for type la)
and 67% (type 6). In our study, types lb and 6 together
accounted for 86% of the samples analysed. Higher sensi¬
tivities have been reported previously (87-90%) [Zhang
et al., 1995b; Dixit et al., 1995; Simmonds et al., 1993c],
although in these studies the range of virus genotypes
was biased towards types la, 2a, 2b, and 3a.
The ELISA could be less sensitive to genotypes lb
and 6a if the peptides used did not fully represent the
antigenic variability within those genotypes. However,
sequence analysis indicated that this region is highly
conserved within most type 6 viruses from Hong Kong
(Fig. 1). Another possibility is that certain variants of
these genotypes possess sequence changes which result
in greater cross reactivity with other genotypes. For
example, peptides in antigenic region 1 of type 6 are
similar to those of types 1, 4, and 5 [Bhattacherjee et
al., 1995], Further sequence analysis of samples giving
nontype-specific results in the NS4 region should reveal
the cause of such reactivity.
Within Hong Kong, Macau, and Vietnam, type 6a was
responsible for a significant proportion of HCV infec¬
tions. In this study of HCV infected Hong Kong blood
donors, 27% were found to be infected with type 6a.
This figure was comparable with that reported from a
previous, smaller survey in which HCV-6a accounted for
32% infections in blood donors [McOmish et al., 1994].
In contrast, an investigation of anti-HCV-positive pa¬
tients in Hong Kong found only 14% to be infected with
type 6a [Zhang et al., 1995a], The fact that fewer patients
are infected with type 6a than blood donors suggests
that infections with this genotype may have been present
in the population for a shorter time period than other
genotypes, such as type lb. Alternatively, it may be that
type 6 is less pathogenic than type 1. Differences between
genotypes 1 and 2 in their propensity to cause disease
have been reported by some [Dusheiko et al., 1994; Booth
et al., 1995], but not all investigations [Mahaney et al.,
1994; Nousbaum et al., 1995].
Seventy-six percent of HCV-positive blood donors
from Hong Kong were male, similar to the relative pro¬
portions of male and female subjects donating blood in
this population. Similar frequencies of males and fe¬
males were observed in type lb infected donors (75%),
while a slightly increased proportion of males were in¬
fected with type 6a (84%).
A history of drug abuse was reported in 66% of donors
infected with HCV-6a, compared to only 7% of donors
infected with type lb. These results differ from a recent
survey of HCV infected patients from Hong Kong [Zhang
et al., 1995a], Of eight patients infected with type 6, the
source of infection was identified as blood transfusion/
renal dialysis in seven and as occupational exposure in
the remaining one.
The median ALT level of type 6 infected donors was
lower than with type lb (Fig. 4). Many studies have re¬
ported no significant difference in ALT levels associated
with infections caused by different genotypes [Dhaliwal
et al., 1996; Smith et al., 1996; Dusheiko et al., 1994], al¬
though other groups have identified distinct variations
among ALT levels, particularly with type 3. However,
these findings have been inconsistent, as HCV-3
has been associated with abnormal ALT more often than
HCV-1 and HCV-2 [McOmish et al., 1993; Preston et al.,
1995], although it also has been connected with having
lower ALT values than other genotypes in other studies
[Lau et al., 1995],
The future control of HCV infection lies partly with
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TABLE III. HCV Genotype Distribution and Clinical Data of Hong Kong Blood Donors
Genotype No. positive (%)
Donor sex Mean age
(range)
Risk factors
Male (%) Female (%) Transfusion IVDA" Tattoo Acupuncture None
Type 1 137 (65.0) 103 (76) 34 (24) 34 (16-59) 16 3 5 1 9
HCV-la 13 (6.2) 10 (77) 3 (23) 35 (16-47) 1 1 0 0 0
HCV-lb 124 (58.8) 93 (75) 31 (25) 33 (17-59) 15 2 5 1 9
Type 2 11 (5.2) 5 (45) 6 (55) 34 (25-48) 0 0 2 0 0
HCV-2a 8 (3.8) 2 (25) 6 (75) 31 (25-48) 0 0 2 0 0
HCV-2b 3 (1.4) 3 (100) 0 (0) 37 (34-39) 0 0 0 0 0
HCV-3a 4 (1.9) 4(100) 0 (0) 35 (24-42) 1 2 1 0 0
HCV-6a 57 (27.0) 48 (84) 10 (16) 34 (16-52) 3 6 4 0 0
Mixed 1 (0.5) 1(100) 0 (0) n/a 0 1 1 0 0
"Intravenous drug abuse.
TABLE IV. Reactivity of Blood Donor Samples in Abbott Matrix Assay According to Genotype
Total no Number of reactive samples to Matrix antigens (%)
Genotype samples All antigens Core NS3 NS4 (yeast) NS4 (E. coli)
la 13 13 (100) 13 (100) 0 (0) 0 (0) 0 (0)
lb 125 110 (88) 124 (99) 0 (0) 111 (89) 116 (93)
2a 8 3 (38) 8 (100) 0 (0) 3 (38) 4 (50)
2b 3 2 (67) 3 (100) 0 (0) 2 (66) 2 (66)
3a 4 2 (50) 4 (100) 0 (0) 2 (50) 2 (50)






































Fig. 3. Age distribution of blood donors infected with different geno¬
types in Hong Kong.
Fig. 4. Comparison of ALT values of donors infected with different
genotypes in Hong Kong. Line indicates upper normal range (U/l).
the successful screening and detection of the virus
among the blood donor population. Screening assays to¬
day use antigens based on sequences from a type la
prototype virus, and a major concern is that these assays
are less effective in the detection of nontype 1 infections
[Dhaliwal et al., 1996]. The Abbott Matrix assay was
used in the initial screening of these samples, and a
lack of sensitivity to type 6 was noted, with 32% being
nonreactive to the NS4 antigen. The lack of reactivity
to RIBA antigens 5-1-1 and cl00-3 by divergent geno¬
types has previously been reported in other studies
[McOmish et al., 1994], and gives rise to concerns that
in countries where genotypes other than 1, 2, and 3 exist,
routine screening of blood donors could be less effective.
One possible safeguard against this would be to include
antigens specific to genotypes known to exist in that
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area. For example, a screening assay including antigens
specific to type 6 as well as type 1 could be used for
routine screening in Hong Kong, Macau, and Vietnam.
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Assays that detect antibody to hepatitis C virus (HCV) are used to screen blood donors and patients with
hepatitis. Current enzyme-linked immunosorbent assay (ELISA)-based methods are invariably based upon
antigens from expressed recombinant proteins or oligopeptides from HCV type 1. Some HCV antigens used in
screening assays are coded by regions of the HCV genome that show extensive variability; therefore, HCV type
1-based assays may be less effective for the detection of antibody elicited by infection with other genotypes. In
this study, we have measured antibody reactivity of sera from 110 hepatitis C patients infected with type lb,
3a, or 4a to genotype-specific and cross-reactive epitopes present in recombinant proteins from HCV genotypes
lb (core, NS3, and NS5), 3a (NS3, NS5), and 4a (core, NS3), corresponding to those used in current third-
generation screening ELISAs. By comparing the serological reactivities of sera to type-homologous and type-
heterologous antigens, we detected a significant type-specific component to the reactivity to NS3 (61 to 77% of
the total reactivity) and NS5 (60% of the total reactivity). Furthermore, despite the similarities in the amino
acid sequences of the core antigens of type lb and type 4a, we also found significantly greater reactivity to
type-homologous antigens, with approximately 25% of reactivity being type specific. These findings are con¬
sistent with previous findings of fivefold weaker reactivity of sera from HCV type 2- and HCV type 3-infected
blood donors in the currently used third-generation ELISAs and suggest that these assays are suboptiinal for
screening populations in which the predominant genotype is not type 1.
Detection of antibody to hepatitis C virus (HCV) has be¬
come the principal method for the diagnosis of HCV infection
in individuals with chronic hepatitis and for the screening of
blood donors. Although the original assay based upon the
clOO-3 recombinant proteins derived from NS4 showed non-
specificity and insensitivity, the more recently developed assays
that use recombinant proteins from the core and NS3 regions
of the HCV genome (second-generation assays) and the NS5
region of the HCV genome (third-generation assays) have
proved to be more effective for the screening of blood donors.
Their use has led to a substantial reduction in the incidence of
posttransfusion hepatitis. In prospective studies, the incidence
of HCV transmission among recipients of blood screened by
first-generation assays was 1.5% in Spain (15), 3.7% in Japan
(27), and 11% in Taiwan (6). Screening by second-generation
assays reduced or would have reduced the incidence to 0.9% in
Japan (27), 1% in Spain (15), 2% in Greece (20), and 2.5% in
Taiwan (6).
One reason for the failure to detect antibody to HCV in
donated blood specimens that transmit HCV infection is that
the blood was collected from an individual with acute infection
before seroconversion for antibody. This so-called "window"
period is long for HCV compared with other viruses for which
blood from donors is screened, such as human immunodefi¬
ciency virus, with means of 88 to 66 days in second- and third-
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generation assays, respectively (9). By measuring the incidence
of HCV infection in blood donors, it has been estimated that
the current residual risk of HCV transmission through collec¬
tion of "window" samples is 1 per 100,000 donations in the
United States (24). This frequency of infection is similar to the
residual risk of infection from blood screened by third-gener¬
ation assays from French blood donors (10).
In addition, samples false negative for antibody have been
reported for a small proportion of immunocompetent individ¬
uals persistently infected with HCV (2, 17). Indeed, even in
anti-HCV-positive individuals, there is considerable variability
in the frequency of reactivity to the individual HCV proteins
used in supplementary assays, such as the Ortho 3rd genera¬
tion recombinant immunoblot assay (RIBA-3), and in the titer
of antibody to HCV among persistently infected individuals.
Among 90 anti-HCV-positive blood donors, antibody reactivity
in the Ortho third-generation screening assay varied over a
range of 5,000-fold, with some serum samples having antibody
levels only just above the cutoff for the assay (12).
HCV can be classified into at least six major genotypes,
whose nucleotide and inferred amino acid sequences over the
whole genome differ by approximately 30%. This degree of
amino acid sequence variability is similar to that observed
between variants of other RNA viruses (e.g., dengue virus
types 1 to 4), in which significant antigenic differences have
been documented and which form the basis of their classifica¬
tion into serotypes. We have previously measured the serolog¬
ical reactivities of individuals infected with different HCV ge¬
notypes to antigens used in two third-generation anti-HCV
assays (Ortho 3rd generation anti-HCV EIA; Murex VK48).
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Samples from HCV type 1-infected individuals showed an ap¬
proximately five times greater reactivity than those infected
with HCV type 2 or 3, and the reactivity was independent of
other factors that may have influenced the antibody response,
such as the degree of vircmia, donor age, and severity of
hepatitis as assessed by alanine aminotransferase measure¬
ments.
In the current study we have addressed two of the main
shortcomings of the first study. First, we have measured sero¬
logical reactivities to the individual component antigens used
in a third-generation assay (core, NS3, and NS5). These mea¬
surements extend previous investigations of type-specific and
cross-reactive serological reactivity to the NS4 antigen used in
the first-generation screening assays and in second- and third-
generation confirmatory assays (1,5,14, 21,26,28). Second, we
have carried out titrations with antigens derived from HCV
type 1 as well as corresponding proteins from other HCV
genotypes (types 3a and 4a). This allows levels of antibodies to
both type-homologous and type-heterologous antigens to be
measured, allowing for a more rigorous assessment of the
relative levels of type-specific and type-common reactivity to
each.
MATERIALS AND METHODS
Samples. Samples LJ516, EG21, and ED43 were obtained from individuals
infected with genotype 3a (LJ516) or 4a (EG21 and ED43 [3, 25]). Sequences
amplified from the core, NS3, and NS5 regions of types 3a and 4a were used for
the synthesis of antigens for antibody screening. Recombinant antigens from the
core (amino acid positions 1 to 140), NS3 (amino acid positions 1360 to 1454),
and NS5 (amino acid positions 2234 to 2318) (numbered according to Choo et al.
[7]) regions of HCV-UK (type lb) were derived from an existing, commercially
available anti-HCV assay (VK48).
Serum samples were obtained from 110 anti-HCV-positive individuals with
chronic hepatitis C attending hospital liver clinics in Edinburgh and London,
United Kingdom; Karachi, Pakistan; and Cairo, Egypt. Among the samples, we
selected 33 infected with genotype lb, 34 infected with genotype 3a, and 43
infected with genotype 4a. Genotypes were identified by restriction fragment
length polymorphism analysis of the 5' noncoding region as described previously
(11).
Development of enzyme-linked immunosorbent assays (ELISAs) based upon
type 3a and 4a antigens. RNAs from samples LJ516 (type 3a), EG21 (type 4a),
and ED43 (type 4a) were extracted as described previously (16): Reverse tran¬
scription was carried out with avian myelobastosis virus reverse transcriptase and
RNasin (both from Promega, Southampton, United Kingdom), in each case by
using the external antisense primer, and incubation at 42°C for 30 min as de¬
scribed previously (4). The sequences were amplified by using the following heat
cycle: 94°C for 18 s, 45°C for 21 s, and 72°C for 90 s for 30 cycles, followed by 6
min at 72°C with the primers listed in Table 1. The core region of type 4a was
amplified with primers 954 and 410, followed by amplification with primers D236
and 597. The NS3 region was amplified with primers 751 and 753, followed by
amplification with primers 594 and 593 (type 3a) or 750 and 007 and then primers
594 and 593 (type 4a). For the type 4a NS3 region, a third PCR was carried out
with the product of the second PCR by using the same inner primers. The NS5
region of genotype 3a was amplified by using primers 991 and 993, followed by
amplification with primers 3155 and 3156. The amplified sequences were cloned
and sequenced as described previously (23).
Expression of recombinant proteins. The sequences of the core, NS3, and NS5
regions from the different HCV genotypes indicated above were subcloned into
Escherichia coli or baculovirus expression vectors, as appropriate, by standard
molecular biology techniques. The NS3 and NS5 sequences of each genotype
were cloned into the E. coli vector pTrcHis (Invitrogen BV, Leek, The Nether¬
lands) and were expressed in TOP 10 cells by standard isopropyl-p-D-thiogalac-
topyranoside induction. Core sequences were cloned into the baculovirus expres¬
sion vector pBlueBacHis2 (Invitrogen), and recombinant virus was derived by
cotransfection into insect cells along with linear Antographa califomica nuclear
polyhedrosis virus DNA. Recombinant antigens were produced in Sf.9 insect
cells in an LH Series 210 bioreactor by infection at multiplicity of infection of 2
for 48 h.
Both the E. coli and baculovirus vector expression vectors place a tract of six
histidine residues at the amino terminus of each recombinant protein. Recom¬
binant proteins were therefore subsequently prepared by metal chelate chroma¬
tography on Probond nickel affinity resin (Invitrogen) to approximately 90%
purity.
ELISA for detection of antibody to core, NS3, and NS5 regions. To optimize
plate coating, purified antigens were titrated to levels giving acceptable specificity
and sensitivity and approximately equivalent amounts of protein per well (25 to
TABLE 1. Primers used for amplification of core,
NS3, and NS5 regions
Primer no. Sequence''
954 act gcc tga tag ggt gct tgc gag
410 gag cgg aat gta ccc cat gag gtc ggc
D236 ggt aga ccg gat err atg agc acg aat cct
597 gaa aga agc tta gac gag cgg aat gta ccc
751 tty cgg gcn gcy gtg tgc acc
753 gcg tca tag cac tca cag agg ac
594 acc rct gca gay ccy aac atn gag gar gt
593 cac aag ctt arc agt agt cka tsa cng art
750 tgg tya cnn gnn ayg cyg atg tca tyc c
007 acc tcg agt atc cca ctg atg aag ttc cac
991 tgg cna gct cnt cng cna gcc a
993 ggc tcc ccc tca agg grg gca trg a
3155 gga tcc aay atn acy cgy gtr gag tcw sa
3156 aag ctt gtg gtg gya agg cac ayc c
" International Union of Pure and Applied Chemistry ambiguity codes were
used: Y, C/T; R, A/G; N, G/C/A/T; K, GAT; S, C/G; W, A/T. Cleavage sties for
restriction enzymes are underlined: CTGCAG, Pstl; AAGC'TT. Hindlll; GGA
TCC, BamHl.
50 ng). Binding of antigen was assessed both by functional enzyme immunoassay
(EIA) with positive and negative sera and by probing for the histidine tag present
on each protein by using horseradish peroxidase chemically modified to bind
nickel ions. All antigens were coated overnight in 50 mM Tris (pH 8.5) contain¬
ing 0.02% sodium dodecyl sulfate. The plates were then blocked by the addition
of 2% degraded gelatin and were finally dried to ensure stability.
For each antigen assay, each serum sample was diluted 1:10, 1:40, 1:160, and
1:640 in anti-HCV-negative sera. Aliquots of 20 |xl from each titration were
added to 180 p.1 of sample diluent, mixed, and then added to a well of the ELISA
plate. A solution of 1:50 E. coli blocker was added to the diluent for all assays for
NS3 genotype 3a antigen. The plates were then incubated at 37°C for 1 h,
followed by five washes in glycerate-borate buffer. Bound antibody was detected
by the addition of 100 p.1 of horseradish peroxidase-labelled antibody to human
immunoglobulin G conjugate and by incubation for 30 min at 37°C. After wash¬
ing, 100 |xl of 3,3',5,5'-tetramethylbenzidine substrate was added, and the mix¬
ture was incubated for 30 min at 37°C. The color development reaction was
stopped by the addition of 50 pi of 2 M H2S04, and optical densities (ODs) were
measured at 470 nm. All assay plates included a dilution series of the reference
genotype la sample (dilutions of 1:2 to 1:2,560) for calculation of antibody levels.
The NS3 genotype 3a recombinant antigens were expressed in E. coli and re¬
quired the addition of 1:50 E. coli blocking solution in the sample diluent for all
assays.
Quantification of antibody levels. Antibody reactivity to each recombinant
protein in each of the test serum samples was determined by titration and
reference to a standard positive control as described previously (12). This
method is based upon the observation of a linear relationship between OD (over
the range of values of 0.02 to 1.0) and concentration of antibody in both ELISAs
based upon single antigens, as in the current study and in the currently used
third-generation screening assays from Ortho and Murex (12). Because of this
relationship, the antibody reactivity of a test sample can be expressed relative to
that of a reference control by the following formula: test antibody level = (test
OD x reference concentration)/(reference OD x test concentration). Antibody
levels were obtained for each sample in each antigen assay in this way.
Estimation of relative proportions of type-specific and cross-reactive antibod¬
ies. The ratio of antibody levels measured to type-homologous and type-hetero¬
logous antigens indicates the relative proportions of type-specific and cross-
reactive reactivities. This calculation is complicated by the possible existence of
differences in the antigenicity or presentation of proteins from different geno¬
types in the ELISA and differences in antibody levels elicited by infection with
different genotypes.
The proportion of antibody reactivity that is cross-reactive between genotypes
is measured by reciprocal assays of reactivity between sera and antigens from two
genotypes, genotypes A and B. In the following relations, EBA represents the
antibody reactivity of a serum sample infected with genotype B with antigen of
genotype A, Aab is the overall antigenicity of the genotype A antigen relative to
that of the genotype B antigen, and Tc and Ts are the proportions of the antibody
response that are type common and type specific, respectively, such that Tc +
Ts =1.
Ems
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FIG. 1. Comparison of the inferred amino acid sequences of antigens expressed from recombinant clones of (A) core (HCVUPCP, type lb; DX387, type 4a), (B)
NS3 (HCVUPCP, type lb; DX506, type 3a; DX499, type 4a), and (C) NS5 regions (HCVUPCP, type lb; DX507, type 3a) with representatives of each of the major
HCV genotypes and subtypes. Periods indicate identity with the HCV prototype sequence, HCV-PT (7). Numbers refer to amino acid positions on HCV-PT.
Therefore,
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These relations make the assumption that the relative proportions of type-
specific to type-common reactivity in a type A antiserum are the same as those
found in a type B antiserum.
Nucleotide sequence accession numbers. The sequences obtained in the
course of this project have been submitted to GcnBank and bear the following
accession numbers: DX387, AF029298; DX506, AF029297; DX499,
AF029296; DX507, AF029299.
RESULTS
Variability of core, NS3, and NS5 region sequences. The
amino acid sequences of the recombinant proteins used in the
ELISA were deduced from the nucleotide sequences of the
corresponding clones and were compared with other published
sequences of these regions of HCV (Fig. 1). In the core protein
only 9 amino acids differed between genotypes lb and 4a over
the 140-amino-acid length (6% divergence). Substitutions were
generally conservative, where only one resulted in a change in
the ionic charge. The NS3 sequences exhibited more variabil¬
ity, with the sequence of genotype lb differing from that of
genotype 3a by 15 of 95 amino acids (16% divergence) and
from that of genotype 4a by 13 amino acids, while genotypes 3a
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FIG. 1—Continued.
and 4a differed from each other by 14 amino acids. In the NS5
sequence there were 23 differences between genotypes lb and
3a over a length of 85 amino acids (27% divergence). Six of
these substitutions affected the charge of the protein: four
substitutions of nonpolar amino acids for basic groups and two
substitutions of acidic groups for nonpolar groups.
Quantitation of antibody reactivity to core, NS3, and NS5
antigens. The serological reactivities of sera from 33 individ¬
uals with genotype lb, 34 individuals with genotype 3a, and 43
individuals with genotype 4a HCV infections to each of the
recombinant antigens from genotypes lb, 3a, and 4a were
measured. To investigate the reproducibility of the method
used to quantify antibody levels, each of the serum specimens
was assayed in replicate against the type lb and 4a core pro¬
teins (Fig. 2). A close correlation was observed between the
two measured antibody levels, with nonparametric correlation
coefficients being 0.877, 0.889, and 0.862 for type lb, 3a, and 4a
antisera, respectively. For the type 4a core antigens, the cor¬
responding correlation coefficients were 0.784, 0.721, and
0.802.
There was also a close correlation between reactivity to the
core protein of type lb and that to type 4a (Table 2), with
correlation coefficients of 0.834, 0.765, and 0.767 for type lb,
3a, and 4a antisera, respectively. Significant correlations were
also consistently observed between the reactivities of antisera
to NS3 proteins of types lb, 3a, and 4a, as well as between the
reactivities of antisera to NS5 proteins of type lb and 3a. In
contrast, there was little if any correlation between antibody
reactivity to different regions of the genome. For example, the
reactivity of sera from type lb-infected individuals to the type
lb core protein showed no correlation with reactivity to type lb
NS3 or NS5 proteins (correlation coefficients, —0.118 and
-0.181, respectively; Table 2). The only exceptions were weak
correlations (0.443 and 0.471) between the reactivities to 3a
NS3 and NS5 (but only for type lb sera) and between NS5 of
type lb with NS3 of 4a (restricted to type 3a sera).




























FIG. 2. Measurement of the reproducibility of measurement of levels of
antibody to type lb (A) and type 4a (B) core protein by sera from study subjects
by repeat testing. The correlation is indicated by a regression line.
Genotype dependence of serological reactivity. Sera col¬
lected from individuals infected with different genotypes varied
in their frequency of reactivity to NS3 and NS5 antigens of
different genotypes (Table 3). For NS3, frequencies of reactiv¬
ity for type lb, 3a, and 4a antisera to type-homologous NS3
proteins were 85, 100, and 76%, respectively, compared with a
range of 44 to 76% for type-heterologous combinations. Sim¬
ilarly, the frequency of reactivity of type lb sera with type lb
NS5 antigen (65%) was higher than that of heterologous sera
(47 and 51%), as was reactivity to type 3a NS5 (58% type-
homologous reactivity, compared with 24 and 45% for type-
heterologous combinations). In the core region, high frequen¬
cies of reactivity were observed for both type-homologous (95
to 97%) and type-heterologous (86 to 97%) combinations, indi¬
cating the greater antigenicity of this region of the genome and/or
a greater proportion of shared epitopes between genotypes.
To compare the strength of reactivity with type-homologous
and type-heterologous antigens, antibody levels relative to
those for the positive control calculated from OD readings at
dilutions ranging from 1:10 to 1:640 were used to calculate
antibody levels relative to those for the positive control (Fig.
3). There were significant differences in antibody reactivity to
the type lb core protein between samples from individuals
infected with genotype lb and those from individuals infected
with genotype 4a (P = 0.033) but not those with genotype 3a
(P = 0.811). The distribution of antibody levels directed to the
genotype 4a core antigen showed no significant difference be¬
tween genotypes.
Antibody reactivity against NS3 was frequently undetectable
among sera from individuals infected with HCV with type-
heterologous antigen (Table 3; Fig. 3C). The distribution of
levels of antibody to type-homologous antigens was consis¬
tently greater than those to type-heterologous antigens. For
example, the median level of antibody to type lb NS3 in type
lb sera was 0.225, which was substantially greater than the
median reactivities of type 3a and 4a sera to this protein (0.003
[P = 0.004] and 0.02 [P = 0.005], respectively). Similar, pre¬
dominant type-specific reactivities against type 3a and 4a an¬
tigens were observed (Fig. 3D and E).
Only 54% of the samples reacted with the NS5 genotype lb
antigen and 43% reacted with the genotype 3a antigen. The
median antibody level of genotype lb sera (0.031) was eight¬
fold higher than that for type 3a samples (0.004) and threefold
higher than that for type 4a (0.012). The distribution of anti¬
body levels among genotype lb samples was significantly
higher than that among genotype 4a samples (P = 0.029) but
not genotype 3a samples. The reactivity of type 3a sera against
TABLE 2. Correlation between reactivity to different antigens
Antigen HCV
Correlation for the following antigens
and genotypes":
and geno¬ genotype Core NS3 NS5
type in serum









lb lb -0.118 0.023 (1)
3a 0.133 0.279 (1)
4a 0.100 -0.035 (1)
3a lb -0.270 -0.066 0.456 (1)
3a 0.153 0.274 0.363 (1)
4a 0.159 0.030 0.627 (1)
4a lb 0.048 0.224 0.710 0.518 0)
3a 0.215 0.130 0.570 0,393 (1)
4a -0.058 -0.087 0.497 0.272 (1)
NS5
lb lb -0.181 -0.220 0.150 0.275 0.157 (1)
3a 0.066 0.000 0.218 0.265 0.471 (1)
4a 0.058 -0.192 0.069 0.168 0.055 (1)
3a lb -0.141 -0.43 0.247 0.443 0.348 0.630 (1)
3a 0.051 0.172 0.216 0.266 0.202 0.649 (1)
4a -0.076 -0.108 0.186 0.179 0.041 0.303 (1)
" Correlation is indicated by Spearman's rank correlation coefficient. Separate
values are provided for antisera of each genotype. Significant values (P < 0.05)
are underlined.
I
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TABLE 3. Frequency of reactivity to core, NS3, and NS5 proteins
No. of specimens reactive to the following antigen/total no. of specimens (%):
Antiserum Core NS3 NS5
lb 4a lb 3a 4a lb 3a
Type lb 32/33 (97) 32/33 (97) 28/33 (85) 25/33 (76) 24/32 (76) 21/33 (64) 8/33 (24)
Type 3a 33/34(97) 30/34 (88) 15/34 (44) 33/33 (100) 9/33 (27) 16/34(47) 18/31 (58)
Type 4a 37/43(86) 41/43(95) 31/43(72) 27/43 (63) 31/41 (76) 22/43(51) 19/42(45)
NS3 of genotype 3a was significantly greater than that of the
type lb or 4a sera (P = 0.002 and 0.01, respectively).
Ratio of type-specific and cross-reactive reactivities. The
ability to measure the reactivity of the same antiserum to
antigens of different genotypes allowed for an estimation of the
relative levels of genotype-specific and cross-reactive serolog¬
ical reactivities. For the core proteins, the levels of antibody to
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FIG. 3. Distribution of antibody reactivity of sera from individuals infected with type lb, 3a, and 4a to core proteins of genotypes lb and 4a (A and B, respectively);
NS3 of genotypes lb, 3a, and 4a (C, D, and E respectively); and NS5 of types lb and 3a (F and G, respectively). Median values are indicated by short horizontal bars.
Pairwise comparison of the distributions of values was carried out by the nonparametric Kruskall-Wallis test.





FIG. 4. Ratios of reactivity of type lb and 4a sera to type lb/type 4a core
antigens. Median ratios are indicated by short horizontal bars. Pairwise compar¬
ison of Ihe distributions of values was carried out by the Kruskall-Wallis test.
Ratios of reactivities to other antigens are presented in Table 4.
divided by their levels to the genotype 4a antigen (Fig. 4; Table
4). The median ratio of reactivity to type lb/reactivity to type
4a antigens for type lb antisera was 1.49, compared with a
median ratio of 0.809 for the type 4a antisera. This indicates
that type lb sera react more strongly against the type lb (ho¬
mologous) core protein, while the type 4a sera react slightly
more strongly against the type 4a antigen. If it were shown that
both core proteins were coated equivalently on the solid phase
and showed equal antigenicity, then the type-specific reactivity
to these proteins could be calculated from the difference from
the ratio of 1 that would be expected from exclusively type-
common reactivity. However, it is possible that some antigens
are present at higher available concentrations than others
through differences in binding to the solid phase or solubility.
These differences were taken into account by using the deri¬
vation described in Materials and Methods. In this instance,
the term EABIEAA represents the median of the ratio of reac¬
tivity between type 4a antisera with type lb and type 4a anti¬
gens (0.809). The term EBB/EBA is similarly represented by the
median ratio of the type lb antisera (1.49). Therefore, the
proportion of type-common reactivity can be calculated as
0.74, with type-specific reactivity forming the remainder of the
reactivity (0.26).
The median ratio of reactivity of the type 3a sera to type 3a
and lb NS5 antigens (0.654) was substantially lower than that
of type lb sera (median, 4; Table 4). Therefore, the propor¬
tions of type-common and type-specific reactivity were 40 and
60%, respectively; i.e., the majority of the serological reactivity
to this antigen was type specific. Finally, three sets of pairwise
comparisons can be made for the NS3 region, in which anti¬
gens for all three genotypes were available. Sixty-two percent
of the serological reactivity between type lb and 3a proteins
was type specific, similar to the proportions of 61% between
type lb and 4a proteins and 77% between type 3a and 4a
proteins (Table 4).
DISCUSSION
Antigenic variability of HCV. The aim of this study was to
investigate the degree of type-specific serological reactivity to
antigens used in current, third-generation screening assays.
The use of recombinant antigens expressed from different ge¬
notypes in the enzyme immunoassay allowed reciprocal mea¬
surements of type-homologous and type-heterologous reactiv¬
ity to be made, and these provided a more rigorous assessment
of the type-specific components of reactivity to the core, NS3,
and NS5 regions. This addresses a potential criticism of previ¬
ous investigations that showed weaker reactivity of sera from
individuals infected with non-type 1 genotypes in either of the
screening ELISAs or to individual antigens in the confirmatory
recombinant immunoblot assay (5, 8, 12, 14, 21, 28), in that
there is a possibility that these observations resulted from a
generally weaker serological response to infection than that
elicited by type 1. In the current study we were able to consis¬
tently show stronger reactivity of sera to antigens of a homol¬
ogous type than to antigens of heterologous types.
From pairwise reciprocal measurements of antibody reactiv¬
ity (such as type lb and 4a antisera against type lb and 4a
antigen), it was possible to quantify the relative contributions
of type-specific and cross-reactive antibody reactivities by using
the relation derived in Materials and Methods (Table 4). These
calculations were independent of possible differences in the
strength of the serological response elicited by infection with
different genotypes and were also independent of differences in
antigen concentration or overall antigenicity between proteins
of different genotypes (expressed as the ratio Aab). This re¬
moves the potential criticism that the coating efficiency of
antigens from different genotypes onto the solid phase was not
compared prior to measurement of antibody levels. From this
analysis we found a relationship between the degree of amino
acid sequence divergence between recombinant proteins and
their degree of cross-reactivity. The sequence of the core pro¬
tein was the most conserved and the core protein showed
approximately 25% type-specific reactivity, while the more di¬
vergent sequences, those of the NS3 and NS5 regions, showed
substantially greater proportions of type-specific reactivity.
These results are consistent with previous comparisons of the
type-specific component of reactivity to peptides correspond¬
ing to linear epitopes in NS4. By absorption in solution with
peptides of heterologous genotypes, it was shown that reactiv¬
ity to type-homologous peptides was reduced but was rarely
eliminated (1, 26), allowing development of a sensitive and
specific serological typing assay. The type-specific component
of serological reactivity to NS4 and, in some studies, to the core
protein has been also used in typing assays without cross-
absorption, because it has consistently been observed that re¬
activity to type-homologous antigens in these (13, 19, 22) and
other regions (29) is stronger.
Implications for screening assays. The effect of the demon¬
strated antigenic variabilities of the components of third-gen-
TABLE 4. Type-specific and type-common serological reactivity
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" Ratio of reactivity to antigens of genotypes A and B.
h Comparison of the distribution of ratios of reactivity of individual antisera to
antigens of genotypes A and B by the Kruskall-Waliis nonparametric test.








Vol. 35, 1997 ANTIGENIC VARIATION OF HCV 3069
eration screening assays on their overall sensitivity for screen¬
ing is difficult to estimate with precision for two reasons.
Individuals vary in their serological responses to different an¬
tigens, and therefore in the extent to which these responses
may result in cross-reactivity with antigens of heterologous
genotypes. For example, if reactivity were directed solely to the
core protein, this protein would cross-react with antigens of
heterologous genotypes, whereas sera monoreactive with NS3,
such as is found upon seroconversion, would be expected to be
predominantly type specific.
Furthermore, each of the three antigens investigated is likely
to contain a range of linear and conformational epitopes, and
these will vary in their degree of cross-reactivity. Recognition
of different epitopes in the antigens may be one explanation for
the wide range of ratios of reactivity to type-homologous and
type-heterologous antigens observed between sera of the same
genotype (Fig. 4). In the extreme case, it is possible that reac¬
tivity confined to epitopes in the core protein that are type
specific would lead to poor or absent reactivity to the core
protein of other genotypes. Conversely, the high degree of
cross-reactivity observed between certain sera with NS3 or NS5
proteins of heterologous genotypes may have resulted from
their recognition of shared epitopes.
The observed differences in reactivity of sera to homologous
and heterologous proteins would only lead to false-negative
results on serological screening if antibody levels in samples to
be tested were close to the cutofF sensitivity of the assay. In a
previous study, we measured antibody reactivity in the Ortho
third-generation assay and found a wide range of antibody
levels (approximately 5,000-fold) among samples from blood
donors infected with genotypes 1,2, and 3, with the lowest level
found to be 0.0007, which is just above the cutoff value of the
test (12). Low antibody levels and reactivity to a restricted
range of epitopes, such as those in NS3, are found in acutely
infected individuals (18), and it is likely that earlier detection
of seroconversions, and therefore a reduction in the window
period associated with non-type 1 infection, may be achieved
by assays containing NS3 and other antigens from a wider
range of genotypes.
The finding of significant antigenic variability of antigens
used for serological screening will form the basis for a number
of future investigations. Now that antigens from other geno¬
types have been produced, it will be possible to carry out
large-scale screening of populations infected with non-type 1
genotypes (for example, with the type 4a antigens for testing
individuals in the Middle East). This may reveal the frequency
with which anti-HCV samples are being missed by conven¬
tional assays and may ultimately help reduce the frequency of
posttransfusion hepatitis further, particularly when popula¬
tions with a high frequency of acute infection are screened.
Similarly, the incorporation of antigens from other genotypes
(particularly NS3) in confirmatory assays may resolve the re¬
sults for a number of the indeterminate samples identified in
blood donor screening and for which interpretation of results is
currently problematic.
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Previous surveys of the prevalences of genotypes of hepatitis C virus (HCV) in different populations have
often used genotyping assays based upon analysis of amplified sequences from the 5' noncoding region
(5'NCR), such as restriction fragment length polymorphism (RFLP) or hybridization with type-specific probes
(e.g., InnoLipa), Although highly conserved, this region contains several type-specific nucleotide polymor¬
phisms that allow major genotypes 1 to 6 to be reliably identified. Recently, however, novel HCV variants found
in Vietnam and Thailand that are distantly related to the type 6a genotype (type 6 group) by phylogenetic
analysis of coding regions of the genome often have sequences in the 5'NCR that are similar or identical to
those of type 1 and could therefore not be identified by any assay of sequences in this region. We developed a
new genotyping assay based upon RFLP of sequences amplified from the more variable core region to
investigate their distribution elsewhere in southeast (SE) Asia. Among 108 samples from blood donors in seven
areas that were identified as type 1 by RFLP in the 5'NCR, type 6 group variants were found in Thailand (7
from 28 samples originally identified as type 1) and Burma (Myanmar) (1 of 3) but were not found in Hong
Kong (« = 43), Macau (n = 8), Taiwan (n = 6), Singapore (n = 2), or Malaysia (n = 18). Although this small
survey suggests a relatively limited distribution for type 6 group variants in SE Asia, larger studies will be
required to explore their distribution in other geographical regions and the extent to which their presence
would limit the practical usefulness of 5'NCR-based genotyping assays for clinical or epidemiological pur¬
poses.
Hepatitis C virus (HCV) is a positive-stranded RNA virus of
approximately 9,400 nucleotides and has been shown to be the
major etiologic agent of parentally transmitted non-A, non-B
hepatitis (7). Sequence comparisons of variants from different
geographical areas have led to the identification and classifi¬
cation of at least six major genotypes, many of which contain a
number of more closely related, yet distinct subtypes of the
virus (5, 20, 24). Phylogenetic analysis of complete genomic
sequences (16) or even relatively short subgenomic regions
(core [6, 15, 24], El [5], NS-4 [2, 21], or NS-5 [11]) may be used
for virus classification into genotypes. The overall sequence
similarities over complete genomic sequences are at least 91%
within variants of the same genotype, approximately 79%
(range, 77 to 80%) between subtypes, and about 68% (range,
66 to 69%) between different types (26).
Infection with different genotypes may produce clinically
relevant differences in the liver disease caused by HCV. For
example, there are now several reports describing a greater
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sensitivity of HCV genotypes 2 and 3 to interferon treatment
than is found in type 1-infected patients (for recent reviews,
see references 4 and 19). Assays that can identify the infecting
genotype without having to sequence the virus directly are
therefore becoming important in patient management and in
epidemiological studies of HCV transmission. Published geno¬
typing methods fall into one of two categories, those based
upon direct virus detection by reverse transcription-PCR, fol¬
lowed by analysis of the amplified DNA, or indirect (serolog¬
ical) assays, in which the infecting genotype is inferred from
the pattern of antibody reactivity to type-specific epitopes in
the core or NS-4 region (2, 14, 21, 25).
Although the 5' noncoding region (5'NCR) of HCV is
highly conserved between genotypes, it is an attractive target
for genotyping assays, because of the strong association of
specific nucleotide polymorphisms with genotype (for a recent
review, see reference 22). These genotypes may be readily
identified by restriction endonucleases or by type-specific
probes (9, 27), although the accuracy for the detection of
genotypes 1 to 6 is limited to 96 and 84% for the two assays,
respectively (22), mainly because of misidentification of more
recently described genotypes.
Recently, several new variants have been identified among
blood donors and hepatitis C patients in Vietnam (26) and
Thailand (1, 15). Sequence comparisons of the core, NS-5, and
El regions indicated that these new genotypes often showed
sufficient nucleotide differences from existing variants to be
classified as new major genotypes. However, we have found
that these novel variants group with type 6 upon phylogenetic
analysis in both the El and NS-5 regions (15), producing what
may equally well be interpreted as a single, highly diverse
single genotype that includes the previously described type 6a
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genotvpe found in Hong Kong and Macau (5. 9, 20). These
new variants are referred to as type 6 group variants in this
study.
Although type 6a and all of the previously described major
genotypes (types 2 to 5) show conserved nucleotide differences
from type 1 in the 5'NCR that allow them to be differentiated
by restriction endonucleases or by type-specific probes in In-
noLipa, many (but not all) of the novel variants from Vietnam
and Thailand have sequences in the amplified region used for
genotyping that are identical to those of type la or lb. Al¬
though mixed infection could lead to the detection of se¬
quences of different genotypes in different amplified regions,
this explanation was ruled out by finding continuous clones
that contained type 6 group sequences in the core and El
regions but a 5'NCR sequence similar to that in type 1 in
several samples from Vietnam (26). This finding leads to new
difficulties when interpreting results from genotyping assays
based upon the 5'NCR; samples that appear to be type 1 in the
restriction fragment length polymorphism (RFLP) assay (9) or
InnoLipa (9) may instead have been variants within the type 6
phylogenetic group.
The core gene encodes a putative nucleocapsid protein,
which is the most conserved protein in the HCV genome.
Nevertheless, it is considerably more variable than the 5'NCR
and contains sufficient sequence information to identify all
known subtypes and major genotypes, including those in the
type 6 group that are misclassified by using the 5'NCR (15). To
investigate the distribution of these novel sequences in South¬
east (SE) Asia, we have developed a genotvping assay in which
sequences in the core region are amplified and cleaved by
restriction enzymes that reliably differentiate type 1 variants
from type 6 variants. These results provided information on the
distribution of type 6 variants in SE Asia and the frequency
with which conventional genotyping assays produced incorrect
results in different countries.
MATERIALS AND METHODS
Samples. Plasma samples that had been previously genotvped in the 5'NCR by
RFLP (9) from blood donors in Macau. Malaysia. Singapore, Taiwan, and Thai¬
land were used in the current study. Additional samples from Hong Kong (n =
66), Malaysia (n = 8), and Burma (Mvanmar) (// = 8) were also obtained and
genotyped by the same method prior to analysis in the core region. From the
blood donor population in Hong Kong, genotypes la (Myanmar) (n =3). lb (n
= 40), 2 (n = 1), and 6a (n = 22) were present, similar to the results of our
previous survey (9). From Malaysia, genotypes la (n = 10). lb (n = 8). and 3 (n
= 9) were found upon combining the original and new samples. From Burma,
types lb (n = 3), 2 (// = 2). and 3 (n = 3) were identified.
The survey group in the current study was confined to samples of genotype 1
in the 5'NCR RFLP assay that could be amplified in the core region (see below).
From Thailand, it was possible to amplify 28 of the 34 type 1 samples in the core
region. All of the samples from Burma (n = 3), Hong Kong (/i = 43), and
Malaysia (n = 18) could be amplified. Lower frequencies of amplification in the
core region were obtained from the survey countries surveyed: Macau. 8 of 13:
Taiwan, 6 of 53: and Singapore. 2 of 5. Although the core primers are similar in
sensitivity to those in the 5'NCR. it is likely that storage conditions influenced
the effectiveness of the PCR for the amplification of samples from some coun¬
tries. A total of 108 samples from all of the countries were used. Previously
published sequences from Vietnam and Thailand (1. 6. 26). as well as 25 new
core sequences for type 6a (17a). were also included in the analysis.
RNA extraction and nested PCR amplification. Virus RNA was extracted
directly from 100 p.1 of serum with proteinase K-sarcosyl; this was followed by
phenol-chloroform extraction and precipitation in ethanol as previously de¬
scribed (9). RNA was reverse transcribed by using the specific outer antisense
core primer 410. This was followed by the first round of PCR with primers 410
and 954 and a second round with primers 951 and 953, described previously (15).
to give a 405-bp product between positions -21 and +383; the numbering of
nucleotides is from reference 8. Sequences in the 5'NCR between positions -245
and -72 were obtained by using primers 209, 939. 211. and 940 (9). The NS-5
region was amplified by using primers 1204. 1203. 518. 517. and 123. as described
by Mellor et al. (15).
RFLP analysis. Cleavage reactions were performed on the reverse transcrip-
tion-PCR 5'NCR product as described previously (9). The restriction enzymes
a)
II a1 94 101 38 24 148
a2 94 101 62 148
a3 94 139 24 148
I a4 94 139 72
a5 94 139 24 64 84
a6 233 24 148
a 7 94 52 87 24 148
a8 94 52 87 172
a9 94 101 38 172
a10 94 163 148
a11 94 51 | 260
a12 94 311
a13 94 101 210
B)
||s1 94 163 148
s2 257 148
S3 94 52 259
S4 94 52 111 148
I I 94 311
FIG. 1. Restriction endonuclease cleavage patterns of amplified core se¬
quences using enzymes Aval (A) and SmaI (B) for published variants and
samples analyzed in the current study. The numbers are the sizes (in base pairs)
of the DNA fragments produced.
HpaII and DeleI identified nucleotide sequence differences in the 5'NCR be¬
tween type 1 variants and some type 6 group variants (see Results). Restriction
endonuclease cleavage of amplified core sequences was carried out by using the
restriction endonucleases Aval and Sma 1. DNA was electrophoresed through a
4% Metaphor agarose gel in 1 x TBE (Tris-borate-EDTA) containing 0.5 pg of
ethidium bromide per ml. The combined results of the core and 5'NCR RFLP
analyses were used to predict the genotype of HCV within the samples.
Direct sequencing of PCR products. Samples showing restriction patterns
different from those predicted from published sequence data were reamplified bv
using biotinylated primers. In order to obtain single-stranded DNA for sequenc¬
ing, the biotinylated products were bound onto paramagnetic streptavidin-coated
beads (Dynabeads M280: Dvnal) as previously described (12). Dideoxy-termina-
tion sequencing reactions were performed by using the Sequenase sequencing kit
from United States Biochemical Corp. according to the manufacturer's instruc¬
tions, except that reactions were carried out in 10% dimethyl sulfoxide and the
template DNA was heat denatured before primer annealing. Sequences were
read manually from autoradiograms and analyzed by using standard sequence
software.
Phylogenetic analysis. Phylogenetic analysis was carried out by using the
program NEIGHBOR in the PHYLIP package, as previously described (20).
Nucleotide sequence accession numbers. New sequences obtained in this study
have been submitted to GenBank and have been assigned accession numbers
L49473 to L49485, respectively.
RESULTS AND DISCUSSION
Development of core RFLP assay. Published nucleotide se¬
quences in the core region of types 1 and 6 and novel variants
that grouped with type 6 upon phylogenetic analysis were an¬
alyzed with DNAnalyz software to identify restriction enzymes
that recognized sequence polymorphism between HCV geno¬
types. Cleavage with Aval and SwaI consistently showed dis¬
tinct predicted restriction patterns for type 1 and non-type 1
sequences (Fig. 1; Table 1). From the total of 13 different
restriction patterns obtained using Aval (al to a 13 [Fig. 1AJ)
and the five patterns obtained using Sma I (si to s5 [Fig. IB]),
published sequences of the type 6 group produced a total of
three combinations of patterns.
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TABLE 1 . Association of different HCV genotypes with RFLP patterns in the core region
Genotype
No. of samples with restriction pattern": Total no. of














Total no. of samples 14 i 43 5 2 45 1 112
" Combination of restriction patterns as defined in Fig. i; alsl corresponds to pattern 1 with Aval and pattern 1 with SmaI.
h Variants of HCV within the type 6 clade but excluding the previously classified type 6a genotype.
Among published sequences, the most common restriction
pattern for type la sequences was alsl (n = 14), while the
majority of type lb sequences showed the a3sl pattern (n =
43) (Table 1). With the exception of three sequences (VN540,
VN787, and VN507), all variants in the type 6 group (includ¬
ing type 6a) could be predicted to produce the al2s5 pattern
upon cleavage with Aval and Smal (Table 1). In every case,
RFLP patterns distinct from those of type 1 variants were
obtained.
Geographical distribution of surveyed samples. To investi¬
gate the distribution of type 6 group variants in SE Asia, a total
of 108 samples from Malaysia, Thailand, Macau, Hong Kong,
Singapore, Burma, and Taiwan that had been previously iden¬
tified as type 1 (9) were retested in the new core RFLP assay
(Table 2). A much wider range of restriction patterns than was
obtained from our analysis of published sequences was ob¬
tained from this survey. Although the vast majority of samples
produced RFLP pattern alsl or a3sl and could therefore be
identified as type la or lb, the remaining 26 samples produced
a total of 11 distinct RFLP patterns with the two enzymes,
many of which corresponded to those previously associated
with type 6 group variants (Table 1).
Each of the 26 samples was sequenced in the core region to
make a definitive identification of the genotype. Of the 26
samples, 18 could be classified as type 1, while the remaining
8 contained sequences in the core region that placed them
within the type 6 group (see below). These type 6 group se¬
quences were found in samples from Thailand (/; = 7) or
Burma (n = 1) and showed the restriction pattern a 11 s5 or
al2s5 (Table 2).
Phylogenetic analysis of novel genotypes. To demonstrate
the relationship between the eight type 6 group variants with
those previously found in Vietnam and Thailand, we carried
out phylogenetic analysis of sequences from the core and NS-5
regions of these variants (Fig. 2 and 3). All eight core se¬
quences grouped with the type 6 clade and showed various
relationships with variants previously found in Vietnam and
Thailand (13, 15) (Fig. 2). Three samples from Thailand
(EUTH5230, EUTH7, and EUTH13) grouped closely with
variants previously found in Thailand and provisionally classi¬
fied as NGII (15). The sample from Burma was closest to but
distinct from variants in Thailand referred to as NG1, while the
remaining four samples (EUTH1, EUTH21, EUTH22. and
EUTH39) showed a distant relationship to variants from Viet¬
nam described as type 9a (13).
To investigate further the relationship of the new variants to
those previously found in SE Asia, we compared sequences in
the more variable NS-5 region (Fig. 3). Each new sequence
clustered within the type 6 group, although the addition of the
new sequences from Thailand increased still further the diver¬
sity within the group as a whole. Sequence relationships found
in the core region among members of the type 6 group were
closely reproduced in the NS-5 region. For example, the NS-5
sequences of EUTH1 and EUTH22 were distinct from all
previously analyzed variants in the type 6 group but were
closest to VN004 and VN085 from Vietnam, which were de¬
scribed as tvpe 9a (13). Similarly, the close relationship be¬
tween EUTH5230, EUTH7, and EUTH13 with NGII in the
core region was also found in NS-5. The NS-5 sequence of the
sample from Burma (EUBUR1) was found to be the same
genotype as variants B4-92 and PC found in northern Thailand
(!)■
Identification of type 6 group sequences in the 5'NCR. All
published type 6a sequences in the 5'NCR are distinct from
type 1 sequences, because they contain characteristic insertions
(CA at position -146 and C at position —138) which are
generally not present in other genotypes (22). However, other
variants in the type 6 group show a range of different 5'NCR
sequences, none of which contain the CA insertion at position
-146 and which infrequently show the C insertion at position
TABLE n Distribution of different core RFLP patterns in the places surveyed
Place
No. of samples with restriction pattern": Total no. of
samplesalsl a2sl a3s1 a4sl a4s5 a5sl afiss a7s4 a8s.3 a9s2 a 10s 1 allsn al2s5 al3s5
Burma n 1 3
Thailand 9 9 1 1 1 4 3 28
Malaysia 9 1 5 2 1 18
Singapore 1 1 n
Hong Konc 3 38 1 1 43
Macau 1 n 1 12 8
Taiwan .1 1 2 6
Total no. of samples on 1 60 3 2 2 2 2 1 14 4 4 0 108
" Combination of restriction patterns as defined in Fig. 1: alsl corresponds to pattern i with/4u/I and pattern 1 with Sma\.
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FIG. 2. Phylogenetic analysis of core sequences from the type 6 clade includ¬
ing those of eight variants identified in the current group. The phylogenetic tree
was rooted by using sequences from HCV-PT (type la [8]) and NZLI (type 3a
[18]) as outgroups. Previously published provisional genotype assignments are
indicated.
-138. Furthermore, few nucleotide differences are found be¬
tween these variants and type 1. In the extreme case, for
VN540, VN843, VN235, VN507, VN530, and VN531. the
5'NCR sequences were identical to those of type lb and the
5'NCR sequence of VN085 was identical to that of type la
(Fig. 4). On the other hand, most of the variants from Thailand
showed 5'NCR sequences that differed at several sites from
type 1 sequences; in the case of sequences previously described
as NGI (15). a conserved pair of covariant changes in the
proposed stem-loop region 3 (3) that could be identified by
cleavage with HpaII (which recognizes the CCGG sequences
present in type 1 sequences but which is disrupted by the
substitution of A for C at position - 155 in NGI sequences) was
found. Cleavage of 5'NCR sequences using the combination of
DdeI and HpaU from NGI produced pattern B (Fig. 5), clearly
distinguishable from pattern A found in all type I 5'NCR
sequences analyzed to date. A different covariant change in the
same stem-loop structure was found among the sequences de¬
scribed as NGII. In this case, cleavage with Dde I identified the
polymorphism at position -127 (G for A in NGII) and pro¬
duced pattern C with the Ddel-Hpall enzyme combination
(Fig. 5). Although pattern D (produced by type 6a 5'NCR
sequences [22]) is different from pattern A for type 1, the 3-
base size difference of the large fragment (127 and 130 bp)
would not necessarily be identifiable by agarose gel electro¬
phoresis of the cleaved DNA (9).
With this limited ability to identify at least a proportion of
type 6 group variants, we used the Ddel-Hpall enzyme com¬
bination to cleave amplified 5'NCR sequences from the survey
population. All 100 sequences that were classified as type 1 by
RFLP or sequence analysis of the core region produced pat¬
tern A. Among the 8 samples identified in this study as be¬
longing to the tvpe 6 group, EUBURI produced pattern B.
while EUTH5230, EUTH7, and EUTH13 produced pattern C.
EUTH1, EUTH21. EUTH22, and EUTH39, which were not
closely related to any of the variants within the type 6 group,
produced pattern A (and had sequences in the 5'NCR similar
or identical to type lb [data not shown]). From this analysis it
can be seen that only half of the type 6 group variants would
have been identified even when using new enzymes designed to
detect observed sequence differences between NGI and NGII
with type 1 sequences.
HCV genotype distribution in SE Asia. The identification of
only eight samples in the type 6 group of HCV genotypes
indicates an extremely limited distribution of these variants in
most of the places surveyed. Seven of these variants were
found in Thailand, consistent with previous observations that
they represent one of the principal variants (with type 3) in
blood donor and hepatitis C patient populations (1, 15). Type
6 group variants (including type 6a) are well documented in
Vietnam (26), and the finding of a single example of this geno¬
type in Burma hints at a wider westward distribution in SE
Asia.
In attempts to review current information from other groups
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FIG. 3. Phylogenetic analysis of NS-5 sequences from the type 6 clade in¬
cluding those of eight variants identified in the current group. The phylogenetic
tree was rooted by using sequences from HCV-PT (type la [8]) and NZLI (type
3a [18]) as outgroups. Previously published provisional genotype assignments are
indicated.
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A 67 27 12 18 127
B 67 27 12 145
C 67 27 12 18 CMoLOCM
D 67 27 12 18 130
FIG. 5. DNA fragments produced upon cleavage of amplified 5'NCR se¬
quences from type 1 and type 6 groups using restriction endonucleases DdeI and
HpuII. The numbers are the sizes (in base pairs) of the DNA fragments pro¬
duced.
on the distribution of HCV genotypes in SE Asia, most data
obtained from genotyping assays such as the RFLP assays (9).
InnoLipa (23), and assays using type-specific primers in the
core region (17) cannot be relied upon because of the limited
range of HCV variants that can be identified. In the current
study, we have shown that type 6 group variants may appear as
type 1 in an RFLP assay based upon the 5'NCR, whether or
not it is modified by the use of additional restriction enzymes
such as Dde I and Hpa I. In this respect, the survey recently
published by Greene et al. (10) is particularly informative,
because genotype assignments were made bv nucleotide se¬
quence determinations of several regions of the HCV genome.
The absence of type 6 group variants from a total of 45 samples
collected from Singapore, Indonesia, Philippines, and South
Korea is consistent with the finding in this study of a restricted
distribution of type 6 group variants in Malaysia, Singapore,
Taiwan, Macau, and Hong Kong. However, the survey by
Greene et al. (10) failed to detect type 6 group variants in
Thailand (3 type la, 8 type lb, and 10 type 3a and 3b variants)
and appears inconsistent with their frequent detection in this
study and previous studies (1, 15). It is possible that the fre¬
quency of infection with type 6 group variants differs between
geographical regions within Thailand, or it is possible that
there are differences in its distribution in different risk groups
for infection or age of subjects.
Figure 6 attempts to summarize current knowledge of gen¬
otype distributions of HCV throughout SE Asia and the Far
East using information obtained from this study and previously
published information (9, 10, 26). The pie charts represent the
relative frequencies of genotypes 1 to 6 as determined by
sequence comparisons in coding regions (9, 15, 26), RFLP
analysis in the 5'NCR (9), and genotyping using type-specific
primers in the core region (26). Figure 6 includes a separate
representation of type 6 group variants (indicated as NG, dis¬
tinct from type 6a) in the three countries where it has been
detected so far (Vietnam, Thailand, and Burma).
Although the number of samples from some places was
small, this combined analysis reveals some clear geographical
trends in relative genotype frequencies. Type lb variants ap¬
pear ubiquitous throughout the region, and a steady increase in
the frequency of type 3 infection in more westward countries is
apparent, which is not found in the Far East. Type 6 group
variants were found in a single, possibly continuous block that
includes Vietnam, Thailand, and Burma but were not detected
elsewhere. The distribution of type 6 group variants overlaps in
Vietnam with type 6a, with the latter also being prevalent in
Hong Kong and Macau.
Little is currently understood concerning the past epidemi¬
ology of HCV transmission that is responsible for the current
distribution of HCV variants. However, the information ob¬
tained in this study will be of future use in the understand¬
ing of HCV sequence variation and the ancestry of the cur¬
rently identified HCV genotypes. In particular, the overlapping
ranges of type 6a with other variants in the type 6 clade in the
mainland of SE Asia provides an insight into their interrela-
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FIG. 6. Map of SE Asia summarizing the HCV genotype distributions iden¬
tified in the current study and by previously published analyses. Pie charts
indicate the proportions of various HCV genotypes in each place surveyed,
although the sample numbers available were small in some places, such
as Burma. In addition to the current study, data for Indonesia, Philippines,
and South Korea were obtained from reference 10, data for Vietnam were
from reference 26. and data for Japan were from sequence information in
GenBank.
tionship that will be of value in future evolutionary analyses of
these sequences.
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Distribution of Hepatitis C Virus Genotypes Determined by Line
Probe Assay in Patients with Chronic Hepatitis C Seen at Tertiary
Referral Centers in the United States
Johnson Y.N. Lau, MD; Gary L. Davis, MD; Linda E. Prescott, BSc; Geert Maertens, PhD;
Karen L. Lindsay, MD; KePing Qian, PhD; Masashi Mizokami, MD; Peter Simmonds, PhD;
and the Hepatitis Interventional Therapy Group*
Objective: To 1) verify the validity of a new line probe
assay for hepatitis C virus (HCV) genotyping and 2) deter¬
mine the distribution of HCV genotypes and the associa¬
tion between HCV genotype and clinical variables in pa¬
tients with chronic hepatitis C seen in tertiary referral
centers in the United States.
Design: Retrospective cross-sectional analysis.
Patients: 438 patients with chronic hepatitis C from 10
tertiary referral centers.
Measurements: The validity of the line probe assay was
first verified against a panel of serum specimens that had
previously been characterized by six different HCV geno¬
typing methods. Specimens from all 438 patients were
then genotyped using this line probe assay. The associa¬
tions between HCV genotype and clinical variables were
examined using analysis of variance. Pairwise testing was
used when the F test showed a statistically significant
difference. Nonparametric alternatives were used for vari¬
ables for which normality could not be assumed.
Results: The line probe assay was quick and reproducible,
and it showed good concordance with other tests. In our
sample, the proportions of patients with HCV types 1, 2, 3,
and 4 were 71.5%, 13.5%, 5.5%, and 1.1%, respectively.
Subtypes 1a and 1b were seen in approximately equal
proportions of patients with HCV type 1. Mixed infection
was detected in 3.7% of specimens, and 4.8% of specimens
either had negative results on polymerase chain reaction
or could not be typed. A higher proportion of patients
with HCV type 1 than of patients with HCV-type 1 had
acquired HCV through transfusion of blood products (50%
compared with 25%; P < 0.001). Patients with HCV type 1
also had a longer estimated duration of infection com¬
pared with patients with HCV type 3 (P = 0.004) and type 4
(P = 0.049). Disease activity did not differ among patients
infected with HCV types 1, 2, or 3. Levels of viremia were
similar in patients with HCV types 1, 2, or 3, but patients
with HCV type 4 had a lower level of viremia than did
patients with HCV type 1 (P = 0.047).
Conclusions: The line probe assay can be used in patients
with chronic HCV infection in the United States. In patients
with chronic hepatitis C referred to tertiary centers in the
United States, type 1 is the most common HCV genotype.
Disease activity and viremia levels do not differ among
patients chronically infected with HCV types 1, 2, or 3.
Ann Intern Med. 1996;124:868-876.
For author affiliations and current author addresses, see end of text.
*For a listing of additional members of the Hepatitis Interven¬
tional Therapy Group, see the Appendix.
Hepatitis C virus (HCV) has a high spontaneousmutation rate with an estimated frequency of
1.4 to 1.9 X 10~3 mutations per nucleotide per year
(1-3). As a result, HCV exists as a heterogeneous
group of viruses sharing approximately 70% homol¬
ogy. On the basis of nucleotide sequence homology,
HCV has been classified into six major genotypes
and a series of subtypes. A proposed consensus
system for nomenclature, based on sequence homol
ogy in at least two regions with confirmation by
phylogenetic tree analysis, has been adopted by
most HCV investigators (4). The relation between
this nomenclature and other commonly used no¬
menclature systems is shown in Table 1.
Various methods have been used for HCV geno¬
typing, including genomic amplification and sequenc¬
ing (10, 14-16), polymerase chain reaction (PCR) with
genotype-specific primers (5, 8), restriction fragment
length polymorphism of the PCR amplicons (13, 17),
differential hybridization (18), and serologic genotyp¬
ing (11, 19). Genomic amplification and sequencing,
followed by sequence comparison and phylogenetic
tree construction for confirmation, is currently con¬
sidered the gold standard; the genomic regions com¬
monly used for this approach include the HCV core
region, envelope 1, and nonstructural region 5 (NS5).
This method, however, is expensive and labor inten¬
sive, making it difficult to study HCV genotypes in a
large number of patients.
Several alternative methods have been proposed.
Okamoto and colleagues (5) and Chayama and co¬
workers (8) have described PCR done with geno¬
type-specific primers derived from the HCV core
region and from NS5, respectively. These methods
rely on the use of genotype-specific primers that
anneal to sequences unique to specific HCV geno¬
types. Genotype-specific primers derived from the
HCV core region allowed the differentiation of
HCV types la, lb, 2a, and 2b (5); genotype-specific
primers derived from NS5 allowed the differentia¬
tion of HCV types la, lb, 2a, 2b, and 3b. Restriction
fragment length polymorphism of the PCR ampli¬
cons relies on the presence of unique and genotype-
specific nucleotide substitutions that are recognized
and digested by restriction enzymes into fragments
that can be separated be gel electrophoresis (13, 17).
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The 5' untranslated region (5'UTR) is commonly used
for this approach. Hybridization of PCR amplicon
mounted on a solid phase using genotype-specific
probes has also been used for HCV genotyping
(18). Finally, serologic approaches have also been
used to determine HCV genotypes. These ap¬
proaches rely on the different amino acid sequences
encoded by different nucleotide sequences from dif¬
ferent HCV genotypes. Patients infected with differ¬
ent HCV genotypes may therefore have antibodies
directed to genotype-specific amino acid sequences.
Polypeptides and synthetic peptides derived from
nonstructural region 4 (NS4), as well as synthetic
peptides derived from the HCV core region, have
been used for serologic genotyping (11, 19). These
peptides are used to coat enzyme immunoassay
plates, and specific binding by a serum specimen is
determined by peptide competition. The HCV ge¬
notypes assigned by this method are commonly re¬
ferred to as serotypes. Conventionally, the term
"HCV serotype" refers to different viral types de¬
termined by a panel of cross-neutralization antibod¬
ies. Because recognition of genotype-specific pep¬
tides by a patient's antibody response reflects the
difference in amino acid sequences and thus nucle¬
otide sequences, the results of this approach are
more appropriately referred to as "serologically de¬
fined genotypes" or "serologic genotypes."
The concordance among these different HCV
genotyping methods has been questioned. In a pre¬
vious study (20), we compared six different genotyp¬
ing methods and found that most of them had high
concordance with each other. The only method that
we identified as unsuitable for U.S. patients was
PCR with genotype-specific primers derived from
the HCV core region, proposed by Okamoto and
colleagues (11). This method gave false-positive sig¬
nals for HCV type lb in patients who were actually
infected with types la and 3a (20).
Because all molecular biological genotyping meth¬
ods rely on PCR as a first step, those systems based
on the 5'UTR, the most conserved genomic region,
should be the most sensitive. Recently, a new geno¬
typing system based on reverse hybridization of the
labeled PCR amplicon derived from the 5'UTR
(line probe assay, INNO-LiPA HCV, Innogenetics,
Ghent, Belgium) was developed and has been used
widely by investigators in Europe (21, 22). Whether
this line probe assay is also useful in patients with
chronic HCV infection in the United States is un¬
known.
In this study, we sought to 1) assess the concor¬
dance of this line probe assay with other assays on
a panel of well-characterized serum specimens to
verify the line probe assay's validity; 2) determine
the distribution of various HCV genotypes in a
large sample of patients with chronic hepatitis C
Table 1. Commonly Used Hepatitis C Virus Genotype
Nomendature Systems*
Okamoto/ Chayama Houghton/ Kohara Enomoto Simmonds Proposed
Mori (8) Cha (11) (12) (13) System
(5-7) (9, 10) (4)
1 1 I I PT 1a 1a
II II II I K1 1b 1b
1c
III III III II K2a 2a 2a
IV IV III
III
II K2b 2b 2b
2c







seen in tertiary referral centers in the United States;
and 3) evaluate the clinical characteristics of pa¬
tients infected with different HCV genotypes.
Methods
Patients
We studied 438 patients from three different
groups (Table 2). All patients were from the United
States, had chronic hepatitis C, and were seen in
tertiary referral centers. Most had been referred by
their physicians or by a gastroenterologist or hepa-
tologist for inclusion in experimental antiviral ther¬
apy programs. The first group consisted of 137 pa¬
tients with chronic HCV infection whose serum
specimens had previously been characterized with
six different genotyping methods (20). The speci¬
mens of these patients were studied to verify the
validity of the line probe assay. The second group
consisted of 248 patients from nine centers in the
United States who had participated in a random¬
ized, controlled study of interferon-a therapy. One
of these 248 patients was negative for the antibody
to HCV (anti-HCV), and another had no serum
specimen available, which left a total of 246 patients
for this study. A careful review of the serum bank
showed that 40 patients were included in both
group 1 and group 2. To avoid duplication, we used
only the specimen obtained from each patient be¬
fore interferon-a therapy was started. For patients
for whom serum specimens obtained before treat¬
ment on the day of study entry were not available,
specimens collected 1 or 2 months before treatment
were used for HCV RNA quantitation and geno¬
typing. A previous study (23) has shown that the
viremia levels of patients with chronic HCV infec¬
tion usually remain about the same over time. The
details of the role of HCV genotype as a predictor
of subsequent response to interferon-a therapy will
be discussed in another report (Lindsay KL and
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Table 2. Clinical, Biochemical, and Histologic Characteristics of Study Patients
Characteristic Group 1 (n = 97) Group 2 (n = 246) Group 3 (n = 95)
69:28 175:71 45:50







10.0(1-26) 8.2(1-41) 4 (1-26)
136 ± 113 189 ± 109 123 ± 117
97 246 95
97 208 91
4.1 (PCR+ to 46.7) 2.61 (PCR- to 75.2) 3.6 (PCR- to 105.1)
10(3-14) 13 (4-18) 10(3-14)
6(2-10) 9(2-14) 7(2-10)
Male:female ratio
Mean age (range), y







Median estimated duration of HCV infection (range), y *
Mean serum alanine aminotransferase level ± SD, U/L
Positive for anti-HCV§, n
Positive for serum HCV RNA, n||
Median serum HCV RNA level (range), x 106 genome eq/mLM
Histologic characteristics**
Median Knodell score (range)
Median histologic activity index (range)
* anti-HCV = antibody to hepatitis C virus; HCV = hepatitis C virus; PCR* = positive results on polymerase chain reaction; PCR~ = negative results on polymerase chain reaction,
t Available in 317 patients,
t Available in 258 patients.
§ By enzyme immunoassay.
|| By polymerase chain reaction.
H By polymerase chain reaction and branched-DNA assay.
** Available in 262 patients.
colleagues. In preparation). The third group con¬
sisted of 95 patients seen at the University of Flor¬
ida in a prospective study of immune-mediated mech¬
anisms of hepatocellular damage.
All patients studied were seropositive for anti-
HCV and had had abnormal serum aminotransfer¬
ase levels for at least 6 months. None had biochem¬
ical or serologic evidence of other causes of liver
disease; in particular, all were seronegative for hep¬
atitis B surface antigen. Duration of HCV infection
was established by detailed history taking and was
estimated by the clinical investigator (available in
258 patients).
Antibody to Hepatitis C Virus and Detection and
Quantitation of Hepatitis C Virus RNA
We detected anti-HCV by using second-genera¬
tion enzyme immunoassay (Ortho Diagnostics, Rari-
tan, New Jersey or Abbott Diagnostics, North Chi¬
cago, Illinois). Serum specimens were tested for
HCV RNA by reverse transcription "nested" PCR
with primers derived from the highly conserved
5'UTR and quantitated by branched DNA (bDNA)
signal amplification assay (Quantiplex HCV RNA,
version 1.0, Chiron Corp., Emeryville, California) as
described previously (24, 25). All reverse transcrip¬
tion PCR assays were done in a single laboratory;
the performance of the PCR assays has been pre¬
viously verified to have specificity and sensitivity of
100% against a coded serum panel prepared by the
Chiron Corporation.
Serum HCV RNA levels were measured by
bDNA signal amplification assay (bDNA, Quanti¬
plex HCV, version 1.0, Chiron Corp.). Because the
bDNA assay underestimates HCV RNA levels in
patients infected with HCV types 2 and 3, the ap¬
propriate correction factors (X3 for type 2 and X2
for type 3) were applied to obtain accurate levels of
viremia (26-28). The bDNA assay accurately mea¬
sures HCV RNA levels for HCV types 1, 4, 5, and
6; thus, no conversion was necessary for these types.
Hepatitis C Virus Genotyping
The details of the six HCV genotyping methods
used to characterize the serum specimens of group
1 have been described previously (20). These meth¬
ods are PCR with genotype-specific primers based
on the HCV core region and the genomic region of
NS5, restriction fragment length polymorphism based
on the 5'UTR, direct sequencing of the NS5B region,
and serologic genotyping based on NS4 recombinant
and synthetic peptides.
The line probe assay was used to assess HCV
genotyping as previously described (21). Briefly, the
5'UTR was amplified using "nested" PCR with bi-
otinylated primers. The labeled amplicon was al¬
lowed to hybridize with probes derived from various
HCV genotypes mounted on a strip. After stringent
washing, streptavidin labeled with alkaline phos¬
phatase was used to trace the hybridized products,
and nitroblue tetrazolium and 5-bromo-4-chloro-3-
indoyl-phosphate were used as substrates. To ensure
that this assay was consistently concordant with
other tests, 342 specimens were tested by restriction
fragment length polymorphism of the PCR ampli¬
con generated from the 5'UTR, and 339 specimens
were tested by a serologic genotyping assay based
on the use of peptides derived from two regions of
NS4 (amino acid positions 1691 to 1708 and 1710 to
1728) as capture antigens (20, 29).
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The HCV genotype nomenclature used in this
report is that proposed by an international panel (4)
and is the most widely accepted of all nomenclature
systems. We use "genotype" as a general term. The
major types, designated 1, 2, 3, and so on are re¬
ferred to as "types," and the subtypes a, b, c, and so
on are referred to as "subtypes" (Table 1).
Hepatitis C virus types 2a and 2c cannot be dis¬
tinguished on the basis of the 5'UTR, but they
clearly separate into different subtypes by phyloge-
netic tree analysis of the subgenomic region of NS5
(30). Therefore, it is possible that specimens geno-
typed as 2a were in fact 2c. In our study, the NS5B
nucleotide sequences from three patients with HCV
type 2a were determined by the dideoxy chain ter¬
mination method and analyzed with both neighbor-
joining and maximum likelihood analyses. All three
were specimens assigned as HCV type 2a (data not
shown).
Liver Histology
Baseline liver biopsy specimens were available for
262 patients, and the investigators assessing these
specimens were blinded. The Knodell score and its
individual components (periportal, lobular, and portal
inflammation and fibrosis) (31) and the histologic
inflammatory index (summation of the lobular, peri¬
portal, and portal inflammation scores) (32) were
assessed.
Statistical Analysis
All data were analyzed using SPSS for Windows
(SPSS, Inc., North Chicago, Illinois). Once a speci¬
men was included in the study, the data were used
for the final analysis; this includes serum specimens
that were negative on reverse transcriptase PCR.
This approach is similar to the intention-to-treat
analysis in clinical studies on therapeutic agents.
For the analysis of clinical associations, we used
analysis of variance, which assumes normality, to
compare the means for the variables across groups.
For those cases in which the F test indicated statis¬
tically significant differences, pairwise multiple com¬
parisons using the Student-Neuman-Keuls test were
applied. The Mann-Whitney rank-sum test and the
Spearman rank correlation coefficient were applied




Amplification of the 5'UTR using the labeled
primers and subsequent genotyping by the line
probe assay have a sensitivity similar to that of our
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in-house PCR assay, which is also based on the
5'UTR (our in-house assay was determined to have
a consistent sensitivity <1000 genomes/mL; in most
runs, our detection limit was <500 genomes/mL).
The line probe assay was repeated on 25 specimens,
and the results were 100% reproducible on this
small number of specimens. The line probe assay,
which relies on differential hybridization of PCR
amplicons derived from the 5'UTR, is probably
more sensitive in identifying mixed infection than
other genotyping methods, which amplify less con¬
served regions of the genome. Accordingly, if a
specimen is found to have genotypes la and 3a by
the line probe assay and la by another method, the
results should still be considered concordant.
In the 137 specimens that had previously been
genotyped by six other methods, the concordance of
the line probe assay and the other methods was
100% (specificity of 100%). In the 342 specimens
that were genotyped by both restriction fragment
length polymorphism analysis of the 5'UTR and
line probe assay, the concordance of the two meth¬
ods was 98.2%. The results were discordant in 6
specimens (in 1 specimen, restriction fragment length
polymorphism assigned type 1 and the line probe
assay assigned type 2; in 5 specimens, restriction
fragment length polymorphism assigned type 2 and
the line probe assay assigned type 1). Of the 339
specimens that were serologic genotyped on the ba¬
sis of the NS4 genomic region, the line probe assay
and serotyping had a concordance of 98.5%. Five
specimens were discordant (in 1 specimen, serologic
genotyping assigned type 1 and the line probe assay
assigned type 2; in 1 specimen, serologic genotyping
assigned type 1 and the line probe assay assigned
type 3; and in 3 specimens, serologic genotyping
assigned type 2 and the line probe assay assigned
type 1).
Three patients who were positive by PCR as
determined by ethidium bromide staining showed
no hybridization signals on the line probe assay
strips. Overall, the line probe assay was able to
assign HCV genotype in 417 of the 421 specimens
(99.1%) that were positive for HCV RNA by PCR.
If all 438 specimens tested were considered, the line
probe assay assigned HCV genotype to 95.2%.
Distribution of Hepatitis C Virus Genotypes
On the basis of the line probe assay, the distri¬
bution of various HCV genotypes in patients with
chronic hepatitis C seen in tertiary referral centers
in various regions of the United States was evalu¬
ated (Table 3). Several important points emerged.
First, 96.1% of the specimens were positive by PCR,
indicating that these specimens were fairly well pre¬
served. Second, types la and lb were the most
common HCV genotypes in this population. Third,
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the overall distribution of various HCV types in
different geographic locations was similar.
Clinical Characteristics of Patients Infected with
Different Hepatitis C Virus Genotypes
For patients infected with HCV type 1, genotyp-
ing by the line probe assay may show the following
possible patterns: type la; type lb; type la plus
type lb; and type 1 in which subtype a or b could
not be defined. As a first step, we compared all of
the subtypes within the major types, and no differ¬
ences were seen in clinical characteristics between
the subtypes within the major types. In particular,
no differences in any clinical variables were seen
between patients infected with HCV type la and
those infected with HCV type lb. Therefore, pa¬
tients with each major HCV type were grouped
together regardless of subtype (for example, pa¬
tients with type la, type lb, type la plus type lb,
and type 1 without specified subtype were all
grouped together as HCV type 1). Patients with
mixed infection were combined into a single group,
and patients who had negative results on PCR were
also considered as a group.
No difference in age was seen among patients
infected with HCV types 1, 2, and 4. Patients in¬
fected with HCV type 3 were younger than patients
infected with type 1 and type 2 (type 3 compared
with type 1 [F = 0.002]; type 3 compared with type
2 [P = 0.004]; see Table 4). No difference in sex
distribution was seen among patients infected with
different HCV genotypes. Of the 258 patients in
which the estimated duration of HCV infection was
documented, no difference in duration was seen be¬
tween patients infected with HCV type 1 and those
infected with HCV type 2. However, patients in¬
fected with HCV type 1 had a longer estimated
duration of infection than did patients infected with
types 3 and 4 (P = 0.004 for type 3 and P = 0.049
for type 4). Of the 317 patients in whom the
method of acquisition was documented, 108 of 216
(50%) of the patients with HCV type 1 infection
had acquired HCV through the transfusion of blood
products compared with 16 of 65 (25%) of the
patients infected with another HCV type (P <
0.001; Table 4).
In this data set, no statistical differences were
seen in serum alanine aminotransferase or aspartate
aminotransferase levels among patients infected
with different HCV genotypes, except that the few
patients infected with HCV type 4 had lower serum
alanine aminotransferase levels (70 ± 38 U/L
[n = 5]) than patients infected with other HCV
types (ranging from 154 ±118 U/L [n = 24] for
HCV type 3 to 163 ±118 U/L [n = 313] for HCV
type 1), but this did not reach statistical significance
(P = 0.07; Table 4).
Of the 262 patients who had baseline liver biopsy
specimens, 182 had HCV type 1, 35 had type 2, 12
had type 3, and 2 had type 4. Because so few
patients with HCV type 4 infection had liver biopsy
specimens available, analysis was done only on pa¬
tients with HCV types 1, 2, and 3 (Table 4). No
significant difference was seen in the total histologic
inflammatory index or Knodell scores among pa¬
tients infected with different HCV genotypes. Addi¬
tionally, no differences were seen in individual histolo¬
gic scores (lobular, periportal, and portal inflammation
and fibrosis) among patients infected with different
HCV types. The only exception was that patients with
HCV type 2 infection had more periportal inflam¬
mation (mean rank, 124.4; n = 35) than did patients
with type 1 infection (mean rank, 106.0; n = 182),
Table 3. Prevalence of Various Hepatitis C Virus Genotypes in Different Areas of the United States Based on the Line
Probe Assay*
Location Total Hepatitis C Virus Genotype







Gainesville, Florida 142 97 56 37 4 29 8 19 0 9 5 2 0 0
St. Louis, Missouri 61 49 22 23 0 5 2 2 0 3 0 1 0 3
Los Angeles, California 59 46 21 24 0 7 2 2 3 2 0 4 0 0
Miami, Florida 34 21 8 8 3 3 0 0 3 0 0 2 0 8
New Orleans, Louisiana 30 24 11 12 1 1 1 0 0 1 0 1 2 1
Providence, Rhode Island 30 17 8 6 1 4 1 2 1 4 0 4 1 0
Boston, Massachusetts 28 22 14 5 2 1 0 1 0 2 0 0 1 2
Denver, Colorado 24 17 9 8 0 4 1 0 2 1 0 0 0 2
Louisville, Kentucky 14 6 3 2 0 4 1 1 1 1 0 2 0 1
San Francisco, California 16 14 8 6 0 1 0 1 0 1 0 0 0 0
Total patients, n (%) 438 313(71. 5) 160 (36. 5) 131 (29. 9) 11 (2. 5) 59 (13. 5) 16(3.7) 28 (6.6) 10(2.3) 24(5.5) 5(1.1) 1 6(3.7) 4 (0.9) 17
* The difference between patients with type 1 and total patients with types 1a, 1b, and 1a + 1b represents the number of patients whose genotypes were assigned as type 1 but subtype
(a or b) was not assigned by line probe assay. The same is true for type 2. PCR+ = positive results on polymerase chain reaction; PCR" = negative results on polymerase chain reaction.
+ n refers to number of patients.
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Table 4. Clinical, Biochemical, Virologic, and Histologic Characteristics of Patients Infected with Different Hepatitis C
Virus Genotypes*
Characteristic Patients with Patients with Patients with Patients with Patients with Patients PCR or
HCV Type 1 Infection HCV Type 2 HCV Type 3 HCV Type 4 Mixed HCV Untypable
(n = 313) Infection Infection Infection Infection (n = 21)
(n = 59) (n = 24) (n = 5)t (n = 16)
Male:female ratio 205:108 34:25 20:4 4:1 13:3 13:8
Mean age ±SD,y 47 ± 13 46 ± 11 39 ± 9 44 ± 13 48 ± 13 42 ± 12
Median estimated duration of
HCV infection (range)t, y 8.4(1.0-41.1) 4.6(1.0-38.2) 2.8(1.0-10.1) 3.0(1.0-6.0) 5.3(1.2-10.6) 11.8(1.6-34.3)
Mode of acquisition of HCV, n§
Blood product transfusion 108 12 3 1 4 9
Health care workers 2 4 1 0 2 0
Intravenous drug use 73 10 8 4 5 7
Sporadic 33 15 6 0 4 5
Sexual 0 1 0 0 0 0
Median serum HCV RNA level
(range), x/06 genome
eq/mL 3.8 (PCR+to 105.10) 2.8 (PCR+to 99.10) 2.8 (PCR+to 41.40) 0.5 (PCR+to 32.90) 1.0 (PCR+to 88.5)
Mean alanine aminotransferase
level ± SD, U/L 163 ±118 162 ±115 154 ± 107 70 ± 38 159 ± 88 188 ± 108
Median Knodell score (range)|| 12(3-18) 12(7-15) 12(6-16) 12(8-15) 13(10-17)
Median histologic activity index
(range)|| 9(2-14) 9(3-12) 9(4-12) 9(5-11) 10(7-14)
Patients with cirrhosis/patients
assessed for cirrhosis, n/n
(%) 71/181(39) 17/35(49) 4/12 (33) 5/13(39) 4/19(21)
* HCV - hepatitis C virus; PCR = polymerase chain reaction; PCR+ = positive results on polymerase chain reaction.
t The number in some categories was small (<3), and therefore no data are given, because these patients may not have been adequately representative,
t Available in 258 patients.
§ Available in 317 patients.
|[ Available in 262 patients.
but this difference was not statistically significant
(P = 0.088).
In all patients, HCV viremia levels were docu¬
mented by reverse transcriptase PCR and quanti-
tated by bDNA assay (Table 4). Patients infected
with HCV types 1, 2, and 3 had similar levels of
viremia. However, patients infected with HCV type
4 had lower viremia levels than did patients infected
with type 1 (P = 0.047).
When patients with mixed infection (across types
[for example, la and 3a] and not within types [for
example, la and lb]) were considered as a group,
they were older than patients infected with HCV
type 3 (P = 0.018). No differences were seen in sex
distribution, mode of HCV acquisition, or serum
biochemical and histologic features between pa¬
tients with mixed infection and patients infected
with other HCV types (Table 4).
The demographic, biochemical, and histologic
features of patients who had negative results on
PCR did not differ from those of patients in other
groups (Table 4).
Discussion
Our study makes several important points. First,
for HCV genotyping, the line probe assay based on
the 5'UTR is sensitive and reproducible and has
good concordance with other tests. Second, the dis¬
tribution of HCV types 1, 2, and 3 in patients with
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chronic HCV infection who are referred to tertiary
centers in the United States is fairly uniform: Type
1 is the most common HCV type. Third, a higher
proportion of patients infected with HCV type 1
than of patients infected with other HCV types
appears to have acquired HCV through transfusion
of blood products. Fourth, disease activity does not
differ significantly among patients infected with
HCV types 1, 2, and 3. Finally, patients infected
with HCV types 1, 2, and 3 have similar serum
HCV RNA levels, whereas patients infected with
HCV type 4 have lower levels of viremia than pa¬
tients infected with type 1.
The line probe assay is relatively simple and stan¬
dardized. Recently, Smith and associates (30) re¬
ported that, theoretically, the line probe assay might
assign HCV genotype incorrectly in patients in¬
fected with HCV types 3 and 4 and that restriction
fragment length polymorphism based on the 5'UTR
may be more reliable. Although this may be true in
some geographic locations in which more genotypes
are present, we show that the HCV genotype as¬
signment produced by line probe assay is highly
concordant with that produced by other tests, in¬
cluding restriction fragment length polymorphism,
in this field study in the United States. This is
probably because HCV types 1 and 2 are the most
common HCV genotypes in the United States. In
addition, the probes used in the line probe assay
have been modified to accommodate the recently
identified genetic variations of HCV.
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Given that this line probe assay is based on the
initial amplification of the 5'UTR, a highly con¬
served area of the HCV genome, it is not surprising
that it is very sensitive. As reported previously (20),
genotyping assays based on other genomic regions
have lower sensitivity. This is believed to be because
of the lower efficiency of amplification related to
the higher genetic heterogeneity of these genomic
regions. In this previous study of patients in the
United States with chronic hepatitis C (20), geno¬
typing based on the HCV core region as described
by Okamoto and colleagues has a sensitivity of
89.2%, whereas genotyping based on NS5 has a
sensitivity of only 83.5%. The specificity of this line
probe assay is also excellent. The concordance of
the assay with restriction fragment length polymor¬
phism assay based on the 5'UTR, which we have
previously shown to be very reliable (20), was 98.2%.
As of October 1995, the cost of each line probe
assay strip was about U.S. $65.00. Adding the cost
of PCR, reagents, and supplies and the institutional
running cost for PCR and genotyping, excluding
technician time, the total cost should be about $100
to $120 (estimated from the cost at the University
of Florida). Genotype assignment is reported in a
strip form with dark bands. We made photocopies
of the strips, and the photocopies seemed to have
sufficient quality for evaluation. This will allow in¬
vestigators to compare results easily. We also sent
the photocopies through a standard facsimile ma¬
chine and found that most of the bands were ade¬
quately visible on the facsimile.
On the basis of this line probe assay, HCV type
1 was found to be the most common HCV genotype
in patients referred to tertiary referral centers for
inclusion in experimental antiviral therapy programs
in the United States; it was assigned in 72% of
cases. Types 2 and 3 were found in all geographic
areas, with average overall distributions of 14% and
6%, respectively. Type 4 was identified in Florida.
Recently, type 4 was also found in California (Zhou
S and coworkers. In preparation), suggesting that
our detection of HCV type 4 only in Florida might
be related to the larger number of patients that we
studied in that state. Because HCV type 5 is found
mainly in South Africa and Belgium, and type 6 is
found primarily in Hong Kong and Macau, all of
which are developed countries or cities with heavy
traffic to the United States, we anticipate that these
genotypes will eventually be seen in the United
States. We might have identified these types if we
had studied more patients.
One potential pitfall of our study was that the
persons we studied were referred to tertiary referral
centers for consideration for inclusion in experimen¬
tal antiviral therapy programs in the United States.
We attempted to include patients from various geo-
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graphic locations, and, as discussed above, the distri¬
bution of HCV genotypes was fairly similar in all
study centers. Our data are important to clinicians
and research scientists in the United States, because
HCV genotype la is only prevalent in the United
States, and data generated in other countries will
not provide detailed information on the clinical
characteristics of patients infected with this HCV
type.
Another important issue is whether patients in
different phases of infection (for example, healthy
blood donors with normal liver test results who
are seropositive for anti-HCV, patients with mild
liver disease who are seen by primary care physi¬
cians, and patients referred for liver transplantation)
have the same distribution of HCV genotypes. To
date, no published data on the distribution of HCV
genotypes in these groups are available. A recent
analysis based on more than 100 patients with
HCV-related cirrhosis who were referred to the
University of California, San Francisco, for liver
transplantation showed that these patients had a
distribution of HCV genotypes similar to that seen
in our study (Zhou S and coworkers. In preparation).
No differences were seen in any of the demo¬
graphic, clinical, biochemical, virologic, and histo¬
logic features of patients with different HCV sub¬
types within each major HCV type. In particular,
patients infected with HCV types la and lb had
similar profiles in all of the variables examined. We
wish to emphasize that the duration of HCV infec¬
tion was estimated on the basis of clinical history,
and the data on the correlation of estimated dura¬
tion of HCV infection with HCV genotype should
be interpreted with caution. Several differences
were found between patients infected with different
HCV types. A higher proportion of patients in¬
fected with HCV type 1 than of patients infected
with other HCV types had acquired HCV through
the transfusion of blood products. It has been sug¬
gested that HCV type 3 infection is more prevalent
among intravenous drug users in Scotland (29).
However, for the 16 patients in our study with HCV
type 3 infection, intravenous drug use was not the
predominant method of acquisition. This suggests
that the association between HCV type 3 infection
and intravenous drug use may not apply in the
United States.
Patients with HCV type 3 infection were younger
than patients infected with HCV types 1 and 2, and
patients infected with types 3 and 4 had a shorter
estimated duration of HCV infection than patients
infected with type 1, as assessed from clinical his¬
tory. There are three possible explanations for these
observations. First, HCV types 3 and 4 may have
been introduced into the United States more recently.
Second, types 3 and 4 may be transmitted primarily
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within younger generations through intravenous drug
use. Third, there might be a bias in the estimation
of HCV infection in patients infected with different
HCV genotypes. That HCV type 3 is more preva¬
lent in India and Scotland and type 4 is more prev¬
alent in the Middle East favors the first explanation.
In contrast, the observation that the proportion of
patients who acquired HCV through intravenous
drug use is higher for patients with types 3 and 4
than for patients with type 1 favors the second
hypothesis. However, we must emphasize that a sig¬
nificant proportion of patients with HCV types 3
and 4 did not acquire HCV through intravenous
drug use, which suggests that other factors are in¬
volved. In fact, these two possibilities are not mu¬
tually exclusive, and both may be operative.
An important observation in our study was that
disease activity did not differ among patients in¬
fected with different HCV genotypes. A previous
study in fewer patients (20) suggested that HCV
type 2 infection was associated with a higher level of
disease activity. Given the absence of an association
in this larger, present study, it is possible that the
previous association was the result of a type II
statistical error. Nousbaum and colleagues (33) re¬
ported that patient age and presence of cirrhosis
were independently associated with HCV type lb
infection in France and Italy. There are at least
three possible explanations for the difference be¬
tween their data and our observations. First, they
had only 4 patients with HCV type 2 and 20 pa¬
tients with HCV type 3, and thus a type II statistical
error may have existed. Second, their patients with
HCV type lb infection were older and had longer
estimated durations of disease compared with their
patients infected with HCV types 2 and 3. Types 2
and 3 may have been introduced more recently to
France and Italy and, therefore, the effect of these
HCV genotypes on liver disease may not have been
obvious at the time the study was done. Third, a
significantly higher proportion of patients with HCV
type 1 had acquired HCV through blood transfu¬
sion. Other clinical or epidemiologic factors may
have been associated with the development of liver
disease in patients with HCV type lb infection. As
discussed earlier, the distribution of HCV genotypes
in patients receiving liver transplants was similar to
that detailed in our current study, and this further
supports the hypothesis that all HCV genotypes are
equally able to induce active and potentially pro¬
gressive liver disease.
With appropriate adjustments for an accurate as¬
sessment of viremia in different genotypes, we found
that patients chronically infected with HCV types 1,
2, and 3 had similar levels of viremia. Similar results
were recently seen in a large study of blood donors
infected with different HCV genotypes (27). In con-
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trast, in our study, the few patients with HCV type
4 had a lower level of viremia than patients with
HCV type 1. The clinical and virologic implications
of this low-level viremia in patients with HCV type
4 infection remains to be established.
Finally, it has been suggested that patients in¬
fected with HCV types 2 and 3 have a better chance
of developing a long-term biochemical response to
interferon-a (33-36). The patients in group 2 in our
study received a complicated dose-adjustment pro¬
tocol, and patients switched treatment arms if they
did not show a complete biochemical response after
12 weeks of interferon-a therapy. Hence, our anal¬
ysis of response to interferon-a therapy is compli¬
cated and is based on different criteria. These data,
together with the treatment response data that in¬
volved the effect of changing interferon-a dose, will
be addressed in a separate manuscript (Lindsay KL
and colleagues. In preparation).
In conclusion, this line probe assay is applicable
to patients in the United States who have chronic
HCV infection. Type 1 is the most common HCV
genotype in patients with chronic hepatitis C who
are referred to tertiary centers in the United States.
Half of patients with HCV type 1 have acquired
HCV through the transfusion of blood products. No
difference in disease activity or viremia levels was
seen among patients chronically infected with HCV
types 1, 2, or 3. The distribution of various HCV
genotypes in other clinical settings (such as blood
donors seropositive for anti-HCV and patients with
chronic HCV infection seen by primary care doc¬
tors) and the relation between HCV genotypes and
response to interferon therapy remains to be estab¬
lished.
Appendix
Additional members of the Hepatitis Interven¬
tional Therapy Group are Robert P. Perrillo, MD
(St. Louis Veterans Affairs Medical Center, St.
Louis, Missouri); Eugene R. Schiff, MD (University
of Miami, Miami, Florida); Henry C. Bodenheimer,
MD (Rhode Island Hospital and Brown University,
Providence, Rhode Island); Luis A. Balart, MD, and
Frederic Regenstein, MD (Ochsner Clinic, New Or¬
leans, Louisiana); Jules L. Dienstag, MD, and William
N. Katkov, MD (Massachusetts General Hospital,
Boston, Massachusetts); Carlo H. Tamburro, MD
(University of Louisville, Louisville, Kentucky); John
S. Goff, MD, and Gregory T. Everson, MD (Univer¬
sity of Colorado, Denver, Colorado); Zachary Good¬
man, MD (Armed Forces Institute of Pathology,
Washington, D.C.); and Janice Albrecht, PhD (Scher¬
ing-Plough Research Institute, Kenilworth, New Jer¬
sey).
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Prevalence of Hepatitis C Genotypes among
Patients with Chronic Hepatitis C in Norway
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Among 116 patients with biopsy-confirmed chronic hepatitis C (Riba 2 or Riba 3 positive) in a multicenter study in southern
Norway on interferon, we determined hepatitis C virus genotype by restriction fragment length polymorphism (RFLP) of the
5 NCR. The RFLP method was supplemented by and compared with a serological typing method based on the detection of
type-specific antibody to peptide from the NS-4 region. A total of 102/1(16 (96%) patient sera showed detectable type-specific
antibody to NS-4 peptides and corresponded in all cases, except two, to the genotype detected by polymerase chain reaction.
Combining the results from RFLP genotyping and serotvping, genotype 1 was found in 40 (35%) (27 with la and 10 with lb,
3 subtypes not determined), genotype 2 in 15 (13%) (subtype 2b in 14 and 1 subtype not determined), and genotype 3 in 58
(50%) of patients. The low mean age of the patients (34 years), the low prevalence of cirrhosis (3.5%), the short duration of
the disease, and a high prevalence of intravenous-drug abusers may account for the low prevalence of infection with genotype
lb (9%). The epidemiological features of hepatitis C patients are markedly different from patient groups described in southern
Europe in terms of risk factors, age, and genotype distribution.
//. Bell, Unit of Hepatology, Department of Medicine, Aker University Hospital, 0514 Oslo, Norway
INTRODUCTION
Hepatitis C virus (HCV) exists as multiple, distinct geno¬
types. To date, six major genetic groups and at least 30
subgroups have been identified by analysis of complete or
partial HCV genomic sequences (1). The genotype distribu¬
tion has been found to be different in blood donors com¬
pared with patients with liver disease (2), and in
intravenous drug abusers compared with other infected
groups (3). A number of studies have shown that genotype
1 is widely distributed, being the predominant genotype in
both the USA and Europe, particularly type lb. Type 2 is
also widely distributed around the world, and type 3 occurs
with a prevalence of 5-42% in Europe. Type 4 shows a
* Other members of the Construct group are: Medical Depart¬
ments of Bierum Hospital, Sandvika (Aira Bucher. Even Lind);
Central Hospital of Aust-Agder, Arendal (Tom Schulz); Central
Hospital of Vest-Agder, Kristiansand (Anders Sundoy); Central
Hospital of Rogaland, Stavanger (St&le Barstad, Svein Storset);
Rikshospitalet, Oslo (Ingvild Nordoy); Central Hospital of Vest-
fold (Per Bjark); Central Hospital of Gjovik (Ole-Gunnar
Anfinsen); Oslo Kretsfengsel; Oslo (Ketil Klem); Deakon Hospi¬
tal, Oslo (Nj&l Stray, Ragnar Weberg); Moss Hospital, Moss
(Magnus Melsom); Deakoness Hospital, Oslo (Jacob Mosvold);
Origosenteret, Svinndal (John Haug); Orkdal Hospital, Orkdal
(John Langtind); Kongsvinger Hospital. Kongsvinger (Sigurd
Wetterhus); Haugesund Hospital, Haugesund (Jens Ostborg);
and Aker University Hospital (Erling Aadland, Morten Mowe,
Jorgen Jahnsen, Fredrik Muller).
high prevalence in central Africa and Egypt (4), and type 5
is dominant in southern Africa (4, 5). Genotype 6 was
found in up to 20-30% of patients in Vietnam and Hong
Kong (6, 7), and HCV variants described as types 7, 8, and
9 have recently been identified in Vietnam (6) and Thailand
(8). There is evidence to support the hypothesis that genetic
variability of HCV is clinically significant (3). Many studies
have shown that genotype 1 b is an independent prognostic
factor for a lack of response to interferon treatment (1, 3).
In Scandinavia, Widell et a!. (9) found a high prevalence of
genotype la (57%) among Swedish blood donors, while
Shev et al. (10) found a low prevalence of type lb (10%).
We therefore studied the genotypes of Norwegian patients
with chronic hepatitis C in a multicenter interferon study
by means of restriction fragment length polymorphism
(RFLP) analysis. The results obtained with this method
were compared with a serological assay based on the detec¬
tion of type-specific antibody to NS-4 peptides.
MATERIALS AND METHODS
A total of 116 patients (85 male, and 31 female; median age 34
years, range 19-66 years) with biopsy-confirmed chronic hepatitis
C (all were HCV antibody positive as assessed using Ortho's 2nd
generation anti-HCV test (EIA-2) and RIBA2 or 3) were included
in a multicenter interferon study (Roceron, A.F. Hoffman-La
Roche Ltd. Basel). Risk factors for acquisition of HCV were
previous intravenous drug abuse in 74 patients (64%), sporadic or
unknown causes in 37 patients (32%), and blood transfusion in 5
© 1996 Scandinavian University Press. ISSN 0036-5548
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Unknown 3 1 4 1 0 9 - -
Total 36 16 56 112 3 115 95.7 98.2
a Determined by RFLP of 5' NCR sequences.
b Detection of type-specific antibodies by ELISA to HCV genotypes 1 -6. NR, non-reactive; NTS, non-type-specific antibody reactivity
to NS-4 peptides.
°Number typeable by ELISA/number tested.
d Number concordant with genotype determination by RFLP/number typeable by ELISA.
patients (4%). Liver biopsy was performed within I year prior to
the start of treatment. Histological evaluation was performed by
one pathologist who had no knowledge of the clinical course or the
biochemical and virological values. Chronic persistent hepatitis
was found in 58 (50%), chronic active hepatitis with minimal
activity in 26 (22%), chronic active hepatitis in 24 (21%), cirrhosis
in 4 (3.5%), steatosis and fibrosis in 1 patient each, and 2 biopsies
were too small for a definite diagnosis. The mean Knodell index
was 5.5 ± 2.6 (range 3-11). Hepatitis C genotypes were identified
by RFLP of the 5' NCR. and serotyping was performed using
NS-4 peptides to identify type-specific antibody to HCV (11, 12).
The HCV viral load was analyzed according to Amplicor Monitor
(Roche Diagnostics Systems. F Hoffman La-Roche Ltd, Basel,
Switzerland) (13). Hepatitis Bs antigen was negative in all patients.
Statistics
Results are given as medians and ranges. Categorical variables
were compared using the x2 test or the Kruskal- Wallis 1-way
ANOVA. Comparison between two groups was done using the
Mann-Whitney U test.
RESULTS
RFLP genotyping revealed type 1 in 37 patients (32%) (la
in 27 and lb in 10), type 2b in 14 (12%), type 3 in 54 (47%),
type 4 in 1 (1%). In 9 patients (8%) the RFLP were negative
and the initial serum sample from 1 patient was missing.
Detectable type-specific antibody to NS-4 peptides was
demonstrated in 102/106 (96.2%) patients, in 9 of the
patients with RFLP-negative samples, serotype 1 was found
in 3 patients, serotype 2 in 1, serotype 3 in 4, and in I
patient a non-type-specific antibody reactivity to NS-4 was
found. In all cases except 2 (98.1%), the serotypes corre¬
sponded to the genotype detected by the RFLP assay
(Table I).
Combining the results of the RFLP genotyping and the
serotyping, genotype 1 was found in 40 patients (34%)) (10
of genotype lb), genotype 2 in 15 (13%), genotype 3 in 58
(50%>), and genotype 4 in 1 patient.
The sex distribution and the median age was similar in
patients with genotypes 1. 2, and 3 (34, 36. and 32 years.
respectively; p = 0.40). Genotype 3 was marginally more
prevalent among intravenous drug abusers compared with
sporadic cases (55%> versus 38%o, p = 0.051). Patients with
more advanced liver disease, such as moderate or severe
chronic active hepatitis (CAFI), were evenly distributed
among the different genotypes. Analysis of variance
showed a significant difference concerning baseline serum
ALAT between genotypes 1, 2, and 3 (ALAT =111, 120,
and 161 U/l, respectively; p = 0.02). However, the baseline
viral load in the different genotypes was not significantly
different (395,000, 270,000 and 165,000 copies/ml for geno¬
types 1, 2, and 3, respectively; /? = 0.08).
DISCUSSION
Studies from Europe (3) and the USA (13) have shown that
the most common HCV genotype is lb, with a prevalence
of 50-70%). In contrast, in the present study from Norway
only 9%> of patients were infected with this genotype, with
genotype 3 accounting for most cases of chronic HCV.
There are several possible reasons for these discrepancies.
Most of our patients were relatively young (median age 34
years) and only 4 had cirrhosis. The median duration of
known disease in our study was 4 years, which is much
shorter than in many other studies from Europe. In one
study (3) the prevalence of genotype lb was around 80% in
subjects aged above 60 years or with HCV infection lasting
for more than 15 years. Nearly two-thirds of our patients
were former intravenous drug abusers, and some studies
have shown a higher prevalence of genotype 3 in these
patients (3).
Of the 115 patients, 106 were RFLP positive, and all but
1 were Amplicor reacative. This distinction may indicate
that the RFLP was less sensitive than the Amplicor Moni¬
tor assay, probably due to the different detection systems
used. The variation may also be due to improper sample
handling. The distinction between genotypes la and lb by
RFLP is based on the difference in a single nucleotide.
Scand J Infect Dis 28 Hepatitis C genotypes 359
Sporadic cases tended to be due to type 1, whereas type
3 was predominant among drug abusers {p = 0.051). The
reason for this is not obvious. Perhaps these cohorts were
infected not only by different routes, but also at different
times and places. Drug abuse may have been introduced
relatively late in Norway and a rapid spread of imported
type 3 may have occurred recently.
We found no significant difference of viral load between
genotypes 1, 2, and 3. This supports the hypothesis that
viral load and genotype are independent predictors of
reponse to treatment with interferon.
We found almost complete agreement between the results
of serotyping with NS-4 peptides and typing with RFLP, as
described recently (14, 15). This is of practical importance,
since serotyping may be performed in most laboratories
using an enzyme-linked immunosorbent assay (ELISA) and
this method is now commercially available in Europe and
elsewhere.
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fluence of Viraemia and Genotype Upon Serological
^activity in Screening Assays for Antibody to
epatitis C Virus
, Dhaliwal, L.E. Prescott, B.C. Dow, F. Davidson, H. Brown, P.L. Yap, E.A.C. Follett, and
immonds
irtment of Medical Microbiology (S.KD., P.S.) and Medical Statistics Unit (H.B.), University of Edinburgh,
ot Place, Edinburgh and South East Scotland Blood Transfusion Service, Edinburgh (L.E.P., FT)., P.L.Y.),
tish National Blood Transfusion Service Microbiology Reference Laboratory, Ruchill Hospital, Glasgow (B.C.D.,
CF.), United Kingdom
etection of antibody to recombinant proteins
erived from hepatitis C virus (HCV) genotype 1
ipresents the principal method for diagnosis of
CV infection. A method was developed for
uantifying antibody reactivity in two third-gen-
-ation enzyme immunoassays (Ortho EIA 3.0
nd Murex VK48), and the influence of viraemia,
CV genotype, and host factors such as age,
ender, and risk group upon antibody levels
ere investigated in a consecutive series of 117
iti-HCV-positive volunteer blood donors. Vi-
lemic donors (as assessed by the polymerase
lain reaction; PCR) showed significantly higher
vels of anti-HCV by the Ortho EIA than those
ho were nonviraemic (adjusted mean differ-
ice of 10.1 fold after multiple regression analy-
s). The only other factor to influence signifi-
intly antibody level was genotype, where it was
>und that donors infected with type 1 showed 4
) 4.5 times greater serological reactivity by the
rtho assay than those infected with type 2 or 3.
ntibody levels by the Ortho assay correlated
osely to those detected by the Murex VK48 as-
ay, and similar differences between PCR-posi-
ve and negative donors and between those in-
icted with different genotypes were found,
ifferences in serological reactivity between
anotypes indicate that a large proportion of
aitopes of the type 1a or 1b recombinant pro-
:ins used in current assays are genotype spe-
fic. Variation in sensitivity of screening assays
ir different genotypes is of potential concern
hen used in countries where non-type 1 geno-
pes predominate in the blood donor or patient
Dpulation. © 1996 Wiley-Liss, Inc.
INTRODUCTION
Following the identification of hepatitis C virus
(HCV) as the principal aetiological agent of posttrans¬
fusion non-A, non-B hepatitis [Kuo et al., 1989; Choo et
al., 1989], many countries have established routine
screening ofall blood donors for anti-HCV-specific anti¬
body by enzyme immunoassay (EIA). Most commonly
used assays use recombinant proteins derived from the
prototype HCV clone, HCV-PT (genotype la). However,
other variants of HCV may differ substantially in nu¬
cleotide sequence from one another and show varied
geographical and epidemiological distributions [Bukh
and Miller, 1994; Simmonds, 1995]. In particular, the
inferred amino acid sequences of the envelope glycopro¬
teins and nonstructural proteins differ considerably,
leading to the possible existence of type-specific as well
as shared epitopes between genotypes. It remains un¬
clear whether such assays are equally effective for de¬
tecting antibody elicited by heterologous genotypes.
Previous investigations of serological reactivity to
individual HCV proteins by immunoblotting assays in¬
dicated type-specific reactivity to nonstructural pro¬
teins used as antigens in current screening enzyme-
linked immunosorbent assays (ELISAs). For example,
reactivity to cl00-3 and 5-1-1 antigens used in the orig¬
inal first-generation screening assays for HCV was
found more frequently in blood donors infected with
HCV type la or lb (90%) than in those infected with
type 2 or 3 [30-35%; Chan et ah, 1992; McOmish et ah,
1993]. Although second and third-generation screening
assays for antibody to HCV contain a wider range of
antigens, the frequency and strength of serological re¬
activity to each component have also been shown to
vary between genotypes. For example, individuals in-
EY WORDS: blood donor, screening, AhT,
antigenic variation
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cted with type 3 were statistically more likely to show
[determinate results by second-generation recombi-
ant immunoblot assay (RIBA-2; Chiron, Emeryville,
A) generally reacting with only the highly conserved
12-3 protein (90% amino acid sequence similarity be-
veen genotypes), and not to the more variable non-
ructural proteins NS-3 and NS-4 [McOmish et al.,
394].
Although differences in serological reactivity exist
atween HCV genotypes, it has proved extremely diffi-
llt to obtain direct information on whether this is
ifficient to reduce significantly the effectiveness of
irrent screening assays for anti-HCV used for blood
mor screening. This is partly because analyses of sero-
gical reactivity have so far been confined to samples
lat have already been identified as anti-HCV positive,
l addition, no practical antibody assay has been pro-
jced that is based upon a different HCV genotype so
reventing a comparison with conventional assays,
ther methods of detection of infection that are inde-
mdent of serology, such as the polymerase chain reac-
on (PCR), are impractical for use on large numbers of
ood donor samples.
In the current study a method was developed to quan-
fy levels of antibody to HCV antigens using two com-
Lercial assays (Ortho EIA 3.0 [Ortho Diagnostic Sys-
ims, Raritan, NJ] and Murex VK48 [Murex, Dartford,
ent, U.K.] currently employed for blood donor screen-
ig amongst blood donors infected with different geno-
rpes. Both assays are third generation and contain
itigens corresponding to regions within the core,
S-3, NS-4, and NS-5 proteins encoded by viruses of
motype la (Ortho) or lb (Murex). Quantitation of an-
body levels allowed a detailed analysis of the factors
lat influenced serological reactivity to genotype 1 re-
imbinant proteins, including viraemia status, geno¬




Aliquots of plasma were obtained from consecutive
sottish blood donors who were repeatedly reactive by
;cond or third-generation anti-HCV screening using
bbott, Ortho, or Murex assays. A total of 117 study
imples were selected for the study according to the
llowing criteria: a) Samples were either confirmed by
IBA-2 (n = 108), or were RIBA-2 indeterminate but
CR positive (n = 9; all type 3). b) For each sample
sed, it was possible to recall the blood donor and ob-
lin a range of baseline data, such as age, gender, risk
ictor(s) for infection, alanine aminotransferase level,
ad geographical origin.
HCV Genotyping
HCV genotypes were determined by a serological
rping assay based upon the detection of antibody to
rpe-specific epitopes in the NS-4 region [Bhattacherjee
, al., 1995], This assay shows high sensitivity and
<cellent concordance with genotyping assays such as
TABLE I. Genotypes, Viraemia Status, and Background of
the Study Group
HCV genotype1
1 2 3 Total1
Total 50 15 52 117
Viraemia status
PCR+ 37 .13 44 94
PCR- 13 2 8 23
Gender
Male 27 10 34 71
Female 20 2 15 37
Risk group
IVDU 20 3 21 44
Other" 16 6 15 37
Unknown 11 4 8 23
Age ranged
20-29 20 1 18 39
30-39 17 3 20 40
40-19 6 7 5 18
"Genotype determined by serotyping assay [Bhattacherjee et al.,
19951.
bBackground information was not available from a small, variable
proportion of donors, so that this column does not always add up to
H7.
This category includes previous transfusion (n = 17); tattooing/other
parenteral exposure (n = 9), IVDU contact (n = 10), and family con¬
tact (n = 1).
Treated as a continuous variable by multivariate analysis.
restriction fragment length polymorphism (RFLP) as¬
says in this blood donor population and in patients with
chronic hepatitis [Lau et al., 1995; Bhattacherjee et al.,
1995]. The majority of samples used in the current
study had been the subject of a previous comparison
with an RFLP genotyping assay, and showed concor¬
dant results in 121 of the 122 samples that could be
tested by both methods [Simmonds et al., 1993]. The
single discrepant sample (type 3 by RFLP, type 1 by the
serological genotyping assay) was not used in this
study. The advantage of the serotyping assay was its
ability to determine genotype in samples that were
PCR negative (22 of the 116 donations described here;
Table I), although in these there can by definition be no
corroborating evidence from genotyping assays that the
genotypes were correctly identified. However, inclusion
of these results allowed the contributions of viraemia
and genotype to be assessed simultaneously by multi¬
ple regression analysis (see below).
Viraemia was assessed by PCR as described previ¬
ously [Chan et al., 1992], 0.5 ml aliquots of plasma was
ultracentrifuged at 100,000g for 2 hours at 4°C and
RNA was extracted from the pellet by incubation in
proteinase K/Sarkosyl prior to phenol/chloroform extrac¬
tion, ethanol precipitation, and resuspension in 20 p.1 nu-
clease-free water. Five microlitres of RNA was reverse
transcribed using an antisense primer (209) specific for
the 5' noncoding region (5'NCR), followed by amplifica¬
tion using primers 209 and 939 for the first round and 211
and 940 for the second, nested PCR. This method has an
overall sensitivity of 200 copies of RNA/ml.
Antibody to individual antigens c22-3, c33c, cl00-3,
and 5-1-1 was assayed using RIBA-2 (Chiron) in accor¬
dance with the manufacturer's instructions.
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"ig. 1. O.D.s of anti-HCV-positive plasma samples (A-G) and an
d-HCV-negative control assayed at different dilutions in the Murex
A8 ELA. Sample dilutions expressed as concentration (e.g., a 1/40
ition corresponds to a concentration of 0.025, 1/160 to 0.00625).
Measurement of Antibody Levels
Quantitation of antibody by the Ortho third-genera-
m EIA (Ortho 3.0 EIA) and Murex VK48 EIA was
rried out by assay of multiple dilutions (in anti-HCV-
gative plasma) of samples as described in Results. In
other respects, each EIA was carried out in exact
lordarxce with the manufacturer's instructions. To
lintain consistency, the same anti-HCV-negative
isma sample was used for all dilutions. The positive
ntrol was another large volume plasma sample from
HCV type la-infected individual that was assigned a
minal antibody concentration of 1.0 unit, and which
is used in all assay runs.
Because of the linear relationship between optical
nsity (O.D.) and concentration of sample added to
ch well (over the range from 0 to 1.0; Fig. 1), anti-
2V reactivity could be quantified in terms of O.D.,
ovided each sample was diluted sufficiently to pro-
ce an O.D. in the linear range of the assay. Each EIA
ite included replicate dilution series of the reference
mple, providing at least four absorbance values (two
each dilution) within the linear range of the assay,
itibody levels in test samples were measured relative
the mean value obtained from the reference sample
the plate on which they were tested. This controlled
■ the observed minor variation between plates and
tween batches in the performance of the EIA (±10-
% in absorbance values). For calculation of antibody
/els, the O.D. value obtained from the negative con-
>1 (also used as diluent for the test and reference
ecimens), representing nonspecific binding to the
ills, was subtracted from both test and reference
D.s. Insufficient volumes were available to measure
tibody levels for one sample in the Murex VK48 as-
y and for seven samples in the Ortho EIA 3.0.
This method was chosen over titration to an end-
int as it has advantages of accuracy, and controls for
the effect of plate-to-plate variation. However, because
of the linear relationship between concentration of
sample added and absorbance, it would be possible in
principle to convert each antibody level measured in
this study to a dilution at which an O.D. assigned as the
cut-off value (e.g., 0.1) would be obtained. This would
allow results to be expressed as end-point titres. An
analysis of several different methods for antibody
quantitation has been presented elsewhere [Simmonds,
1987],
RESULTS
Measurement of Antibody Levels
Over a wide range of values, O.D.s by the Murex
screening assay were proportional to the concentration
of anti-HCV-positive plasma added (Fig. 1). Although
the concentration of antibody within each specimen
varied, a linear relationship was found between O.D.
values of 0 to 1.0. For the following calculations we
have assigned sample C as the reference antiserum
with a nominal antibody level of 1.0 unit. Antibody
levels in other samples relative to C can be calculated
using the following formula:
Test O.D. x reference
concentration
Test antibody level = •
Ref. O.D. x test
concentration
For example the O.D. of sample E is 0.632 at a concen¬
tration of 0.0125 (dilution of 1/80), while the reference
sample has an O.D. of0.812 at 0.00625. Therefore, sample
E has a level of (0.632 x 0.00625)/ (0.812 x 0.0125)
= 0.39 arbitrary units of antibody (or about 4/10 the level
in C). Because of the proportionality between O.D. and
antibody concentration, essentially the same results can
be obtained by selecting different test or reference dilu¬
tions. For example, the antibody level of sample E was
0.38 using the O.D. at a concentration of 0.00625
(O.D. = 0.315). Using the above formula the amounts of
anti-HCV antibody for the samples are as follows: A) 3.1
units; B) 1.4 units; C) 1.0 units; D) 0.67 units; E) 0.38
units; F) 0.28 units; G) 0.18 units. A similar linear rela¬
tionship between antibody concentration and O.D. was
observed upon titration of the same samples in the Ortho
EIA 3.0 (data not shown).
Clearly, the most accurate results are obtained using
dilutions of antibody that produce O.D.s of at least 0.2
and less than 1.0, beyond which point the linear rela¬
tionship with antibody amount was lost (Fig. 1). These
limits were applied to antibody level measurements for
all samples by both assays in this study.
Study Group
Approximately 80% of samples from the study group
were HCV RNA PCR positive and the frequency of vi-
raemia was similar amongst the three HCV genotypes
detected in this population (74% type 1; 87% type 2;
85% type 3). Genotype distributions varied in male and
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Fig. 2. Comparison of antibody levels in the Ortho EIA 3.0 and
[urex VK48 EIAs for the study samples, plotted on a log10 scale.
;male donors (males accounted for 57%; 83%; 70% of
lfections with types 1, 2 and 3 respectively), and there
'as under-representation of type 2 amongst donors in
■horn drug abuse was identified as the principal risk
ictor (3/13 for type 2 compared with 20/47 and 21/23
>r types 1 and 3). Possibly related to this observation is
le marked difference in age distribution between type
infected donors (median 41 years) compared with type
(30 years) and type 3 (30 years).
Antibody Levels in Blood Donor Samples
Each of the study samples was assayed by both Ortho
nd Murex screening EIAs at a series of dilutions (usu-
lly 1/40, 1/160, and 1/640) to measure antibody level
dative to the reference sample. Values ranged from
.0007 to 3.5 in the Ortho assay (a 5,000-fold range),
nd from 0.0008 to 1.02 in the Murex assay (range
,275-fold). A close correlation was found between anti-
ody levels measured in the two assays (Fig. 2), which
■as highly significant by regression analysis (r =
.787; P = 0.0001).
Analysis of Factors Influencing Antibody Levels
The levels of circulating antibody detected by the two
:reening assays could be influenced conceivably by a
ide range of virus and host-specific factors. These in-
ude viraemia, HCV genotype (see Introduction), route
f infection/risk group, donor age, and gender. With the
'rtho assay, the distribution of antibody levels differed
etween samples that were PCR positive and negative
rig. 3A) and also between genotypes (Fig. 3B). There
as a 20-fold difference in the median antibody level
>r PCR-positive samples (0.215), compared with PCR
egatives (0.010), and a similar difference was found
>r the Murex VK48 assay (0.126 compared with 0.013;
ig. 3E). A similar difference in antibody levels by both
ssays was also detected between different genotypes
Hg. 3A,D). In the Ortho assay, median antibody levels
■ere approximately fivefold higher in type 1-infected
donors compared with those infected with type 3 (medi¬
ans 0.275 and 0.056, respectively), similar to the differ¬
ence observed using the Murex assay (medians of 0.185
and 0.065).
There was no significant differences in antibody lev¬
els by either assay between males and females (data not
shown), age (Fig. 3C,F), or risk group (data not shown).
Thus, there was no evidence from this preliminary
analysis that these host factors could account for the
observed differences in antibody level between geno¬
types or between PCR positives and negatives.
In order to investigate the relative contribution of
viraemia and genotype to antibody levels, and the ex¬
tent to which these are influenced by other factors, we
carried out multiple regression analyses of both assays
fitting genotype, risk group, gender, and age as covari-
ates. This allowed the size and significance of differ¬
ences between groups to be calculated and controlled by
other factors.
By this analysis, viraemia and genotype proved to be
the principal influences upon antibody level by both
assays. Adjusted antibody levels by the Ortho assay
were 10.2 times higher in viraemic donors, and between
4 and 4.5 times higher in type 1-infected donors com¬
pared with genotypes 2 and 3. Similar although less
marked differences between these categories emerged
from comparison of antibody levels by the Murex VK48
assay. The only other comparison that approached sig¬
nificance was the observed higher levels of antibody by
the Murex assay in intravenous drug abusers (IVDUs)
compared with donors infected by other parenteral
routes. No difference, however, was found by the Ortho
assay. Age was not correlated with antibody level in
either assay (P = 0.52, P = 0.33, respectively; n.s.).
Alanine Aminotransferase (ALT) Levels
Although antibody levels were the principal out¬
comes investigated in this study, ALT levels were in¬
vestigated as an alternative outcome of these host fac¬
tors. Multiple regression analyses of ALT fitting
genotype, risk group, gender, and age as covariates
were carried out. The only significant influence upon
ALT levels was viraemia, where PCR-positive donors
showed an adjusted mean ALT level approximately 20
times higher than PCR negatives. With adjusted data
there was no evidence for a difference in ALT levels
between genotypes, risk group, gender, or age (Table II;
age: P = 0.70).
DISCUSSION
The main influences upon anti-HCV antibody level
as measured by either Ortho or Murex assays in this
study were viraemia and genotype, with significantly
higher levels being found in donors who were PCR pos¬
itive and infected with genotype 1. The detection of
circulating virus by PCR indicates the presence of ac¬
tive HCV infection, and the higher antibody levels ob¬
served in this group may result from persistent stimu¬
lation of the immune system. This explanation is
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Fig. 3. Distribution of antibody levels in Ortho EIA 3.0 (A, B, C) and Murex VK48 EIA (D, E, F) in
study group categorised for viraemia status (A, D), genotype (B, E), and age (C, F). Median values
indicated by horizontal bar.
TABLE II. Adjusted Influence of Viraemia, Genotype, and Host Factors Upon a Antibody and ALT Levels
Ortho EIA 3.0 Murex VK48 ALT
'actor3 Adjusted ratiob P value* Adjusted ratio P value* Adjusted ratio P value*
'iraemia
Positive-negative 10.2 <0.00001 3.54 0.0011 0.053 0.032
lenotype
Type 1-type 2 4.12 0.005 3.72 0.014 0.97 0.95 (n.s.)
Type 1-type 3 4.48 <0.00001 2.35 0.0070 0.84 0.47 (n.s.)
Type 3-type 2 0.93 0.88 (n.s.) 1.58 0.38 (n.s.) 1.16 0.76 (n.s.)
lender
Female/male 1.06 0.83 (n.s.) 1.63 0.13 (n.s.) 0.68 0.12 (n.s.)
tisk
IVDU-other 1.22 0.52 (n.s.) 2.31 0.049 0.84 0.50 (n.s.)
IVDU-unknown 1.24 0.59 (n.s.) 1.81 0.075 (n.s.) 1.03 0.93 (n.s.)
Other-unknown 1.01 0.97 (n.s.) 1.28 0.57 (n.s.) 1.23 0.55 (n.s.)
Age is a continuous variable and cannot be represented in the table (see text).
Adjusted ratio of antibody or ALT levels after multiple regression analysis between the first and second category (e.g., PCR positive compared
nth PCR negative).
Significant P values (<0.05) are underlined; nonsignificant values indicated (n.s.).
iraemia with ALT abnormalities, presumably reflect-
ng a link between virus replication and liver damage,
imongst the PCR-negative group, most had ALT levels
rithin the normal range for blood donors (0-55 IU/ml),
suggesting low levels of virus replication or complete
clearance of HCV.
In this study we sought to investigate the extent to
which antigenic variation between genotypes affects
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e sensitivity of current screening assays. Lower sero-
gical reactivity was found to the type la or lb anti-
ins used in the EIAs with samples from donors in-
cted with non-type 1 genotypes. The study was
isigned to examine the separate influences of host
ctors that might compound the observed differences
itween genotypes in serological reactivity. By multi-
iriate analysis, no evidence was found for any signifi-
nt effect of age, risk group, or gender upon antibody
activity, while the genotype differences were shown
be independent of the differences in antibody levels
itween PCR-positive and -negative samples (see
>ove). The magnitude of the difference in levels pro-
des an estimate of the relative amounts of genotype-
iecific and cross-reactivity antibody to the core, NS-3,
S-4, and NS-5 antigens. For example, the 4-4.5-fold
fference between type 1 with types 2 and 3-infected
mors could be interpreted as indicating that a major
oportion of antigenic determinants in the EIAs are
motype specific. This conclusion is consistent with the
iding of type-specific epitopes in core, NS-4, and NS-5
gions [Machida et al., 1992; Simmonds et al., 1993;
inaka et al., 1994; Bhattacherjee et al., 1995; Zhang
al., 1995]. Although detailed mapping of type-spe-
Eic epitopes in the NS-3 and NS-5 regions used in
reening assays has not been published, the existence
significant amino acid sequence variability in both of
ese regions predicts the existence of substantial anti-
mic variation that may also contribute to the ob-
rved differences in this study.
This analysis cannot rule out completely the possibil-
f that type 1 infections elicit higher levels of antibody
an other genotypes, although if this were the case
en it would be expected that type 1 infections would
i associated with a higher mean ALT level ifantibody
vel was related to a greater severity of disease. This is
^arly not the case, as it was found that adjusted mean
LT values were within 16% of each other (Table II).
milarly, although there is abundant evidence that
pe 1-infected patients are less likely to respond to
terferon treatment than types 2 and 3, evidence for a
fference in pathogenicity between genotypes has
oved more elusive. A similar spectrum of liver disease
is been described in patients infected with each of the
motypes, with little evidence that type 1 is more patho-
rnic once the effect of age (and duration of infection) is
ken into account. Recently, it has been shown that
ean levels of viraemia are similar between genotypes 1,
and 3, once the greater sensitivity of the bDNA assay
r type 1 sequences is taken into account [Smith et al., in
ess; Lau et al., submitted], effectively discounting any
herent difference in replicative capacity or immunolog-
al control between them in vivo. Consistent with these
;w data is the previous observation that multiple-ex-
ised individuals such as haemophiliacs do not show an
errepresentation of any particular genotype compared
ith the distribution of genotypes in the plasma from
tiich the blood products were manufactured [Jarvis et
., 1994], indicating that type 1 in particular shows no
ndency to replace other genotypes upon reinfection.
This study provides grounds for concern that anti¬
genic variability of HCV impairs the performance of
current assays. For example, if the current assays were
4.5 times less sensitive than they currently are (the
difference between antibody levels of type 1 and 3 do¬
nors; Table II), then it is possible that a proportion of
samples currently detected by screening assays would
become negative. We have retested samples from the 50
type 1-infected donors in the Ortho EIA at a 1/90 dilu¬
tion compared with the recommended 1/20 dilution
(therefore making the assays equivalent to their cur¬
rent sensitivity for type 3-infected donors), and ob¬
served a decrease in O.D.s for many of the samples. Of
interest was the observation that one RIBA-confirmed
sample became borderline at the 1/90 dilution (O.D.
0.69; assay cut-off 0.65). Further studies are required to
investigate the clinical significance of these differences
in sensitivity.
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The 5' end of the NS-4 protein of different genotypes of
hepatitis C virus (HCV) is highly variable in nucleotide
and inferred amino acid sequence, with frequent pre¬
dicted amino acid substitutions between all six of the
major HCV genotypes described to date. This region has
been shown to be antigenic by epitope mapping, and
elicits antibody in HCV-infected individuals with a
detectable type-specific component. We have used this
sequence data to specify branched peptides for an
indirect binding/competition assay to detect type-
Introduction
Hepatitis C virus (HCV) is the major causative agent of
post-transfusion non-A, non-B hepatitis. The viral
genome is a single-stranded, positive-sense RNA of
about 9400 nucleotides in length (Choo et al., 1991),
encoding a single, continuous polyprotein that is cleaved
into putative core. El, E2/NS-1 (envelope), NS-2, NS-3.
NS-4 and NS-5 (non-structural) proteins. Comparisons
of published complete genome sequences have found
that isolates fall into distinct virus types (Choo et al.,
1991; Kato et al., 1990; Okamoto et a!., 1991;
Takamizawa et al., 1991; Okamoto et al., 1992b;
Sakamoto et al., 1994). According to recent proposals
(Simmonds et al., 1994a), based upon extensive sequence
comparisons of HCV in the core (Bukh et al., 1994), El
(Bukh et al., 1993) and NS-5 regions (Simmonds et al.,
1993 a), variants of HCV can be usefully classified into
six major genotypes (designated 1 to 6), many of which
can be further subdivided into a number of more closely
related subtypes.
* Author for correspondence. Fax +44 131 650 6531.
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specific antibody to each major genotype. A total of 183
out of 210 samples (87%) from blood donors and
patients with chronic hepatitis C infected with genotypes
1 to 6 showed detectable type-specific antibody to NS-4
peptides that in almost all cases (> 97 %) corresponded
to the genotype detected by a PCR typing method.
These findings demonstrate the existence of major
antigenic differences between genotypes of HCV, and
indicate how infection with different variants of HCV
may be detected by a serological test.
The variation in nucleotide sequences between HCV
isolates is expressed in the translated amino acid
sequences and may alter the antigenic properties of viral
proteins. For example, sera from individuals infected
with non-type 1 genotypes react infrequently with
recombinant proteins derived from NS-4 (5-1-1 and
c 100-3) used in current screening and confirmatory
assays for HCV (McOmish et al., 1993; Chan et al.,
1991); there is also evidence for less frequent reactivity to
the NS-3 protein (c33c) amongst those infected with
types 2 to 6, leading to a statistically significant over-
representation of 'indeterminate' results from these
variants in confirmatory assays such as the 2nd gen¬
eration recombinant immunoblot assay (RIBA-2)
(McOmish et al., 1994).
At present PCR-based methods are the principal
means by which variants of HCV may be identified
(Okamoto et al.. 1992c; Stuyver et al., 1993a; Chayama
et al., 1993; McOmish et al., 1994). The major drawbacks
of PCR-based methods, however, are the expense and
complexity of the procedure which makes difficult the
processing of large numbers of clinical samples on a
routine basis. Serological methods for HCV typing,
based upon the ability to distinguish antibody elicited by
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infection by different genotypes of HCV are necessarily
indirect, and not always appropriate (as they rely upon a
humoral immune response in the infected individual),
but do have important practical advantages over PCR-
based methods in ease of use and cost. The problem with
developing such tests lies in finding protein sequences
which are both type-specific and antigenic.
Epitope mapping of the core and NS-4 proteins has
revealed the existence of linear antigenic determinants in
regions of variability between HCV genotypes
(Tsukiyama Kohara et al., 1993; Simmonds et al.,
1993c). ELISAs based on peptides corresponding to
these regions have been used to identify type-specific
antibody elicited by genotypes 1 and 2 (core or NS-4;
Tsukiyama Kohara et al., 1993; Tanaka et al., 1994;
Mondelli et al., 1994), and 1, 2 and 3 (NS-4; Simmonds
et al., 1993 c). In the latter assay, cross-reactivity due to
epitopes shared between genotypes was minimized by co-
incubation of serum with peptides in solution hetero¬
logous to those on the solid phase.
In this paper, we have obtained nucleotide sequences
of the antigenic region of NS-4 for the more recently
described genotypes of HCV (types lc, 2c, 3b, 4a, 5a and
6a) and have developed a competition ELISA to detect
type-specific antibody to each of the six genotypes. The
frequency with which type-specific antibody to NS-4
could be detected was measured by testing sera from
individuals infected with a range of different genotypes.
Methods
Samples. HCV sequences from the 5' non-coding region (5'NCR)
were amplified by PCR from plasma or serum samples from anti-HCV
positive blood donors from Egypt. South Africa and Hong Kong.
Genotypes were identified by sequence comparisons with previously
published 5'NCR sequences for identification of genotypes (see Fig. I).
Sequences were obtained in the NS-4a region from those infected with
genotypes 4. 5 and 6. as well as from samples from individuals
previously shown to be infected with type lc and 2c (Simmonds el at..
1993 a).
Investigation of the frequency of type-specific antibody to NS-4
peptides was carried out using a combination of anti-HCV positive
blood donors (n = 39) and patients with HCV-induced liver disease
(n = 171) infected with genotypes 1 to 6 as identified by RFLP of the
5'NCR as previously described (McOmish et at.. 1994; Davidson et at.,
1995).
PCR amplification of NS-4 sequences. RNA was reverse transcribed
using an antisense primer with the sequence AACTCGAGTATCCC-
ACTGATGAAGTTCCACAT (primer 007 from Simmonds et at..
1993c) which is complementary to a conserved sequence from the HCV
NS-4 coding region. The outer and inner sense primers for nested PCR
amplification were designed from the two regions of greatest con¬
servation towards the 5' end of known NS-4 sequences of genotypes la.
lb. 2a. 2b and 3a. Complementary DNA was amplified in the first
round using 007 in combination with sense primer CACCCCATCA-
CCAAATACAT (5' base: 4915; nucleotides numbered as in Choo et
al.. 1991). The second round of PCR amplification used sense primer
TTTTGGATCCATGCATGTCAGCTGATCTGG (5' base: 4941) and
antisense primer TTTTGGATCCACATGTGCTTCGCCCAGAA (5'
base: 5278). Both primers used in the second PCR step included
terminal BamHI restriction sites (in bold) to allow cloning via cohesive
ends. The NS-4 sequence of genotype 6 was found to amplify better
using a combination of primers that matched genotypes 1. 2 and 3
(Simmonds et at., 1993c) for the first and second rounds of PCR
followed by a third round employing primers 5351 and 594 to enable
cohesive-end cloning.
Cloning of amplified NS-4 sequences. All cloning steps followed
standard protocols (Ausubel el al., 1992) using Boehringer Mannheim
enzymes except where stated. The amplified NS-4 DNA bands
(% 0-4 kb) were excised from 1 % agarose gels and the DNA was
recovered by low-speed centrifugation through glass wool (Heery et al..
1990). Extracted DNA was cleaved with BamHl and ligated into
BamHI-digested pUC18 vector (Yanisch-Perron et al.. 1985) at 16 °C
overnight, and used to transform competent Escherichia colicells (XL I -
Blue from Stratagene). Plasmid DNA from colonies containing inserts
was sequenced with forward and reverse pUC/M13 primers using the
United States Biochemical Sequenase kit. The manufacturer's protocol
for double-stranded sequencing with alkaline denaturation was
followed except that the reactions were carried out in 10% dimethyl
sulphoxide.
Sequence analysis of NS-4. Phylogenetic analysis of NS-4 sequences
was carried out with the programs DNADIST. NEIGHBOR and
DRAWTREE in the PHYLIP package version 3.5c kindly provided
by Dr J. Felsenstein (Felsenstein, 1993). Unrooted trees were
constructed by the neighbour-joining algorithm as previously described
for analysis of NS-5 sequences (Simmonds el al.. 1993a).
Synthesis of peptides for HCV serotyping assay. Synthetic peptides
were prepared on p-hydroxymethylphenoxymethylpolystyrene (HMP)
resin bearing a branched-lysine core to give eight copies of the same
sequence per molecule, using the multiple antigenic peptide (MAP)
system (Fmoc MAP 8-Branch: ABI Ltd: Tarn. 1988). Synthesis was
performed using Fastmoc chemistry on an Applied Biosystems model
432A automated peptide synthesizer (ABI Ltd). Purity of the peptides
was determined by reverse-phase HPLC. Integration of peaks by
computer analysis (PE Nelson. Perkin Elmer) showed all peptides to be
greater than 80% pure. Peptides were not purified further prior to use
in the assay.
Serotyping ofserum samples using the 1-6 ELISA. Each peptide was
reconstituted in distilled water at an approximate concentration of
1 mg/ml. A small volume of 30 % acetic acid was added to the type 3
peptides to help them dissolve, while the remaining peptides dissolved
more easily after bubbling ammonia vapour through the solution.
Polypropylene microtitre wells (Immunoplate, GIBCO BRL) were
coated with 100 pi volumes of phosphate buffered saline (PBS)
containing all 21 peptides, each at a concentration of 50 ng/ml. The
plates were incubated at 4 °C overnight, washed in PBS and blocked
with 125 pi volumes of blocking solution (PBS, 2% bovine serum
albumin) for a minimum of I h at room temperature. After blocking,
plates were air-dried and kept at 4 °C prior to use. Plates prepared in
this way could be stored for several months without loss of reactivity.
Prior to the addition of the serum to the wells, blocking solutions of
competing peptides (in a 100-fold excess over those used for coating)
were added to the appropriate wells on the microtitre plate in volumes
of 10 pi per well. Plasma, diluted in 800 pi of sample diluent (Murex
Diagnostics) at a concentration of 1:20, was immediately added to each
of the eight wells used per sample (100 pi per well). This was followed
by incubation overnight at 4 °C.
Plates were washed four times in PBS + 005% Tween 20 (PBST).
and then incubated with 100 pi of conjugate (Murex; VK 47-
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horseradish peroxidase-labelled mouse monoclonal antibody to human
IgG) for 1 h at 37 °C. The plates were washed again, four times in
PBST, before adding 100 pi substrate to each well (TMB. Murex) and
incubating for 30 min at 37 °C. Sulphuric acid (8 M. 50 pi) was added
to each well before reading the plate against a negative control blank
at 450 nm. with a reference wavelength of 690 nm.
Statistical analysis. Analysis of the median and variance of the
absorbance values recorded for plasma samples was carried out using
standard statistical software (SYSTAT). Box plots represent the 25th
and 75th quartiles of a non-parametric distribution as the boundaries
of the box. and the median as the line dividing the box (Tukey, 1977).
The whiskers represent the range of values that lie within 1-5 times the
interquartile range (inner fence). Values between 1-5 and 3 times the
interquartile range are plotted as asterisks (*), while open circles (O)
represent outlying values greater than three times the interquartile
range (outer fence). For calculation of median values and ranges of
serological data, a value of 2-0 was substituted for samples with
absorbance values greater than 2.
Results
Phylogenetic analysis of the NS-4 region
HCV types 4, 5 and 6 were identified by sequence
comparison of the 5'NCR with those of published
variants (Fig. 1). In order to obtain cloned NS-4
nucleotide sequences from these genotypes, RNA was
reverse transcribed and amplified using conserved
primers from the NS-4 region, as described in Methods.
Sequences were obtained from six type 4a samples (EG-
1.-13,-21, -24. -25 and -33). four type 5a (T478. SC-6.
SC-23 and SC-24) and two type 6a (HK-4 and T3950).
NS-4 sequences were also amplified from previously
identified samples of genotypes lc (4TY4), 2c (T983), 3b
(B4. B9) identified by sequence comparisons in NS-5
(Simmonds et al.. 1993a) and unpublished data).
The NS-4 region used in the phylogenetic analysis
covers the nucleotide sequence positions 4941 5282
(numbered as in Choo et al.. 1991) and is 341 bases in
size. Previously published nucleotide sequences, and the
corresponding regions of complete genomes (numbered
1-33: Fig. 2) were included in the comparison with the
newly isolated NS-4 sequences (nos 34-50; Fig. 2). The
unrooted phylogenetic tree displays three levels of
branching which reflects different levels of variability
between isolates. The major branches correspond to the
six major genotypes of HCV based on analysis of NS-5
(Simmonds et al.. 1993a) and El sequences (Bukh et al..
1993). The second level of branching occurs between
variants of HCV previously described as subtypes
(Simmonds et al.. 1993a). As found in NS-5 and El, NS-
4a sequences show discontinuous, 'hierarchical', as
opposed to continuous, variation between isolates. The
grouping of the individual isolates was in all cases
consistent with genotype classifications obtained using
the 5'NCR (Fig. 1), and El and NS-5 (Simmonds et al.,
1994 h).
Analysis of the distribution ofpairwise distances
The relationship between sequence diversity between
major genotypes and subtypes was investigated by
comparison of the distributions ofevolutionary distances
of separate pairwise comparisons between major geno¬
types, subtypes, and variants within a subtype (isolates)
(Table la). The median nucleotide distance of com¬
parisons between members of different major genotypes
was 0-381. greater than those calculated for subtypes and
isolates (0-168 and 0-037). Although the range of values
of type, subtype and isolate overlapped, the 95th
percentile ranges did not. The range of nucleotide
distances corresponded closely to three discrete normal
distributions, as previously described for NS-5
(Simmonds et al., 1993 a), as shown by the similarity of
mean and median values, and between the actual 95th
percentile ranges with those calculated from the mean ± 2
standard deviations (Table la).
The analysis was extended to the distribution of
pairwise distances calculated between inferred amino
acid sequences (expressed as the proportion of different
residues). Such comparisons are more likely to reflect the
degree of antigenic relatedness between different HCV
variants than evolutionary distances between nucleotide
sequences. A similar set of distinct approximately
normally distributed values was observed for type,
subtype and isolates comparisons (Table lb), each
showing numerically distinct median values and non-
overlapping 95th percentile ranges. The amino acid
sequence differences between major genotypes (38 %;
range 25-50%) are consistent with antigenic differences
greater than those found between subtypes and isolates
(median values 17% and 4%), although this analysis
cannot compute the differing contributions to changes in
antigenicity produced by biochemically similar or dis¬
similar amino acid substitutions (see below).
Description of NS-4 amino acid sequences for HC V
types 4 to 6
The inferred amino acid sequence of 111 residues
translated from the NS-4a sequences between positions
1653-1764 (Choo et al., 1991) includes the region
corresponding to the immunoreactive clone 5-1-1 (1683—
1735) (Fig. 3). In the region compared, only 47 sites are
conserved between all variants analysed, while many of
the variable sites contain substitutions of amino acids
possessing side-chains with different biochemical proper¬
ties, and which could potentially alter the structure and
antigenic properties of the protein (highlighted in bold).
Previous epitope mapping of this region for genotypes
la, lb, 2b. and 3a (Simmonds et al., 1993c) identified
regions of greatest antigenicity at positions 1691-1708
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Fig. 1. Comparison of sequences in the 5'NCR of different genotypes of HCV from variants used for sequence determination in
NS-4 (listed in the legend to Fig. 2): differences from the HCV prototype strain HCV-PT (Choo el al.. 1991) are indicated. The genotype
assigned to each sequence, following proposed nomenclature (Simmonds ei al.. 1994a) on the basis of the sequence in the 5'NCR is
shown in the first column. Nucleotide sequences -332 to —225. —214 to —168 and - 153 to 145 are omitted as they are invariant
between the sequences shown. (.). Sequence identity to HCV-PT; (-). gap introduced into the sequence to preserve alignment; (N).
sequence not determined.
(designated region 1) and 1710-1728 (region 2), under¬
lined in the prototype sequence.
Genotypes 3a. 3b. 4a. 5a. and 6a show similar amino
acid sequences in antigenic region 1, although the type 4a
sequences contain a possible antigenically significant
change to a glutamine residue at position 1691 in place of
basic amino acids (Fig. 3). Type 3b has a glutamine in
place of an otherwise universal glutamate at position
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1699 and, along with 3a, a tyrosine residue instead of
phenylalanine at 1705. Region 2 displays a high degree of
antigenically significant type-specific variation between
all the genotypes. The type 5a sequences contain a
glutamate-alanine-arginine motif (EAR) at position
1720-1722, while type 6 has a specific motif alanine-
glutamate-residue x-glutamine-glutamine (AE-QQ) at
1719-1723. Genotype 4a contains four amino acid
changes of biochemical significance in this region, i.e.
lysine at position 1713, leucine at 1717, histidine at 1720
and glutamine at 1724. A lesser degree of sequence
variability is found amongst sub-types of HCV. The
single examples of types lc and Id possess specific
histidine residues at positions 1720 and 1723 respectively,
while type 2c has threonine, histidine and arginine
residues at positions 1715, 1722 and 1724. Sub-type 3b
contains specific amino acid residues at positions 1720
(proline) and 1726 (glutamine).
Fig. 2. Phylogenetic analysis of a 342 base region of NS-4 (nucleotide
positions 4941-5282) of sequences from HCV genotypes 1 to 6. 1-33,
previously published sequences; 34-50, new NS-4 sequences obtained
in this study corresponding to more recently described genotypes.
Phylogenetic groups are labelled according to proposed nomenclature;
sequence 13 (labelled Id) from Indonesia is described as 'lc' in
Okamoto et at. (1994) and ' 1 d' in Hotta et al. (1994). Type 4 sequences
from Egyptian blood donors correspond to variants described as '4a'
in Simmonds el al. (1993a), but are different from "4a' in Bukh et al.
(1993). Sources of published NS-4A sequences (number, clone name,
geographical origin, genotype, source reference) are as follows: (I) PT-
1, USA. la (Choo et al., 1991); (2) HCV-H, USA, la (Inchauspe et al.,
1991); (3-7) T16. T42. T77. T1801, T1825, Scotland. UK. la
(Simmonds et al.. 1993c); (8) HCV-J, Japan, lb (Kato el al., 1990); (9)
HCV-BK, Japan, lb (Takamizawa et al., 1991); (10) HPCJTA. Japan,
lb (Tanaka et al.. 1992); (11. 12) J483, J491, Japan, lb (Okamoto et al.,
1992a): (13) HCVJKIG, lb (M. Honda and others, GenBank number
X61596); (14) T. Taiwan, lb (Chen et al., 1992); (15) HPCGENOM.
China, lb (X. Bi and others, GenBank number L02836); (16) HC-J9,
Indonesia, Id (Okamoto et al., 1994); (17) HC-J6, Japan. 2a(Okamoto
et al., 1991); (18) K2A, Japan. 2a (Enomoto et al., 1990); (19) D11353,
Japan, 2a (Sarashina et al., 1993); (20) T351, Scotland, UK, 2a
(Simmonds et al., 1993 c); (21) Clone A, Clone E, Japan, 2b (Tsukiyama
Kohara et al.. 1991); (23) HC-J8. Japan, 2b (Okamoto et al.. 19926);
(24-26) T59 (E-bl2), T810, T940. Scotland. UK. 2b (Simmonds et al.,
1993c); (27, 28) BR36-20, HD10-1, Brazil, 3a (Stuyver et al., 19936);
(29-33) T26 (E-b3), T32 (E-b7), T38 (E-b2), T40 (E-bl), T1787,
Scotland, UK, 3a (Simmonds et al., 1993 c). Sources of the new NS-4A
sequences are as follows: (34) HCVUK. UK, lb (Garson et al., 1990);
(35) 4TY4, Lebanon, lc (Simmonds et al., 1993a); (36) T983. Scotland,
UK, 2c (Simmonds et al., 1993a); (37) B4. Bangladesh. 3b; (38) B9,
Bangladesh, 3b; (39-44) EG-1, EG-13, EG-21, EG-24. EG-25, EG-33,
Development of an ELISA to detect genotvpe-specific
antibody
Peptides corresponding to the two previously identified
antigenic regions of NS-4 (underlined in Fig. 3) for
genotypes 1 to 6 were synthesized in branched form and
used as antigens for detection of genotype-specific
antibody. Consensus sequences for regions 1 and 2 were
decided upon for each genotype, although it was clear
from the outset that the region 1 peptides for genotypes
4 to 6 were all very similar to 3a (Fig. 4). In some cases,
it was necessary to synthesize more than one peptide for
a particular genotype to cover intra-typic sequence
heterogeneity, but not to introduce combinations of
amino acid polymorphisms that did not exist in native
sequences. For example, different consensus sequence
peptides were synthesized for each of the three subtypes
of type 2 (Fig. 4).
The format of the current assay differs considerably
from those of previously described serotyping assays that
were based upon the coating of different antigens
corresponding to different genotypes into different wells
(Tsukiyama Kohara et al., 1993; Yunomura et al., 1994;
Tanaka et al., 1994; Mondelli et al., 1994). In the current
assay, all wells were coated with peptides from all six
genotypes. Type-specific antibody was detected by
competition between the solid phase antigens with a 100-
fold molar excess of peptides added in solution with the
plasma or serum sample. For example, detection of
genotype-specific antibody to type 1 is achieved by
Egypt, 4a (Simmonds el al., 19936); (45) T478. UK. 5a; (46-48) SC6.
SC23, SC24, South Africa, 5a (Davidson et al., 1994); (49, 50) HK-4,
T3950, Hong Kong, 6a (Simmonds et al., 1993a).
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Table 1. Distribution ofpairwise nucleotide (a) and amino acid (b) sequence
distances between HCV types, subtypes and isolates
Type Subtype Isolate
No. of pairwise
comparisons... 959 145 121
(a) Nucleotide distances
Median 0-617 0-275 0-083
Range Min 0-359 0-180 0-000
Max 0-888 0-380 0146
95% percentile Lower 0-449 0-228 0-006
Upper 0-815 0-364 0-135
Mean 0-617 0-279 0-079
SD ±0113 + 0-030 + 0-031
(6) Amino acid divergence
Median 0-381 0-168 0-037
Range Min 0-230 0-106 0-000
Max 0-550 0-240 0-115
95% percentile Lower 0-245 0-108 0-000
Upper 0-502 0-221 0-094
Mean 0-374 0164 0-041
SD + 0-071 ±0-029 + 0-023
addition of peptides from genotypes 2 to 6 to the test
serum or plasma samples (see Methods). This method
guarantees that only those antibodies that can bind to
the solid phase are those that do not cross-react with
heterologous genotypes to HCV.
The frequency of antibody reactivity to type-specific
antibody to this region of NS-4 was assayed using a total
of 210 PCR-positive plasma samples from blood donors
or patients with chronic hepatitis, and whose circulating
genotype was determined by RFLP as recently described
(Davidson et al., 1995). To investigate the frequency of
non-specific reactivity to the NS-4 peptides, we also
tested a total of 20 anti-HCV negative blood donor
control sera. For each sample, we recorded the
absorbance produced upon reaction with all of the
peptides coated onto the solid phase (unblocked control),
in competition with all peptides in solution (blocked
control), and finally a series of six wells for detection of
type-specific antibody to each of the genotypes in¬
dividually (Fig. 5).
The relative proportion of type-specific and cross-
reactive antibody to the epitopes presented by the NS-4
peptides was estimated by comparison of the median and
interquartile ranges of the absorbance values upon
reaction with homologous NS-4 peptides with the
unblocked control (Fig. 5). The absorbance value from
the blocked control was in each case subtracted from the
values obtained from the other wells to control for any
non-specific binding to the solid phase. For all genotypes,
antibody reactivity was almost always confined to
peptides of the same genotype as determined by
PCR-RFLP typing, whereas binding was not observed
amongst any of the anti-HCV negative controls (Fig.
5A). For the anti-HCV positive sera, a wide range of
antibody reactivity was observed, both against the
homologous type peptide and in the unblocked control
well. For each genotype, the median values were greater
in the unblocked wells than they were to the homologous
peptide, indicating a mixture of antibody to type-specific
and cross-reactive epitopes. Precise measurement of the
relative proportions could not be carried out without
titration of the samples, because there was not a linear
relationship between absorbance and amount of anti¬
body for absorbance values greater than 1 (unpublished
observations), and because absorbance values recorded
for many of the samples were greater than 2-0 (see
Methods).
For genotypes 4, 5 and 6, levels of type-specific
antibody were markedly lower than for types 1 to 3,
while total anti-NS-4 antibody (unblocked control) was
similar to that found in the other genotypes. These
findings could be explained by the greater similarity of
the first antigenic region of genotypes 4, 5 and 6; it is
possible that the principal component of the type-specific
reactivity is directed solely to the more divergent second
region. Little difference was found in total reactivity to
NS-4 or to homologous peptides between subtypes la
and lb. or between 2a and 2b, apart from the slightly
weaker reactivity of type lb antibody to the type 1
peptides (Fig. 5C). As described above, this could be the
consequence of a greater similarity of type lb NS-4
sequences to other genotypes than type la. For example,
the alanine (A), serine (S) and glutamine (Q) substi¬
tutions at positions 1711, 1712 and 1722 (all in region 2)
found in the lb sequences are shared with type 2 (Fig. 3),
and antibody reactivity with epitopes dependent upon
these amino acid residues would be more likely to be
absorbed by heterologous peptides.
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Fig. 4. Sequences of peptides used for ELISA, corresponding to
antigenic regions 1 (positions 1691-1708) and 2 (1710-1728) of HCV
genotypes 1 to 6. For types 1 and 2, more than one peptide was used
to allow for sequence heterogeneity within the genotype.
The presence of type-specific antibody within an
individual sample was scored by comparison of the
antibody reactivity within each well with that of the
blocked control. Samples with absorbance values two or
more times that of the blocked control were considered
positive, provided the absorbance was greater than
0-1. Using this scoring system, we compared the detection
of type-specific antibody by ELISA with the circulating
genotype detected by PCR (Table 2). We found an
overall concordance of 97% (177 out of 182 samples
reactive in the ELISA contained type-specific antibody
to the genotype detected by PCR), with no significant
difference between genotypes. Only single instances were
found where samples contained antibody to a different
genotype in the RFLP assay. No sample showed
antibody to more than one genotype. The frequency of
detection of type-specific antibody was 87%, although
variation was observed between genotypes. High rates
(92-100%) were found for genotypes la, 2a, 2b and 3a,
while type lb and 4 were lower at 83% and 81%
respectively. Detection rates for types 5 and 6 were based
upon relatively fewer samples (16 and 6), and require
further investigation with more extensive panels of
genotyped samples.
Discussion
Sequence variability in the NS-4 region
Variability in the NS-4a region of the HCV genome
between positions 4941-5282 appeared comparable to
relationships between genotypes and subtypes of HCV in
other coding regions of the genome (Simmonds et al.,
1993a; Bukh et al., 1993, 1994). In each case, three levels
of sequence variability were found, with a clear dis¬
tinction into major genotypes and subtypes that has been
proposed as the basis for classification of HCV
(Simmonds et al., 1994a). The region of NS-4a analysed
in this report shows similar degrees of sequence di¬
vergence to the other non-structural proteins of HCV,
NS-3, NS-4B. NS5A and -5B. It is more conserved than
El with nucleotide evolutionary distances ranging from
0-46-0-80 between major genotypes, compared with
0-43-0-85 for El (positions 574-1149, Bukh et al., 1993),
and much more than core (0-13-0-25, Chan et al., 1992.
and our unpublished observations). Similar relationships
were found between the inferred amino acid sequences of
the different parts of the genome (data not shown).
Pairwise comparisons of amino acid sequences of
major genotypes showed 23-55% variation, and did not
significantly overlap with any of those between subtypes
(11-24%) nor between individual variants within a
subtype (0-12%). Furthermore, genotype identifications
of samples on the basis of sequence data obtained
elsewhere in the genome, such as NS-5 (Fig. 2, seq. nos
6, 7, 20, 24, 25, 29-33) or the 5'NCR (Fig. 1; Fig. 2. seq.
nos 34-50) are in each case consistent with the groupings
observed in the NS-4 tree (Fig. 2), providing further
evidence that sequence variability in NS-4a is rep¬
resentative of the virus as a whole.
Frequent amino acid substitutions were found between
genotypes in regions of NS-4a previously shown to be
antigenic by epitope mapping (Simmonds et al., 1993c),
apart from the unexpected similarity found within the
first antigenic region for genotypes 4. 5 and 6 (Figs 4 and
5). It is possible that this accounts for the slightly
reduced sensitivity of the ELISA for type-specific
antibody to these genotypes, and suggests the use of
peptides from other regions of NS-4 as additional
antigens for the ELISA. For example, we have been able
to detect type-specific antibody using peptides from part
of NS-4 downstream from the 2nd antigenic region that
is highly variable between genotypes (unpublished data),
and are currently investigating the possibility of using
this region in a modified and more sensitive serotyping
ELISA.
Detection of genotype-specific antibody
The incubation of samples with blocking concentrations
of heterologous peptides provides an effective and
sensitive assay for genotype-specific antibody. The
method largely eliminates the possibility of false de¬
tection of antibody through shared epitopes between
different genotypes, a problem that is inevitable and
limiting for assays based upon indirect ELISAs (Tanaka
et al., 1994; Tsukiyama Kohara et al., 1993; Yunomura
et al., 1994; Mondelli et al., 1994). In contrast, the
detection of reactivity to more than one genotype in the
assay described in this report is more likely to indicate
antibody produced by multiple infection with different
HCV variants. This is shown by the previous finding of
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Fig. 5. Box plot of the net absorbance value. A (A — blocked control) for negative controls (A. n = 20), and samples representing each
HCV genotype [la-B (rt = 24), lb-C (n = 9). 2a-D (n = 13), 2b-E (n = 17), 3-F (n = 50), 4-G (n = 48), 5-H (n = 10), 6-1
(« = 6)] against type-specific NS-4 epitopes from each genotype (wells 1-8) and to the unblocked control (well 7). Median value and
interquartile ranges are indicated by the internal line and the upper and lower sides of the box; the single line represents values lying
within 1-5 times the interquartile range. Outliers with values greater than 1-5 or 3 times the interquartile range are indicated by (*) and
(O) symbols respectively (see Methods).
a high frequency of antibody to genotypes 1 and 2, or 1
and 3 in haemophiliacs exposed to multiple contaminated
batches of clotting factor (Jarvis el al., 1994), which
contrasts with the reactivity to single genotypes found in
this study for all 182 reactive samples from blood donors
and hepatitis C patients.
Few of the amino acid differences between HCV
subtypes, for example between la and lb, would be
expected to lead to significant antigenic variability. We
have previously found that reactivity to peptides derived
from type la and lb sequences produced almost identical
patterns of reactivity upon epitope-mapping the NS-4a
region, (Simmonds et al., 1993 c). Similarly, sera from
type 2a- and 2b-infected blood donors showed no
consistent differences in reactivity with overlapping
peptides from type 2b. This antigenic similarity (par¬
ticularly between la and lb) has provided an obstacle
for the development of an ELISA to detect infection with
different subtypes for all but a small proportion of
samples. It remains possible that other (more variable)
regions of the genome might be more suitable for such an
assay. Alternatively, the sequence variability that does
exist between subtypes might lead to antigenic differences
between native proteins absent from linear peptides.
However, the apparent inability of an NS-4 based
serotyping assay based upon recombinant polypeptides
to separately identify antibody to subtypes (Tanaka et
al., 1994) argues against the second possibility. Fur-
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Table 2. Detection of type-specific antibody in plasma samples of HCV-
infected patients and blood donors of known genotype
Serotypet
Sensitivity Concordance
Genotype* 12 3 4 5 6 NTS NR Total (%)+ ' (%)§
1II All 35 - - _ 1 1 2 39 92-3 97-2
a 24 0 1 25 960 100
b 9 - - - / 1 1 12 83-3 900
2 11 All 1 30 - - 'W; 0 1 32 96-9 96-8
a 13 - - _ _ 0 I 14 92-9 100
b I 17 - - - - 0 0 18 100 94-4
3 - 1 50 _ - - 2 2 55 92-7 98-0
4 - 1 - 49 _ - 9 3 62 80-6 980
5 1 - - - to - 2 3 16 68-8 90-9
6 4 1 1 6 66-6 100
Total 37 32 50 49 10 5 15 12 210 87-1 97-3
Neg. 20 20 - _
* Genotype determined by RFLP of 5'NCR sequences as previously described (McOmish et at.,
1994: Davidson et at.. 1994).
t Serotype: detection of type-specific antibody to HCV genotypes 1-6 in these samples: no sample
showed type-specific antibody to more than one genotype. Results concordant with genotyping by
RFLP shown in bold. NR. non-reactive; NTS, non-type-specilic antibody reactivity to NS-4
peptides.
+ Number typeable by ELISA/number tested.
§ Number concordant with genotype determination by RFLP/number typeable by ELISA.
II Totals for type 1 and 2 samples; results for subtypes la, lb and 2a, 2b are shown in italics.
thermore. there is little evidence that antigens derived
from other regions of the HCV genome might be more
appropriate for the detection of antibody to subtypes.
For example, the degree of amino acid sequence
variability in the El gene is similar to that found in NS-
4 (see above), while E2 contains antigenic regions that
are so variable that they are not conserved within a
subtype.
The frequent detection of specific antibody to the
circulating genotype identified by PCR indicates a
potential role for this serotyping assay as an alternative
to conventional PCR-based typing assays. However, the
assay is dependent upon a normal immune response to
virus infection, and would not necessarily be able to
detect NS-4a antibody in individuals who are severely
immunosuppressed, or in samples collected around the
time of seroconversion following primary infection. In
individuals who are multiply-exposed, antibody to more
than one genotype was frequently found, even though
only one circulating genotype was detected by PCR
(Jarvis et al1994), indicating that the ELISA may
detect past as well as current infection. The appearance
of new type-specific antibody in those haemophiliacs in
whom the circulating genotype spontaneously changed
was frequently delayed by several months, providing a
further cause of discrepant results in this risk group
(Jarvis et al., 1994).
Information on risk behaviour and previous exposure
to HCV was not available for the blood donor and
hepatitis C patients in this study, and it is possible that
past infection with different genotypes accounted for the
discrepant results in Table 2. It is also possible that the
peptides used do not represent the full range of antigenic
variation within each genotype; to take one example
from Table 2, epitopes present on an unusual variant of
type 1 might also be found in type 6 NS-4a sequences.
This possibility could be explored by sequence analysis
of the NS-4a region sequences of samples producing such
discrepant results. It would also exclude the possibility
that the differences between genotyping in the 5'NCR by
PCR and serotyping by ELISA result from infection with
recombinants of HCV. with sequences corresponding to
different genotypes in different parts of the genome.
However, sequence analysis of variants of HCV in more
than one region of the genome has so far failed to
produce any evidence for the existence of recombinant
viruses in vivo (Figs 1 and 2) (Simmonds et al., 1994b;
Lau et al., 1994), and must be considered an unlikely
explanation for the discrepant results reported here.
Clinical utility of genotyping
Although there is no evidence for genotypes of HCV that
are completely non-pathogenic or perhaps non-hepato-
tropic, there are many reports of differences between
them in the rate of disease progression, and particularly
in the probability of achieving a sustained response to
anti-viral treatment (reviewed in Dusheiko, 1994). These
clinical differences indicate the potential utility for
identification of the infecting genotype in patients for
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patient selection, and in calculating the most effective
duration and dose of interferon treatment to achieve a
long-term response. The serological typing method
described here may be of major value in service
laboratories that require a quick and simple assay for
identification of HCV genotypes, without the necessity to
purchase expensive items of equipment for PCR or to
introduce unfamiliar working techniques into the lab¬
oratory. The use of different combinations of competing
peptides in the ELISA allows the design of different
formats of the assay to maximize its clinical utility and
ease of use. For example, in Europe it may be more
practical to screen patients for genotypes 1, 2 and 3
separately, and to detect other genotypes (4, 5 and 6)
together by competition with peptides from genotypes 1,
2 and 3 only. It would also be possible to incorporate
additional peptides corresponding to newly discovered
major genotypes (e.g. Apichartpiyakul et al., 1994) into
the ELISA for screening populations where these
variants occur.
The authors would like to thank Dr E. A. C. Follett, Brian Dow and
staff at the SNBTS Microbiology Reference Laboratory, Ruchill
Hospital, Glasgow. Dr R. Crookes, South African Blood Transfusion
Service, and Dr C. K. Lai. Hong Kong Red Cross Blood Transfusion
Service, Kowloon, Hong Kong, for providing samples for sequence
analysis and serotyping.
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summary. Hepatitis C virus (HCV) genotype 4 is the
principal HCV genotype found in Egypt and the
Middle East. Little is known concerning its propensity
to cause disease and the frequency with which
infected individuals respond to interferon-a (IFN-a).
We have investigated the response to treatment in a
cohort of 100 chronic hepatitis C patients infected
with genotype 4. All patients had biopsy-proven
chronic active liver disease. Each was treated with
3 million units (MU) IFN-a, thrice weekly. Response
was monitored, in 92 patients who completed treat¬
ment, by alanine aminotransferase (ALT) measure¬
ments and by polymerase chain reaction (PGR) for
HCV. ALT levels remained abnormal in 64 patients
during treatment (69.6%). Of the 28 patients who
showed a biochemical response during treatment
(30.4%), 18 maintained this over the 6-month post-
treatment period. Amongst the sustained biochemical
responders, HCV RNA was cleared from serum in only
four of the 18 (22.2%) in this period. Histological
improvement was observed in 26/51 (50.9%) of the
patients who had a second biopsy.
Hence, patients infected with HCV genotype 4 show
a poor response to IFN-a therapy compared with geno¬
types 2 and 3, but a similar response to IFN-a com¬
pared with those infected with type lb HCV. These find¬
ings have major implications for treatment strategies in
the Middle East, including Egypt, where HCV genotype
4 is widely distributed.
Keywords: antiviral, Egypt, genotype 4, interferon
treatment.
INTRODUCTION
Hepatitis C virus (HCV) is a positive-stranded RNA
virus that has been identified as the principal cause of
post-transfusion non-A, non-B hepatitis [1,2]. HCV
shows substantial sequence diversity, and sequence
comparisons in El and non-structural regions of the
genome has led to classification of HCV into a series of
genotypes that show distinct geographical distribu¬
tions [3,4]. Currently HCV can be classified into six
major genotypes that typically differ from each other by
up to 30-3 5% in nucleotide sequence in non-struc-
Abbreviations: ALT. alanine aminotransferase; HCV. hepatitis C
virus: IFN-a. interferon-a: 5'NCR, 5'non-coding region: RFLP.
restriction fragment length polymorphism.
Correspondence: Dr A. El-Zayadi. Faculty of Medicine. Ain Shams
University, Cairo. Egypt.
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tural proteins, and between 35-50% in the El and E2
regions encoding putative envelope glycoproteins. The
5' non-coding region (5'NCR) is highly conserved and
genotyping assays are frequently based upon this
region, where specific nucleotide differences between
HCV genotypes can be detected by cleavage of amplified
DNA sequences by restriction endonucleases (restric¬
tion fragment length polymorphism, RFLP) [5], or by
hybridization to genotype-specific probes [6,7].
In the Middle East, including Egypt, HCV type 4 is the
most frequently detected genotype in blood donors and
patients with hepatitis C [8-10], A recent study on
HCV genotyping in Egyptian patients showed a preva¬
lence of type 4 in 92% of HCV antibody (HCVAb) posi¬
tive patients (unpublished data). HCV genotypes may
differ in their biological properties, such as severity of
disease and response to interferon. For instance, indi¬
viduals infected with types 2 and 3 appear to respond
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more frequently to interferon-a (IFN-a) therapy than do
those with type 1 [11,12], although little is currently
known concerning the response ofgenotypes 4. 5 and 6.
In this study, we have studied responses to treatment in
a large group of HCV-infected patients from the Cairo
Liver Centre who were infected with type 4 HCV.
Responses were assessed by measurement of alanine
aminotransferase (ALT) and clearance of viraemia by
polymerase chain reaction (PCR), and are compared
with those previously reported for other HCV genotypes.
MATERIALS AND METHODS
Study subjects
One hundred patients were identified as HCVAb posi¬
tive by second generation enzyme immunoassay (EIA-2),
and were viraemic as assessed by PCR. The study group
who completed treatment comprised 77 males and 15
females, with a mean age of 39.5 years. Each patient
was treated with IFN-a2a (Roche) at a dose of 3 million
units (MU) thrice weekly (t.i.w.) rising occasionally to
5 MU t.i.w., for a total duration of 6 months. Eight
patients were withdrawn from the study owing to intol¬
erable side effects, allowing complete evaluation in 92
patients. Risk factors and clinical presentation were
evaluated in these patients.
5'NCR as previously described [13.14]. HCV genotypes
were determined by RFLP analysis of amplified DNA




The main risk factor for HCV infection in this study
group was a past history of intravenous antischistoso-
mal therapy (30.4%; Table 1). Other potential expo¬
sures to HCV included past blood transfusion (15.2%),
previous surgery (15.2%) and dental therapy (21.7%).
Over 70% of the patients were asymptomatic and HCV
infection was discovered incidentally during a medical
examination before employment or surgery. About
20% of patients suffered from flatulent dyspepsia, possi¬
bly as a result of congestive gastropathy secondary to
portal hypertension. Only 10% of patients presented
with fatigue.
Histopathological and virological findings
The predominant pathological findings among the
study patients were chronic active hepatitis (CAH) +
Table 1 Pre-treatment characteristics of the study group
Monitoring of response to treatment
Liver biopsy was performed on 8 5 patients before IFN-a
treatment and on 51 patients 6 months after the end of
therapy. Patients' refusal prohibited liver biopsy in the
rest of the study group. ALT levels were monitored
monthly during the course of therapy in all patients,
and for the first 6 months following treatment in those
showing an initial response. Responders to IFN therapy
were categorized as:
1 non-responders (NR), maintenance of abnormal
ALT level during treatment;
2 complete responders (CR), steady normalization of
ALT level by the end of 6 months of treatment;
3 sustained responders (SR), complete response last¬
ing for 6 months after discontinuation of therapy.
PCR and genotyping
HCV RNA sequences were amplified from plasma by
























More than one risk factor 16(17.4)
Biopsy appearance
Chronic lobular hepatitis 8 (9.4)
Chronic persistent hepatitis 16(18.8)
Chronic active hepatitis 22(25.9)
Chronic active hepatitis + cirrhosis 39 (45.9)
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cirrhosis (45.9%) and CAH alone (25.9%) (Table 1).
Chronic persistent hepatitis was found in 18.8% and
chronic lobular hepatitis in 9.4%. All patients were
infected with genotype 4 HCV as identified by RFLP
analysis of amplified sequences from the 5'NCR using
restriction enzymes Haelll/Rsal and Mval/Hinfl.
Response to IFN-a treatment
A total of 28 patients (31%) showed a complete response
to IFN-a treatment as monitored by normalization of ALT
(Table 2). Of these, 18 maintained normal ALT levels over
the 6 months following treatment, while the remainder
relapsed. All patients were HCV RNA positive before the
start of IFN-a treatment. PCR was repeated 6 months after
the end of therapy to calculate the sustained virological
response to treatment. Serum HCV RNA was negative in
only four of the 18 individuals (22%) showing a sustained
normalization of ALT. Long-term sustained virus clear¬
ance was thus obtained only in four of the 92 members of
the study group (4%). Histological improvement by histol¬
ogy activity index (HA1) score was observed in 26 of 51
(50.9%) patients in whom a post-treatment liver biopsy
was carried out. Biopsies in those who responded to treat¬
ment showed evidence of an anti-inflammatory response
with a decrease in periportal and lobular inflammation
(Table 3). Patients with cirrhosis were less likely to respond
to treatment than those without evidence of fibrosis.
DISCUSSION
A large number of published and ongoing investiga¬
tions have shown differences between HCV genotypes
in the frequency of response to interferon therapy.
However, almost all of these have been confined to the
investigation of an extremely restricted range of geno-
Table 2 Biochemical responses to IFN-a
Response n %




* Patients showing normalization of ALT levels during
treatment, subdivided into those who maintained normal
ALT levels in the 6-month post-treatment period, and those
who relapsed (see Materials and methods).
Response ofHCV genotype 4 to IFN-a 263




Biopsy appearance n n %
CLH* 7 6 86
CPH1 15 12 80
CAH* 15 6 40
CAH + cirrhosis 14 2 14
* CLH, chronic lobular hepatitis,
t CPH, chronic persistent hepatitis.
£ CAH, chronic active hepatitis.
types. This particularly applies to studies reported from
Japan and Southern Europe, which are usually confined
to patients infected with HCV types lb. 2a and 2b, and
to those from the USA where types la and lb predomi¬
nate. In this study we were able to investigate response
to treatment in a large cohort of patients infected with
genotype 4 HCV, for which there is currently little infor¬
mation concerning its propensity to cause disease and
the extent to which it responds to antiviral treatment.
In general, an extremely low rate of response was
observed. Combining biochemical and virological
markers of response, only four of the 92 patients who
completed treatment showed sustained normalization
of ALT levels and clearance of viraemia 6 months after
the cessation of treatment. Furthermore, a high fre¬
quency of patients (70%) showed no normalization of
ALT even during the treatment period.
The rate of sustained normalization of ALT in this
study group was low (20%), and within the range
found upon treatment of HCV genotype 1 (9-40%)
[9,12,16-20]. This contrasts with rates of 45-91% for
genotype 2 [17-19] and 5 5% for genotype 3 [12],
Similarly, the extremely low rate of sustained virus
clearance for type 4 in this study (4%) was similar to
that observed for type 1 infected patients (6%) and
lower than those infected with type 3 (3 3%) [20],
Although most of the patients presented with subclini¬
cal infection, a high frequency of active liver disease
was found upon biopsy. Approximately 25% of the
group had CAH and 45% had cirrhosis and this high
rate of severe disease compared with other cohorts of
patients may have independently contributed to the
poor response to treatment [17,18,21-2 3],
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This first large-scale investigation of responses to
treatment of Egyptian patients provides no grounds for
optimism that conventional IFN-a therapy (3 MU t.i.w.).
for infections with HCV genotype 4, will be of benefit for
the majority of those treated. The poor rate of response
suggests a need for higher dose IFN-a treatment, or IFN-
a treatment combined with other antivirals such as rib¬
avirin. This combination (3MU t.i.w. IFN-a. 1.0-1.2 g
ribavirin for 6 months) achieved a sustained virological
response (PCR-negative after 6 months from cessation of
treatment) in 5/10 patients who had previously failed to
respond to interferon monotherapy [24], and may be of
value in the study group described here.
REFERENCES
1 Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW.
Houghton M. Isolation of a cDNA derived from a blood-
borne non-A, non-B hepatitis genome. Science 1989;
244: 359-362.
2 Kuo G, Choo QL. Alter HJ et al. An assay for circulating
antibodies to a major etiologic virus of human non-A.
non-B hepatitis. Science 1989; 244: 362-364.
3 Bukh J, Purcell RH. Miller RH. At least 12 genotypes of
hepatitis C virus predicted by sequence analysis of the
putative E1 gene of isolates collected worldwide. Proc Natl
AcadSci USA 1993; 90: 8234-8238.
4 Simmonds P. Holmes EC, Cha TA et al. Classification of
hepatitis C virus into six major genotypes and a series of
subtypes by phylogenetic analysis of the NS-5 region. /
Gen Virol 1993; 74: 2391-2399.
5 Davidson F. Simmonds P, Ferguson JC et al. Survey of
major genotypes and subtypes of hepatitis C virus using
RFLP of sequences amplified from the 5' non-coding
region./Gen Virol 1995; 76: 1 197-1204.
6 Stuyver L. Rossau R. Wyseur A et al. Typing of hepatitis C
virus isolates and characterization of new subtypes using
a line probe assay. /Gen Virol 1993; 74: 1093-1102.
7 Tisminetzky SG, Gerotto M. Pontisso P et al. Genotypes of
hepatitis C virus in Italian patients with chronic hepatitis
C.Int Hepatol Commun 1994; 2: 105-112.
8 Simmonds P. McOmish F. Yap PL et al. Sequence variabil¬
ity in the 5' non coding region of hepatitis C virus: identi¬
fication of a new virus type and restrictions on sequence
diversity. / Gen Virol 199 3; 74: 661-668.
9 Dusheiko G. Schmilovitzweiss H. Brown D et al. Hepatitis C
virus genotypes—an investigation of type-specific differ¬
ences in geographic origin and disease. Hepatology 1994:
19: 13-18.
10 Mellor ], Holmes EC. Jarvis LM. Yap PL. Simmons P.
International Collaborators. Investigation of the pattern
of hepatitis C virus sequence diversity in different geo¬
graphical regions: implications for irus classification.
JGen Virol 1995; 76: 2493-2507.
11 Yoshioka K, Kakumu S, Wakita T et ,. Detection of hep¬
atitis C virus by polymerase chain re .ction and response
to interferon-alpha therapy: relation hip to genotypes of
hepatitis C virus. Hepatology 1992; 1 >: 29 3-299.
12 Chemello L. Alberti A. Rose K, Simmonds P. Hepatitis C
serotype and response to interferon therapy. N Engl J Med
1994: 330: 143.
13 Chan S-W, McOmish F. Holmes EC et al. Analysis of a new
hepatitis C virus type and its phylogenetic relationship to
existing variants. / Gen Virol 1992; 73: 1131-1141.
14 Jarvis LM, Watson HG, McOmish F. Peutherer JF, Ludlam
CA, Simmonds P. Frequent reinfection and reactivation
of hepatitis C virus genotypes in multitransfused
hemophiliacs. / Infect Dis 1994; 170: 1018-1022.
1 5 Davidson F, Simmonds P. Ferguson JC et al. Survey of
major genotypes and subtypes of hepatitis C virus using
restriction fragment length polymorphism of sequences
amplified from the 5' non-coding region. / Gen Virol
1995: 76:1197-1204.
16 Gerolami V. Halfon P. Bourliere M et al. Hepatitis C virus
genotypes in chronic hepatitis and response to inter¬
feron-alpha therapy. J Infect Dis 1993; 168: 1 328—1 329.
1 7 Tsubota A, Chayama K, Ikeda K etal. Factors predictive of
response to interferon-alpha therapy in hepatitis C virus
infection. Hepatology 1994: 19: 1088-1094.
18 Hino K. Sainokami S, Shimoda K et al. Genotypes and
titers of hepatitis C virus for predicting response to inter¬
feron in patients with chronic hepatitis C. / Med Virol
1994:42:299-305.
19 Mita E, Hayashi N. Hagiwara H et al. Predicting inter¬
feron therapy efficacy from hepatitis C virus genotype
and RNA titer. Dig Dis Sci 1994; 39: 977-982.
20 Garson JA, Brillanti S. Whitby K et al. Analysis of clinical
and virological factors associated with response to alpha
interferon therapy in chronic hepatitis C. / Med Virol
1995:45: 348-353.
21 Piccinino F, Felaco FM. Aprea L, Messina V. Pasquale G,
Sagneili E. Non responders to interferon therapy among
chronic hepatitis patients infected with hepatitis C virus.
Arch Virol 1993: 257-263.
22 Pagliaro L. Crazi A, Cammaa C et al. Interferon-alpha for
chronic hepatitis C—an analysis of pretreatment clinical
predictors of response. Hepatology 1994; 19: 820-828.
2 3 Lam NP. Deguzman LJ. Pitrak D, Layden TJ. Clinical and
histologic predictors of response to interferon-alpha in
patients with chronic hepatitis C viral infection. Dig Dis
Sri 1994;39:2660-2664.
24 Schvarcz R. Yun 7.B, Sonnerborg A, Weiland O.
Combined treatment with, interferon alpha-2b and rib¬
avirin for chronic hepatitis C in patients with a previous
non-response or non-sustained response to interferon
alone. J Med Virol 1995; 46: 43-47.
© 1996 Blackwell Science Ltd. Journal of Viral Hepatitis. 3, 261-264
